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Dedication	  
The impossible is possible tonight 
Billy Corgan, "Tonight Tonight" 
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Abstract	  
Introduction	  
Varicose veins are a common problem with 25-50% of the population 
symptomatically affected, and chronic venous disease leads to significant 
impairments in quality of life with substantial health system cost implications.  
Significant variability exists in the symptoms suffered by patients, the treatment 
offered and the outcomes achieved.  Identification of the optimal treatment 
pathways for patients remains difficult. 
Aims	  
i. To ascertain primary care disease knowledge. 
ii. To assess what affects treatment and identify which patients benefit most. 
iii. To generate a predictive model of varicose vein outcomes. 
iv. To assess the impact of altering treatment of varicosities in the context of 
endovenous truncal vein ablation 
v. To investigate the early impact of new technologies  
Methods	  
i. Two survey studies were completed: 
⁃ 21 questions assessing venous disease management pathways was 
disseminated to General Practitioners. 
⁃ 19 questions assessing the management of superficial venous 
thrombosis and was distributed to General Practitioners and Vascular 
Surgeons. 
ii. A cohort of consecutive patients with symptomatic chronic venous disease 
were assessed and completed quality of life questionnaires pre and post-
intervention. 
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iii. Uni-variable and multi-variable analysis of patient cohort data to facilitate 
the creation of generalised model of venous treatment outcomes 
iv. A randomised clinical trial assessing the timing of varicosity avulsion in the 
context of local anaesthetic endovenous truncal ablation. 
⁃ Ambulatory Varicosity avUlsion Later or Synchronised (AVULS) trial. 
v. Assessment of new technologies 
⁃ The European Sapheon Closure system Observed ProspectivE 
(eSCOPE) study a multi-site cohort observational study of 
cyanoacrylate glue occlusion of truncal vein incompetence 
⁃ The VNUS Versus Clarivein for Varicose Veins (VVCVV) multi-centre 
randomised clinical trial comparing the procedural pain profile of 
radiofrequency and mechanochemical ablation. 
Results	  
i. Education outcomes 
⁃ 138 responses were received.  The management of chronic venous 
disease in the primary care setting is disparate and knowledge of 
current techniques is poor, despite extensive guidance. 
⁃ 369 responses were received, from 197 vascular specialists and 172 
primary care physicians.  Superficial thrombophlebitis management is 
shown to be diverse and does not adhere to recent evidence. 
ii. 461 patients were recruited.  Patients suffering from chronic venous disease 
suffer from substantial quality of life impairment, including previously 
under-recognised depressive symptoms.  Treatment of the underlying venous 
condition provides relief from venous symptoms and improves quality of life. 
⁃ Patient symptoms and quality of life do not correlate with anatomical 
vein diameter, however clinical severity scores do. 
iii. Predictive modelling produces models that account for 30-41% of the 
variability in post-operative scores for disease specific quality of life tools, 
generic quality of life tools, and clinical severity scores. 
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iv. The AVULS trial recruited 101 patients.  Simultaneous treatment leads to 
improved clinical outcomes at up to 1 year and early quality of life 
improvement.  Delayed treatment has a significantly increased risk of 
requiring further treatment (Odds Ratio 27.78, Relative Risk 18.36, 
p<0.0001).  95% of patients declining randomisation opted for simultaneous 
treatment. 
v. New Technology Outcomes 
⁃ The eSCOPE study recruited 70 patients in Europe with good technical 
outcomes.   
⁃ The VVCVV trial (ongoing) has recruited 85 patients, with 
significantly reduced procedural pain found with mechanochemical 
ablation. 
Conclusions	  
Varicose veins are a widespread problem with effective treatment that leads to a 
significant improvement in quality of life.  Education and communication between 
community and hospital-based medicine is lacking.  Predictive modelling of varicose 
vein symptoms remains difficult due to the multifactorial nature of the disease.  
Simultaneous treatment of varicosities during endovenous truncal ablation 
produces improved outcomes and is the option of choice for most patients.  Early 
data on new technologies show they provide less painful procedures with similar 
outcomes as the established modalities. 
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1.1.	  Varicose	  Veins	  
 
Figure 1:  Varicose Veins with skin changes 
Varicose veins are defined as subcutaneous dilated veins ≥ 3mm in diameter on 
standing which are normally tortuous in nature (Bergan 2007).  They are commonly 
found on the leg, associated with the saphenous veins (Great Saphenous Vein, GSV 
and Small Saphenous Vein, SSV), but can be found in the arms or on the trunk in 
certain circumstances. 
1.1.1.	  Epidemiology	  
Varicose veins are a common and poorly understood problem, with an extensive 
history, with documentation of treatment existing in the Ancient Greco-Roman era 
(Perrin 2011).  Varicose veins are dilated tortuous veins and they can cause a 
constellation of symptoms, from simple cosmesis to severe intractable ulceration 
and even death (Campbell et al. 2007; Bradbury et al. 1999; Evans et al. 1973; 
Cocker & Nyamekye 2008). 
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25-50% of the population suffer from varicose veins (Callam 1994; Beebe-Dimmer et 
al. 2005) and indeed only 10% of the sample population studied in the Bonn had no 
signs of venous disease (Rabe et al. 2003).  Varicose veins show an increased 
prevalence with age and are more common in women (Beebe-Dimmer et al. 2005; 
Dimakakos et al. 2012).  However recent work has shown that pregnancy rather 
than gender is a contributing factor to the development of venous disease (Jawien et 
al. 2003; Bihari et al. 2011). 
 
Epidemiological studies have been performed but classification criteria has been 
disparate leading to difficulty assimilating those studies that have been published, 
leading to limited population level data (Beebe-Dimmer et al. 2005; Clark et al. 
2010; Eklöf et al. 2009). 
 
Recent work by international consensus bodies has lead to the formation of unified 
definitions of anatomy and venous disease (Eklöf et al. 2009; P. Gloviczki et al. 
2011; P. Gloviczki & M. L. Gloviczki 2012; Murad et al. 2011; Vasquez & 
Munschauer 2010).  This has lead to firm clinical and symptom scoring systems 
that allow for comparability between studies (Eklöf et al. 2004; Vasquez & 
Munschauer 2012; Vasquez et al. 2010).  Future studies of epidemiology utilising 
these systems should provide robust evidence of the true epidemiological status of 
varicose veins. 
 
Cohort data from the Edinburgh Vein Study, Bochum Study and the Bonn Vein 
Study (Robertson et al. 2013; Rabe et al. 2010; Schultz-Ehrenburg & Reich-Schupke 
2009) has begun to provide data on progression of venous disease - 0.7-2.1% 
incidence of chronic venous insufficiency per year. 
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1.1.2.	  Aetiology	  
The pathophysiological basis of varicose veins remains unclear with differing 
theories advanced for the development of a symptomatic condition (Cleave 1972; 
Cleave 1959; Lim & Davies 2009; Bergan et al. 2008). 
 
The two main competing theories are the descending theory and the ascending 
theory. 
 
The descending theory was first popularised by Trendelenburg in 1891 
(Trendelenburg 1891), with a description of the incompetence of venous valves 
causing reflux of blood and consequently hydrostatic pressure on the valves below.  
This causes dilatation of the vein, leading to valvular incompetence.  This is 
purported to lead to a step-wise progression in incompetence down the lower limb.  
This theory is supported by anatomical studies of cadavers (Cotton 1961), which 
showed an significant reduction in the number of venous valves present in the 
incompetent long saphenous vein.  The valves themselves have been shown to be 
hypotrophic and sclerosed (Corcos et al. 1996; Corcos et al. 2000).  Additionally work 
on venous haemodynamics indicate that venous pressure in varicose veins does not 
reduce on exercise, in contrast to the normal venous tree (Corley et al. 2010; 
Broderick et al. 2010; Broderick et al. 2009; Araki et al. 1994).  These studies also 
support an increased venous hydrostatic pressure, which would necessarily come 
from a column of uninterrupted venous blood in an incompetent vein.  Work by Kan 
and Delis identified improvements in venous volume ejection with exercise which 
had no effect on the reflux shown in incompetent veins despite a reduced 
compartment volume and pressure (Kan & Delis 2001) and this was confirmed with 
longer duration studies (Padberg et al. 2004).  This would indicate that incompetent 
venous valves are the precursor to incompetent veins.  This is supported by cohort 
data from the Bochum study (Schultz-Ehrenburg & Reich-Schupke 2009). 
 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
34 
However, with the advent of ultrasonography, patterns of venous reflux which were 
not consistent with this theory emerged - competent segments existed in refluxing 
veins and vice-versa as well as incompetent veins anatomically separate from the 
hydrostatic columns (Labropoulos et al. 1997; Labropoulos et al. 2001; Labropoulos 
et al. 2005; Labropoulos et al. 2010; Abu-Own et al. 1994; Caggiati et al. 2006).  
Work describing the deterioration and degradation of the venous wall, leading to 
venous dilatation and consequently valvular incompetence has been put forward to 
explain these clinical scenarios.  Interestingly, the cadaveric data that supports the 
descending theory also supports the ascending theory - the sapheno-femoral 
junction valve ( SFJ - the "terminal" valve) was intact in the majority of cases 
dissected (Cotton 1961).  Further cadaveric work has shown that 39.8% of 'normal' 
great saphenous veins (GSV) contain segmental narrowing with complete aplasia in 
17.4% and these areas had a weaker vein wall (Caggiati & Ricci 2000). 
 
A retrospective study assessing over 4000 individual legs showed that neither the 
ascending nor descending theories can fully explain the various patterns of reflux 
seen in the population (Qureshi et al. 2010; Shepherd & Davies 2011; Wing et al. 
2010).  The complex nature of reflux seen implies that whilst both theories have a 
role, there is also a potential systemic component to chronic venous disease, which 
remains elusive despite extensive basic science research (Lim et al. 2012; Lim, Qiao, 
et al. 2011b; Lim, Gohel, et al. 2011a; Urbanek et al. 2004). 
 
What is clear is that at a crucial point the superficial veins in the leg become dilated 
and their valves incompetent with a consequent raised venous pressure (Browse 
1986; Pollack & Wood 1949).  The development of varicose veins is a complex multi-
factorial pathway, with genetic and environmental variables (Criqui et al. 2007). 
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1.1.3.	  Classification	  of	  venous	  disease	  
Varicose veins have been subject of many differing classification criteria and 
present a therapeutic challenge as the symptomatology encountered by patients is 
so diverse (Campbell et al. 2007).  Therefore, scoring systems have been developed 
in an effort to quantify the baseline and post-operative status. 
1.1.3.1.	  Clinical	  Scoring	  Systems	  
Clinical scoring systems exist to provide an objective clinician delivered assessment 
of varicose vein disease.  There have been many attempts to provide a structure on 
which to hang the difficult signs and symptom spectrum of this common disease 
(Bergan 2007). 
1.1.3.1.1.	  Widmer	  Classification	  
The Widmer Classification or Basle criteria described in 1978 was based on the 
extensive Basle epidemiological studies performed in Switzerland during the 1960s 
and 1970s (Zinniker et al. 1978; Widmer et al. 1978; da Silva et al. 1979; Widmer & 
da Silva 1991). 
 
The classification was blunt, using only 3 stages: 
1. Oedema and dilated subcutaneous veins with corona phlebectatica 
2. Trophic lesions of the skin with hyper- or depigmented areas 
3. A healed or active ulcer. 
 
This criteria lacks finesse due to the minimal differentiation of stages 2 and 3 and 
the lack of specificity of stage 1 being very broad.  However, despite this it has been 
used in large scale studies such as the Edinburgh vein study which ran between 
1994 and 1996 (Bradbury et al. 1999; Evans et al. 1997). 
1.1.3.1.2.	  Hach	  Grading	  
Hach theorised that an incompetent GSV would lead to an internal circular shunt, 
overloading and dilating the deep venous system, leading to deep venous 
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incompetence as a consequence of superficial incompetence (Hach et al. 1980).  In 
this theory the following four grades were explained in purely anatomical and reflux 
terms of the GSV: 
I. Reflux in the groin 
II. Reflux to above the knee 
III. Reflux to just below the knee 
IV. Total reflux to the ankle 
1.1.3.1.3.	  The	  Sytchev	  Criteria	  
In 1985 Sytchev published the precursor to the currently used classification systems 
(Sytchev 1985; Bergan 2007), using a combination of clinical stages, aetiology and 
haemodynamics. 
 
The clinical classes described stages signs such as oedema, time of day of onset and 
degree of functional change, the aetiology described primary, secondary and 
congenital and the haemodynamics classified compensated, underloaded or 
overloaded (Bergan et al. 2007). 
1.1.3.1.4.	  Clinical	  Etiology	  Anatomy	  and	  Pathology	  (CEAP)	  
The CEAP is a clinician completed classification score that allows careful 
quantification of the clinical status, etiology, anatomical location and pathological 
status of the patient's venous disease (Eklöf et al. 2004). 
 
The earlier classification attempts prompted an international consensus conference 
of the American Venous Forum in 1994.  This created the CEAP classification - this 
acronym stands for Clinical, Etiological, Anatomical and Pathophysiological.  In 
2004 this criteria was modified into the current revised CEAP classification (Eklöf 
et al. 2004). 
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The clinical component indicates disease severity, ranging from zero points, for 
completely asymptomatic patients, up to 6 points for active ulcers. The etiologic 
component denotes the venous disease as congenital, primary, or secondary in 
nature. The anatomic classification pinpoints the veins involved as superficial, deep, 
or perforating. The pathophysiological classification identifies the presence of reflux 
in the superficial, communicating, or deep systems, as well as the existence of 
outflow obstruction. The CEAP classification is doctor driven, and highlights the 
cause of the underlying venous abnormality however it is not sensitive in tracking 
progressive changes, with only 6 levels covering the whole spectrum of venous 
disease from its absence (C0) to an active venous ulcer (C6). 
 
Clinical Stages 
 0:  No visible or palpable signs of venous disease 
 1:  Telangiectasia or reticular veins 
 2:  Varicose veins (≥3 mm) 
 3:  Oedema 
 4:  Skin changes 
4a venous ecezma or pigmentation 
4b lipodermatosclerosis and/or atrophie blanche 
 5:  Healed ulceration 
 6:  Active ulceration 
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Figure 2:  The Clinical Stages of the CEAP Score 
 These stages are then further sub-divided with A (asymptomatic) or S 
(symptomatic) 
 
"Basic" CEAP using all 4 aspects of the scoring system allows a full description of 
the venous problem in each patient - for example a patient with a symptomatic 
ulcer, varicosities and swelling due to primary superficial refluxing disease would 
be C6,3,2,S; Ep; As; Pr.  This information is now easily available due to the gold-
standard investigation of venous duplex, however is of limited value in most clinical 
practices and is therefore poorly reported (Eklöf et al. 2004).  Often the highest 
clinical stage reached is the reported term. 
 
An example scoring box is shown in Figure 3: 
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Figure 3:  Example CEAP Scoring Proforma 
Examples of the Clinical stages of the CEAP criteria are shown below: 
 
"Advanced" CEAP utilises the full "Basic" CEAP criteria with the addition of named 
venous segments to allow mapping of the refluxing veins.  These are numbered from 
1-18 as below (Bergan 2007): 
 
Superficial Veins: 
1 Telangectasia or reticular veins 
2 GSV above knee 
3 GSV below knee 
4 Small Saphenous Vein (SSV) 
5 Non-Saphenous Veins 
 
Deep Veins: 
6 Inferior Vena Cava 
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7 Common Iliac Vein 
8 Internal Iliac Vein 
9 External Iliac Vein 
10 Pelvic: Gonadal, Broad Ligament Veins, Other 
11 Common Femoral Vein 
12 Deep Femoral Vein 
13 Femoral Vein 
14 Popliteal Vein 
15 Crural: Anterior Tibial, Posterior Tibial, Peroneal Veins (Paired) 
16 Muscular: Gastrocnemial, Soleal veins, Other 
 
Perforating Veins: 
17 Thigh 
18 Calf 
 
Therefore, a full description of the above patient with an isolated incompetent GSV 
to the ankle would be C6,3,2,S; Ep; As; Pr 2,3. 
1.1.3.1.5.	  Venous	  Severity	  Score	  
The Venous Severity Scoring System was designed by consensus of the American 
Venous Forum ad hoc committee (Rutherford et al. 2000).  This was designed to 
complement and extend the CEAP scoring system by offering reactive scoring 
instruments.  This includes the Venous Clinical Severity Score (VCSS), the Venous 
Segmental Disease Score (VSDS) and the Venous Disability Score (VDS). 
1.1.3.1.5.1.	  Venous	  Clinical	  Severity	  Score	  (VCSS)	  
The VCSS is a clinician-completed tool, which includes 9 hallmarks of venous 
disease, each scored on a severity scale from 0 to 3. In order to generate a dynamic 
score, VCSS categories are scored individually  (Rutherford et al. 2000). These 
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categories are pain, use of stockings, swelling skin changes and pigmentation, 
inflammation and induration, and ulcers (including number, size, and duration). 
 
In 2007, an international ad hoc working group was created to revise the VCSS to 
update the terminology, simplify the application, and clarify ambiguities which was 
completed in 2010 (Vasquez et al. 2010). 
 
 The value of the VCSS is its ease of use along with an emphasis on the most severe 
manifestations of venous disease which are likely to show the greatest response to 
therapy allowing tracking and quantification of improvement (or deterioration) 
(Vasquez & Munschauer 2012). 
1.1.3.1.5.2.	  Venous	  Disability	  Score	  (VDS)	  
The VDS is a three point  score first introduced in the 1996 as a consensus 
document (Nicolaides et al. 1996) as part of the initial CEAP scoring system, and 
then revised in 2000 (Rutherford et al. 2000) as part of the VSS.  This clinician 
completed score provides a blunt assessment tool for the impact chronic venous 
disease has on the patient. 
 
0 is asymptomatic, 1 symptomatic but able to complete normal activities without 
compression, 2 dependent on compression therapy to complete normal activities and 
3 is unable to complete normal activities despite compression therapy. 
 
Whilst this is a blunt instrument it is easy to separate patients into categories and 
to assess general improvements.  However, it is not very sensitive to change or 
clinical status (Sritharan et al. 2012). 
1.1.3.1.5.3.	  Venous	  Segmental	  Disease	  Score	  (VSDS)	  
The VSDS utilises data derived from duplex ultrasound assessment of the varicose 
veins of the leg (Rutherford et al. 2000).  Segments of refluxing vein are added up 
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with various weighting factors to provide a score assessing the haemodynamics of 
the affected leg.  This does not represent a clinical assessment but an anatomical 
assessment. 
 
The score is out of a maximum of 20, with 10 points available for venous reflux and 
10 for venous obstruction.  The score was developed as an adjunct to the CEAP 
scoring system using a consensus approach (Rutherford et al. 2000), but has been 
found to be difficult to interpret and is seldom used in clinical practice (Vasquez et 
al. 2007; Perrin et al. 2006).  Interestingly, despite being developed in conjunction 
with the VCSS and VDS the correlation between VSDS and VCSS has been found to 
be statistically significant but very weak (r=0.29, p=0.048 (Kakkos et al. 2003)).  
Additionally after treatment for venous reflux the score is insensitive to the clinical 
outcome and successful treatment can lead to static or even increased scores 
(Kalodiki et al. 2012). 
1.1.3.1.6.	  Saphenous	  Treatment	  Score	  
A newly developed scoring system, the Saphenous Treatment Score (STS) (Lattimer 
et al. 2012) aims to bridge the gap currently found in venous scoring systems - 
response to treatment.  This would equate to the VCSS, with the CEAP and VSDS 
scores being less useful for disease change. 
 
The score is derived from duplex ultrasound data, with venous reflux and occlusion 
scored differently and a composite score providing information on disease 
progression in a dynamic fashion.  It scores and marks Above Knee (AK) and Below 
Knee (BK) segments separately and then adjusts the score depending on 
seriousness of the factor. 
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Table 1:  STS Scoring System 
GSV Status AK Score BK Score Total (=AK+ BK) 
Complete Occlusion without reflux 1 1  
Competency without occlusion or reflux 2 2  
Reflux irrespective of occlusion or 
competency 
3 3  
 
This initial score is then weighted according to the following algorithm 
Table 2:  STS Scoring Algorithm 
Explanation Weighting 
If 3 present = final score for segment 3 
If 1 present and no reflux precedent. 1 
If no reflux or obstruction = final score.  This 
is the normal "healthy score" 
2 
 
The score can be from 2-6.  Therefore the normal "healthy" score would be 4, a 
completely obliterated vein following treatment would be 2 and a vein with reflux 
both above and below the knee would be 6.  Whilst initially difficult to interpret, it 
is more user-friendly than the VSDS, and can equally be applied to the short 
saphenous vein. 
 
The STS is designed for ablative techniques, however it has also been modified to 
allow the use in CHIVA and other saphenous vein sparing treatments where return 
of competency is the treatment aim (Lattimer et al. 2012). 
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1.1.3.2.	  Symptom	  Scoring	  Systems	  
Symptom scoring systems are designed to quantify the subjective improvement of 
patients varicose vein symptoms.  They allow assessment of change due to disease 
progression and clinical intervention.  These scores also assess the impact of the 
disease on the patient with worsening scores indicating larger impact of the disease 
in question.  As has been found in other fields, the clinical or anatomical status of 
venous disease is often out of kilter from the patient's symptomatology (Bradbury et 
al. 2000; Bradbury et al. 1999; Guyatt et al. 1993; Guyatt et al. 1987; Guyatt et al. 
1985; Cook et al. 1993). 
 
These scoring systems can be generic and assess the patient as a whole, or they can 
be disease specific and are termed quality of life assessment (Guyatt et al. 1993). 
1.1.3.2.1.	  Generic	  Quality	  of	  Life	  Assessment	  
Quality of life (QOL) is the objective assessment of the level of health and wellbeing 
a person has at that point in time (Fayers & Machin 2007).  It has been extensively 
developed over the past thirty years to allow quantification of a singularly 
subjective thing (Watson & Preedy 2010; Romney & Evans 1996; Treurniet et al. 
1997; Dolan et al. 1996; Kind & Rosser 1988; Torrance 1986; Fairclough 2010).  The 
development and adjustment of the scales employed are driven by differing 
interpretations of quality of life using various differing models, such as functional, 
expectational, needs and satisfaction models in addition to the health status model 
(Fayers & Machin 2007).   
 
The overall aim of the assessment is to allow the persons state to be defined as a 
numerical value between 1.00 (perfect health) and 0.00 (death).  Negative values 
are allowed, as some levels of suffering are described as worth than death (Dolan 
1997; Dolan et al. 1996).  This allows comparison of the sampled group with the 
population as a whole. 
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Today's scales are a very different proposition compared to the Karnofsky 
Performance Scale in 1948 (Fayers & Machin 2007; Karnofsky et al. 1962), which 
offered a clinician a scale between 0 (dead) to 100 (alive).  This scale evolved into 
health profile measures such as the Sickness Impact Profile (Bergner et al. 1981) 
and the Nottingham Health Profile (Hunt et al. 1980; Hunt & McEwen 1980).  
Health profiles produce scores in differing domains, rather than an overall person 
score.  These domains vary with the profile used, but include can mental, physical 
and social aspects.  The Sickness Impact Profile (Bergner et al. 1981) assessed the 
affect of illness on the patient, but required 136 individual questions covering 12 
domains to do so.  The Nottingham Health Profile (Hunt et al. 1980) is a more 
holistic assessment with 38 questions in 6 domains including social isolation and 
emotional reaction (Fayers & Machin 2007). 
 
The next generation of scoring systems encompass the commonly used Medical 
Outcomes Study Short-Form Series (now owned by QualityMetric) and the EuroQol 
questionnaires (Ware & Sherbourne 1992; The EuroQoL Group 1990).  These 
questionnaires were designed to provide sensitive measurement tools but remain 
simple and short, encouraging completion (Fayers & Machin 2007). 
 
The Short-Form series includes the SF36, SF12, SF8, SF6, with each variation 
applying to the number of questions asked (Ware & Sherbourne 1992; McHorney et 
al. 1993; Mutebi et al. 2011; Hurst et al. 1998; Walters & Brazier 2005).  These 
questionnaires remain health profiles, with the SF-36 assessing 8 health domains, 
split between mental and physcial health.  Improvements in individual domains are 
shown, and summary values for physical and mental status are produced.  However 
conversion is required to give a single overall improvement figure (Brazier et al. 
1998). 
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The EuroQol EQ5D and EQ-VAS is a 5 domain 3 or 5 level scoring system with a 
companion, but independent visual analogue scale (The EuroQoL Group 1990; 
Brazier et al. 1993; Dolan 1997).  Systems of this nature are called "Utilities" and 
provide a single outcome score.  Improvements in QOL can be seen, but the area of 
improvement is often difficult to identify clearly.  The EuroQol  EQ5D was designed 
to be a simple summation tool for use with other tools (The EuroQoL Group 1990; 
Dolan 1997). 
 
Unlike the extensive Sickness Impact Profile, the modern generic scoring system 
provide a holistic measurement of QOL at the expense of relative insensitivity to 
changes in disease status (Guyatt et al. 1993).  Good correlation has been shown 
between the SF-36 and the EQ5D (Brazier et al. 1993). 
1.1.3.2.2.	  Disease	  Specific	  Quality	  of	  Life	  Assessment	  
Disease specific QOL investigates the effect of a disease on the patient.  The 
development of disease specific QOL measures allows comparison of different 
patients suffering from the disease.  The scores do not allow extrapolation to the 
general population, but does provide quantification of difficult symptomatology 
(Guyatt et al. 1993; Bradbury et al. 1999; Garratt et al. 1993). 
1.1.3.2.2.1.	  Aberdeen	  Varicose	  Vein	  Questionnaire	  (AVVQ)	  
The AVVQ is a 13-question patient completed survey addressing multiple elements 
of varicose vein disease, first developed in 1993 (Garratt et al. 1993).  It is designed 
for patient self-completion with a timescale of two weeks. 
Physical symptoms along with social issues, including pain, ankle oedema, ulcers, 
compression therapy use, and limitations on daily activities are examined, as well 
as the cosmetic effect of varicose veins. The questionnaire is scored from 0 (no effect) 
to 100 (severe effect), and utilises a drawn picture of where patients feel affected by 
their veins. 
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1.1.3.2.2.2.	  Venous	  Insufficiency	  Epidemiological	  and	  Economic	  Study	  Quality	  Of	  Life	  and	  
Symptom	  Severity	  Questionnaires	  (VEINES-­‐QOL/Sym)	  
The VEINES-QOL/Sym is a 26-question patient completed survey developed in 
2003, which addresses symptoms, daily life limitations, change in condition and 
psychological impact of the venous disease.  Responses are rated on 2-point to 7-
point response scales of intensity, frequency, or agreement.  The time frame for 
questions is the previous 4 weeks.  The raw scores are then translated into a 
standardized scale for comparison (Lamping et al. 2003). 
1.1.3.2.2.3.	  ChronIc	  Venous	  Insufficiency	  quality	  of	  life	  Questionnaire	  (CIVIQ)	  
The CIVIQ is a 20 or 14 question survey developed in 1996 and then refined in 2011 
(Launois et al. 1996), which again assesses patient reported symptoms and the 
impact of chronic venous disease on quality of life.  It has four principle domains 
and a maximum score of 100 with lower being a better quality of life. 
1.1.3.2.2.4.	  Homburg	  Varicose	  Vein	  Severity	  Score	  (HVVSS)	  
The Homburg Varicose Vein Severity Score (HVVSS) (Rass et al. 2011) is a recently 
designed venous disease questionnaire comprising of 4 patient completed symptom 
questions scored from 0-5, 2 clinician completed clinical staging questions scored 
from 0-5 and one haemodynamic benchmark requiring the use of 
photoplethysmography, scored from 0-3. 
 
This gives a total score of 0-33, which is then standardised to 100 (via dividing the 
score by 33 and multiplying by 100). 
1.1.3.2.2.5.	  Specific	  Quality	  of	  Life	  and	  Outcome	  Response	  –	  Venous	  (SQOR-­‐V)	  
The SQOR-V is a 45-item survey for patient completion, which assesses physical 
and psychosomatic symptoms providing a score out of 100 for each category.  Each 
item is scored from 1-5 and grouped into 1 of 5 sub-categories with normalization to 
a maximum score of 20 per sub-category.  As quality of life due to venous disease 
improves the score decreases (Guex et al. 2007; Guex et al. 2010). 
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1.1.3.2.2.6.	  Assessment	  of	  Burden	  in	  Chronic	  Venous	  Disease	  (ABC-­‐V)	  
Recently developed, this 39-point survey assesses the burden of venous disease as 
opposed as the specific quality of life due to venous disease.  It has a scale of 0 (best) 
– 90 (worst).  The tool is aimed primarily at population scale assessment (Guex et 
al. 2010). 
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1.1.4.	  Outcome	  Measures	  
Outcome measures provide the clinician with four major benefits: 
1. Assessment of the interventions value. 
2. Opportunity to refine patient treatment 
3. Ability to improve patient information and informed consent 
4. Clinical Governance. 
 
In venous treatment, outcome measures in venous treatment can be difficult - which 
should we use as our gold standard - technical success or patient improvement? 
 
 
Figure 4:  Outcome Measures and Assessment Techniques for Venous Disease 
As the above Figure 4 shows, there are many ways to assess venous treatments.  
Due to this it is difficult to assimilate the many trials performed due to 
heterogenous reporting (Thakur et al. 2010).  This is despite clear guidance given 
regarding reporting standards (Kundu et al. 2007) and the use of international vein 
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registries (American Venous ForumAmerican Venous Forum 2012; European 
Venous Forum et al. 2012). 
1.1.4.1.	  Vein	  Occlusion	  Rate	  
Vein occlusion rates are the standard classical tool for assessment of treatment 
success (Gohel & Davies 2008; Ulloa 2012; Parente & Rosenblatt 2003; Proebstle et 
al. 2004; Proebstle et al. 2006).  This does not equate to clinical success, as only 10% 
of the population in some studies have been shown to have no signs of venous 
reflux, however not all of these patients have venous disease that is symptomatic 
(Callam 1994; Rabe et al. 2003).  This is assessed with formal venous duplex 
ultrasonography with assessment of vein patency and reflux, as in initial diagnostic 
scans. 
 
Difficulties have arisen comparing occlusion rates, as different studies have 
reported different criteria for "occlusion" and "technical success".  Some classify 
success as complete occlusion, some as partially patent but no reflux and some as a 
short section of patent vessel with reflux (Rasmussen et al. 2010; Rasmussen et al. 
2013; Proebstle et al. 2008; Bisang et al. 2012).  This has led to the American 
Venous Forum and Society of Interventional Radiology publishing guidance on 
reporting standards.  This describes that technical success should be complete 
occlusion without reflux of blood (Kundu et al. 2007; Kundu et al. 2009).  It is yet to 
seen whether this has affected reporting standards with new trials. 
1.1.4.2.	  Recurrence	  Rate	  
The rate of recurrence has traditionally been the primary outcome for open 
stripping procedures especially prior to duplex ultrasound.  However, recurrence of 
varicosities does not depend on the failure of the primary procedure, as it may 
relate to progressive disease or alternative feeding vessels (Kostas et al. 2004; 
Allegra et al. 2007; Blomgren et al. 2004). 
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As the progression rate of venous disease is difficult to determine, utilising 
recurrence as an outcome measure may lead to conflicted reports (Davies & Lim 
2010). 
1.1.4.3.	  Ulcer	  Prevention	  
One of the major goals of venous treatment, ulcer prevention is an extremely 
difficult outcome measure, as progression is difficult to determine (Davies & Lim 
2010) and once ulcers have occurred the relative risk of relapse is far greater than 
the initial risk (Nelzén & Bergqvist 1991).  Finally the length of time that ulcers 
take to heal and recur can prevent adequate results due to duration of follow-up 
required (Gohel et al. 2007). 
 
Recent work by the Bonn Vein Study has assessed patients 6 years after initial 
review (Rabe et al. 2003; Rabe et al. 2010).  This showed an annual incidence of 2% 
for varicose veins and also 2% for chronic venous insufficiency.  Interestingly, and of 
great concern on an epidemiological scale, is the number of patients who progress 
from uncomplicated venous disease (CEAP C2 stage) to chronic venous insufficiency 
(CEAP C3-6 stages).  Over 6 years, 19.8% of those with non-saphenous vein C2 
disease progressed (3.3% per year) and 31.8% of those with saphenous vein C2 
disease progressed (5.3% per year).  With the current climate of rationing of 
treatment (Audit Commission 2011) this may have extreme consequences on future 
treatment. 
 
However, reduced recurrence and improved quality of life can be obtained with good 
treatment (Gohel et al. 2007; Gohel et al. 2005). 
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1.1.4.4.	  Health	  Status	  Assessment	  
Health status assessment is designed to allow decisions on an epidemiological scale 
- are treatments effective and are they beneficial to the patient?  It allows 
assessment beyond simplistic technical success rates to patient success rates. 
 
The driving force behind such assessments is the need to plan and provide 
appropriate care for all patients, and the difficulty in tallying this with the outputs 
of hospitals and care providers (Rosser & Watts 1972). 
1.1.4.4.1.	  Quality	  of	  Life	  
Quality of life (QOL) as described before is a key component of Health Status 
Assessment.  With the use of the various generic scoring systems (Guyatt et al. 
1993; The EuroQoL Group 1990), and if necessary utility conversion tools (Brazier 
et al. 1998; Ware 2000), a single summation score can be generated to provide a 
QOL measure. 
1.1.4.4.2.	  Quality	  Adjusted	  Life	  Year	  
QOL summation scores can be extrapolated into the QALY - the quality adjusted 
life year.  This is a value of disease burden and represents the quality and quantity 
of life lived, and is used to assess interventions from a cost-effectiveness viewpoint. 
 
This calculation is performed using a combination of QOL, life expectancy and 
standardised discount tables producing the value for a QALY (Sugden & Williams 
1978; Gudex 1986; Sassi 2006). 
1.1.4.4.3.	  Disability	  Adjusted	  Life	  Year	  
The Disability Adjusted Life Year or DALY is essentially the inverse of the QALY.  
It represents the life lost to living with a condition (Murray & Acharya 1997; 
Arnesen & Nord 1999; Anand & Hanson 1997; Sassi 2006) - the burden of the 
disease. 
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1.1.4.5.	  Economic	  Analysis	  
Once a quantification of the quality of life or disability level has been arrived at, the 
principles of health economic analysis (HEA) can be used to develop outcomes using 
probability models.  The generation of utility scores are required. 
 
This allows cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) to 
show whether treatment interventions are of benefit to the wider population 
(Torrance 1986; Sugden & Williams 1978; Gomes et al. 2010; O'Brien & Briggs 
2002; Barshes et al. 2012).  The aim of HEA is to provide the best treatment at the 
best price, but has been unfairly categorised as championing the cheapest 
treatment (Marsden & Wonderling 2013).  Through HEA more expensive 
treatments with good level improvements can be put forward instead of cheap 
treatments with minimal improvements (Marsden & Wonderling 2013). 
 
 
Figure 5:  A schematic describing costs and effectiveness for economic assessment. 
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1.1.4.5.1.	  Cost-­‐Effectiveness	  Analysis	  
Cost-effectiveness analysis (CEA) is defined as "a comparison of alternative 
interventions in which costs are measured in monetary units and outcomes are 
measured in non-monetary units, e.g. Reduced mortality or morbidity" (Facey 2006; 
Marsden & Wonderling 2013). 
 
It is a key factor in justifying treatment for a patient compared to the population. 
 
The principles include calculating the costs and effects of treatment A and the costs 
and effects of treatments B and/or C etc.  Then the differences in cost and effect are 
calculated.  Finally a cost per unit of effect is calculated (Gray et al. 2011).  Whilst 
this is of general interest, in a comparison of the differences, this is generally 
converted into an incremental cost-effectiveness ratio (ICER) - the difference in 
costs divided by the difference in effects. 
 
Whilst the definition of costs is self-explanatory, the definition of effect can vary 
with the treatment or intervention.  For standardisation, the QALY is commonly 
used to compare different conditions and treatments.  The outcome of ICER being 
£x per QALY is now a standard outcome, with NICE ascribing a ICER of £20, 000 
per QALY as appropriate (Gohel et al. 2010).  New NICE produced guidelines in 
2013 performed extensive cost-effectiveness analysis on multiple questions 
regarding the outcomes of varicose vein intervention.  This led to recommendations 
of endothermal ablation as a first line treatment over surgery, as it is more cost-
effective than open surgery {NationalInstituteforHealthandCareExcellence:2013vv}-
CITATION_IS_EMPTY. 
1.1.4.5.1.1.	  Cost-­‐Utility	  Analysis	  
This can be described as a sub-set of CEA as the process of creating QALYs uses 
utility theory and utilities to process the QOL values gathered.  The use of this 
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description is mainly to clearly differentiate a study as using generic measures of 
health outcome (Torrance 1976; Drummond et al. 2005; Gray et al. 2011). 
1.1.4.5.2.	  Cost-­‐Benefit	  Analysis	  
This defined by the International Network of Agencies for Health Technology 
Assessment (INAHTA) as: "A comparison of alternative interventions in which costs 
and outcomes are quantified in common monetary units" (Facey 2006). 
 
This is a key factor in assessing the economic benefit of a treatment to the 
population as a whole. 
 
Cost-Benefit Analysis (CBA) attempts to quantify the monetary value of the 
additional health benefits gained and then to assess whether this is more or less 
than the costs involved (Gray et al. 2011).  This in theory offers an ideal assessment 
model for health treatment decisions, however due to the difficulty in defining 
monetary values for human life both from a practical and moral viewpoint, CBA has 
not been utilised extensively in the medical literature (McIntosh et al. 2010). 
1.1.4.5.3.	  Alternative	  Methods	  
Other methods such as Cost-Consequence Analysis and Cost-Minimisation Analysis 
are available, but are uncommonly used. 
 
Cost-Consequence Analysis presents the data on costs and the data on outcomes 
separately, allowing the reader to interpret the information.  This can be complex 
data and therefore seldom presented in such a way (Gray et al. 2011). 
 
Cost-Minimization Analysis uses the assumption that all intervention outcomes are 
equal and therefore aims to reduce costs - the "race to the bottom".  This is seldom 
performed as the assumption of equivalence is difficult to prove and can lead to 
dangerous mis-leading results (Gray et al. 2011). 
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1.1.5.	  Consequences	  of	  varicose	  veins	  
Varicose veins cause a myriad of symptoms causing significant morbidity.  The 
condition also causes clinical problems. 
1.1.5.1.	  Symptoms	  
Symptoms of varicose veins can vary extensively but the vast majority of patients 
report tired heavy legs that ache, itch and can swell.  The lumpy varicosed veins can 
be quite painful and lead to avoidance of activity (Campbell et al. 2007; Bradbury et 
al. 1999). 
 
Varicose vein disease is complicated in that often the patient reported symptoms 
are not well correlated with the clinical severity of the disease (Conway et al. 2011), 
and the size of the incompetent vein is also not a good screening tool (Gibson et al. 
2012; Shepherd et al. 2011). 
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1.1.5.2.	  Superficial	  Thrombophlebitis	  
 
Figure 6:  Appearances of Superficial Thrombophlebitis 
Superficial venous thrombophlebitis or more correctly superficial venous thrombosis 
(SVT) is inflammation of a superficial vein in the context of thrombus in the vein. 
Superficial venous thrombophlebitis has previously been described as a benign self-
limiting condition, however it is becoming increasingly apparent that it has a 
significant association with deep venous thrombosis (DVT) and consequently 
pulmonary embolism (PE) (Decousus et al. 2011).  Up to 30% of patients presenting 
with a SVT has a concomitant DVT. 
The majority of SVTs have traditionally been treated with non-steroidal anti-
inflammatories (such as ibuprofen), however often it is mistaken for an infection 
and treated with antibiotics and rarely are compression hosiery prescribed. 
1.1.5.3.	  Deep	  Venous	  Thrombosis	  
Varicose veins have traditionally been described as benign and without significant 
morbidity outside of its own disease, however recent work by Heit et al. (Heit et al. 
2000) and as previously mentioned Decousus et al. (Decousus et al. 2011) has shown 
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that not only are varicose veins associated with deep venous thrombosis via 
superficial thrombophlebitis, but also that they are an independent risk factor, with 
an Odds Ratio of 4.19 at the age of 40 years.  This therefore translates into a 
significant burden of disease due to deep venous thrombosis and subsequent post-
thrombotic syndrome (Heit 2005; Prandoni & Kahn 2009). 
1.1.5.4.	  Skin	  Changes	  and	  Venous	  Ulceration	  
Uncomplicated chronic venous disease (CVD) can lead to chronic venous 
insufficiency (CVI), which via a multifactorial process revolving around increased 
venous hydrostatic pressure (Pollack et al. 1949; Pollack & Wood 1949; Browse & 
Burnand 1982; Ghauri & Nyamekye 2010; Bergqvist et al. 1999; Nelzén et al. 1994) 
lead to cell level changes and essentially a build-up in toxins and cellular by-
products that cannot be transported away from the distal dependent areas leading 
to tissue damage and ultimately tissue breakdown. 
 
This becomes clinically evident when venous skin changes appear (CEAP clinical 
class C4) - these progress from the early stages of venous eczema, through 
lipodermatosclerosis, to finally open ulceration.  Whilst venous eczema can be 
reversed with appropriate treatment, lipodermatosclerosis is irreversible.  It 
represents the deposition of fibrin on a microscopic level, which inhibits cellular 
transport and creates a vicious circle of degradation, which impairs many other 
signalling and transport pathways (Browse & Burnand 1982; Lim & Davies 2009). 
 
Venous ulceration is the end-point of the disease pathway and is a chronic 
debilitating wound that is extremely slow to heal without assistance.  Epithelial 
breakdown leads to an oozing, painful smelly wound which has a significant 
stigmatic and morbidity effect (Palfreyman et al. 2010).  Despite effective treatment 
with compression bandaging (Nelson 2010) the ulcers are slow to heal and relapse 
frequently.  Finally the rate of recurrence without invasive treatment is 35-56% 
(Marston et al. 1999; Ruckley 1997; Gohel et al. 2007).  Surgical treatment in the 
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context of elderly patients with venous ulceration showed a significant reduction in 
both ulcer recurrence at 3 years (56% to 31%, p<0.001) and a significant increase in 
ulcer free time (100 vs 85 weeks, p=0.007) (Gohel et al. 2007). 
 
Compression therapy has been the mainstay of treatment and is extremely 
expensive - estimated at costing 1% of the NHS total budget per year (Callam 1994; 
O'Donnell & Balk 2011).  The average cost of healing a venous ulcer in a formalised 
study protocol varies between $1327 for a 2.5 cm diameter ulcer (5 cm2) to $5289 for 
a 5 cm diameter ulcer (20 cm2) (Marston et al. 1999).  Although ulceration can be 
healed, the scarred skin (in addition to other co-existent skin damage such as 
atrophie blanche) is at high risk of recurrent ulceration (Magnusson et al. 2006). 
 
It is therefore vital to try and prevent venous ulceration - the aim of the current 
joint programme of the American Venous Forum and American College of Phebology 
is to reduce the rate of venous ulceration in the USA by 50% (O'Donnell & Balk 
2011).  A new trial investigating the role of endovenous technologies on ulcer 
healing is underway currently in the UK - the Early Venous Reflux Ablation 
(EVRA) trial (EVRA Trial Participants 2013). 
1.1.5.5.	  Progression	  of	  venous	  disease	  
Chronic venous disease and venous ulceration is a disease of the elderly (Heit et al. 
2001; Rabe et al. 2003; Criqui et al. 2003) however, venous ulcers do not just appear 
- they are the end point of the venous incompetence disease spectrum.  How and 
who progress remains difficult to quantify. 
 
Longitudinal studies in varicose vein disease are rare and technically challenging 
(Heit et al. 2001).  To fully encapsulate the disease screening programmes must be 
performed such as the San Valentino, San Diego or Bonn Vein studies (Rabe et al. 
2003; Cesarone et al. 2002; Kaplan et al. 2003; Criqui et al. 2003).  Prevalence rates 
in these studies vary from 7% (Cesarone et al. 2002) to 30% (Rabe et al. 2003; 
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Kaplan et al. 2003).  These studies included duplex ultrasound investigation and 
found a rate of reflux of 20% in the superficial system and 10% in the deep system 
(Rabe et al. 2003; Kaplan et al. 2003; Criqui et al. 2003) 
 
Recent studies have confirmed the prevalence rates in other populations such as 
Greece (15%) (Dimakakos et al. 2012), and Pakistan (34.8%) (Khan et al. 2012) 
though these studies were based on questionnaire and clinical assessment only.   
 
These studies have all provided point prevalence rates, however rates of progression 
and therefore indications of at risk populations is lacking.  This is likely due to the 
timescales involved and the highly mobile young population with the initial stages 
of venous disease.  CEAP Class C1 female patients (spider veins and telangiectasia) 
have been shown to have a reflux rate of 46% (Engelhorn et al. 2007) and 44% even 
if the leg is asymptomatic (Engelhorn et al. 2007). 
 
Another study from this Brazilian group has assessed 92 female patients with 
primary varicose veins with two duplex ultrasound scans 33 months apart 
(Engelhorn et al. 2012).  This showed an increase in SSV reflux from 24% to 30% 
(p<0.001) and a change from isolated segmental to multi-segmental GSV reflux.  
Additionally normal GSVs and SSVs developed segmental reflux in 25% and 11% 
respectively.  Overall the venous reflux progressed in 33% of GSVs and 13% of 
SSVs.  This would provide an annual progression rate of 11% for GSVs and 4% for 
SSVs. 
 
The Bonn Vein Study II (Rabe et al. 2010) has re-assessed 64.4% of the original 
Bonn Vein Study (Rabe et al. 2003) patients (n = 1978/3072) after 6.6 years.  The 
study found that 19.8% of C2 patients with non-saphenous disease progressed to 
higher CEAP classes and 31.8% with saphenous disease.  That produces a 
progression rate of 3% and 4.8% per annum. 
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The rate of progression coupled with the falling rate of intervention into varicose 
veins (Lim et al. 2010) provides sobering information for the elimination or even 
reduction of chronic venous disease and venous ulceration.  With constrained 
budgets and a lack of understanding from primary care physicians {Lane:2013eo}-
CITATION_IS_EMPTY and vascular specialists (Scurr et al. 2011), this will become 
a much more important issue in years to come. 
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1.1.6.	  Investigations	  
Due to their complex nature of varicose veins with low flow rates and advanced 
haemodynamics, a multitude of differing investigations are available to the clinician 
and researcher. 
 
Contrast venography of the lower limb venous system was originally the only 
investigation available but was invasive, required the use of iodinated contrast and 
x-ray imaging.  This necessarily limited its use in clinical practice, as did the 
difficulty in interpreting the ascending and descending venographic imaging in the 
superficial system(Gloviczki et al. 2011).  However it continues to be used for 
assessment and treatment of deep venous disease. 
 
Computed Tomographic Venography (CTV) and Magnetic Resonance Venography 
(MRV) are increasingly being used for assessment of central and deep venous 
abnormalities in conjunction with conventional contrast venography.  Venography 
itself - the previous gold standard - shows a reproducibility of 0.6 (Kalodiki et al. 
1998).  MRV is of special interest in the assessment of arterio-venous malformations 
(Gloviczki et al. 2011; Lee et al. 2007). 
1.1.6.1.	  Duplex	  Ultrasonography	  
The introduction of duplex ultrasound revolutionised the management and 
diagnosis of venous incompetence in the context of varicose veins (Gloviczki et al. 
2011).  Duplex ultrasound uses a combination of B-Mode ultrasound to give an 
anatomical two dimensional picture linked to colour doppler processing that 
superimposes pulsed wave ultrasound with Doppler signal processing onto the 
image and was developed between 1959 and 1974 with further improvements since 
(Satomura 1959; Strandness 1996; Jaffer & Aslam 2009). 
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Duplex ultrasound allows anatomical, haemodynamic and reflux details to be 
extracted at the same time during a non-invasive imaging method without the use 
of ionising radiation.  It remains the "gold standard" investigation for venous 
disease (Marston 2002; Gloviczki et al. 2011).  The clear images obtainable allow 
measurement of structures at variable depths from the skin's surface.  Colour 
duplex allows clear identification of individual veins that are refluxing or obstructed 
(Marston 2002; Szendro et al. 1986; Vasdekis et al. 1989). 
 
In the assessment of venous reflux an augmentation of standing venous flow by calf 
muscle compression is completed.  Once the compression is released, a normal 
reflux time (until the valves close) is defined as < 500 milliseconds (Sarin et al. 
1994; Marston 2002; P. Gloviczki & M. L. Gloviczki 2012; Vasdekis et al. 1989).  
This is then repeated for all veins and all vein segments creating a venous tree 
diagram of the limb.  This is a lengthy procedure even in the most skilled of hands, 
and requires multiple calf compressions with the patient standing still.  This can 
lead to non-completed scans and less than perfect information.  It has been 
estimated that the experienced vascular scientist will take 40 minutes to perform 
one venous duplex of a lower limb (Marston 2002).  In addition, ultrasound is a 
dynamic 'online' imaging modality requiring interpretation and completion skills 
that vary from person to person(Singh et al. 1998; Jaakkola et al. 1996) despite 
standardised training (The Society for Vascular Technology of Great Britain and 
Ireland 2012). 
 
However, to counter these difficulties, studies into the reproducibility of the 
measurements obtained have shown excellent accuracy with very low levels (<10%) 
of intra- and inter- observer variability (Asbeutah et al. 2005; Vasdekis et al. 1989).  
In addition compared with the previous "gold standard" diagnostic test - descending 
digital subtraction venography, duplex ultrasound was found to be far more 
sensitive - 77% vs 35-44% (Neglén & Raju 1992; Nicolaides 2000). 
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Venous duplex ultrasound also allows a quantification of venous reflux via the 
measurement of peak reflux velocity (PRV), peak reflux flow (PRF), reflux time 
(RT), time averaged flow (TAF), time averaged velocity (TAV) and vessel diameter 
(VD).  However, these values do not all correlate with the clinical scenario found in 
the patient - RT has been shown to poorly correlate with clinical and haemodynamic 
outcomes, but peak reflux velocity and flow have been shown to differentiate 
between clinical stages (Yamaki et al. 2002; Neglén et al. 2004).  Additionally these 
values have not been shown to indicate progression or classify limbs with any 
greater accuracy than the CEAP clinical staging system, and so are not of benefit 
outside of the research community. 
 
Advanced calculation techniques assessing the inflow and outflow of the limb have 
led to some researchers investigating an index called the venous arterial flow index 
(VAFI).  This assesses the flow in the common femoral artery (CFA) and the 
common femoral vein (CFV) in a supine patient.  An index of less than 1 indicates a 
normal competent venous system with figures above 1.2 indicating chronic venous 
disease (Kahle et al. 2002).  This index has also been shown to improve back to 
normal levels after treatment (Kahle et al. 2001; Rass et al. 2010; Kahle & Leng 
2004).  However, it remains a research tool at present with limited literature 
available and it is yet to be assessed compared to other measures such as clinical 
scoring systems such as the VCSS or patient reported outcome measures such as 
the AVVQ or EQ-5D. 
 
Recent studies have shown the presence of a saphenous vein pulsation due to 
conduction of arterial pressure waveforms through the venous tree, and that that 
the presence of the pulsation is associated with a worsened CEAP clinical stage 
(Hingorani et al. 2009; Lattimer et al. 2012).  The pulsation is found in 75% of 
patients with reflux, and reflux was present in 88.9% of those with a pulsation 
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(Lattimer et al. 2012).  These early studies have identified further complex 
haemodynamics detectable with duplex ultrasonography, and thus this remains a 
research tool at this stage. 
1.1.6.2.	  Ambulatory	  Venous	  Pressure	  
Ambulatory venous pressure represents the gold standard of invasive 
haemodynamic assessment (Nicolaides & Zukowski 1986; Marston 2002).  A 
cannula is placed in a pedal vein and connected to a pressure transducer.  This 
allows the measurement of a baseline standing pedal venous pressure, the mean 
ambulatory venous pressure (AVP) and venous refill time (RT).  AVP is measured 
as the steady state achieved after 10 tiptoe movements which empty the calf veins.  
RT is defined as the time for the pressure to return to 90% of baseline venous 
pressure. 
 
As is clear from the physics of hydrostatic pressure, the baseline measurement is 
not of importance and merely related to the column of blood above the cannulation 
site (I.e. The patient's height) (Nicolaides & Zukowski 1986). 
 
The AVP and RT allow a clear delineation of the whole venous system of the leg.  A 
normal value for AVP is 15-30 mmHg and as the AVP increases, the risk of skin 
changes, ulceration and increased CEAP grading increases (Nicolaides & Zukowski 
1986; Marston 2002).  In the worst cases, AVP actually increases with the exercise.  
This is seen in patients with both deep venous reflux and obstruction.  AVP 
therefore represents a quantifiable measure of venous claudication and can be as 
high as 110 mmHg (Nicolaides & Zukowski 1986).  RT should be longer than 18 
seconds in the normal limb, but may reduce down to 3 seconds in the worst deep 
venous reflux situations (Nicolaides & Zukowski 1986), as this indicates filling from 
reflux rather than capillary bed inflow. 
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These measurements are of great interest to the research community as they offer a 
way of validating offer non-invasive investigation methods, but are invasive and 
limited value in clinical practice except in the limited cases of venous claudication 
or deep venous reconstruction. 
1.1.6.3.	  Plethysmography	  
Plethysmography is the determination of changes in volume, and as such multiple 
different procedures have been developed. 
1.1.6.3.1.	  Air	  Plethysmography	  
Air plethysmography offers a further non-invasive test of venous reflux which 
allows quantification of reflux in difficult cases where venous duplex is inconclusive.  
However it can be difficult to perform and interpret (Gloviczki 2007). 
 
Air plethysmography utilises the concept of volume displacement during the reflux 
filling of varicose veins.  The patient is placed supine with the foot to be 
investigated elevated.  An air filled cylinder is placed around the lower leg, 
connected to a pressure transducer.  The air bag is filled to a baseline level air 
pressure to ensure good leg contact (6 mmHg) This is then calibrated by filling a 
smaller bag (placed in between the cylinder and leg) with 50 ml increments of body-
temperature water (Christopoulos et al. 1987; Lattimer et al. 2013; Lattimer et al. 
2012).  Then the calibration water is removed and a baseline recording is taken.  
The device is demonstrated in Figure 7. 
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Figure 7:  The air-plethysmograph consists of a poly-vinyl chloride (PVC) air chamber (5 litre 
capacity) connected to pressure transducer (P) and a smaller PVC bag (1 litre capacity) used for 
calibration by injecting known volumes of water (V).   Reproduced with Permission from 
Christopoulus et al (1987) 
 
The patient then stands and on plateauing of the volume a measurement is taken 
which represents the functional venous volume (VV).  The time taken to reach 90% 
of the VV is the venous filling time 90 (VFT90) with the venous filling index (VFI) 
representing 90% of the VV divided by the VFT90. 
 
The patient then performs a tiptoe manoeuvre to provide the ejected volume (EV) 
before then performing 10 tiptoe manoeuvres to produce a the residual volume (RV).  
This allows calculation of the ejection fraction (EF) and residual volume fraction 
(RVF).  The procedure is demonstrated in Figure 8. 
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Figure 8:  Diagrammatic representation of typical recording of volume changes during standard 
sequence of posmral changes and exercise. Patient in supine position with leg elevated 45 degrees 
(a); patient standing with weight on nonexamined leg (b); single tiptoe movement (c); ten tiptoe 
movements (d); same as in (b)/(e). VV = functional venous volume; VFT = venous filling time; VFI 
=venous filling index; EV = ejected volume; RV = residual volume; El: = ejection fraction; RVF = 
residual volume fraction.  Reproduced with Permission from Christopoulus et al (1987) 
Finally, the air plethysmograph is removed and the leg immersed in water with 
volume displacement measurements being take at the ankle and at the top of where 
the air cylinder was - this represents the volume of leg inside the cylinder that 
corresponds to previous measurements (Christopoulos et al. 1987; Christopoulos et 
al. 1988). 
 
As can be seen from the above methodology this is a complex and lengthy process, 
but does provide excellent haemodynamic information, with an 80% sensitivity and 
99% positive predictive value for abnormal reflux (Marston 2002; Criado et al. 
1998).  A VFI of <2ml/s is considered normal, with increasing VFI results 
correlating with increased severity of clinical disease (Marston 2002; Lattimer et al. 
2012; Lattimer et al. 2013).  A normal VFT 90 is >70 seconds, and RVF 20% 
(Christopoulos et al. 1987). 
Again, after interventional treatment these parameters return to normal and the 
return of VFI has been shown to be predictive of good clinical outcome (Owens et al. 
2000; Ibegbuna et al. 2003). 
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However, the reproducibility of air plethysmography is controversial, with 
coefficients of variation ranging from 7.5% to 27%.  With repeated measures (3 or 
more) a variability of 10% or less can be obtained (Yang et al. 1997; Asbeutah et al. 
2005). 
 
In view of the length of time taken for each assessment (approx 15-20 minutes 
(Marston 2002)) this is a tool best used for research and venous disease 
quantification, especially as venous duplex ultrasound is required for anatomical 
data in all cases (Gloviczki et al. 2011). 
1.1.6.3.2.	  Strain	  Gauge	  Plethysmography	  
Strain gauge plethysmography utilises the same principle as air plethysmography 
but instead of a pressure transducer connected to the air chamber, it has air 
chambers connected to strain gauges which provide a change in electrical resistance 
in response to a change in leg diameter and therefore strain gauge length (Brakkee 
& Vendrik 1966; Persson et al. 2009; Rosfors & Blomgren 2013). 
 
An occlusive (60mmHg) cuff is placed around the the thighs of a supine patient with 
strain gauge wires around the largest part of the calf.  When the leg has been filled 
to a maximum volume the cuff is released and blood is allowed out of the limb 
(Rosfors & Blomgren 2013).  An alternative dynamic method is to measure before, 
during and after 15 knee bends (Persson et al. 2009). 
 
The observed volume curves (see Figure 9) are obtained and allow the calculation of 
the Outflow Fraction at 1 second (OF1) and at 4 seconds (OF4).   
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Figure 9:  Strain Gauge Plethysmography Curve.  OF1 = Outflow Fraction at 1 second, OF4 = 
Outflow Fraction at 4 seconds, OV1 = Outflow Volume at 1 second, OV4 = Outflow Volume at 4 
seconds, V = Volume. 
 
Normal has been quantified as OF1 of 0.2 and OF4 of 0.62 with reduced values 
indicating outflow obstruction (Persson et al. 2009; Rosfors & Blomgren 2013).  
Reproducibility variation has been shown to be within 6% (Rosfors & Blomgren 
2013). 
 
Strain gauge plethysmography is utilised mainly in the assessment of venous 
obstruction and remains a research tool due to the complexity of application and the 
need for an occlusive cuff. 
1.1.6.3.3.	  Photophlethysmography	  
Photophlethysmography (PPG) utilises a light emitting diode to transmit infrared 
light into the dermis which is then backscattered to a receiver, and this varies with 
capillary blood flow (Abramowitz et al. 1979; Nicolaides & Miles 1987; Marston 
2002).  The time taken for the capillaries to refill is an indication of the arterial 
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inflow and the venous outflow (Sam et al. 2006), and is defined as the venous refill 
time (VRT). 
 
The PPG probe is attached 10cm above the medial malleolus and then baseline 
measurements are taken with the patient standing motionless.  After 10 tiptoe 
manoeuvres further measurements are taken with the patient motionless, with 
automatic calculation of the VRT curve (Sam et al. 2006). 
 
The VRT has been shown to be shortened in patients with venous disease and 
decreases with CEAP stage (Marston 2002; Darvall et al. 2010).  Some studies have 
defined a normal VRT as >18-20 seconds (Nicolaides & Miles 1987; Darvall et al. 
2010), however this is not a standardised measure and dependant on local protocols 
(Marston 2002).  Following treatment VRT normalises in patients who have 
symptom resolution (Darvall et al. 2010), and those with normal VRT but symptoms 
do not have symptomatic resolution after treatment (Darvall et al. 2010).  
Additionally there is no correlation between improvement in VRT and QOL 
(Shepherd et al. 2011).  However, wide ranges of AVP have been demonstrated for 
similar VRTs (Nicolaides & Miles 1987) and indeed for C3-C6 clinical stages 
(Darvall et al. 2010), and its use for fine measurement is debatable. 
 
The utility of PPG is limited as it does not offer quantifiable haemodynamic data 
but does provide a screening test for symptomatic chronic venous insufficiency.  
Venous duplex ultrasound is still required for anatomical detail. 
1.1.6.4.	  Cross	  Sectional	  Imaging	  
Computed tomographic venography (CTV) and Magnetic Resonance Venography 
(MRV) are axial imaging techniques that provide intra- and extra-luminal 
information on the anatomical basis of the venous tree.  These techniques require 
dedicated protocols for timing of contrast and imaging and can be difficult to 
interpret (Min et al. 2010).  They offer excellent anatomical data but no 
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haemodynamic data and little intra-luminal data (Marston et al. 2011).  The use of 
such cross-sectional imaging is limited to the investigation of deep venous system, 
which may be the driving force in 10-15% of cases (Arnoldussen et al. 2013). 
1.1.6.4.1.	  Computed	  Tomography	  Venography	  
CTV allows the assessment of the central venous system, which is becoming more 
important with the recognition that iliac vein stenoses and inferior vena cava 
abnormalities account for a proportion of patients with distal disease and normal 
leg veins (Smith et al. 2011; Iqbal & Nagaraju 2008). 
 
The concept of stenting the iliac vein abnormalities including deep vein thromboses 
leading to incompetent but low resistance vessels has emerged with the use of 
duplex and intravascular ultrasound providing extensive data sets.  Raju and 
Neglen have revolutionised the principles of deep venous intervention (Neglén & 
Raju 1992; Neglén & Raju 1993; Neglén & Raju 2000; Raju 2013; Raju et al. 2006; 
Raju et al. 2012; Raju et al. 2002).  This has gradually become more accepted 
worldwide, with further studies confirming initial findings (Rosales et al. 2010; 
DeRubertis et al. 2013; Delis et al. 2007). 
1.1.6.4.2.	  Magnetic	  Resonance	  Venography	  
Magnetic resonance imaging and magnetic resonance venography (MRV) has 
advanced in recent years with advances in imaging and computing power 
(Fitzgerald et al. 2006; Wadajkar et al. 2013; Priest et al. 2012; Arnoldussen et al. 
2012; Glockner & Lee 2010).  Now with the potential to provide dynamic flow 
images, MRV has become the research tool of choice for deep venous disease.  It's 
use in the treatment of superficial venous disease is limited to investigating for the 
presence of proximal stenoses or occlusions, and for planning of deep venous 
intervention (Fitzgerald et al. 2006).  This is due to cost, patient acceptability, 
access to scan time and the complexity of scanning protocols. 
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1.1.6.5.	  Intravascular	  Ultrasound	  
Intravascular ultrasound (IVUS) is an invasive test that utilises a 360 degree 
ultrasound probe inserted into the vein of interest.  This provides a multi-planar 
dynamic assessment of vein segment, with simultaneous digital subtraction 
venography (Neglén et al. 2007; Raju et al. 2010).  This has been popularised by 
Raju and Neglen with placement of venous stents for demonstrable lesions seen on 
venography and IVUS (Raju et al. 2002). 
 
Initial work performed by the same authors discovered additional findings with 
IVUS - intraluminal and mural details that are not possible to see with the so-called 
"lumen-o-gram" of venography (Neglén & Raju 2002).  The diameter and affected 
cross-sectional areas of the veins can be analysed and calculated and this can allow 
careful monitoring of the grades of stenosis and outcomes of venoplasty and venous 
stent placement (Neglén & Raju 2000). 
1.1.6.6.	  Digital	  Subtraction	  Venography	  
Digital subtraction venography allows the visualisation of flow using an invasive 
test.  Use of ascending and descending venograms allow the visualisation of 
obstruction (ascending) and reflux (descending) pathologies.  It also allows 
intervention in the form of stenting and venoplasty.  It is reserved for deep venous 
investigation. 
 
The use of venography has recently expanded due to the increased knowledge of 
iliac vein compromise and the beneficial effects of stenting without reflux correction 
(Raju 2013).  However it suffers from a lack of sensitivity in single planes, with the 
complex nature of haemodynamics and stenoses, additionally the inter-observer 
agreement (kappa) is only 0.7 (Kalodiki et al. 1998; Phillips et al. 1995; Neglén & 
Raju 1992).  Therefore, multi-planar imaging is needed to identify stenoses. 
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However, the ability to perform interventions and to provide detailed planning for 
deep venous bypass procedures means that venography remains in the phlebologists 
armoury (Khanna & Singh 2012). 
 
 
Figure 10:  An image from the a digital subtraction venography procedure showing extensive deep 
venous disease and collateralisation 
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1.1.7.	  Current	  Treatment	  Methods	  of	  Superficial	  Venous	  Disease	  
The treatment of superficial venous disease had been standard for hundreds of 
years  until the recent development of sclerotherapy in the mid 20th century and 
then ultrasound guided endovenous ablation (Perrin 2011).  Prior to this the 
treatment available was open surgery using segmental avulsion or sapheno-femoral 
junction ligation and stripping of the long saphenous vein (Mayo 1904; Babcock 
1907; Dodd 1955). 
 
These recent advances have greatly changed the patient experience, the logistics of 
intervention and have provided the opportunity for ambulatory treatment. 
Treatment has previously been assessed by merely technical means – occlusion and 
recurrence rates, however patient preference and quality of life assessments are 
also vital components of treatment analysis. Quality of life assessment pre and post 
intervention allows a vital stratification of treatment methods (Gohel & Davies 
2008). 
 
Due to the lack of a perfect 'one-size-fits-all' solution to superficial venous disease 
many treatments are available (Lane et al. 2011).  This can make it extremely 
difficult for the clinician to make a fully informed choice between modalities let 
alone between equipment. With the huge patient population optimum treatment 
can lead to vast improvements in both individual and population health and well-
being, in excess of that offered by optimal treatment of arterial disease (Rasmussen 
et al. 2011; Gohel et al. 2010; Carradice et al. 2011; Chard et al. 2011).  Despite 
these beneficial outcomes total procedure numbers are falling in the UK – see 
Figure 11 (Lim et al. 2010).  In 2011-2012, the total number of procedures 
performed had fallen further to 27, 605, a further fall of 26% {HESOnline:2013uk}-
CITATION_IS_EMPTY.  New guidance from NICE has recently been published 
advocating treatment for symptomatic varicose veins (Marsden et al. 2013). 
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Figure 11:  Total number of varicose vein procedures performed in NHS England from 2002-2006, 
reproduced from Lim et al (Lim et al. 2010). 
1.1.7.1.	  Compression	  Hosiery	  and	  Bandaging	  
Compression therapy using either graduated elastic hosiery or compressive 
bandaging has become the standard conservative treatment for patients with 
uncomplicated varicose vein disease. It has also become a screening method for 
patients with nonspecific symptoms, with a trial of compression hosiery allowing 
symptom improvement assessment and risk stratification for treatment. Such 
stratification is becoming especially important in the current age of austerity. 
The evidence base for compressive hosiery is sparse, and a recent systematic review 
(Palfreyman & Michaels 2009) showed a heterogeneous evidence base with 
stockings were shown to improve symptoms, but not to effect progression or 
recurrence of varicose veins (Carpentier et al. 2011). 
 
Compressive hosiery is not without its own morbidity, leading to poor compliance 
(Raju et al. 2007). This led over half of those patients randomised to conservative 
treatment in the large REACTIV randomised controlled trial to chose to withdraw 
and undergo surgery within 3 years (Michaels et al. 2006).  Additionally only 
patients with adequate arterial systems are eligible for treatment (Mosti et al. 
2012). 
 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
77 
Unsurprisingly therefore, in the recent publication of guidance from the UK's 
National Institute for Clinical Excellence (NICE) it was recommended that 
compression hosiery should not be offered as standalone treatment, unless patients 
are not suitable for intervention (Marsden et al. 2013). 
 
Compression bandaging is effective but expensive and time consuming.  It is 
therefore reserved for the management of venous ulceration (O'Meara et al. 2012).  
The technique involves the wrapping of layers of bandage around the leg to invoke 
increased pressure and improve venous flow.  The bandage is routinely changed 
once or twice a week, and prevents the patient from bathing fully (Moffatt 2006).  A 
randomised clinical trial has shown that four layer bandaging offers the optimum 
bandaging technique (Moffatt et al. 2003).  After completion of ulcer healing, 
compression hosiery is recommended for life to try and prevent recurrent ulceration 
of the damaged skin (O'Meara et al. 2012). 
 
Interestingly, in a study of 129 patients who have had an ulcer healed by 
compression bandaging and for whom lifelong compression hosiery is advocated, 
only 52% wore them everyday and 16% on most days.  The two key factors 
associated with non-compliance were that patients felt stockings were 
uncomfortable or unnecessary (Jull et al. 2004). 
 
Surgical intervention has been shown to provide significant quality of life 
improvement for minimal additional healthcare cost when compared to conservative 
management (Ratcliffe et al. 2006). 
 
Compression therapy is advocated after intervention, aiming to reduce post-
operative pain, haematoma and oedema (Huang et al. 2013).  Duration and type of 
compression are controversial with limited data available (Huang et al. 2013).  
Huang et al.'s recent meta-analysis on compression after open surgery indicates 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
78 
that short-term duration of 1 week post-operatively is optimal, as recommended by 
NICE (Huang et al. 2013; Marsden et al. 2013). 
 
In a recent cost effectiveness study, conservative management was considered to 
have a cost of zero for comparison with intervention (Gohel et al. 2010). However 
this does not take into account the significant expenditure in time and materials 
associated with symptomatic venous disease requiring compression hosiery or 
bandaging.  Intervention was found to be cost-effective even though conservative 
management was free.  Ulcer disease increases the cost of chronic venous 
insufficiency enormously (Marston et al. 1999). The benefits of intervention to 
prevent such complications are clear, with 2 million working days lost to venous 
disease in 2002 (Rabe & Pannier 2010). 
1.1.7.2.	  Neuromuscular	  Stimulation	  
Neuromuscular stimulation is a new modification of an old technique, which utilises 
electrical signals transmitted through the skin to either stimulate the calf muscle 
bulk or the peroneal nerve to elicit a muscular jerk and pump blood out of the leg. 
Research is on-going, but these devices may provide a treatment option for patients 
unable to be treated with compression and unsuitable for venous intervention 
(Tucker et al. 2010). 
1.1.7.3.	  Intermittent	  Pneumatic	  Compression	  
Intermittent pneumatic compression utilises an inflatable sheath (or boot) which is 
placed around the lower limb.  This is connected to an air pump which inflates 
bladders in the sheath to produce extrinsic pressure and hence force fluid out of the 
blood.  This increases lymphatic and venous return and arterial inflow (Delis, 
Slimani, et al. 2000b; Delis, Labropoulos, et al. 2000a; Harfouche et al. 2005; 
Sheldon et al. 2012; Patterson & Cardullo 2013).   
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Figure 12:  Schematic of the IPC device 
These devices are effective, however they do require the patient to be stationary and 
can be disturbing due to the recurrent inflation/deflations.  The devices are also 
expensive at £800 for the pump and £80 per pair of sheaths. 
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1.1.7.4.	  Open	  Surgery	  
Open surgery has been the surgeons primary armament, and until recent advances 
in endovenous therapy, surgical intervention was the main treatment option 
available. 
 
Figure 13:  Representation of the Sapheno-Femoral Junction reproduced from Gray's Anatomy 
(Gray & Lewis 1918) 
1.1.7.4.1.	  Saphenofemoral	  Junction	  Ligation	  and	  Great	  Saphenous	  Vein	  Stripping	  
Saphenofemoral Junction ligation and stripping of the great saphenous vein 
remains the commonest standard treatment, with extensive experience allowing for 
high quality results including outpatient clinic and local anaesthetic treatment 
(Rasmussen et al. 2011; Disselhoff et al. 2011; Menyhei et al. 2008; Perrin 2011). 
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Figure 14:  SaphenoFemoral Junction Dissection (a), Ligation (b), Great Saphenous Vein Stripping 
(c), and Multiple Stab Phlebectomies (d). 
Traditional surgery requires open dissection of the groin, identification of the 
saphenofemoral junction (SJF) and ligation of the junction and major tributaries (a 
"high-tie" or "crossectomy".  The great saphenous vein (GSV) can be left in situ or 
"stripped" using a mechanical device or a cryoablation probe (described in more 
detail below) (Menyhei et al. 2008).  Long-term trials have shown a significantly 
reduced reoperation rate with stripping of the GSV in addition to SFJ ligation, 
though not recurrent visible varicosities (Jones et al. 1996; Dwerryhouse et al. 1999; 
Winterborn et al. 2004). 
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Figure 15:  Detail of SFJ Dissection {Scheltinga:ux}-CITATION_IS_EMPTY. 
 
Figure 16:  Detail of Application of PIN stripper at the proximal aspect of the GSV {Scheltinga:ux}-
CITATION_IS_EMPTY. 
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Figure 17:  Detail of the removed GSV {Scheltinga:ux}-CITATION_IS_EMPTY. 
Different stripping devices such as 'Perforate Invagination' (PIN) strippers have 
been shown to have equivalent outcomes to standard stripping devices (Durkin et 
al. 1999). 
 
Varicosed branch veins are then "avulsed" or "phlebectomised" using standard stab 
incisions and hooking out the vein (Ramelet 2002; Bull & Hiatt 1948). 
 
Ligation and stripping removes the source of reflux, however requires a significant 
procedure, and can lead to severe post-operative morbidity (Rasmussen et al. 2011).  
Saphenous nerve lesions are found in approximately 5-15% of cases, though some 
series have found a rate of 39% if the below knee segment is stripped (Flu et al. 
2008; Holme et al. 1990; Kostas et al. 2007). 
 
Recurrence post treatment is relatively common (van Rij et al. 2003), up to 45% at 
10 years (Nelzén & Fransson 2013), and predominantly due to either strip-track 
recurrence or groin neovascularisation (Munasinghe et al. 2007; Egan et al. 2006; 
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Carradice et al. 2011; van Rij et al. 2003).  Additionally due to anatomical variation, 
careful dissection may still miss important tributaries (Vaz et al. 2013; van Rij et al. 
2003). 
 
It remains the most common procedure available (Shepherd et al. 2010) to most UK 
clinicians.  This is due to the relatively low costs of equipment and the procedure 
(£980 in the UK (Gohel et al. 2010)).  The most performance recent data available - 
2011-2012; from the Hospital Episode Statistics show that of a total of 27,605 
procedures 40% of treatment was open surgery (11,120), 36% was endovenous 
ablation (9,826) and 16% foam sclerotherapy (4,502) {HESOnline:2013uk}-
CITATION_IS_EMPTY.  This must be compared to 2006 when 31,642 open 
procedures were performed (Lim et al. 2010) - a 65% reduction in numbers 
performed. 
 
The open procedure has extensive patient reported outcome measure data which 
allows robust conclusions to be drawn that it remains a suitable and appropriate 
treatment if endovenous treatment is unavailable (Gohel et al. 2010; Lim et al. 
2010; Marsden et al. 2013).  A demonstration of this is seen in Figure 18 - the 
proportion of patients treated with open stripping has fallen significantly, however 
the combined outcome scores have only risen marginally. 
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Figure 18:  Combined Patient Reported Outcomes for Varicose Vein Surgery 2009-2012 
{HESOnline:2013uk}-CITATION_IS_EMPTY. 
Indeed recent long term studies have shown good outcomes for open procedures 
which are equivalent to endovenous procedures (Rasmussen, Lawaetz, Bjoern, et al. 
2013a; Rasmussen, Lawaetz, Serup, et al. 2013b).  Patient satisfaction remains high 
even at ten years (Nelzén & Fransson 2013).  In this ten year study of 104 mixed 
primary and recurrent legs, 85% of patients were satisfied with the outcome, 
despite a duplex ultrasound proven recurrence rate of 45%.  Interestingly, there was 
no correlation between ultrasound detected recurrence and symptomatology - 65% 
of those with recurrence reported no symptoms, and 63% described an excellent 
cosmetic result at 2 years and 10 years (Nelzén & Fransson 2013). 
1.1.7.4.2.	  Varicosity	  Avulsion	  -­‐	  Ambulatory	  Selective	  Varices	  Ablation	  under	  Local	  anaesthetic	  
(ASVAL)	  
The Ambulatory Selective Varices Ablation under Local anaesthesia or ASVAL 
technique utilises standard stab avulsion technique to remove all visible varicosities 
(Pittaluga et al. 2009; Pittaluga et al. 2010).  This corrects all visible signs of 
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varicose vein disease, which leads to a substantial improvement in certain areas of 
symptom scores however it does not necessarily remove the source of reflux, though 
in one study (Pittaluga et al. 2010) it has reversed reflux in the truncal vein. 
 
The abolition of the venous reservoir is purported to be the mechanism via which 
symptoms improve, as without a low resistance tank to fill, the venous blood 
returns to the heart via normal routes. 
1.1.7.4.3.	  Haemodynamic	  Normalisation	  -­‐	  Conservatrice	  et	  Haemodynamique	  de	  l'insuffisance	  
Veinuse	  en	  Ambulatoire	  (CHIVA)	  
Haemodynamic normalisation or Conservatrice et Haemodynamique de 
l'insuffisance Veinuse en Ambulatoire (CHIVA) is a technique where the truncal 
veins are preserved but incompetence is tracked and interrupted throughout the 
leg.  The preservation of GSV allows for it to be used as bypass graft conduit in the 
future.  The flow of blood is tracked carefully with ultrasound to elucidate flow loops 
and abnormal "shunts".  These shunts are classified according to location, and 
direction and then ligated under local anaesthetic  to provide appropriate flow from 
superficial to deep systems (Mowatt-Larssen & Shortell 2010; Franceschi 1992; 
Mendoza 2002).  Six different shunt types have been described, with multiple sub-
types.  These describe the anatomical and pathological spread of the incompetence 
seen in most cases (Mendoza 2002). 
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Figure 19:  A representation of shunts described by the CHIVA methodology.  Reproduced with 
permission from Mendoza 2002 (Mendoza 2002). 
 
This procedure leads to good results overall, however the procedures can be 
intellectually and technically challenging with few centres able to reproduce results 
(Mowatt-Larssen & Shortell 2010; Maeso et al. 2001; Carandina et al. 2008; Parés 
et al. 2010). In those centres, the results compete with the best outcomes of other 
techniques - recurrence rates of 18% at ten years compared to 35% for stripping in 
the same centre (Carandina et al. 2008). 
 
Additionally, expert ultrasonography in the presence of the treating physician is 
required to identify the flow loops and to provide information on the appropriate 
haemodynamic reconstruction. 
The process of CHIVA involves multiple steps and these are named "CHIVA 1" and 
"CHIVA 2", and have more than one step in their completion (Mowatt-Larssen 
2010). 
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Figure 20:  Part of the CHIVA Technique. HCP = Hydrostatic pressure column.  Reproduced from 
Pares et al. 2010 (Parés et al. 2010) 
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1.1.7.5.	  Endovenous	  Ablation	  
The principles of endovenous ablation are the same – minimally invasive 
destruction of the incompetent veins using either thermal energy or sclerosant and 
mechanical disruption. This leads to fibrosis of the vein wall and ablation of vessel 
lumen, thus removing the incompetent vein from the circulation. The advantages of 
endovenous treatment are faster procedure times, reduced post- operative pain, 
optional general anaesthesia, patient preference and the possibility of truly 
ambulant treatment. The various endovenous methods are detailed below. The 
qualities of endovenous treatment have been reviewed in depth with a meta-
analysis of 64 studies, covering over 12, 000 treated limbs, with a mean 2.5 year 
follow-up period in 2009 {VanDenBos:2009dy}-CITATION_IS_EMPTY and again in 
2012, with 5 year follow-up data (Siribumrungwong et al. 2012). 
 
Whilst such analyses are hindered by non-standardised reporting (Thakur et al. 
2010), it has produced significant positive data for endovenous treatment. 
Endovenous procedures have been shown to be at least equivalent to open surgery 
for technical success (Xenos et al. 2009). Coupled with ease of use and patient 
acceptability, this has led to a huge, increasing practice and success of the 
procedure. 
 
 
Figure 21:  Endovenous Modalities 
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These new modalities also offer concurrent treatment of reflux for patients with 
venous ulceration providing reduced recurrence and relapse rates.  The use of these 
techniques may also offer improved healing rates, however there is currently no 
significant evidence backing this hypothesis. 
 
All techniques are based on the passage of the treatment catheter inside the vein 
from an ultrasound guided needle puncture in the caudal aspect of the vein.  
Standard Seldinger technique {Seldinger:1953tk}-CITATION_IS_EMPTY under 
ultrasound guidance is used to gain access to the vein as shown by the schematic 
Figure 22. 
 
Figure 22:  Seldinger Technique for Endovenous Ablation 
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1.1.7.6.	  Endovenous	  Thermal	  Ablation	  
 
Figure 23:  Tumescent Anaesthesia under Ultrasound 
Recent work by NICE has recommended that endothermal ablation should be the 
first line treatment on outcomes of cost-effectiveness analysis.  It offers lower cost 
treatment with improved outcomes (National Institute for Health and Care 
Excellence 2013). 
1.1.7.6.1.	  Cryoablation	  
Cryoablation is a hybrid of open and endovenous techniques, utilising an open groin 
dissection and ligation of the SFJ with tributary ligation before feeding of a 
cryoprobe down the GSV to the knee.  Using either liquid nitrogen dioxide or carbon 
dioxide fed to the cryoprobe tip cools the tip to -85°C.  The cryoprobe is then 
removed, stripping the vein by cryoadhesion (Breuninger 2001).  Whilst it has not 
been widely adopted, studies have shown equivalent results compared to standard 
stripping techniques in terms of pain, return to normal activities and recurrence 
rates (Stotter et al. 2006).  Disselhoff et al have shown equivalence between EVLA 
and cryostripping at 5 years with respect to recurrence and neovascularisation (62% 
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versus 51% p=0.264) and quality of life measures (reduction of AVVQ of 66% versus 
and 72% p=0.72, and reduction of VCSS of 69% versus 71%, p=0.23) (Disselhoff et 
al. 2011). 
1.1.7.6.2.	  Endovenous	  Laser	  Ablation	  (EVLA)	  
This technique utilises a diode laser of varying wavelength transmitted via a glass 
optic fibre to the area of interest.  Laser ablation has been used in certain arterial 
cases since the 1980's with limited uptake, and remains a niche procedure (Wissgott 
et al. 2004; Wissgott et al. 2013; Todd et al. 2013).  The laser ablation provides 
removal of atherosclerotic plaque lesions present in occluded arteries.  This 
technique initially used a bare optical fibre, but due to significant rates of vessel 
perforation a jacketed tip was developed (Welch et al. 1987; Ashley et al. 1990).  
However, even in the jacketed tips the temperatures in blood reach 700 ∘C 
(Verdaasdonk et al. 1991).  The basic principles of arterial laser atherectomy have 
been modified for use in the venous system.  Access sheaths must accomodate 600 
nm fibres, and are generally 4-5 French in size (1.35-1.67 mm). 
 
The technique of endovenous laser ablation (EVLA) has advanced greatly since its 
description in Spanish by Boné in 1999 (Boné 1999) and then in English in 2001 by 
Navarro et al (Navarro et al. 2001).  These studies described local anaesthetic (with 
and without sedation) treatment of incompetent truncal veins using an 805 nm and 
810 nm diode laser. 
 
Following Food and Drug Administration approval, the technique has grown 
enormously. The major drawback of laser technology is the requirement for a 
specially shielded; secure treatment room and the requirement for laser goggles for 
all in that room.  In addition, all practitioners must be fully accredited in the safe 
application of the laser device. 
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The advancement of technology has lead to a proliferation of different laser 
wavelengths, with the wavelengths offering different treatment profiles. The wave-
lengths used for venous treatment were initially based on the absorptive properties 
of deoxygenated haemoglobin - venous blood (Friebel et al. 2006).  Subsequently, 
however, longer wavelengths have been investigated, as these are absorbed by 
water in the vein wall cells.  In theory this should be a more effective and direct 
method of treatment and reduce the energy requirement for fibrosis (Almeida et al. 
2009).  This has led to many different wavelengths being available for use, with 810, 
940, 980, 1064, 1320, 1470 and 1540nm lasers available, with 2100nm in the 
prototype phase (Ash & Moore 2010; Massaki et al. 2013).  Longer wavelength 
lasers have been shown in some studies produce a better post-operative 
complication profile, with reduced pain being the major benefit  (Kabnick 2006; 
Proebstle et al. 2005; Doganci & Demirkilic 2010; Sadek et al. 2011). 
 
Technical success is highly dependent on energy delivered by unit length (J/cm) 
with the target for occlusion being > 70 J/cm, but no ill effects of increased energy 
delivery are seen until 160 J/cm (Carradice et al. 2010; Proebstle et al. 2002). 
 
A meta-analysis in 2009 found that EVLA showed significantly better technical 
success characteristics, compared to open surgery, sclerotherapy and radiofrequency 
ablation {VanDenBos:2009dy}-CITATION_IS_EMPTY.  However the analysis did 
produce a surprising improvement in occlusion rates over successive years despite 
no further intervention, which is difficult to explain.  A more recent meta-analysis 
including modern devices shows no significant difference in occlusion rates 
(Siribumrungwong et al. 2012). 
 
However, the exact mechanism of action of laser treatment is unknow, with 
multiple theories being put forward: 
1. Heat conduction through residual blood in the vein from the fibre tip 
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2. Direct contact conduction via the vein wall 
3. Steam bubble transfer 
4. Direct absorption of laser light energy by the vein wall (van der Geld et al. 
2010; Disselhoff et al. 2008; Van Den Bos et al. 2009; Van Den Bos et al. 
2012; Mordon et al. 2007; Proebstle et al. 2002; Vuylsteke & Mordon 2012). 
 
A recent in vitro experiment found identical temperature profiles for both 940nm 
and 1470nm lasers (Van Den Bos et al. 2012), indicating that the different 
treatment profiles found in vivo are more related to procedural differences than 
wavelength.  Further work by Amzayyb et al assessed the deposition of carbon onto 
laser fibre tips in the presence of blood.  This study showed no difference between 
laser wavelengths (Amzayyb et al. 2010).  The data available to compare 
wavelengths is confusing as some wavelength comparison trials have compared 
bare tipped forward firing laser fibres with radial firing jacketed tip laser fibres 
(Almeida et al. 2009; Doganci & Demirkilic 2010).  Kabnick's 2006 study using 
identical fibres demonstrated a reduction in pain and bruising for the 980nm 
wavelength compared to 810nm (Kabnick 2006), and Proebstle et al.'s 2005 study 
compared 940nm with 1320nm again with identical fibres and found similar results 
(Proebstle et al. 2005), however other studies have shown no difference in outcomes 
between laser wavelengths (980nm vs 1470nm) (Duman et al. 2013). 
 
A major cause of postoperative pain following EVLA is thought to be due to vein 
perforation and inconsistent pullback speed leading to over and under treatment 
zones (Schmedt et al. 2006; Proebstle et al. 2002).  The use of a special tips to 
prevent contact with the vein wall have been shown in vitro and in vivo to 
produce a more even treatment, less wall perforations and lower post-operative pain 
and bruising (Vuylsteke et al. 2010; Vuylsteke et al. 2012; Massaki et al. 2013).  
However, unfortunately these tips have also been shown to have worsened occlusion 
rates (88.9% vs 97.7%, p<0.0001 at 5 months) (Prince et al. 2011).  A study by 
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Schwarz et al. showed improved pain and bruising outcomes with no difference in 
occlusion when comparing 1470nm bare forward firing and radial firing fibres 
(Schwarz et al. 2010).  Unfortunately, the radial firing group was also treated with 
a reduced energy delivery and so conclusions on the cause of the improved side-
effect profile cannot be drawn.  Finally, ex vivo models have found that pulsed 
wave laser treatment provides a different profile of wall damage, with pulsed 
treatment appearing to reduce the number of wall perforations, except for the 
2100nm laser tested (Massaki et al. 2013). 
 
Figure 24:  An example of specialised "Tulip" Tip (Vuylsteke et al. 2012) 
Long-term outcomes are few in number, due to the young nature of the technique 
and the constantly changing laser wavelengths available. However, in series 
reporting follow-up beyond one year, occlusion rates remain high, from 82% at 5 
years in 62 legs(Rasmussen et al. 2013) to 97.1% at 4 years in 511 limbs 
(Desmyttère et al. 2007). 
 
Overall EVLA offers a reliable, technically successful technique for endovenous 
ablation, which can be done in the day surgery or clinic setting. Current advances in 
longer wavelength lasers are allowing stepwise progression to the ultimate aim of 
technical success without post-operative complication. 
1.1.7.6.3.	  Endovenous	  Radio-­‐Frequency	  Ablation	  (RFA)	  
Endovenous Radiofrequency ablation (RFA) was first described by Goldman et al. in 
2000 (Goldman 2000).  A systematic review in 2009 outlined the literature and 
status of the two main competing radiofrequency catheter brands licensed for use in 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
96 
the UK and Europe – Covidien Venefit (previously named VNUS) and Olympus 
Celon (Gohel & Davies 2009). In the USA, only the VNUS brand is licensed for 
endovenous ablation.  Worldwide, the catheter choice has expanded from the initial 
VNUS ClosurePlusTM to include Covidien ClosureFASTTM 7cm and 3cm catheter, 
the Olympus Celon RFITTTM catheter and the new FCare EVRFTM. 
1.1.7.6.3.1.	  Covidien	  ClosurePlus	  and	  ClosureFAST	  -­‐	  The	  Venefit	  Procedure	  
The technique is the same as utilised for endovenous laser ablation – ultrasound 
guided, under tumescent local anaesthesia and Seldinger cannulation technique. 
General anaesthesia is optional in most cases and the procedures can be done in a 
clean clinic room environment. The Venefit system requires the use of tumescent 
anaesthesia to ensure adequate pain relief and adequate compression of the vein to 
allow secure ablation.  It requires access via a 7 French sheath (2.3 mm). 
 
The system has recently been renamed from VNUS to Venefit, with the 
ClosureFAST catheters changing from VNUS ClosureFAST to Covidien 
ClosureFAST. 
 
The current Venefit catheters are the second generation of the VNUS Closure 
PlusTM technology first launched in 2000, and upgraded in 2006.  VNUS Closure 
Plus required a continuous pullback technique whereas the ClosureFASTTM 
catheter operates in either 7cm or 3cm segments.  The 3cm ClosureFAST catheter 
was launched in 2012.  All the VNUS catheters use the same generator - the 
Covidien ClosureRFGTM.  The two differing catheter generations represent different 
energy modalities.  Both catheters use a thermocouple in the tip of the electrode to 
provide a feedback loop to the generator.  This then provides variable wattage in 
real-time to provide a stable therapeutic temperature. 
 
The Closure Plus treatment technique used bipolar radiofrequency energy to cause 
induction heating to 85°C in the vein wall.  This leads to collagen protein 
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denaturing and constriction of the vein wall.  In theory, this does not require 
tumescent anaesthesia, but the initial studies produced a 3% rate of full-thickness 
skin burns and a 33% rate of paraesthesia (Manfrini et al. 2000).  This provoked the 
use of tumescent fluid with optional anaesthetic as a requirement of the procedure 
(Manfrini et al. 2000).  It also requires a slow pullback speed of 3cm/min (0.05cm/s). 
 
Figure 25:  The Closure Plus Catheter (Manfrini et al. 2000) 
The EVOLVeS study of 86 limbs compared SFJ ligation and stripping with RFA 
using the VNUS Closure PlusTM device.  This showed improved quality of life 
outcomes and reduced pain profiles for the RFA device which persisted at 2 years of 
follow-up and a closure rate of 92% (Lurie et al. 2003; Lurie et al. 2005).  Gale et al's 
study in 2010 compared EVLA and RFA using the Closure Plus catheter and 
showed reduced bruising and perioperative pain but a worsened 1 year ablation rate 
{Gale:2010ka}-CITATION_IS_EMPTY. 
 
The catheter was refined as the VNUS ClosureFASTTM (now Covidien 
ClosureFASTTM).  This produces a thermocoagulation effect, with a target 
temperature of 120°C at the treatment section.  The treatment is performed in 
segments, with treatment temperature applied over 7cm segments for 20 seconds.  
The thermal energy causes protein degradation through conduction.  The segmental 
approach ensures that all sections of the vein are treated equally.  It also improves 
treatment speed - sections of 7 cm or 3 cm segments treated per 20 seconds (0.35 
cm/s or 0.15 cm/s respectively). 
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The initial report of treatment of 252 limbs obtained a 99.6% closure rate at 6 
months, 96.9% at 1 year and 92.6% at 3 years (Proebstle et al. 2008; Creton et al. 
2010; Proebstle et al. 2011).  Peri-procedural complications were low with a 0.4% 
rate of paraesthesia and pigmentation at 3 years.  Zero DVTs or PEs were reported 
(Proebstle et al. 2011).  Recent work on 667 limbs has shown the superiority of the 
newer generation catheter, with a higher rate of occlusion (98% vs 88%, p<0.001) 
(Zuniga et al. 2012). 
 
The ClosureFAST catheter is limited to veins larger than 2.33mm in internal 
diameter due to catheter size, however it can be argued that veins smaller than this 
size are unlikely to produce haemodynamically significant venous reflux, though 
diameter alone is a poor criterion (Gibson et al. 2012; Perrins et al. 2013). 
 
Several studies have been published showing significantly improved quality of life 
scores and improved venous clinical severity scores after RFA when com- pared to 
laser (Almeida et al. 2009) as well as reduced post-operative pain (Shepherd et al. 
2010; Gale et al. 2010; Goode et al. 2010). A 2009 meta-analysis of endovenous 
treatment found that RFA offered at least equivalent technical success as 
sclerotherapy and open surgery {VanDenBos:2009dy}-CITATION_IS_EMPTY.  A 
more recent meta-analysis in 2012 showed improved, but not statistically so, rates 
of occlusion with the ClosureFAST compared to EVLA (Siribumrungwong et al. 
2012). 
1.1.7.6.3.2.	  Olympus/Celon	  RFITTTM	  
The RFITT system utilises an induction heating method rather than conduction, so 
is similar to the original Closure Plus catheter (Boon et al. 2010; Camci et al. 2009; 
Goode et al. 2010).  The RFITTTM system uses the same continuous pullback 
mechanism as EVLA, which can lead to areas of over and under treatment.  It has a 
recommended pullback speed of <1.5cm/s (Braithwaite et al. 2013).  The technique 
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can be used with or without tumescent anaesthesia due to the inductive nature of 
treatment (Braithwaite et al. 2013), however due to the earlier results from the 
Closure Plus studies (Manfrini et al. 2000) most reports in the literature describe 
the use of tumescent in the majority of patients, whether treated under general, 
regional or local anaesthetic - up to 85% (Camci et al. 2009; Boon et al. 2010; 
Braithwaite et al. 2013).  The LARA study which compared RFITT to EVLA 
describes a tumescentless approach as standard in the RFITT arm of the trial.  
However, of 44 limbs randomised to RFITT, 11 (25%) were treated with tumescent 
anaesthesia (Goode et al. 2010). 
 
Outcomes are good with this device, with occlusion rates of 92.4% at 1 year, with 
experienced operators obtaining 98.4% (Braithwaite et al. 2013).  Pain profiles and 
complication rates are similar to ClosureFAST, and improved compared to 810nm 
EVLA (Goode et al. 2010; Braithwaite et al. 2013; Proebstle et al. 2011).  However, 
no comparative studies between ClosureFAST and RFITT have been performed. 
1.1.7.6.3.3.	  EVRF 
The EVRF system by F Care Systems was first developed in 2009 and utilises a 
pulsed radiofrequency 4Hz signal to thermocoagulate the vein wall.  It uses 
different size needles for thread veins (K3i and K6i) and catheters for 1-3 mm veins 
(CR12i and CR30i) and 4 mm veins and above (CR45i) {EVRF:wq}-
CITATION_IS_EMPTY.  The thread vein and 1-3 mm vein systems do not require 
tumescent anaesthesia, however the CR45i is a standard thermal ablation 
technique requiring tumescent anaesthesia and utilises a constant pull-back 
technique {EVRF:wq}. 
 
There is no peer-reviewed data regarding this device, however, two studies are 
available from the UK distributor website {ModernAestheticSol:th}.  The first pilot 
study from Belgium describes 40 patients treated in 2011-2012.  This achieved a 
100% 1 month vein occlusion rate and 92.5% at 6 months (Thomis 2013).  The 
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second study describes 313 limbs treated with EVRF, and described a 99% 1 month 
occlusion rate and a 97.2% 1 year occlusion rate (Szabo 2013).  These initial studies 
indicate good outcomes and good patient satisfaction, however peer-reviewed 
publications and comparator studies are required prior to firm decisions being made 
about this additional device. 
 
Overall, whichever catheter is used, RFA offers a safe, reliable, fast technique for 
the treatment of varicose veins. 
1.1.7.6.4.	  Steam	  
The newest of the thermal ablation catheters, the SVS (Steam Varicose System, 
CermaVEIN, France) has recently been presented as a new and novel technique. 
Initial pilot studies have shown an encouraging occlusion rate (90% at 6 months in 
20 limbs) using small amounts of thermal energy transferred by puffs of steam (Van 
Den Bos et al. 2011). The catheter transfers pulses of pressurised steam at 120°C to 
a treatment tip via a narrow (1.2mm diameter) flexible steel catheter.  The steam 
pulses then condense in the area of the tip, transferring energy to the surroundings 
at a rate of 60 joules per pulse.  The technique requires standard tumescent 
anaesthetic technique as do EVLA and RFA.   The catheter tip is positioned 2-3 cm 
from the SFJ. 
 
Pilot studies in sheep and humans have shown good occlusion rates as above, 
however 35% had some evidence of non-refluxing recanalisation.  The pilot studies 
used one pulse per cm, or 60 joules/cm, to match equivalent EVLA energy densities 
(Van Den Bos et al. 2011).  Histological studies of animal vein have shown 
equivalent outcomes to RFA treatment (Van Den Bos et al. 2011). 
 
A recent multi-centre study assessing 88 limbs in 75 patients showed a 6 month 
occlusion rate of 96% at 6 months and 92% at 12 months, however Kaplan-Meier 
survival analysis indicates a 86% occlusion rate at 12 months (Milleret et al. 2013).  
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This study increased the number of pulses to two or three dependent on vein 
calibre, leading to energy densities of 120-240 joules/cm.  Despite the increased 
energy density, pain >5 on a visual analogue scale was only reported in 10% of 
patients and the median pain reported was 0.75 (Milleret et al. 2013). 
 
Outside of these two published studies, little literature exists on this catheter due to 
its recent development and the far greater market penetration of EVLA and RFA.  
Larger, long-term and comparative studies are required before widespread use of 
this technique over more established modalities can be justified. 
1.1.7.6.5.	  Summary	  
Endothermal ablation has many facets, all of which appear to work with similar 
efficacy, and minor technical differences.  Crucially, recent work is building to 
describe limited differences between modalities (Malskat et al. 2013), confirming 
clinical experience (Shepherd et al. 2010; Rasmussen et al. 2011; Rasmussen, 
Lawaetz, Bjoern, et al. 2013a; Rasmussen, Lawaetz, Serup, et al. 2013b).  This 
allows clinicians to continue to treat patients with their preference of device, as 
their expertise builds with that endothermal ablation device.  
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1.1.7.7.	  Sclerotherapy	  
Sclerotherapy became an avenue of great interest after the development of the 
hypodermic needle in 1841 by Parvaz (Perrin 2011; van den Bremer & Moll 2010).  
Liquid sclerotherapy was initially used for injection into aneurysmal sacs by 
Pravaz, before Chassaignac described its use for varicose veins in 1855 (Tisi et al. 
2006).   However, due to extremely poor results with infection and even gangrene 
(Tisi et al. 2006; Perrin 2011) the technique fell out of favour. 
 
Fegan described an effective method of using liquid sclerotherapy using sodium 
tetradecyl sulfate (STS) and produced excellent results using a diligent empty vein 
technique to cause vein fibrosis, however his prescription of 6 weeks of compression 
bandaging might be a limiting factor today (Bergan 2007; Fegan et al. 1964; Fegan 
1963).  Liquid sclerotherapy produced poor results in general use, requiring very 
careful application with diligent follow-up protocols (Bergan 2007).  Sclerosants are 
deactivated on contact with blood, requiring direct contact with the vein wall for 
effect.  Due to fluid mixing liquid sclerosants have limited efficacy (Coleridge Smith 
2009; Hamel-Desnos et al. 2009). 
 
The liquid sclerotherapy technique was refined into foam sclerotherapy during the 
20th century with the Tessari method being most practiced (Jia et al. 2007) and this 
has lead to improved occlusion and patient satisfaction rates. Foam sclerotherapy is 
thought to improve occlusion rates with smaller quantities of sclerosant by 
displacing more blood and improving wall contact. It allows the treatment of 
varicose veins in a true clinic environment, with no assistance required once skilled 
at the technique (Coleridge Smith 2009). Due to the simple cannulation nature of 
the technique, minimal post-procedure morbidity is encountered, leading to high 
patient acceptance.  However, it is highly physician dependent (Coleridge Smith 
2009; Cavezzi & Tessari 2009). 
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At present two sclerosants are licensed and in common use in mainstream 
European practice - STS and Polidocanol (POL) (Rabe et al. 2013).  Both of these are 
detergents, STS a fatty acid and POL a fatty alcohol.  They are available at differing 
concentrations for differing size veins (Bergan 2007).  Sclerosants cause an 
inflammatory and fibrotic reaction in the vein wall on contact.  However, the 
detergents are deactivated on contact with blood (Bergan 2007; Hamel-Desnos et al. 
2011). 
 
The major failing of foam sclerotherapy has previously been occlusion and 
recurrence rates due to its highly variable technical application. However, with the 
advent of foam, it has been shown that ultrasound guided foam sclerotherapy 
(UFGS) has equivalent success but worse recurrence rates compared to open 
surgery, as shown by recent meta-analyses (Jia et al. 2007; Siribumrungwong et al. 
2012) and a recent Cochrane review (Tisi et al. 2006).  Sclerotherapy has been found 
to be less effective than endovenous ablation (Rasmussen et al. 2013), although 
long-term data are lacking.  The relative low cost and low pain profile of 
sclerotherapy in addition to the ease of retreatment has lead to extensive uptake 
worldwide. 
 
There is sparse evidence in the literature to guide the actual application of 
sclerotherapy, with disparate sclerosant volumes, foaming techniques and 
concentrations used, however Coleridge Smith has published recommendations for 
clinic requirements and suggested technique (Coleridge Smith 2009) and Bergan's 
vein book is also illustrative on this subject (Bergan 2007).  Diligent technique and 
follow-up is vital for the optimum outcome for UGFS - due to this the excellent 
results found in some centres are not necessarily generalisable (Darvall et al. 2011; 
Darvall, Bate, et al. 2010a; Darvall, Sam, et al. 2010b; Darvall et al. 2009; Lattimer 
et al. 2012; Frullini et al. 2002). 
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Overall complications after sclerotherapy are rare, however this much be weighed 
against the relatively benign nature of varicose veins, and the availability of 
effective conservative management and other methods of intervention. Major 
complications include deep vein thrombosis (DVT), pulmonary embolism (PE), 
stroke and transient embolic events. The event rate of these complications is very 
low, with an event rate of 0.6% for DVT, 2.1% for cerebral events and one previously 
reported PE (Jia et al. 2007; Sarvananthan et al. 2012). Air embolism is the most 
feared complication, which can be fatal when associated with gas volumes of > 1 
ml/kg injected into the venous system, with 50 ml able to cause significant 
complications. 
 
Most procedures utilise up to 10 ml of foam, though some report use of up to 30 ml 
(Forlee et al. 2006) - though this was associated with the one case report of stroke 
following UGFS (Forlee et al. 2006).  The cause of stroke and other transient 
cerebral events and migraine is not clear, and there are two hypotheses - 
sclerotherapy microbubbles transferred into the cerebral circulation via a patent 
foramen ovale or the production of endothelin (Frullini et al. 2011; Frullini et al. 
2012; Bush et al. 2008; Sarvananthan et al. 2012).  These theories are still 
undergoing investigation. 
 
European guidelines have been formulated to guide the application of sclerotherapy 
(Rabe et al. 2013).  These recommend a maximum session dose of 10ml of foam to 
reduce complications. 
 
Overall the risk profile of sclerotherapy is not significantly altered in comparison to 
surgery and therefore is gives a reasonable alternative for those patients for whom 
surgery or endovenous ablation is deemed inappropriate or too strenuous. 
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1.1.7.8.	  Endovenous	  Mechanochemical	  Ablation	  -­‐	  Clarivein	  
The ClariVein mechanochemical ablation catheter has recently elicited significant 
interest in the venous community. The technique utilises a dual-modality catheter – 
a motorised spinning catheter tip that causes venospasm and abrades the venous 
endothelium, followed by instillation of liquid sclerosant via the catheter tip.  The 
catheter has a 'hockey stick' profile, allowing for it to be steered up tortuous or 
difficult veins and requires only a single micro-puncture access (4 French - 
1.35mm). 
 
Initial trials have shown a good side-effect profile and effective closure rates (96.7% 
at 6 months) in both the GSV and SSV (Elias & Raines 2012; van Eekeren et al. 
2011; Boersma et al. 2013). 
 
The mechanical component of the mechanochemical ablation procedure has been 
shown to produce subtle, incomplete damage to the venous endothelium, compared 
to RFA which produces extensive tissue destruction (Kendler et al. 2013).  
Theoretically this may produce a reduced peri-procedureal pain profile for the 
device to match the findings of studies investigating post-procedureal pain (van 
Eekeren et al. 2013). 
 
Once again, larger scale trials are needed to show the true efficacy of the procedure. 
It is almost bloodless and fast, but patients do require compression hosiery 
postoperatively.  The device is handheld and portable, and does not require an 
energy generator or tumescent anaesthesia.  Due to the non-thermal nature of the 
treatment, no tumescent anaesthesia is required.  This reduces the procedural time 
and the number of injections required for anaesthesia.  The device does cause a 
vibration feeling as the vein is treated, which some patients find uncomfortable.  
The variable speed motor allows reduction in the case of very superficial veins, 
leading to reduced vibration and in theory discomfort. 
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Current multi-centre departmental studies are investigating the peri-operative pain 
profile of mechanochemical ablation versus the Clarivein catheter (VNUS vs 
Clarivein for Varicose Veins - VVCVV) (ISRCTN Register 2012). 
 
Figure 26:  Clinical Picture of Clarivein Device in Use 
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1.1.7.9.	  Endovenous	  Chemical	  Occlusion	  -­‐	  Sapheon	  
A new and exciting development, the Sapheon Venaseal product has demonstrated 
an early 100% occlusion rate with minimal morbidity attached (Almeida et al. 2011; 
Almeida et al. 2012; Min et al. 2012).  It utilises a proprietary glue compound to 
provide physical occlusion of the vein, which then undergoes fibrosis. 
 
The device uses a standard catheter based delivery technique via a proprietary 
catheter.  This requires 5 French size access (1.67 mm diameter) Treatment protocol 
uses the injection of 0.08ml 'shots' of the cyanoacrylate into the treatment zone at 
the tip of the catheter.  For the first treatment zone, at the SFJ, the first shot is 
applied, then the catheter is withdrawn 1cm and a second 'shot' applied.  The 
catheter is then withdrawn 3cm and the two treated zones are compressed for 3 
minutes (180 seconds).  After this initial treatment zone,  one 'shot' of applied and 
the catheter is withdrawn 3cm and the treatment zone compressed for 30 seconds.  
This process is repeated for the length of the vein to be treated.  
 
Figure 27:  The Sapheon Closure System 
One year follow-up of the initial first-in-man patients has shown a safe, well 
tolerated procedure with occlusion rates of 92.1%, and no cases of DVT in 38 treated 
cases (Almeida et al. 2013).  21% of those cases did develop proximal thrombus 
extension into the deep venous system, but resolved without treatment.  This led to 
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a modification of the positioning of the initial 'shot' to 5cm from the SFJ (Proebstle 
et al. 2013). 
 
These recent first-in-man and initial studies have indicated a well-tolerated 
procedure with minimal anaesthetic required and no requirement for compression 
hosiery.  Our unit has shown that it can be used in therapeutically anticoagulated 
patients, though initial success at 8 weeks did progress to recanalization at 6 
months {Lane:2013hg}-CITATION_IS_EMPTY. 
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1.1.7.10.	  Deep	  Venous	  Stenting	  
 
Figure 28:  Digital subtraction venography of venous stenting procedure 
Work by Raju and Neglen in 2003 demonstrated that chronic venous disease is 
associated with primary proximal deep venous stenoses as assessed by IVUS and 
venography (Neglén et al. 2003; Raju et al. 2011; Neglén et al. 2010).  These 
findings were confirmed by Gaweesh et al using modified CT venography (Gaweesh 
et al. 2013).  Raju et al have shown good symptomatic improvement with stenting 
with reasonable long term patency rates of 79% primary and 100% secondary at 6 
years in non-thrombotic disease(Neglén et al. 2007). 
 
The role of deep venous stenting in the management of non-thrombotic venous 
disease remains specialised and limited to careful patient selection.  Further 
disseminated studies are needed to adequately investigate the technique's 
generalisability.  The level of contribution to and causation of chronic venous 
disease by deep venous stenoses remains unclear and needs further study. 
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Aims	  of	  this	  thesis	  
This thesis aims to examine and identify pathways in the invasive treatment of 
varicose veins, and to provide evidence for the streamlining and improvement of 
current primary-secondary care interchanges. 
Through the use of modelling techniques the outcome of interventional treatment 
will be assessed.  This data aims to allow the construction of a prognostic model 
which aims to identify patients who will benefit most from treatment. 
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Chapter	  2:	  Venous	  Disease	  Education	  
  
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
112 
2.1.	  Current	  State	  of	  Understanding	  of	  Venous	  Disease	  
Venous disease is an extensive and common condition with an extensive morbidity 
as previously described.  However due to the fact that it is rarely fatal, training and 
understanding of the disease has not been extensive. 
 
The creation of dedicated conferences and teaching on venous disease over the past 
25 years and more recently the creation of Phlebology curriculae has strengthened 
the scientific rigour and background for venous medicine.  With a complex disease 
unveiled by duplex ultrasound, both conceptually, and physiologically, this has led 
to traditional teaching being left behind. 
 
Guidelines are formulated in order to aid non-specialists adhere to current evidence 
based medicine (Marsden et al. 2013).  However, guidelines are difficult to create 
and implement (Woolf 1993; Woolf et al. 1999; Grol 2001) and there is little 
evidence to show compliance in the community (Worrall et al. 1997) despite good 
results in trials (Grimshaw & Russell 1993; Eccles et al. 2002; Wigmore et al. 2007).  
Physicians must be aware of the guidelines first, before they can adhere to them 
(Pathman et al. 1996). 
 
Assessing the individual management and outcome of all venous disease patient 
clinical contacts is an impossible task, and so assessing clinician understanding and 
compliance with questionnaires is appropriate methodology (Burgers et al. 2003). 
2.2.	  Principles	  of	  questionnaire	  creation	  and	  validation	  
Questionnaires can be and are used to assess many disparate variables, often in 
qualitative rather than quantative data fields.  These methods have been under 
development for many years leading to extensive literature regarding solely 
questionnaire formulation (Foddy 1993; American Education Research Association 
et al. 1999; Jensen 2003; Bradburn et al. 2004; Fayers & Machin 2000). 
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To achieve a worthwhile questionnaire, one must ensure that the questions asked 
provide useful information which is reproducible in multiple respondents (Jensen 
2003; American Education Research Association et al. 1999). 
 
This means that the questionnaire must be both valid and reliable.  To ensure this, 
multiple prototype versions of questionnaires are produced from expert opinion 
before being tested on focus groups of the intended respondents (Krause & Backonja 
2003). 
2.2.1.	  Validity	  
Validity of a questionnaire consists of: 
 • Content Validity 
This ensures that the scale used is adequate - I.e. Can the questionnaire cover the 
full spectrum of the disease of interest (incorporating Face Validity). 
 • Construct Validity 
This ensures that the questionnaire describes and then assesses the disease of 
interest adequately. 
 • Criterion Validity 
This is to ensure that the output of the questionnaire is associated with a single 
desired outcome measure and is therefore a useful discriminator. 
2.2.2.	  Reliability	  
The reliability of a questionnaire consists of  
• Internal Consistency 
Different questions assessing the same section (or domain) must be consistent.  
Internal Consistency is used to delineate how closely interrelated different items in 
the questionnaire are, and utilises Cronbach's coefficient (Fayers & Machin 2000). 
• Test-Retest Stability 
When the test is repeated the same values should be consistent. 
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These variables and validation techniques allow the production of reliable, 
reproducible scales and questionnaires for abstract concepts of quality of life.  
However, not all aspects of validation are appropriate for all questionnaires.  Expert 
assessment and target group interview leading to iterative improvement using 
content and face validity assessment are sufficient to generate appropriate items to 
formulate the questionnaire. 
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2.3.	  General	  Practitioner	  Survey	  of	  Varicose	  Vein	  Management	  
2.3.1.	  Introduction	  
 
Figure 29:  GP Referral Pathway 
General practitioners (GPs) are the gatekeepers to secondary care in the UK. 
Standard GP training however does not include any formal teaching on CVD and 
GPs have variable exposure to the surgical specialties during their medical training 
(Royal College of General Practitioners 2011).  GP trainees do though undergo an 
extensive apprenticeship with GP trainers and will cover such topics during this 
period. Interestingly, work by Chassany et al demonstrated the disparity between 
patient-reported and GP-reported symptom severity with GPs routinely reporting 
lower levels of pain and quality of life impairment compared to patients (Chassany 
et al. 2006).  Conway et al have also shown that patient reported symptoms are 
unreliable compared to standardised questionnaires due to the subjectivity of 
symptoms (Conway et al. 2011).  In order to aid GPs in the management and 
referral of CVD extensive guidelines have been developed in the UK by the National 
Institute for Clinical Excellence (NICE) (National Institute for Clinical Excellence 
2001) and more recently by the Royal Society of Medicine's Venous Forum (Venous 
Forum of the Royal Society of Medicine et al. 2011).  The release of comprehensive 
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guidelines in July 2013 have redefined the varicose vein treatment evidence base 
for primary care physicians (Marsden et al. 2013). 
 
In the US guidelines on management of CVD patients have also been created 
(Gloviczki et al. 2011).  In order to stratify CVD, various clinical scoring systems 
have also been developed and validated, such as VCSS (Venous Clinical Severity 
Score) (Eklöf et al. 2004; Vasquez et al. 2010).  Despite the existence of guidelines 
and scoring systems, the treatment of varicose veins has been classified and is 
viewed of low clinical value by non-medical funding bodies (Audit Commission 
2011), leading to the creation of disparate and confusing local guidelines and these 
are often in contention with national guidelines. 
 
GPs are now also expected to perform routine post-operative follow-up for surgical 
procedures, such as, varicose veins and hernia repairs (Community Health 
Partnerships 2008) without appropriate remuneration or support. Previous work 
surveying patients, GPs and surgeons after post-operative outpatient attendance 
found that in the context of benign general surgical disease, 95% of patients found 
follow-up specialist consultations useful, and only 49% would prefer to see their GP. 
Importantly, management was changed by the specialist in 44% of cases 
(Gnanalingham & Williams 2004). 
 
Preference for specialty follow-up was mirrored in a similar study by Frew et al. in 
cancer patients (Frew et al. 2010). 
2.3.2.	  Aims	  
The aim of this study was to assess patterns of referral and the management of 
CVD in primary care in the UK. 
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2.3.3.	  Methods	  
Following ethical review and categorisation as service evaluation by the local 
ethical sub-committee, a 23 question electronic survey was created which assessed 
different aspects of CVD management and treatment pathways. 
 
The questionnaire was tested and validated for content and validity by GPs and 
vascular surgeons, with internal, external and independent assessors as previously 
described (Jensen 2003; Fayers & Machin 2000).  Inter and intra-observer 
reproducibility assessments were not appropriate for this questionnaire and 
therefore not completed. 
 
In England there are approximately 34,101 GPs.  Therefore a subset of these were 
targeted.  Invitations to complete the survey were sent via e-mail to an estimated 
300 GPs throughout England (url = http://kwiksurveys.com?u=gpvaricoseveins), at 
random using local and national mailing lists. Please see Appendix 6 for the 
complete survey. 
 
Responses were collated by the survey server (KwikSurveys, Dover, UK) over a 6-
month period (August 2011 to February 2012) and results were analysed using 
Microsoft Excel 2011 (Microsoft Corporation, Redmond, USA) and GraphPad Prism 
(GraphPad Software Inc., La Jolla, USA) software.  
2.3.4.	  Results	  
138 completed responses were received, representing a response rate of 46%.  All 
received surveys were analysed and none were excluded. 
2.3.4.1.	  Cases	  Seen:	  
The vast majority of GPs (85%, p<0.001) stated that they saw less than 50 patients 
with varicose veins per annum, which is an average of less than one per week. 78% 
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managed CVD patients conservatively in the community, with 1 providing 
treatment with sclerotherapy.  
 
If specialist care was required most GPs (78%, p<0.001) referred to a vascular 
surgeon, 10% to a general surgeon and 11% to a vascular nurse specialist.  
2.3.4.2.	  Reasons	  for	  Referral:	  
40% of GPs would refer a patient at their request and 10% for cosmesis, 43% for 
venous skin changes and 58% for pain (Figure 30). 
 
Figure 30:  Reasons for referral from primary care (% of GPs) 
2.3.4.3.	  Available	  Treatments	  
Figure 31 demonstrates which treatments GPs believe are available to their 
patients. 33% believed that endovenous treatments were available in their locality, 
but a surprisingly low figure of 60% believed traditional open surgery to be 
available as a treatment option, despite its universal availability (33% vs 60%, 
p<0.001). 
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Figure 31:  Interventions believed available (% of GPs) 
2.3.4.4.	  Guidelines	  and	  Scoring	  Systems	  
Only one third of GPs (31% vs. 69%, p<0.001) were aware of the NICE Referral 
Guidelines (published in 2001) for CVD. 61% were aware of local Primary Care 
Trust (PCT) referral guidelines, but only 36% agreed with these guidelines. 26% of 
GPs said they were aware of NICE Treatment Guidelines, however these guidelines 
did not actually exist at the time of survey (and had not been commissioned at that 
time). Local PCT guidelines do exist and 41% of GPs were aware of these, though 
again only 26% agreed with them. 11% were aware of clinical scoring systems and 
89% were not (p<0.001). 
2.3.4.5.	  How	  do	  you	  manage	  chronic	  venous	  disease?	  	  
Overall, for patients with varicose veins, 62% of all treatment was conservative 
with reassurance (15%), compression hosiery (38%) or compression bandaging 
(10%). 29% of patients would be referred to a specialist and 8% would undergo 
further investigation prior to referral. One GP would treat varicose veins with 
sclerotherapy in the community. 53% of GPs would refer active ulceration (C6), and 
41% venous skin changes (C4). Pain symptoms would increase the referral rate for 
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CEAP clinical stage C2 disease from 2% to 24% (p<0.001) and from 20% to 55% for 
C3 disease (p<0.001).  
2.3.4.6.	  Role	  of	  intervention	  
Figure 32 illustrates how GPs determined whether there was a role for intervention 
using sample cases. Pain appeared to be the most important factor in this decision 
with 16% agreeing that CEAP class C2a (asymptomatic) warranted intervention but 
with pain (C2s) the referral rate increased to 71% (p<0.001). In patients with leg 
swelling and varicose veins (C3) 42% felt pain-free patients should have treatment 
compared to 83% if patients also had pain (p<0.001). Interestingly, only 62% of GPs 
believed that venous skin changes warranted intervention. Moreover, only 78% 
believed venous ulceration required intervention compared to 8% who did not and 
14% were unsure (p<0.005).  
 
Figure 32:  Role of intervention in example cases (% of GPs) 
2.3.4.7.	  Progression,	  Quality	  of	  Life	  &	  Cost-­‐Effectiveness	  
64% of GPs believed that mild CVD would progress to severe disease, compared to 
36% who did not (p<0.001). 84% of GPs thought that treating varicose veins would 
improve a patient's quality of life, and only 26% felt that it was not a cost effective 
use of NHS resources. The majority (75%) believed that CVD for the purpose of 
improving quality of life could be managed conservatively.  
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2.3.4.8.	  Free	  Of	  Charge	  Treatment	  	  
Figure 33 shows which treatments GPs felt should be provided free of charge on the 
NHS.  Interestingly 11% of GPs believed that CEAP class C2a (visible but 
asymptomatic veins) should be treated free of charge and 8% were unsure. As CEAP 
class increased the proportion favouring free treatment also increased. Once again 
the onset of pain vastly increased the favour for free treatment. 
 
Figure 33:  For whom should treatment be free of charge on the NHS? (% of GPs) 
2.3.4.9.	  Follow-­‐Up	  and	  "Me	  Too"?	  	  
45% of GPs were happy to provide aftercare for varicose vein intervention; 8% felt 
no follow-up was required. 
In the "Me Too" question 71% of GPs stated they would like invasive treatment if 
they have varicose veins, with none wanting traditional open surgery  
2.3.5.	  GP	  Survey	  Discussion	  
The management of CVD is a common scenario encountered in general practice. The 
important aim of treatment is to avoid ulceration. From our results, it is evident 
that there is no clear consensus on the management of CVD in the community. 
Whilst the majority of patients are no doubt treated appropriately, there is a 
reticence of primary care fund holders to allow referral for invasive treatment and 
consequently the burden of disease remains widespread. From our study, the 
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treatment options also appear not to be universally available and in addition, there 
is patchy GP awareness of their availability.  
 
Interestingly GPs saw relatively few patients with CVD – with a 25-50% prevalence 
the average GP practice should have 1600-3200 patients with the condition (The 
Health and Social Care Information Centre 2008). This is likely due to a 
combination of public and medical ignorance of the benefits of treatment. 
 
What has become clear from this survey is that the CVD knowledge base of GPs is 
limited due to both a lack of exposure to the condition in their training and recent 
treatment progress. The number of GPs unaware of classification criteria, local and 
national guidelines, and the treatment options available demonstrates this. A 
substantial portion of GPs were also unsure of the benefits of treatment on a 
patient's quality of life (11%), disease progression (23%) or on cost-effectiveness of 
treatment (34%), despite extensive literature published on these areas in the past 
two decades. Our results would also suggest that follow-up should be with the 
treating physicians, and 92% of GPs felt that this was required, with only 45% were 
happy to provide post-intervention care themselves.  
 
National advice for referral for patients with CVD recommends referral to a 
specialist if there is quality of life detriment from prominent varicosities, not for 
cosmetic reasons or pain specifically. A key finding of the study is that pain is the 
main discriminator for patients being referred to secondary care. Whilst this is 
unsurprising, as patients will not attend without symptoms, our study also 
demonstrates that only about one third of GPs were aware of the NICE Referral 
Guidelines and that among them only about one third agreed with these guidelines. 
Crucially 71% of GPs felt that C2 disease with pain (prominent varicose 
veins) should have intervention compared with 63% (ns) who thought that venous 
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skin changes warranted treatment.  At the point of surveying, pain was not a 
discriminator in the national referral guidelines. 
 
This is concerning as the treatment of C4 disease is vital in the prevention of 
venous ulceration. Moreover, CVD intervention is far quicker and cheaper than 
ulcer treatment.  
 
In an era of austerity and primary and secondary care commissioning there must be 
improved discourse between venous specialists and primary care physicians. This 
must include mutual education sessions in order to disseminate recent advances. 
Surgical exposure in GP training is limited and topics such as venous disease are 
taught during an 18-month mentorship with GP trainers. It would therefore be 
prudent to encourage careful updating of these experienced GP trainers by the 
specialists to whom they refer. 
 
This study is limited by two main factors – numbers and participants. There 
are approximately 34,101 GPs in England. It was not feasible to contact all GPs and 
therefore a representative sample of approximately 300 GPs was sought,. The study 
additionally suffers from responder-bias, as those GPs willing to respond to the 
study are likely to be more engaged with local PCTs and commissioning services. 
They are also more likely to keep abreast of current treatments. Despite this the 
disparity between guidelines and practice was significant.  
 
Subsequent to the completion of this study, extensive NICE guidelines have been 
published with a summary published in the British Medical Journal (Marsden et al. 
2013).  This guidance addresses many of the knowledge gaps seen in this study and 
repetition of the study in 5 years may produce extensively different results.  In 
addition, due to reconfiguration of the primary and secondary care commissioning 
environment there may be improved communication and research dissemination. 
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2.3.6.	  GP	  Survey	  Conclusion	  
Despite clear national guidance and advice, referral and treatment patterns are 
extremely heterogeneous. 
 
This is the driving force behind the formulation of the various guidance documents 
available. CVD education is also lacking from GP training programmes despite CVD 
being a common condition, and venous specialists should aim to aid the lifelong 
learning needs for new and mature GP colleagues. 
 
For the benefit of our patients improved communication with GPs will lead to better 
patient care. We suggest that this should be sought at a local level with the 
development of clearer lines of feedback between primary and secondary care.  With 
the development of Clinical Commissioning Groups (Blake & Parker 2012), 
improved communication and dissemination of cutting edge research should 
improve.  In addition, recent NICE guidelines may drive this improvement and 
reach those GPs not involved in the commissioning network. 
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2.4.	  Management	  of	  Superficial	  Venous	  Thrombosis	  
2.4.1.	  Introduction	  
Superficial venous thrombophlebitis or more correctly superficial venous thrombosis 
(SVT) is inflammation of a superficial vein in the presence of a clot.  It is a common 
disease that has traditionally been regarded as benign and there has been little 
investigation into it's prevalence until recently (Leon et al. 2005; Di Nisio et al. 
2007; Di Nisio et al. 2012; Decousus, Prandoni, et al. 2010a; Decousus, Quéré, et al. 
2010b; Decousus et al. 2011; Hill et al. 2008).  Indeed, the 2013 NICE guidance 
recommends referral of all patients with SVT to their local vascular service 
{NationalInstituteforHealthandCareExcellence:2013vv}-CITATION_IS_EMPTY.  
 
SVT is a pathology that presents commonly and independently to both primary and 
secondary care physicians and surgeons.  Therefore it acts as an excellent surrogate 
marker for comparing the understanding of a "simple" disease and its appropriate 
management between primary and secondary care. 
 
Over the past 10 years extensive work using duplex ultrasound and longitudinal 
cohort studies have provided robust data on the condition.  Its prevalence has been 
estimated at 3-11% (Decousus et al. 2011; Hill et al. 2008) and as such is more 
common than deep vein thrombosis (DVT) (Di Minno et al. 2005).  SVT has been 
shown to be a significant risk factor in the development of DVT and consequently 
PE with an Odds Ratio of 4.3 (Heit et al. 2000; Heit et al. 2002).  Up to 30% of 
patients with a SVT have a concomitant DVT (Decousus et al. 2011), and up to 30% 
have concomitant pulmonary emboli (PE) (Verlato et al. 1999; Heit et al. 2002).  
However, SVT has been found not to be a risk factor for major cardiac events or 
malignancy (Prandoni et al. 2011). 
 
Despite this the literature has previously advised conservative management 
(London & Nash 2000).  This is compounded by the belief that treatment of varicose 
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veins is a low value procedure (Audit Commission 2011).  However, as SVT is a 
complication of varicose veins, varicose veins are therefore a risk factor for SVT as 
well as an independent risk factor for DVT (Decousus et al. 2010; Di Minno et al. 
2005). 
 
Post-graduate teaching on SVT is sparse and it suffers from falling between the 
multiple speciality stools of vascular surgery, medicine and general practice.  This is 
despite clear guidance in the form of a recently revised Cochrane review, and now 
the NICE guidelines . 
 
To investigate this we performed a survey of investigation and management of SVT 
by GPs and vascular surgeons.  The aim of the study was to assess whether current 
practice followed recent evidence, and whether primary care and secondary 
management was matched. 
2.4.2.	  Methods	  
A 19 question electronic survey was created which assessed SVT management, 
investigation and treatment pathways.  This did not require Ethical Approval as it 
is termed Service Evaluation. 
 
The questionnaire was tested and validated for content and validity by GPs and 
vascular surgeons, with internal, external and independent assessors as previously 
described (Jensen 2003; Fayers & Machin 2000). 
 
In England there are approximately 34,101 GPs and 456 members of the Vascular 
Society in the UK. 
 
Invitations to complete the survey were sent via e-mail to all throughout England 
(url = http://kwiksurveys.com?u=gpvaricoseveins), at random using local and 
national mailing lists. Please see Appendix 7 for the complete survey. 
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Responses were collated by the survey server (KwikSurveys, Dover, UK) over a 6 
month period and results were analysed using Microsoft Excel 2011 (Microsoft 
Corporation, Redmond, USA) and GraphPad Prism (GraphPad Software Inc., La 
Jolla, USA) software.  
2.4.3.	  Results	  
369 completed responses have been received, from 165 vascular consultants (36% 
response rate), 172 GPs or GP trainees (14% response rate) and 32 vascular 
trainees (11% response rate). 
 
Most clinicians saw up to 20 cases per year, with vascular surgeons understandably 
seeing more cases (Figure 34).  
 
Figure 34:  Number of Patients seen with SVT 
 
The majority of clinicians performed with venous duplex as the main investigation, 
however 40% performed no investigations at all (Figure 35). 
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Figure 35:  Investigations Performed 
A worrying disparity was shown in the treatment offered for patients with SVT.  At 
one end of the spectrum almost 10% treated with no treatment for a painful and 
potentially serious condition or complete bed rest for a thrombotic disease.  
Fortunately the majority opted for non-steroidal anti-inflammatory drugs (NSAIDs) 
but only 25% treated with anticoagulation and even fewer with compression hosiery 
(Figure 36).  
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Figure 36:  Treatments offered (Consensus Opinion Accepted = Green, Not indicated = Red) 
An overwhelming majority of clinicians (though significantly different proportions, 
p=0.007) believed there is a indeed an association between SVT and DVT, despite 
the disparity in treatment offered (Figure 37).  The relationships with other 
conditions is also disparate, although most clinicians felt that SVT was associated 
with varicose veins – Figure 38 and Figure 39, this was the only non-significantly 
different spread of opinion between GPs and VCs (p=0.057, ns).  All other 
interpretations of relationships between SVT and PE, Deep Venous Incompetence, 
Cancer and Infection were significantly different between GPs and VCs. 
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Figure 37:  Is there an association between SVT and DVT? 
 
Figure 38:  SVT Association with other conditions 
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Figure 39:  SVT Association with other conditions split amongst speciality 
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Finally, the approach to follow-up was variable and inconsistent (Figure 40 and 
Figure 41) - duration of anticoagulation was widely disparate as was the follow-up 
regime (p<0.001). 
 
Figure 40:  Duration of Low Molecular Weight Heparin (LMWH) prescribed for SVT 
 
Figure 41:  Follow-up for SVT 
GPs Vascular Consultants 
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2.4.4.	  Discussion	  
This study demonstrates that the management of SVT is disparate and conflicting 
despite good level 2 evidence indicating that NSAIDs, LMWH and compression 
hosiery are effective and reduce the incidence of DVT (Di Nisio et al. 2012).  This is 
likely to be due to the misconceived belief that SVT is a benign self-limiting disease 
(Decousus et al. 2003), amongst GPs and VCs, despite the increasing literature base 
that identifies its significant association with DVT (Decousus et al. 2010; Decousus 
et al. 2011). 
 
The number of cases seen per year (on average <20) appears at odds to the 3-11% 
prevalence, which would equate to 200-700 cases per year for an average GP 
practice, and more for a specialised vascular centre (if all were referred) (Decousus 
et al. 2011; The Health and Social Care Information Centre 2008).   The cause of 
this disparity is probably attributable to a low level of understanding from both the 
public and from primary care physicians of the condition and its relative importance 
in the venous thromboembolism spectrum.  Venous disease has been shown to have 
a low level of public exposure in previous work from the our unit, and SVT likely 
suffers a similar under-exposure {Lane:2013eo}-CITATION_IS_EMPTY. 
 
No national guidelines exist for the management of SVT, however robust level 1 and 
2 evidence exist to guide clinicians and with venous thromboembolism prevention 
being of topical interest aggressive treatment is becoming standardised outside of 
the UK (Heit 2005; Di Nisio et al. 2012).  It is hoped that with the recent NICE 
guidelines, referral and management in the UK will match this pattern 
{NationalInstituteforHealthandCareExcellence:2013vv}-CITATION_IS_EMPTY. 
2.4.5.	  Conclusion	  
The treatment and understanding of SVT is disparate and unclear.  Knowledge of 
the pathophysiology and the risks of are poor.  Propagation of the recent advances 
in the understanding of SVT and its connection with DVT are vital for improving 
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the outcomes of patients with this condition.  From understanding why some 
patients develop symptomatic SVTs this may be extend our knowledge of 
symptomatic and asymptomatic DVTs.  Guideline formation would improve 
baseline knowledge however, adherence is often poor {Lane:2013eo}-
CITATION_IS_EMPTY. 
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2.5.	  Summary	  of	  Venous	  Education	  
These studies show that whilst an extremely common condition, venous disease is 
poorly understood by frontline members of the medical community.  With the 
disparate management plans used it is clear that education is severely lacking, and 
has not kept pace with the extensive advances in the understanding of venous 
disease. 
 
Careful education and involvement of GPs and non-phlebologists is needed in order 
to provide patients with optimal treatment with robust evidence.  With the aging 
population this will be become a vital component to an efficient health service 
 
The formulation of guidelines is an aid but not a remedy as exemplified by the GP 
survey results.  It remains to be seen whether the recent NICE guidelines (Marsden 
et al. 2013) on covering treatment and diagnosis of varicose veins will affect GP 
opinion and referral patterns. 
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3.1.	  Introduction	  
The introduction of endovenous treatments has heralded new advances in the 
management of chronic venous insufficiency over the past decade (Shepherd et al. 
2010).  Key to understanding the burden of venous disease and the long term 
efficacy of newer endovascular approaches is the use of outcome measures relevant 
to the functional status of the patient. 
 
Traditional objective measures of disease severity that focus on the morbidity and 
mortality of venous disease, whilst readily quantifiable, do not necessarily correlate 
with the functional status of the patient. To meaningfully capture outcomes in 
venous disease, the full biopsychosocial consequence of the disease must also be 
established (Launois et al. 1996).  As the role for patient centered care in venous 
disease increases, the assessment of quality of life (QOL) in venous disease is 
becoming increasingly important. Currently there are a wide variety of validated 
outcome measures in use, and these can be divided into generic and disease specific 
QOL tools. 
 
Generic QOL instruments permit a patient's overall functional status to be 
measured regardless of their specific disease state, and thus have the advantage of 
allowing comparison across different studies of different diseases. The EuroQol 5 
Domain score (EQ-5D) is a well validated generic QOL score (The EuroQoL Group 
1990).  Disease specific QOL tools directly assess attributes related to a particular 
disease. They are increasingly becoming utilized in the study of varicose veins as 
they are more sensitive for assessing venous disease outcomes. The Aberdeen 
Varicose Vein Questionnaire (Garratt et al. 1993) (AVVQ) and the ChronIc Venous 
Insufficiency quality of life Questionnaire (Launois et al. 2012) (CIVIQ-14) are the 
two most commonly used validated disease specific QoL questionnaires.  Other 
examples of disease-specific QOL tools include the Charing Cross Venous Ulceration 
Questionnaire (CXVUQ), (Smith et al. 2000) the Venous Insufficiency 
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Epidemiological and Economic Study instrument (VEINES) (Lamping et al. 2003) 
and the Specific Quality of Life and Outcome Response- Venous questionnaire 
(SQOR-V) (Guex et al. 2007). 
 
In a joint statement by the American Venous Forum and the Society of 
Interventional Radiology, the use of both disease specific and generic QoL tools in 
conjunction with clinician driven assessment is recommended in all clinical trials 
investigating venous insufficiency (Kundu et al. 2007; Kundu et al. 2009).  There 
are significant differences in the choice of QOL tools amongst studies, making it 
challenging for the clinician to make direct comparisons between studies (Thakur et 
al. 2010).  Therefore the correlation between different QOL tools is of huge 
significance if clinicians are to make valid comparisons between studies. However at 
present the relationship between the various QOL tools has not been fully 
characterized. 
 
The aim of this study is to evaluate the relationship between two disease-specific 
QOL tools; the extensively validated AVVQ and more recently validated CIVIQ-14, 
to enable better comparison between studies and to compare these tools with 
generic QOL tools and clinician completed tools (Rutherford et al. 2000). 
3.2.	  Methods	  
3.2.1.	  Patient	  selection	  
Adult patients attending the vascular surgery outpatient clinic at our Institution for 
management of their varicose veins were prospectively invited to participate in this 
study. Patients were recruited over a four-month period, from August 2012 to 
December 2012 in a consecutive manner. Demographic data including patient age 
and gender was collected.  
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3.2.2.	  Intervention	  
All participants were asked to complete the two disease specific QOL tools, the 
AVVQ and CIVIQ-14 prior to their outpatient appointment. The AVVQ consists of 
13 questions addressing various biopsychosocial attributes of chronic venous 
disease, including specific signs and symptoms, use of compression stocking and 
daily functional impact (see Appendix 1) (Smith et al. 1999). The overall score 
ranges from 0 to 100, with a higher score denoting greater burden of disease. The 
CIVIQ-14 is a revised version of the well-validated CIVIQ-20 instrument (Launois 
et al. 1996; Launois et al. 2012), and has shown to be valid in studies of patients 
across different countries (Biemans et al. 2011).  The CIVIQ-14 contains 14 
questions covering three QOL dimensions: physical, pain and psychological, and is 
scored from 0-100, with a higher score denoting a lower QOL (see Appendix 5). 
 
Patients also completed the EuroQol-5D questionnaire (EQ-5D, EuroQoL Group, 
Rotterdam, the Netherlands) (The EuroQoL Group 1990; Herdman et al. 2011) a 
generic QOL questionnaire which separately captures the biological, psychological 
and social aspects of a disease state to generate a numerical overall score. 
The clinical severity of venous disease for each patient was stratified using the 
following clinician driven tools: the Clinical Etiologic Anatomic Pathophysiologic 
(CEAP) score (Eklöf et al. 2004) and the revised Venous Clinical Severity Score 
(VCSS) (Rutherford et al. 2000). The VCSS comprises nine characteristics of venous 
disease and each component is scored independently on a scale from 0 to 3.  
3.2.3.	  Statistical	  analysis	  
Outcomes were scored for each patient. In cases of bilateral venous disease, scores 
were recorded for each leg, and the score of the worst leg was used. Statistical 
analysis was performed using Prism 5.0a (GraphPad Software, Inc, California). The 
relationship between the AVVQ and CIVIQ-14 scores was analysed using 
Spearman's correlation for nonparametric data. Correlation was also analysed 
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separately for patients with less severe (C1-3) disease and more severe (C4-6) 
disease. 
 
The AVVQ and CIVIQ-14 scores were analysed against the EQ-5D. Both the AVVQ 
and CIVIQ-14 were analysed against the VCSS. Spearman's correlation was used to 
assess the relationship for each analysis. P values less than 0.05 were considered 
statistically significant. 
3.3.	  Results	  
3.3.1.	  Patient	  demographics	  
Over a four-month period between August 2012 and December 2012, fully complete 
questionnaires were collected for 100 patients. There were 44 males (44%) and 56 
females (56%). The mean age of participants was 57.5 years (range 22-84 years). 
50% of patients were aged 65 years and over. The mean AVVQ score was 25.1 
(range 0-74; SD 17.1) and the mean CIVIQ-14 score was 33.8 (range 0-89; SD 21.7). 
3.3.2.	  Relationship	  between	  disease-­‐specific	  QoL	  tools	  (AVVQ	  and	  CIVIQ-­‐14)	  and	  EQ-­‐5D	  
The EQ-5D score demonstrated a strong negative correlation with both the AVVQ 
and CIVIQ-14 scores (Figure 42). (r=-0.5; p<0.0001 and r=-0.7; p<0.0001 
respectively). 
 
Figure 42:  Relationship between disease-specific QOL Tools (AVVQ and CIVIQ-14) and generic QOL 
Tool - EQ-5D. 
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3.3.3.	  Relationship	  between	  disease-­‐specific	  QoL	  tools	  (AVVQ	  and	  CIVIQ-­‐14)	  and	  VCSS	  
There was a strong positive correlation between the VCSS and both the AVVQ and 
CIVIQ-14 scores (Figure 43) (r=0.7; p<0.0001 and r=0.7; p<0.0001 respectively). 
 
Figure 43:  Relationship between the VCSS and AVVQ and CIVIQ-14 scores. 
3.3.4.	  Relationship	  between	  the	  AVVQ	  and	  CIVIQ-­‐14	  scores 
Strong positive correlation was seen between the AVVQ and CIVIQ-14 scores (r= 
0.8; p<0.0001). Strong correlation was maintained for patients with C1-3 disease 
(r=0.7; p<0.0001) and C4-6 disease (r=0.8; p<0.0001). 
 
Figure 44:  Relationship between the AVVQ and CIVIQ-14 scores 
3.3.5.	  Conversion	  Factor 
From these data points, a conversion factor was created.  The mean AVVQ was 
25.10 (SD ± 17.05) with the mean CIVIQ being 33.81 (SD ±21.74).  Utilising these 
data, the following correction factor was formulated: 
CIVIQ = (1.06 x AVVQ) + 7.194 
The agreement between the observed CIVIQ-14 scores and the predicted CIVIQ-14 
scores are shown in Figure 45 and Figure 46. 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
142 
 
Figure 45:  Difference between Observed and Predicted values for CIVIQ-14 
 
Figure 46:  Correlation between Predicted and Observed CIVIQ-14 
Wilcoxon testing showed that Predicted and Observed CIVIQ-14 values where not 
statistically different (Mean difference 0.0097, SD -2.386-2.405, p=0.5832), and a 
strong and statistically significant correlation was found (p<0.0001, r=-0.7695). 
3.4.	  Discussion	  
Measurement of QOL is now commonplace in studies of chronic venous disease. 
Over the past decade there has been increasing recognition amongst phlebologists 
that disease specific QOL tools provide a more meaningful correlate of a patent's 
functional status than objective anatomical or hemodynamic outcome measures 
(Shepherd et al. 2011; Guex 2008).  Reporting guidelines published by the American 
Venous Forum now recommend the use of disease specific and generic QOL tools 
along with clinician driven outcome measures in studies of chronic venous disease 
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(Kundu et al. 2007; Kundu et al. 2009).  In 2005, a review commissioned by the 
United Kingdom Department of Health recommended the routine use of patient-
reported outcome measures after intervention for venous disease (Nesbitt et al. 
2012; Smith et al. 2005). 
 
The choice of disease specific QOL questionnaire is crucial to permit both the 
evaluation of the efficacy of current endovenous treatments, and valid comparison of 
results from different trials. Currently there are a number of different disease 
specific and generic QOL tools clinician driven tools being utilized in studies of 
chronic venous disease (Thakur et al. 2010; Vasquez & Munschauer 2008).  The 
AVVQ and CIVIQ-14 were chosen for evaluation in this study. The AVVQ is a 
commonly used validated disease specific QOL tool that has been shown to be 
sensitive in assessing functional outcome after treatment for chronic venous disease 
(Darwood et al. 2008).  The CIVIQ-14 was recently developed as a more stable 
version of CIVIQ-20 instrument, which itself has been commonly used and 
validated since 1996  (Launois et al. 1996; Launois et al. 2010; Launois et al. 2012). 
 
This study has established that a strong correlation exists between the two disease 
specific QOL tools selected for evaluation, the AVVQ and CIVIQ-14, further 
demonstrating that these disease-specific questionnaires are useful tools in the 
assessment of QOL in chronic venous disease. The findings from this study show 
that the relationship between the AVVQ and CIVIQ-14 scores are predictable, 
thereby supporting the validity of making comparisons between studies regardless 
of whether the study has utilized the CIVIQ-14 or AVVQ QOL tool. The AVVQ 
differs in several aspects from the CIVIQ-14 questionnaire. In comparison with the 
CIVIQ-14, the AVVQ assigns a greater proportion of questions to the physical 
aspects of chronic venous disease. The CIVIQ-14 is validated for the entire spectrum 
of chronic venous disease except venous ulcers (Launois et al. 2012), whilst the 
AVVQ specifically targets varicose veins and includes ulceration (Garratt et al. 
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1993).  Despite these differences, the current study shows that two QOL tools 
closely correlate, and the correlation is maintained across the spectrum of disease 
severity, from less severe (C1-3) to more severe disease (C4-6). 
 
Our findings have expanded on the findings from by Shepherd et al. (Shepherd et 
al. 2011) who found that the AVVQ correlated strongly with another disease-specific 
QOL tool, the SQOR-V questionnaire. The degree of correlation (Spearman 
coefficient 0.702) was similar to our findings (Spearman coefficient 0.8). Both the 
SQOR-V (Guex et al. 2007) and CIVIQ-14 place a greater emphasis on patient-
reported symptoms rather than physical signs and this may in part explain the 
comparable degree of correlation. 
 
Other types of outcome measures utilized to assess chronic venous disease were also 
shown in this study to correlate with the AVVQ and CIVIQ-14 QOL tools. The study 
evaluated a generic QOL questionnaire, the EQ-5D, which was shown to correlate 
strongly with both of the disease specific QOL tools. This is in contrast to findings 
from previous studies, which have compared different generic QOL questionnaires 
with disease specific QoL questionnaires. Shepherd et al. (Shepherd et al. 2011) 
found that the AVVQ only correlated weakly with a generic QOL tool, the Short 
Form 12 (SF12) questionnaire (Wee et al. 2008).  The differences between our 
findings are not immediately clear, but may be attributed to the difference in 
construction of health profile-based questionnaires (Short Form series) and 
preference-based questionnaires (EQ-5D) (Franks et al. 2004).  This study also 
evaluated a clinician-completed assessment tool (VCSS) against the AVVQ and 
CIVIQ-14. A very strong correlation was found between the clinical scoring system 
and both of the disease-specific QOL tools. This relationship highlights the 
sensitivity of the AVVQ and CIVIQ-14 towards the physical aspects of QOL in 
chronic venous disease. Our results strongly reinforce the findings by Carradice et 
al. (Carradice et al. 2011), which also found that increasing venous disease severity 
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was associated with poor disease-specific and generic QOL scores as measured by 
the AVVQ and EQ- 5D, respectively. 
 
The lack of consensus on which disease-specific QOL tool to use for measuring 
outcomes in chronic venous disease has contributed to an inconsistency in the choice 
of the QOL tool used in studies of venous disease (Thakur et al. 2010; Jawien 2009).  
The need to make comparisons between studies using different outcome measures 
has highlighted the importance of understanding the relationship between these 
disease specific QOL tools, as well as the relationship with generic QOL and 
clinician driven tools.  Previous work by Carradice et al. investigated the effect of 
CEAP status on disease-specific quality of life and generic quality of life, and found 
similar results.  This study provides additional evidence of the morbidity associated 
with chronic venous disease. 
 
The conversion formula has shown good agreement with observed values, providing 
an option for further meta-analysis and comparison of trials. 
 
A limitation of this study was the relatively small number of participating patients 
with C1 disease. This may limit the generalizability of our findings.  The number of 
patients with C1 disease treated in secondary care is restricted due to the limitation 
of referrals from primary care under the United Kingdom National Healthcare 
System.  In the current study, the patient selection was performed in a consecutive 
manner, and not randomized.  This would have been unlikely to impact on the 
results as the primary purpose of this study was ascertain the correlation between 
the CIVIQ-14 and AVVQ QOL tools, rather than to compare the outcomes between 
interventions.  What remains to be seen is the relationship of the responsiveness 
between the disease specific QOL tools, generic QOL tools, and clinician completed 
outcome measures several weeks post-procedure.  It will be important to see if 
changes in post-procedure AVVQ scores correlate with respective changes in CIVIQ-
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14 scores and this will contribute further to our understanding of these QOL tools 
relative to one other.  Further data points are required to improve upon the current 
conversion formula, throughout the spectrum of disease. 
3.5.	  Conclusion	  
This study demonstrates that there is a strong and significant linear correlation 
between two of the main disease-specific QOL tools for varicose veins (AVVQ and 
CIVIQ-14) across the whole spectrum of disease severity. Strong correlation also 
exists between these disease-specific QOL tools and the generic EQ-5D QOL tool as 
well as the clinician-driven VCSS tool. Our findings support the validity of 
comparisons of results between studies using either the CIVIQ-14 or AVVQ disease-
specific QOL tool. 
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4.1.	  Introduction	  
Disease cohorts are followed in many fields and provide excellent data on the 
breadth of disease.  The benefits of cohort studies include identification of rare 
complications and factors, and are not constrained by the limits of RCTs.  The level 
of evidence produced is not as rigorous as RCTs however, pragmatic planning can 
lead to an excellent evidence base.  Venous disease is complex multi-factorial 
disease and therefore requires large recruitment and analysis for optimal 
investigation. 
 
Venous disease has been the subject of multiple cohort studies (Widmer & da Silva 
1991; Rabe et al. 2003; Evans et al. 1999) which have now started to explore 
progression of the condition (Rabe et al. 2010; Robertson et al. 2013). 
 
Patients present to vascular services for treatment of symptomatic venous disease.  
Assessing this sample of the population as a whole offers a different viewpoint to 
the epidemiological studies of Rabe, Widmer and Evans (Widmer & da Silva 1991; 
Rabe et al. 2003; Evans et al. 1999).  Whilst there is a recruitment bias, it is these 
patients that require treatment for their disease, as opposed to the asymptomatic 
majority.  The vascular surgery clinic therefore represents a prime opportunity to 
assess the disease and its components. 
4.2.	  Methods	  
Regional ethical sub-committee approval was sought and obtained for this study.  
Patients were recruited between January 2011 and July 2012 (18 months).  Patients 
attending Charing Cross Hospital for secondary care varicose vein investigation and 
treatment were invited to complete questionnaires relating to the impact their 
varicose veins had on their lives.  This was correlated with clinician completed 
questionnaires to produce a cohort study group. 
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Clinicians completed the CEAP, VCSS and VDS.  Patients completed the AVVQ, 
EQ5D-5L and CES-D Depression Score (Appendix 3). 
 
Follow-up review in the host NHS Trust was not funded, and no research funding 
for follow-up was limited and so patients were followed-up opportunistically during 
this time.  
4.3.	  Results	  
The summary patient cohort demographics are illustrated in the following table.  
461 patients have been recruited with completed pre-operative questionnaires and 
227 with post-operative questionnaires.  The mean clinical severity and patient 
reported symptoms scores are illustrated in table 3 and show a significantly 
impaired population. 
Table 3:  The venous patient cohort demographics 
 Pre-Operative Post-Operative 
n 461 227 
Age 50.66 51.85 
M:F 43:57 42:58 
BMI>30 9% 22% 
Vein Diameter (mm) 8.06 7.346 
VCSS 6.47 3.32 
AVVQ 21.80 13.22 
EQ5D 0.718 0.80 
EQ VAS 75.70 80.63 
CES-D 11.27 9.61 
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The mean VCSS is higher than many previous studies (Carradice et al. 2012; 
Shepherd et al. 2010) though the AVVQ reported is similar to previous work 
(Darvall et al. 2010; Shepherd et al. 2010; Rasmussen et al. 2011) and this may 
indicate the severity of referral guidelines in the community supporting the 
vascular clinic. 
 
The cohort results compare favourably with that shown by the 2011-2012 NHS 
Health Episode Statistics Patient Reported Outcome Measures (HES Online 2013) 
as shown by Table 4. 
Table 4:  Hospital Episode Statistics Patient Reported Outcome Measures 
 Pre-Operative Post-Operative 
n 13,278 8,133 
AVVQ 20.19 12.29 
EQ5D 0.754 0.848 
EQ VAS 78.50 
78.57 
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4.3.1.	  Depression	  Burden	  in	  Superficial	  Venous	  Disease	  
4.3.1.1.	  Introduction	  
Depression is a common mental health disorder, and affects more than 120 million 
people worldwide (Lépine & Briley 2011). It is characterised by symptoms of 
sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed 
sleep or appetite, low energy and poor concentration (WHO). These symptoms can 
become chronic or recurrent impairing an individual's ability to cope with daily life. 
Depression costs the UK economy over £9 billion in lost working days, and although 
it can be both reliably diagnosed and treated in a primary care setting only a 
quarter of patients with depression seek medical advice or are receiving treatment 
(The ESEMeD/MHEDEA 2000 investigators* et al. 2004). 
 
Overall, 1 in 10 adults in Britain suffer from depression at any one time and 
depression is approximately 2-3 times more common in patients with chronic 
physical health problems, compared to those who have good physical health 
{NationalInstituteforHealthandCareExcellence:2009tj}-CITATION_IS_EMPTY.  
This observation led to the development in 2009 of NICE guidelines in the UK, 
again recommending that all adults, aged 18 years and older, with chronic physical 
illness be screened for depression. 
 
Varicose veins have been shown to impact on quality of life (QOL), (Smith et al. 
1999) with increasing severity of disease having a proportionately greater impact 
(Carradice et al. 2011). Depression has also been shown to adversely affect QOL 
(Culpepper 2011). The effect of symptomatic varicose veins on mental health 
outcomes and on depression specifically is less well defined. The aim of this study 
was to evaluate the burden of depression in patients with symptomatic 
uncomplicated and complicated (associated with skin changes which include 
eczema, lipodermatosclerosis and ulcers) varicose veins presenting to tertiary care 
for treatment (Abenhaim & Kurz 1997). 
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4.3.1.2.	  Centre	  for	  Epidemiological	  Study	  -­‐	  Depression	  (CES-­‐D)	  
The Centre for Epidemiological Study - Depression Score (CES-D - see Appendix 3) 
is a validated 20 question screening tool for depressive symptoms.  A score of >16 is 
indicative of depression, and >26 of severe depression (Weissman et al. 1977; 
Radloff 1977; Lyness et al. 1997; Irwin et al. 1999).  A score of 21 has been shown to 
have a sensitivity of 92% and specificity of 87% for major depression (Lyness et al. 
1997; Schulberg et al. 1985).  This has led to its use as a popular screening tool 
(Irwin et al. 1999). 
 
However, as with the majority of screening questionnaires, the CES-D does not 
equate to a diagnosis but does uncover previously undiagnosed cases (Weissman et 
al. 1977; Lyness et al. 1997; Irwin et al. 1999; Noyes et al. 2011). 
4.3.1.3.	  Methods	  
4.3.1.3.1.	  Patient	  selection	  
All patients referred by their General Practitioner (GP) to the vascular surgery 
outpatients clinic at Charing Cross Hospital, London, for management of their 
varicose veins, over a 6 month period from January to June 2011, were invited to 
complete a validated questionnaire relating to disease-specific quality of life, using 
the Aberdeen Varicose Veins Questionnaire (AVVQ) (Garratt et al. 1993) and 
health-related QOL, using the EuroQol-5D questionnaire (EQ-5D, EuroQol Group, 
Rotterdam, The Netherlands) and EuroQol-Visual Analogue Score (EQ-VAS) 
{TheEuroQoLGroup:1990wb}-CITATION_IS_EMPTY. The presence of depressive 
symptoms was determined using the Centre for Epidemiological Studies Depression 
Scale (CES-D Scale) (Weissman et al. 1977) - Table 5. A 20 item self-reporting scale 
which has been shown to be both a sensitive and valid screening tool for detecting 
depressive symptoms (Weissman et al. 1977) across different populations 
(McCallum et al. 1995). 
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Table 5:  An overview of the questionnaires used in this study 
 
No patients were excluded from the study.  Ethics approval was obtained from the 
Local Research Ethics Committee (LREC), and the study was termed Service 
Evaluation.  Questionnaires were administered in a clinic setting following the 
consultation and prior to any intervention. 
 
Questionnaires typically took 30 min to complete. Patients did not receive any 
direction regarding how they should be filled, but were provided standardised 
guidance notes and given the opportunity to ask questions. 
 
Generic QOL measurement tools, such as the EuroQol (EQ-5D), are divided into 
domains of interest. They thereby allow mental, physical and social aspects of QOL 
to be evaluated independently. Disease-specific QOL measurement tools, such as 
the AVVQ, (Garratt et al. 1993) attempt to quantify the change in QOL due to an 
individual disease state. In combination, these two types of tool provide a powerful 
and robust method for assessing both the baseline QOL and disease-specific QOL 
and were therefore both utilised in this study. 
 
Patient age, occupation, gender, medical co-morbidity and history of previous 
intervention for varicose veins were also determined. The clinical severity of venous 
disease was established by the treating physician using the Clinical Etiologic 
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Anatomic Pathophysiologic (CEAP) classification, Venous Clinical Severity Score 
(VCSS) and Venous Disability Score (VDS) (Rutherford et al. 2000). 
Once completed, all questionnaires were collated and analysed. Patients with CES-
D scores of >16 were referred to their GP for further management.   
4.3.1.3.2.	  Statistical	  analysis	  
Univariate linear correlation analysis was used to assess the relationship between 
two independent variables. Mann-Whitney- U test was used to assess the difference 
between two independent groups. Statistical significance was expressed as both p 
values and 95% confidence intervals. A p value <0.05 was considered statistically 
significant. 
4.3.1.4.	  Results	  
4.3.1.4.1.	  Demographic	  data	  
A hundred patients were recruited from a total of 125 eligible patients (80% uptake) 
over the 6 months study period. There were 37 men (37%) and 63 women (63%). All 
questionnaires were fully completed and included in the analysis. The mean age of 
patients was 52.7 years (range, 24-91 years), 72% of patients were under the age of 
65 and 28% were aged 65 years or more. There was no significant correlation 
between CES-D score and patient age (p = 0.30, r2 = 0.011). There was no difference 
in depression scores between those patients aged over 65 years and those aged less 
than 65 years old (p = 0.60).  Twenty-nine per cent of all patients had CES-D scores 
greater than 16 and 5% of patients had CES-D scores greater than 26. No patient 
had previously been diagnosed or treated, or were on current treatment for 
depression. 
 
In terms of past medical history, no patient had co-existing peripheral vascular 
disease. Thirty-three patients (33%) had previously undergone intervention for their 
varicose veins. There was no significant difference in CES-D scores in patients who 
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had previously undergone treatment for their varicose veins, compared to those who 
had not (p = 0.94). 
4.3.1.4.2.	  Depression	  and	  quality	  of	  life	  
A weak positive correlation was seen between CES-D score and disease-specific 
QOL as evaluated using the AVVQ (p = 0.0009, r2 = 0.11) (Figure 47).  
 
Figure 47:  Correlation between CES-D and disease specific quality of life as indicated by the AVVQ 
score (p = 0.0009, r2 = 0.11). 
A significant negative correlation was seen between CES-D score and health-related 
QOL as indicated by EQ-5D (p < 0.0009, r2 = 0.32) and EQ-VAS scores (p < 0.0009, 
r2 = 0.25) (Figure 48 and Figure 49).  Higher EQ-5D and EQ-VAS, unlike the AVVQ 
score, indicate better QOL and lower EQ-5D and EQ-VAS scores worse QOL. 
 
Figure 48:  Correlation between CES-D and health-related quality of life as indicated by the EQ-5D 
(p < 0001, r2 = 0.32) and EQ-VAS scores (p = 0.0009, r2 = 0.25). 
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Figure 49:  Correlation between CES-D and health-related quality of life as indicated by the EQ-5D 
(p < 0001, r2 = 0.32) and EQ-VAS scores (p = 0.0009, r2 = 0.25). 
4.3.1.4.3.	  Depression	  and	  clinical	  severity	  of	  venous	  disease	  
Patients with severe depression (n = 5) were observed to have venous disease of 
clinical stage 4-6, as defined by the CEAP classification. However, overall there was 
no difference in CES-D scores with varying clinical stage (p = 0.30). CES-D score did 
not correlate with the VCSS (p = 0.07, r2 = 0.03) or VDS (p = 0.75) (Figure 50 and 
Figure 51). 
 
Figure 50:  Venous Clinical Severity Score (VCSS) in relation to CES-D score. No difference in CES-
D scores is seen with VCCS (p = 0.07, r2 = 0.03). 
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Figure 51:  Venous Disability Score (VDS) in relation to CES-D score. No difference in CES-D scores 
is seen with VDS (p = 0.75). 
4.3.1.4.4.	  Depression	  and	  Reponse	  to	  Treatment	  
After initial assessment of the depressive burden, data continued to be collected, 
including after intervention, as part of the venous disease cohort study. 
 
Recruitment of completed CES-D questionnaires totalled 284 pre-operative patients 
and 195 post-operative patients. 
 
Figure 52:  Pre and Post-Operative CES-D score 
Mean pre-operative score was 11.27 (±9.117) and showed a significant improvement 
to 9.61 (±8.997) post-operatively (p=0.049), a drop of 14.7%. 
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4.3.1.5.	  Discussion	  
The presence of depression in patients with varicose veins has undergone only 
limited investigation previously. In contrast, QOL status in patients with varicose 
veins has been extensively investigated, (Garratt et al. 1993; Biemans et al. 2011) 
(Kaplan et al. 2003; Kurz et al. 2001) and is an accepted outcome measure used 
both in clinical practice and in clinical trials investigating varicose vein treatment 
(Carradice et al. 2011; Shepherd et al. 2010; Darvall et al. 2010).  QOL measures 
are also shown to be better correlated with symptomatology and patient satisfaction 
than anatomical or technical measures (Shepherd et al. 2011). 
 
Varicose veins are common with a reported incidence of 20-25% in women, and 10-
15% in men (Beebe-Dimmer et al. 2005; Maurins et al. 2008). A number of studies 
have shown an increased incidence of depression and anxiety in patients with 
venous ulcers, with reported incidences ranging from 40 to 60% (Palfreyman et al. 
2010; Ratcliffe et al. 2007). Our study reports an incidence of depression in patients 
with symptomatic varicose veins of 29% and this falls to 26% when patients with 
healed or active venous ulcers are excluded. This is twice the reported prevalence of 
depression within the general population (Demyttenaere et al. 2004), but is similar 
to that reported in patients with chronic physical health problems. 
 
Esteban et al, in a Spanish study of 7341 subjects aged >15 years with a variety of 
chronic medical diseases, found that depression had a significant impact on health-
related QoL (Esteban y Pena et al. 2010). When looking specifically at the impact of 
venous disease on mental health, Smith et al in their study found no significant 
difference in the mental health domain of the SF-36 in patients with varicose veins 
compared to those without, (Smith et al. 1999) but following treatment with open 
surgery there was a significant improvement in the mental health domain. In our 
study, depressive symptoms correlated with disease-specific and health-related QoL 
outcomes, however, we failed to demonstrate any correlation with clinical disease 
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severity. A possible explanation is that depression may alter a patient's perception 
of the severity of venous disease. Chronic physical health problems are also seen to 
precipitate and exacerbate depression and this may be true for varicose veins 
(Moretti et al. 2011). 
In our study similar depression scores were reported amongst men and women. This 
is in contrast to the incidence within the general population, where women are 
twice as likely to suffer from depression compared to men (Murakumi 2002). The 
reasons for this are unclear. In addition, there was no correlation with depression 
and age as documented in other studies of depression in the general population. 
However, there were few patients in our study over the age of 65 years (27%). 
Both depression and varicose veins are treatable once diagnosed. Work by Chassany 
et al (Chassany et al. 2006) showed that general practitioners 
routinely under-estimate the quality of life impairment due to venous disease whilst 
over-estimating that from peripheral arterial occlusive disease. Notably, no patients 
in our study had previously been diagnosed or were on treatment for their 
depression. 
 
The aim of this study was to assess the burden of disease in ambulatory patients 
with symptomatic varicose veins, who have presented to their GP and subsequently 
to a vascular surgeon for treatment. However, this group of patients may not reflect 
the burden of depression in varicose veins patients within the general population. 
Moreover, the influence of socioeconomic factors and ethnicity on depression scores 
was not ascertained in this study.  
 
Further work has been completed with extended numbers of patients since 
completion of the initial discrete study.  This has provided a larger cohort of pre- 
and post-intervention scores, which have shown a significant drop after 
intervention.  This would be in keeping with resolution of physical symptoms 
improving holistic wellbeing (Katon et al. 2007), and also agree with our findings of 
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strong correlation between CES-D and quality of life (both generic and disease 
specific) prior to treatment. 
 
With the large burden of disease associated with depression simple treatments of 
physical conditions may be a key component in the population level treatment of 
depression. 
4.3.1.6.	  Conclusion	  
Patients with symptomatic varicose veins are at increased risk of depression 
compared to the general population. This study reports a high incidence of 
previously unreported and undiagnosed depression in this group of patients. 
Further investigation of a patient's wellbeing and a more holistic approach in the 
management of patients with venous disease is therefore recommended.  
Additionally, this work has shown that intervention for varicose veins reduces 
patients scores on the CES-D depression screening questionnaire, further 
strengthening the rationale for venous treatment. 
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5.1.	  Introduction	  
Varicose veins are a common but often underestimated condition (O'Hare & 
Earnshaw 2009; Rabe & Pannier 2010).  Epidemiological estimates give a 
prevalence of 25-50% (Beebe-Dimmer et al. 2005) and there is extensive evidence 
that intervention provides significant cost-effective improvements in quality of life 
(Rasmussen et al. 2011; Gohel et al. 2010; Nesbitt et al. 2011).  Modern treatments 
offer minimally invasive procedures with low morbidity (Lane et al. 2011). 
 
Due to financial constraints and the ageing population, rationing of treatment has 
become accepted as a necessary evil (Broqvist & Garpenby 2011), and is best 
assessed on cost effectiveness of the treatment itself (Grassi & Ma 2011) and need 
(Cuff et al. 2012).  Varicose veins have long been classed as a condition with low 
priority {Lindsey:2006vo}-CITATION_IS_EMPTY, partly due to the prevalence and 
partly due to the wide spectrum of symptoms (Campbell et al. 2007). 
 
There has been a recent movement towards using vein diameter to stratify patients 
suitable for treatment and indeed reimbursements in some countries depend on 
vein diameter criteria being met, including the UK (NHS North West London 2011).  
This is despite clear referral recommendations against such rationing (National 
Institute for Clinical Excellence 2001; Venous Forum of the Royal Society of 
Medicine et al. 2011). 
 
The evidence base for this assumption is sparse, and often made on the 
presumption of traditional surgical operations (Abbott et al. 2011).  There is some 
evidence to show that chronic venous insufficiency (CVI - CEAP classification C4-
C6) is associated with worse disease specific quality of life scores (Aberdeen 
Varicose Vein Questionnaire - AVVQ) and a larger vein diameter (VD), when 
compared to chronic venous disease (C1-C3) (Conway et al. 2011; Gibson et al. 
2012).  Previous work in our unit showed no association between anatomical reflux 
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(venous segmental disease score - VSDS) or haemodynamic assessments (venous 
refill time - VRT) and outcomes (Shepherd et al. 2011). 
 
The aim of this study was to assess the association between clinical grading 
(CEAP), clinical severity score (Venous Clinical Severity Score - VCSS), disease 
specific quality of life score (AVVQ) and vein diameter (VD). 
5.2.	  Methods	  
Regional ethical sub-committee approval was sought and obtained for this study.  
Patients were recruited from those attending a tertiary referral vascular clinic for 
assessment and treatment of varicose veins between January 2011 and July 2012 
(18 months). 
 
Patients underwent duplex ultrasound scans of the venous tree in the standing 
position and were then assessed according to the CEAP and VCSS clinical scoring 
systems and were invited to complete a questionnaire assessing disease specific 
quality of life (AVVQ).  Patients were follow-up opportunistically after treatment 
due to lack of funding for follow-up visits in the NHS clinic. 
 
Maximal vein diameter, CEAP, VCSS and AVVQ scores were collated on a database 
(Access 2010, Microsoft, Richmond) and underwent statistical analysis (SPSS v21, 
IBM, Armonk, USA).  Data was analysed using three separate methods - as one 
group (1), as groups dependent on VD (2) and as clinically graded CEAP groups (3). 
 
(1) formed one group which underwent analysis using Spearman's Correlation 
Coefficient 
(2) formed five groups surrounding the mean VD using t tests 
(3) formed two groups (C1-3 and C4-6) which underwent analysis using Mann-
Whitney tests comparing VD, AVVQ and VCSS 
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Additional unpublished and unanalysed data from a previous randomised controlled 
trial (Shepherd et al. 2010) was included in the full dataset (recruitment period July 
2008 - July 2009). 
5.3.	  Results	  
5.3.1.	  Demographics	  
The demographics for patients recruited to the vein diameter assessment (including 
previously unpublished data from the VALVV study) are presented in Table 6. 
Table 6:  Vein Diameter Cohort Demographics 
 Pre-Operative Post-Operative Significant? 
n 461 227  
Age 50.66 51.85 ns 
M:F 43:57 42:58 ns 
BMI>30 9% 22% p < 0.01 
Vein Diameter 8.06 mm 7.346 ns 
VCSS 6.47 3.32 p < 0.001 
AVVQ 21.80 13.22 p < 0.001 
EQ5D 0.718 0.80 p < 0.001 
EQ VAS 75.70 80.63 p < 0.01 
CES-D 11.27 9.61  p < 0.05 
5.3.2.	  Overall	  Comparisons	  
There was no significant correlation between VD and AVVQ (r=0.060, r2=0.011, 
p=0.160), however there was a weak but significant positive correlation between VD 
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and both VCSS (r=0.169, r2=0.017, p=0.001) and CEAP (r=0.169, r2=0.020, p=0.008).  
These results are displayed in Figure 53, Figure 54 and Figure 55. 
 
Figure 53:  Vein diameter vs AVVQ. Correlation r = 0.060, p = 0.111, ns; Linear Regression r2 = 0.011 
 
Figure 54:  Vein diameter vs CEAP. Correlation r = 0.169, p<0.001; Linear Regression r2 = 0.020 
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Figure 55:  Vein diameter vs VCSS. Correlation r = 0.164, p=0.001;  Linear Regression r2 = 0.017 
 
Figure 56:  Vein Diameter vs EQ5D QOL (r=-0.57, r2= 0.003, p=0.181) and EQ5D VAS (r=-0.46, r2= 
0.003, p=0.230)  
There was no significant correlation found with generic quality of life as seen in 
Figure 56. 
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5.4.2.	  Stratification	  by	  Clinical	  CEAP	  Grade	  
The results were divided into two groups depending on clinical grading - CEAP 
score – see Table 7.  Group one represented mild venous disease - C1-C3 
(telangectasia to leg swelling); and group two represented more severe venous 
disease - C4-C6 (skin changes to active ulceration).  55% of patients were graded as 
having mild disease (254 of 461) and 45% as severe.  The severe group had a 
significantly higher mean age (57 years vs 49 years, p<0.001) and proportion of men 
in the group (55.1% vs 32.7%, p<0.001). 
Table 7:  Study population stratified by CEAP Classification into groups C1-C3 (mild venous 
disease) and C4-C6 (severe venous disease).  
 CEAP C1-C3 CEAP C4-C6 Significant? 
Age 49.28 57.29 p<0.001 
Proportion Female (%) 67.3 44.9 p<0.001 
BMI >30 11.1% 7.5% ns 
Vein Diameter (mm) 7.605 8.640 p=0.04 
VCSS 6.41 12.65 p<0.001 
AVVQ 19.016 25.190 p<0.001 
EQ-5D QOL 0.686 0.750 p=0.004 
EQ-5D VAS 76.57 74.83 ns 
CES-D 10.25 12.26 ns 
 
The severe group were found to have significantly larger mean maximal vein 
diameters (8.6 mm vs 7.6mm, p=0.04), higher mean AVVQ scores (25.190 vs 19.016, 
p<0.001) and higher mean VCSS (12.65 vs 6.41, p<0.0001).  These are displayed in 
table 7. 
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5.4.3.	  Stratification	  by	  Gender 
Male patients had a significantly higher CEAP clinical stage (4 vs 3, p=0.001), but 
significantly improved QOL both disease specific and generic - AVVQ (19.485 vs 
23.472, p=0.001), EQ5D QOL (0.759 vs 0.682, p=0.001) and EQ5D VAS (78.34 vs 
73.44, p=0.006).  There was no significant difference between genders in VCSS 
scores (p=0.058), vein diameter (p=0.129), or CES-D (p=0.285). 
5.4.4.	  Receiver	  Operator	  Curve	  Analysis	  of	  Vein	  Diameter	  
As there is no diagnostic test for varicose veins and as patients recruited into this 
cohort are by definition patients with symptomatic varicose veins, surrogate 
markers for a positive diagnosis have to be used.  Therefore, Receiver Operator 
Curve (ROC) analysis was performed on the maximum vein diameter to access it's 
specificity and sensitivity as a diagnostic test. 
 
Previous studies have suggested that the AVVQ be used as a rationing tool to 
indicate patients qualifying for treatment (Ward et al. 2013; Lattimer et al. 2013).  
Therefore, ROC analysis was performed at the following AVVQ points - 10, 15, 20, 
25 and 30.  The ROC graphs are shown in Figure 57.  All of the curves produced 
showed very poor accuracy using maximal diameter as a diagnostic test. 
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Figure 57:  ROC curves for AVVQ = 15-30 cut-offs.  Area under curve: 10=0.522, 15=0.517, 20=0.529, 
25=0.509, 30=0.558. 
Many local referral guidelines suggest using CEAP scoring as a rationing tool, and 
so the ROC analysis was also performed for CEAP classes 3 and 4.  CEAP 2 was not 
used due to the absence of C1 or C0 patients in this cohort (a limitation previously 
seen in (Carradice et al. 2011)).  The CEAP ROC graphs are shown in Figure 58. 
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Figure 58:  ROC curves for CEAP 3 and 4 cut-offs.  Area under curve: 3=0.616 , 4=0.589. 
Finally, VD cut-offs at 6mm, 8mm, 10mm and 12mm were assessed.  These are 
displayed below in Figure 59 and Figure 60 show poor accuracy. 
 
 
Figure 59:  ROC curves for Vein Diameter 6mm and 8mm cut-offs.  Area under curve - all less than 
0.550 
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Figure 60:  ROC curves for Vein Diameter 10mm and 12mm cut-offs.  Area under curve - all less than 
0.550 
5.4.3.	  Response	  to	  treatment	  
Treatment has previously been shown to be successful in improving clinical status, 
disease specific QOL scores and generic QOL scores.  227 patients have completed 
post-intervention questionnaires.  A summary of the results is shown in Table 6. 
5.4.3.1.	  Clinical	  Outcomes	  
5.4.3.1.1.	  CEAP 
CEAP scores are not designed to assess treatment and are therefore relatively 
insensitive to change of disease.  Whilst the median CEAP did not change pre- and 
post-intervention, the proportional makeup did (p<0.001).  CEAP was not correlated 
with VD post-intervention. 
Table 8:  CEAP Scores for Venous Disease Cohort Pre and Post Intervention 
CEAP Stage Pre-Intervention Post-Intervention 
1 0.9% 18.6% 
2 28.4% 24.8% 
3 25.3% 13.8% 
4 37.3% 30.5% 
5 4.3% 3.8% 
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6 3.3% 1.9% 
5.4.3.1.2.	  VCSS	  
The clinician scoring system showed a significant improvement from 6.47 to 3.32 
(p<0.001).  No correlation was seen between VCSS and VD. 
5.4.3.2.	  Generic	  Quality	  of	  Life	  
5.4.3.2.1.	  EQ-­‐5D	  QOL	  
Mean EQ-5D QOL improved from 0.718 to 0.800 (p<0.001).  No correlation was seen 
with post-intervention EQ-5D QOL and VD. 
5.4.3.2.2.	  EQ-­‐5D	  VAS	  
Mean EQ-5D VAS improved from 75.70 to 80.63 (p<0.01).  No correlation was seen 
between EQ-5D VAS and VD. 
5.4.3.3.	  Disease	  Specific	  Quality	  of	  Life	  
5.4.3.3.1.	  AVVQ	  
AVVQ improved significantly from 21.80 to 13.22 (p < 0.001).  AVVQ post-
intervention was negatively correlated with VD (r=-0.140, r2=0.019, p=0.043). 
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Figure 61:  Maximal vein diameter vs AVVQ post-intervention. 
No correlation was found between VD and change in AVVQ at any time point. 
5.4.	  Discussion	  
This study shows that there is a significant correlation between VD and clinical 
scoring systems (VCSS and CEAP).  However, this correlation is extremely weak 
and not clinically significant.  Crucially there is no correlation between VD and 
symptomatology suffered by patients (AVVQ).  However, and more importantly, 
patients with more advanced disease - CEAP clinical classes C4-6, have a larger 
mean vein diameter.  This indicates that vein diameter may be an independent risk 
factor for complicated varicose vein disease.  If so, progression to severe venous 
disease may be preventable by treatment of enlarged veins.  However, this process 
would be complicated by the fact that symptomatology is not associated with VD 
and so patients at risk may not attend - screening would be required, which would 
not be feasible or appropriate on the current evidence base as asymptomatic veins 
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would not benefit from treatment unless individuals at high risk can be accurately 
identified. 
 
Extensive work has shown that varicose vein treatment works and is cost-effective, 
and these treatment pathways offer all types of treatment as day cases whether 
open surgery or endovenous treatment.  Due to the population size, many 
healthcare systems are attempting to limit treatment to those who most need it.  
This rationing has been achieved with the use of VD as a hurdle.  In the UK many 
PCTs have utilised 3 mm, as have insurers in the UK and US.  Whilst this is 
sensible from a technical viewpoint - cannulating a small vein takes considerable 
skill and radiofrequency treatment catheters for example are over 2mm in 
diameter, it has no basis in the literature.  As endovenous skills increase and 
devices become smaller, this "technical" boundary recedes in importance.  
Additionally, due to the nature of the saphenous vein, it is a hidden vein.  
Therefore, if VD is used as a rationing tool, it would require the primary care use of 
venous duplex ultrasound to ascertain whether the vein is large enough for referral 
- this would engender far more ultrasound scans, leading to a much higher cost. 
 
From this study it is clear that not only does this "treat the scan not the patient" 
approach ignore the patient and their symptoms; from the ROC analyses performed, 
it is clear VD has no role as a rationing tool.  Additionally, the true nature of 
progression of venous disease and vein diameter changes are not known (Engelhorn 
et al. 1997; Engelhorn et al. 2007; Engelhorn et al. 2012) - treating a small vein now 
may prevent more costly treatment and extensive morbidity in the future (Lane et 
al. 2013). 
 
From a patient perspective, patients seek medical treatment not due to the size of 
the truncal vein but due to symptoms.  There is no evidence linking varicosed 
surface tributary diameter with truncal vein diameter.  Indeed there is evidence of 
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non-saphenous varicosity reflux in isolation (Labropoulos et al. 2001).  This 
prevents clinicians from making accurate diagnosis on examination alone.  
Therefore, clinical history and validated questionnaires are crucial methods of 
assessing outcomes from this extremely common but relatively benign disease.  The 
use of national Patient Reported Outcome Measures (PROMs) data enables 
conclusions to be drawn from population level venous treatment {Nesbitt:2012bl}-
CITATION_IS_EMPTY, however there is little data published by the Department of 
Health of the impact of the endovenous revolution. 
 
Interestingly, this data agrees with the general trend for men to present with worse 
health conditions than women (Doyal 2001; Farrimond 2012).  Men are over-
represented by in the severe disease group (C4-6) compared to the total group 
(55.1% vs 32.3%, p<0.001).  Whether this is because of delayed presentation or a 
general susceptibility is difficult to hypothesis. 
 
Previous work (Gibson et al. 2012) has shown that great saphenous vein diameter 
does not correlate with patients symptoms and quality of life impairment in a study 
of 91 patients, however only 10 patients had severe disease (C4-6), which means 
assessment of effect of VD on CEAP is unavailable.  Conway et al's work (Conway et 
al. 2011) supports the findings of this study that whilst vein diameter does not 
correlate with quality of life scores it is positively associated with increased CEAP 
category.  Unfortunately the Conway study did not include VCSS scoring, but did 
have a robust data set with 85 C4 - C6 patients.  A recently published retrospective 
cohort study of 55 limbs with maximal GSV diameter < 5mm compared with 116 
limbs of maximal GSV diameter > 5mm found similar improvement between in both 
groups, according to VCSS and CEAP (Perrins et al. 2013).  This study did not 
assess AVVQ, the groups were significantly different in terms of BMI, age, and 
CEAP and follow-up was limited to 3 months. 
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This main strength of this study is the large numbers involved with data collected 
in a prospective manner, with both clinical and quality of life scoring systems 
utilised.  However, limitations exist due to lack of follow-up post-procedure data.  
Most crucially this study does not answer the question of whether large vein 
diameter is associated with the development of venous skin changes and ulceration.  
This would necessitate a large multi-centre long term follow-up study to be 
completed, such as the Bonn or Edinburgh Vein Studies (Rabe et al. 2003; 
Robertson et al. 2013).  Patients in this cohort have already developed the peak of 
their condition prior to treatment, which then causes regression.  A long-term 
cohort study of these patients would enable assessment of recurrence and/or 
progression of the disease. 
 
Multivariable analysis of the vein diameter data will allow clarity on whether the 
size of incompetent vein is a truly an independent risk factor for treatment outcome, 
which will be discussed in the modelling section of this manuscript. 
5.5.	  Conclusion	  
Whilst vein diameter is associated with clinical stage of venous disease, it has no 
significant bearing on patient symptoms and experience.  Therefore it has no role as 
a diagnostic or rationing test.  It should be used as a component of patient selection 
for treatments (Goode et al. 2009) rather as a blunt rationing tool. 
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6.1.	  Introduction	  
Varicose veins are subject to increasing pressure due to limitations on funding and 
an inaccurate perception that the treatment is superfluous (Audit Commission 
2011).  Varicose veins are the most common operation in vascular surgery, but also 
the most commonly litigated (Ray 2005; Markides et al. 2008; Campbell et al. 2002), 
this is despite evidence that over 90% of primary and 75% of recurrent varicose vein 
patients being satisfied with treatment (Gandhi et al. 2010).  Additionally, historic 
anecdotal evidence of significant pain post-operatively with open surgery biases 
patient viewpoints despite extensive studies demonstrating good tolerability and 
low pain scores (Leopardi et al. 2009). 
 
The risk of litigation has been reduced with the use of pre-operative duplex 
ultrasound scans providing key haemodynamic data (Campbell et al. 2002; Ray 
2005; Markides et al. 2008; J. R. H. Scurr & J. H. Scurr 2007). 
 
Therefore, assessing which patients improve and which do not is vital in raising the 
awareness of this debilitating disease. 
 
Extensive work has previously been completed to model the pre-intervention impact 
of venous disease on patients and to assess the utility of treatment both from QOL 
and economic viewpoints (Carradice et al. 2011; Gohel et al. 2010).  This data has 
been used to help form the 2013 NICE guidelines 
{NationalInstituteforHealthandCareExcellence:2013vv}-CITATION_IS_EMPTY.  
These studies have utilised pre-operative data (Carradice et al. 2011) and 
previously published RCT data (Gohel et al. 2010), to create predictive models.    
Modelling of longitudinal data aims to identify key variables that influence patient 
outcomes with the benefit of pre-operative and comparative post-operative outcome 
data. 
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The principle aim of this study is to assess and describe these key factors via the 
cohort of patients that have completed patient outcome questionnaires. 
6.2.	  The	  Development	  of	  a	  Rationing	  Tool	  
The pragmatic purpose for model creation is to predict which patient benefit most 
from treatment.  This is to improve the overall outcomes of varicose vein treatment 
by selecting the most appropriate patients.  Additionally it helps to identify patients 
who do not improve and reasons why. 
 
Once these factors have been discovered, a rationing tool can be developed to ensure 
that patients who will not benefit do not receive inappropriate treatment. 
6.3.	  Principles	  of	  modelling	  
Modelling data uses statistical tools to provide a prospective estimation of 
outcomes. 
6.3.1.	  Multivariable	  Analysis	  
Multivariable statistics deal with multiple inputs to one single outcome - I.e. Many 
independent variables but one outcome dependent variable (Katz 2003). 
6.3.1.1.	  Regression	  
Linear regression concerns a method of examining causal association between an 
independent and dependent variable, and the degree of association (Bland & 
Altman 1994; Bowers 2008).  Multiple linear regression concerns a examining 
multiple independent variables and one dependent variable (Bowers 2008).  Linear 
regression requires linear continuous variables for appropriate model construction. 
 
However, in clinical practice patients may present as symptomatic or not - a binary 
outcome.  This cannot be readily examined with linear regression and so logistic 
regression is an appropriate method to examine relationships.  The benefit of 
logistic regression is to produces an Odds Ratio for the relationship - i.e. The odds 
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that if you have the appropriate risk factor then you will have the disease in 
question (Bowers 2008).  Again logistic regression can be expanded into multiple 
logistic regression 
 
Proportional hazards regression assesses longitudinal studies and provides a 
hazard ratio of reaching a discrete endpoint over a timescale (often the endpoint is 
death) (Bowers 2008; Katz 2011). 
6.3.2.	  Univariate	  and	  multivariate	  analysis	  
Univariate analysis is the assessment of one independent variable in the sample 
data.  Using this method the effect of individual factors can be adjusted and 
modelled. 
 
Multivariate analysis utilises the interplay of many independent variables to adjust 
and formulate a model for factor analysis and risk factor assessment (Katz 2011; 
Hair 2010). 
6.3.2.1.	  Factor	  Analysis	  
The aim of factor analysis is to reduce large number of seemingly independent 
factors to a smaller number of truly independent factors, which then allow for true 
modelling assessment with the use of assumptions and constant values (Hair 2010). 
6.3.3.	  The	  Markov	  Chain	  and	  the	  Monte	  Carlo	  Method	  
The Markov Chain is a decision tree, which has probabilities at each Markov or 
chance node (Gohel et al. 2010).  This provides a probability of reaching each 
endpoint of the decision tree.  Each node has a options whose sum probability is 1.  
This allows all possibilities to be modelled, and the probabilities are constructed 
using available experimental data.  An example is shown in Figure 62.  The 
probability of A->B->C->A = 0.6x0.7x0.8 = 0.336 
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Figure 62:  Example Markov Chain indicating a decision tree. 
The Monte Carlo method is a statistical process of running repeat simulations of 
decision tree to test validity, variance and uncertainty (Spiegelhalter et al. 2004; 
Gohel et al. 2010).  Whilst these simulations can be extremely complex and 
accurate, it must be remembered that they are artificial approximations based on 
real-life study data probabilities.  These testing methods are best used in situations 
where multiple variables are present and many assumptions have to be made, 
essentially where measurements are not possible or feasible (Rogers 2006; Nguyen 
et al. 2013; Hempel et al. 2013; Oono et al. 2013). 
6.4.	  Response	  to	  treatment	  
The aim of factor analysis is to reduce large number of seemingly independent 
factors to a smaller number of truly independent factors, which then allow for true 
modelling assessment with the use of assumptions and constant values. 
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6.5.	  Capacity	  to	  benefit	  
The ability of patients to benefit from venous treatment is key.  Some patients 
suffer from significant recurrences at short time periods, whereas others have a 
single treatment that lasts the rest of their lifetime (Allegra et al. 2007; Blomgren 
et al. 2004).  Differentiating between the groups is key to offering a pragmatic 
bespoke service.  It also prevents patients from having multiple gradually more 
complex procedures for minimal benefit. 
 
Whilst the majority of the difference in the patient groups is phenotypic and genetic 
(Lim & Davies 2009), isolating individual variables is key to the optimisation of the 
treatment pathway. 
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6.6.	  Vein	  Cohort	  Data	  Model	  
The Venous Disease patient cohort data previously described has been utilised in 
advanced statistical analysis using a senior statistician’s assitance to provide 
models looking at 3 main outcomes - symptomatic benefit (AVVQ), Clinician 
Deemed Benefit (VCSS) and Overall Quality of Life Benefit (EQ-5D).  The aim is to 
elucidate key independent variables that affect the outcome of patients. 
 
All patients in this cohort undergo treatment, and therefore a good model should be 
able to predict the outcomes.  The model is created on the pre-intervention data and 
then assessed against the post-intervention data, which was measured at 6 weeks, 6 
months and 1 year. 
6.6.1.	  Symptomatic	  Benefit	  
The Symptomatic Benefit of treatment is assessed using the patient completed 
AVVQ, which as described earlier is a patient completed symptom score, allowing 
outcomes of the surgery to be assessed from the patient viewpoint.  The baseline 
data was assessed to identify factors associated with the outcome, and from these 
predictive models were created. 
6.6.1.1.	  Model	  1	  
6.6.1.1.1.	  Introduction	  
The first model was created using baseline data from the venous patient cohort to 
predict the AVVQ outcome. 
6.6.1.1.2.	  Statistical	  methods:	  
Initial analysis was performed using linear regression, as AVVQ is measured on a 
continuous scale.  The AVVQ outcome distribution showed a positive skew and was 
therefore log transformed.  Repeated univariable analyses then investigated the 
baseline variables for association with the outcome. 
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Those variables which had shown significant association (p<0.02, allowing for 
correction for multiple comparisons) were then subjected to multivariable analysis, 
and using a backwards selection procedure all non-significant values were removed 
leaving only significant variables in the final model. 
 
This technique was used as it allows for the effects of each variable to be adjusted 
for the other variables, which better clarity of the underlying associations between 
these variables.  Only those variables which have a significant effect on the outcome 
variable are then assessed in the multivariable analysis as allows for simplification, 
which is then continued with the incremental removal of all none significant 
variables in the backwards selection procedure.  This should provide only 
significant variables of interest for the final model. 
 
The model was then evaluated with the follow-up data as observed values to 
compare with the predicted values from the model. 
6.6.1.1.3.	  Results:	  
 
Table 9:  Results of AVVQ univariable analysis 
 Category Ratio (95% CI) P-value 
CEAP 0-2    1 0.02 
3 1.42 (1.06, 1.99)  
4-6 1.53 (1.14, 2.04)  
Vein diameter (*) - 1.08 (0.93, 1.26) 0.29 
Sex Female    1 <0.001 
Male 0.60 (0.48, 0.74)  
Age (**) - 1.00 (0.93, 1.08) 0.98 
Leg Right    1 0.03 
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 Category Ratio (95% CI) P-value 
Left 1.06 (0.79, 1.43)  
Both 1.42 (1.06, 1.92)  
Obese (BMI >30) No     1  0.80 
Yes 0.96 (0.73, 1.28)  
Previous VV surgery No     1  0.18 
Yes 1.21 (0.91, 1.61)  
Vein treated LSV    1 0.24 
SSV 1.22 (0.87, 1.70)  
Smoking status Non-smoker    1 0.64 
Smoker 0.90 (0.57, 1.42)  
(*)   Ratio reported for a 5-unit increase in predictor variable 
(**) Ratio reported for a 10-unit increase in predictor variable 
 
The results of the univariable analysis indicate that when examined separately only 
CEAP, sex and leg were significantly associated with AVVQ (Table 9). 
 
The CEAP results indicate as found before that increasing CEAP leads to increasing 
AVVQ.  Patients with CEAP 4-6 had AVVQ scores just over 50% higher than CEAP 
0-2. 
 
Patient gender showed reduced AVVQ scores for men compared to women, with 
men's scores on average only 60% of the women's scores. 
 
Leg results indicated minimal difference between left and right leg single 
symptomatic patients but a 40% increase in symptomatology in bilateral 
symptomatic leg patients. 
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Following multivariable analysis and backwards selection, only CEAP and sex were 
independently associated with AVVQ scores as shown in Table 10, with laterality 
now longer being significant. 
 
Table 10:  Results of AVVQ Multivariable Analysis and Backwards Selection 
 Category Ratio (95% CI) P-value Regression Coefficient 
CEAP 0-2 1   0.004  
3 1.27 (0.94, 1.72)  0.24 
4-6 1.56 (1.20, 2.02)  0.44 
Sex Female 1 <0.001  
Male 0.59 (0.48, 0.73)  -0.53 
Intercept - - - 2.90 
 
This was then converted into a predictive model for AVVQ, and this can be 
expressed as: 
AVVQ = exp(2.90 + (0.24 if CEAP =3 + 0.44 if CEAP≥4 - 0.53 if Male) 
i.e. The model would predict in a 50 year old man with CEAP 3 disease the 
following: 
AVVQ = exp(2.90+0.24-0.53) = exp(2.61) = 13.599. 
This model was then compared with the follow-up data in Figure 63 - a plot of 
AVVQ - Observed vs AVVQ - Predicted.  The diagonal line represents perfect 
agreement. 
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Figure 63:  AVVQ Model outcome - Observed vs Predicted AVVQ.  Diagonal = perfect agreement. 
The accuracy of the model is also explained in Figure 64 showing differences in 
predicted and observed verses observed. 
 
Figure 64:  AVVQ - Observed vs Difference between model prediction and observed AVVQ 
6.6.1.1.4.	  Discussion: 
The two plots suggest a poor predictive ability of this first AVVQ model.  
Predictions are all between 10-30, where as observed values range from 0-50.  The 
model discrimination of high and low AVVQ is poor.  The likely explanation is the 
small number of variables found to be significantly associated with the outcome in 
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the baseline data.  In addition, these variables were categorical and so are not very 
discriminatory. 
 
Additionally, the majority of predictions were 78% higher than those observed, and 
this is likely to be due to the reduction in AVVQ post-intervention.  This will likely 
cause any baseline model to over-predict, however a good model should still be able 
to discriminate between high and low scores. 
The second plot explains that the high values were under-predicted and the low 
values over-predicted. 
 
Overall, there were only two variables independently associated with AVVQ from 
the baseline data.  This predictive model did not adequately predict the AVVQ 
scores observed at follow-up.  This reinforces the known literature that symptoms of 
varicose veins are often difficult (Bradbury et al. 1999) to quantify and may be out 
of proportion to anatomical or clinical features.  This first model attempted to 
predict outcomes wholly independently of outcome, which as shown above leads to 
over-estimation due to treatment and consequent reduction of symptomatic status.  
This model may be suitable to ascribe predicted AVVQ scores to new patients 
presenting to the department prior to completion of the scoring questionnaires.  To 
test this model would however require a separate cohort of patients, ideally from 
the same geographical location. 
6.6.1.2.	  Model	  2	  
6.6.1.2.1.	  Introduction 
The first model used baseline values to predict values at follow-up. This was shown 
to not be particularly effective, mainly as follow-up values were lower than those at 
baseline. So in the second model the follow-up values were considered as the 
outcome in the analyses. 
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6.6.1.2.2.	  Statistical	  Methods 
There are three follow-up timepoints, and due to the decrease in AVVQ values over 
time, in order to obtain any reliable predictions, each timepoint was considered 
separately. To create this second model the AVVQ values at 6 weeks were treated 
as the outcome values in the analysis. The patient characteristics at baseline were 
considered to be the predictor variables. 
 
As before, AVVQ was measured on a continuous scale and so was again initially 
analysed using linear regression.  Once more the distribution suggested a positive 
skew and so the AVVQ values were log transformed prior to analysis.  This analysis 
was again performed in two stages: 
 
• Firstly the separate association between each variable and the outcome was 
assessed separately in a series of univariable analyses.  
• Secondly the joint association between the variables and the AVVQ score was 
assessed in a multivariable analysis. 
 
As the baseline data are the predictor variables and the follow-up data the outcome 
values, there is no independent data on which to test the fit of a predictive model.  A 
statistic which can be used to measure of the fit of the model is the R2 statistic, 
which measures the amount of total variability in the outcome explained by the 
model, and which is expressed as either a proportion, or a percentage. A high value 
would imply a good model fit, and thus a better likelihood of good predictions in the 
future.  
6.6.1.2.3.	  Results	  
6.6.1.2.3.1.	  AVVQ	  at	  6	  weeks	  
Initially the separate association between each of the patient characteristics and 
the AVVQ score at 6 weeks was examined in a series of univariable analyses. The 
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results are summarised in Table 11. Due to the log transformation of the AVVQ 
scores, the results are presented in the form of ratios. For the categorical variables, 
this gives the ratio of AVVQ values in each category relative to the  values in a 
baseline category. For the continuous variables the relative change in AVVQ is 
reported for a given increase in each variable. Associated confidence intervals are 
reported for each ratio, along with p-values indicating the significance of the 
results. 
 
Table 11:  Results of Univariable comparison for AVVQ at 6 weeks. 
  Category Ratio (95% CI) P-value 
AVVQ at baseline (*) - 1.22 (1.13, 1.31) <0.001 
CEAP 0-2    1 0.21 
3 1.50 (0.81, 2.78)  
4-6 1.61 (0.94, 2.76)  
Vein diameter (*) - 0.93 (0.72, 1.20) 0.56 
Sex Female    1 0.02 
Male 0.60 (0.40, 0.91)  
Age (**) - 1.05 (0.91, 1.20) 0.53 
Leg Right    1 0.06 
Left 0.97 (0.57, 1.63)  
Both 1.64 (0.98, 2.76)  
Obese (BMI >30) No     1  0.73 
Yes 1.09 (0.68, 1.74)  
Previous VV surgery No     1  0.01 
Yes 1.86 (1.14, 3.03)  
Vein treated LSV    1 0.32 
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  Category Ratio (95% CI) P-value 
SSV 1.34 (0.75, 2.38)  
Smoking status Non-smoker    1 0.91 
Smoker 0.95 (0.41, 2.22)  
(*)   Ratio reported for a 5-unit increase in predictor variable 
(**) Ratio reported for a 10-unit increase in predictor variable 
 
The results showed that, when variables were examined separately, AVVQ at 
baseline, sex and previous VV surgery were all significantly associated with AVVQ 
at 6 weeks. There was also some evidence of a difference in AVVQ scores between 
legs, although this difference was not statistically significant. The remaining 
variables were not found to be associated with this outcome at 6 weeks. 
 
Higher AVVQ scores at baseline were associated with higher scores at 6 weeks. A 5-
unit increase in the score at baseline was associated with a 22% increase in scores 
at 6 weeks. 
 
The gender differences suggested lower scores for males relative to females. Scores 
for males were only 60% as large as those for females.  
 
Patients with previous VV surgery had higher scores at 6 weeks, on average 86% 
higher than those with no previous surgery. 
 
The second stage in the analysis was to examine the joint association between the 
variables and AVVQ scores at 6 weeks in a multivariable analysis. A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the final model is summarised in Table 12.  
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Table 12:  Results of Backwards Selection for AVVQ at 6 weeks 
 Category Ratio (95% CI) P-value 
AVVQ at baseline (*) - 1.21 (1.13, 1.30) <0.001 
Previous VV surgery No     1  0.01 
Yes 1.78 (1.14, 2.78)  
(*)   Ratio reported for a 5-unit increase in predictor variable 
 
The multivariable analysis indicates that only AVVQ at baseline and previous VV 
surgery were independently associated with the AVVQ scores at 6 weeks. After 
adjusting for these two variables, there was no longer any significant association 
between sex and this outcome. Again patients with higher AVVQ scores at baseline 
and those undergoing previous VV surgery had higher AVVQ scores at 6 weeks. 
 
The regression coefficients from the final model were then calculated, and used to 
create down a predictive model for AVVQ at 6 weeks, which can be expressed as 
follows: 
 
AVVQ 6 weeks = exp(1.27 + 0.039 x AVVQ baseline + 0.58 if previous surgery) 
 
This is shown in Figure 65. 
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Figure 65:  Demonstration of AVVQ at 6 weeks model 
The R2 value from the final model is 0.30 (or 30%). This suggest that 30% of the 
variation in the AVVQ scores at baseline is due to the two variables in the final 
model. This suggests that whilst the variables have some predictive ability, there is 
a lot of variation (70%) which is unexplained by the model. Therefore the model is 
unlikely to give extremely reliable predictions of AVVQ at 6 weeks. 
6.6.1.2.3.2.	  AVVQ	  at	  6	  months	  
Following creation of the model for AVVQ at 6 weeks the same technique was 
completed for the AVVQ values at 6 months. 
 
Again the separate association between each of the patient characteristics and the 
AVVQ score at 6 months was examined in a series of univariable analyses. The 
results are summarised in Table 13.  Due to the log transformation of the AVVQ 
scores, the results are presented in the form of ratios.  For the categorical variables, 
this gives the ratio of AVVQ values in each category relative to the values at 
baseline.  For the continuous variables the relative change in AVVQ is reported for 
a given increase in each variable. 
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Table 13:  Results of Univariable comparison for AVVQ at 6 months. 
 Category Ratio (95% CI) P-value 
AVVQ at baseline (*) - 1.25 (1.16, 1.35) <0.001 
CEAP 0-2    1 0.30 
3 1.23 (0.67, 2.25)  
4-6 1.50 (0.89, 2.55)  
Vein diameter (*) - 0.95 (0.73, 1.22) 0.67 
Sex Female    1 0.04 
Male 0.66 (0.44, 0.98)  
Age (**) - 1.00 (0.87, 1.15) 0.98 
Leg Right    1 0.42 
Left 1.15 (0.70, 1.91)  
Both 1.40 (0.84, 2.35)  
Obese (BMI > 30) No     1  0.14 
Yes 1.42 (0.87, 2.27)  
Previous VV surgery No     1  0.27 
Yes 1.31 (0.81, 2.11)  
Vein treated LSV    1 0.27 
SSV 1.36 (0.78, 2.37)  
Smoking status Non-smoker    1 0.65 
Smoker 0.78 (0.26, 2.30)  
(*)   Ratio reported for a 5-unit increase in predictor variable 
(**) Ratio reported for a 10-unit increase in predictor variable 
 
From the invariable analysis, only AVVQ at baseline and sex were significantly 
associated with AVVQ at 6 months.  Higher AVVQ scores at baseline were 
associated with higher scores at 6 months.  A 5-unit increase in the score at 
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baseline was associated with a 25% increase in scores at 6 months.  The gender 
differences suggested lower scores for males relative to females, with scores a third 
lower for males compared to females.  
 
The second stage in the analysis was to examine the joint association between the 
variables and AVVQ scores at 6 months in a multivariable analysis. A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the final model is summarised in Table 14  
 
Table 14:  Results of Backwards Selection for AVVQ at 6 months 
 Category Ratio (95% CI) P-value 
AVVQ at baseline (*) - 1.26 (1.17, 1.35) <0.001 
Obese (BMI > 30) No     1  0.03 
Yes 1.55 (1.04, 2.33)  
(*) Ratio reported for a 5-unit increase in predictor variable 
 
The results of the multivariable analysis indicates that AVVQ at baseline and 
obesity were independently associated with the AVVQ scores at 6 months. After 
adjusting for these two variables, there was no longer any significant association 
between sex and this outcome. Again patients with higher AVVQ scores at baseline 
had higher AVVQ scores at 6 months. 
 
Obesity was not significant in the univariable analyses. However, after adjusting 
for the AVVQ score at baseline, this was now significant. Obese patients had higher 
values, on average 55% higher than those who were not obese. 
 
The regression coefficients from the final model were also obtained, and then used 
to create the predictive model for AVVQ at 6 months, which can be expressed as 
follows: 
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AVVQ 6 months = exp( 1.06 + 0.046 x AVVQ baseline + 0.44 if obese) 
 
This is shown in Figure 66: 
 
Figure 66:  Demonstration of AVVQ at 6 months model 
The R2 value from the final model is 0.36 (or 36%).  This suggests that 36% of the 
variation in the AVVQ scores at 6 months is due to the two variables in the final 
model.  This suggests that whilst the variables have some predictive ability, there is 
a lot of variation (64%) which is unexplained by the model.  Therefore once again, 
the model is unlikely to give extremely reliable predictions of AVVQ at 6 months. 
6.6.1.2.3.3.	  AVVQ	  at	  12	  months	  
The final AVVQ outcome examined was the AVVQ scores at 12 months, using the 
same procedure as before. 
 
Initially the separate association between each of the patient characteristics and 
the AVVQ score at 12 months was examined in a series of univariable analyses, and 
the results are summarised in Table 15.  
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Table 15:  Results of Univariable comparison for AVVQ at 12 months. 
 Category Ratio (95% CI) P-value 
AVVQ at baseline (*) - 1.36 (1.22, 1.51) <0.001 
CEAP 0-2    1 0.03 
3 1.31 (0.56, 3.03)  
4-6 2.45 (1.19, 5.04)  
Vein diameter (*) - 0.62 (0.41, 0.93) 0.02 
Sex Female    1 0.43 
Male 0.79 (0.44, 1.43)  
Age (**) - 1.04 (0.83, 1.29) 0.73 
Leg Right    1 0.15 
Left 0.90 (0.45, 1.80)  
Both 1.74 (0.83, 3.66)  
Obese (BMI > 30) No     1  0.55 
Yes 1.24 (0.61, 2.50)  
Previous VV surgery No     1  0.01 
Yes 2.31 (1.22, 4.35)  
Vein treated LSV    1 0.70 
SSV 0.85 (0.36, 2.01)  
Smoking status Non-smoker    1 0.74 
Smoker 1.27 (0.31, 5.26)  
(*)   Ratio reported for a 5-unit increase in predictor variable 
(**) Ratio reported for a 10-unit increase in predictor variable 
 
The results suggest that, when each variable is examined separately, AVVQ at 
baseline, CEAP, vein diameter and previous VV surgery are all significantly 
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associated with AVVQ at 12 months.  The remaining variables were not found to be 
associated with this outcome at this timepoint. 
 
Higher AVVQ scores at baseline were associated with higher scores at 12 months. A 
5-unit increase in the score at baseline was associated with a 36% increase in scores 
at12 months. 
 
The results for CEAP suggested that patients with higher values had higher AVVQ 
scores.  Those with a score of 4-6 had AVVQ values at 12 months that were 2.5 
times higher than patients with CEAP value of 0-2. 
 
Increased vein diameter was associated with lower AVVQ scores at 12 months. A 5-
unit increase in vein diameter was associated with a decrease in values of just over 
a third. 
 
Patients with previous VV surgery also had higher AVVQ scores at 12 months. On 
average, these were 2.3 times greater than for patients with no previous surgery. 
 
The second stage in the analysis was to examine the joint association between the 
variables and AVVQ scores at 12 months in a multivariable analysis.  A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the final model is summarised in Table 16.  
 
Table 16:  Results of Backwards Selection for AVVQ at 12 months 
 Category Ratio (95% CI) P-value 
AVVQ at baseline (*) - 1.33 (1.20, 1.47) <0.001 
Previous VV surgery No     1  0.03 
Yes 1.73 (1.06, 2.84)  
(*) Ratio reported for a 5-unit increase in predictor variable 
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The multivariable analysis indicates that only AVVQ at baseline and previous VV 
surgery were independently associated with the AVVQ scores at 12 months.   After 
adjusting for these two variables, there was no longer any significant association 
between either CEAP or vein diameter and the outcome at this timepoint.   Again 
patients with higher AVVQ scores at baseline and those undergoing previous VV 
surgery had higher AVVQ scores at 12 months. 
 
The regression coefficients from the final model can also be obtained, and used to 
write down a predictive model for AVVQ. This can be expressed as follows: 
 
AVVQ 12 months = exp( 0.59 + 0.057 x AVVQ baseline + 0.55 if previous surgery) 
 
This is shown in Figure 67: 
 
Figure 67:  Demonstration of AVVQ at 12 months model 
The R2 value from the final model is 0.36 (or 36%).  This suggest that 36% of the 
variation in the AVVQ scores at 12 months is due to the two variables in the final 
model. This suggests that whilst the variables have some predictive ability, there is 
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a lot of variation (64%) which is unexplained by the model.  Therefore the model is 
unlikely to give extremely reliable predictions of AVVQ at 12 months. 
6.6.2.	  Clinician	  Deemed	  Benefit	  
Clinician deemed benefit was assessed using the VCSS which as described earlier is 
a clinician completed clinical scoring system which allows assessment of treatment 
success from a physician standpoint. 
 
Using the methods from the assessment of the symptomatic benefit modelling 
process, this was repeated for the VCSS outcome for the 6 week, 6 month and 12 
month time points, with a view to create a predictive model from baseline data. 
6.6.2.1.	  Statistical	  Methods	  
The second outcome assessed was the VCSS scores. An examination of the follow-up 
scores suggested that the scores varied over the follow-up period. As a result, a 
separate analyses was performed for each follow-up time period. The analysis of 
this outcome was performed using linear regression.  On examination, the 
distribution of the VCSS scores were not perfectly normally distributed, however 
the assumptions of the regression methods were met in all analyses. 
 
As described previously, the analysis was performed in two stages, with both a 
univariable and multivariable analysis performed. 
6.6.2.2.	  Results	  
6.6.2.2.1.	  	  Overall	  VCSS	  score	  
The scores at the three follow-up time-points were examined, and summaries of the 
scores at each time-point are given in Table 17. The figures reported are the mean 
and standard deviation, as well as the median and inter-quartile range. 
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Table 17:  Overall VCSS Values 
Timepoint Mean (SD) Median (IQR) 
6 weeks 3.0 (2.2) 3 (1, 4) 
6 months 2.5 (2.3) 2 (0, 4) 
12 months 2.0 (2.4) 1 (0, 3) 
 
The results suggested decreasing values over the course of the follow-up period. As 
a result, the data from each follow-up timepoint was analysed separately 
6.6.2.2.2.	  VCSS	  at	  6	  weeks	  
Initially the separate association between each of the patient characteristics and 
the VCSS scores at 6 weeks was examined in a series of univariable analyses.  The 
results are summarised in Table 18 as regression coefficients, along with 
corresponding confidence intervals.  For the categorical variables, this gives the 
difference in VCSS values in each category and the values in a baseline category.  
For the continuous variables the change in VCSS score is reported for a given 
increase in each variable.  P-values indicating the significance of the results are also 
presented. 
 
Table 18:  Results of Univariable comparison for VCSS at 6 weeks. 
 Category Coefficient (95% CI) P-value 
VCSS baseline (**) - 0.4 (0.2, 0.5) <0.001 
CEAP 0-2         0 0.01 
3 0.6 (-0.7, 1.9)  
4-6 1.6 (0.5, 2.8)  
Vein diameter (*) - 0.2 (-0.4, 0.8) 0.48 
Sex Female          0 0.42 
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 Category Coefficient (95% CI) P-value 
Male -0.4 (-1.3, 0.5)  
Age (**) - 0.6 (0.3, 0.9) <0.001 
Leg Right         0 0.03 
Left 0.7 (-0.5, 1.8)  
Both 1.5 (0.4, 2.7)  
Obese (BMI > 30) No          0 0.42 
Yes 0.4 (-0.6, 1.5)  
Previous VV 
surgery 
No           0   0.003 
Yes 1.6 (0.6, 2.6)  
Vein treated LSV         0 0.61 
SSV 0.3 (-0.9, 1.6)  
Smoking status Non-smoker         0 0.71 
Smoker 0.3 (-1.5, 2.2)  
(*)   Coefficient reported for a 5-unit increase in predictor variable 
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
When each variable was examined separately, the VCSS score at baseline, CEAP, 
age, leg and previous VV surgery were significantly associated with values at 6 
weeks. 
 
Higher VCSS scores at baseline were associated with higher scores at follow-up.  A 
10-unit increase in the score at baseline was associated with a 0.4 unit increase in 
scores at follow-up. 
 
The CEAP score results suggested higher VCSS values for increased scores.  
Patients with a score of 4-6 at baseline had the highest values, with VCSS scores at 
6-weeks, on average, 1.6 units higher than for those with a score of 0-2. 
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Older patients also had higher scores, with a 10-year increase in age associated 
with a 0.6 unit increase in outcome.  Additionally those having previous surgery 
also had higher values, on average 1.6 units higher. 
 
The leg results suggested the lowest scores in the right leg group, with the highest 
scores in those in the both leg group.  The both group had VCSS scores that were 
1.5 units higher than the right leg group. 
 
The second stage in the analysis was to examine the joint association between the 
variables and VCSS scores at 6 weeks in a multivariable analysis.  A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the results are summarised in Table 19. 
 
Table 19:  Results of Backwards Selection for VCSS at 6 weeks 
 Category Coefficient (95% CI) P-value 
VCSS baseline (**) - 0.3 (0.2, 0.5) <0.001 
Age (**) -   0.4 (0.1, 0.6) 0.01 
Previous VV surgery No             0 0.01 
Yes 1.2 (0.3, 2.1)  
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results of the multivariable analysis indicated that VCSS score at baseline, age 
and previous VV surgery were independently associated with VCSS score at 6 
weeks. After adjusting for these variables, there was no longer any significant 
association between CEAP or leg and the outcome.  
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Again patients with higher VCSS scores at baseline, older patients and those with 
previous surgery all had higher values at 6 weeks. 
 
The regression coefficients from the final model were obtained, and used to write 
down a predictive model for the VCSS score at 6 weeks and expressed as follows: 
 
VCSS 6 weeks = -1.56 + 0.32. VCSS baseline + 0.036 x age + 1.18 if previous surgery 
 
The R2 value from the final model is 0.35 (or 35%). This suggest that 35% of the 
variation in the VCSS scores at 6 weeks is due to the three variables in the final 
model.  
6.6.2.2.3.	  VCSS	  at	  6	  months	  
Next the VCSS scores at 6 months were considered. Initially the separate 
association between each of the patient characteristics and the VCSS scores was 
examined in a series of univariable analyses. The results are summarised in Table 
20.  
 
Table 20:  Results of Univariable comparison for VCSS at 6 months. 
 Category Coefficient (95% CI) P-value 
VCSS baseline (**) - 0.3 (0.1, 0.4) 0.01 
CEAP 0-2         0   0.003 
3 -0.1 (-1.5, 1.3)  
4-6 1.7 (0.5, 3.0)  
Vein diameter (*) - -0.1 (-0.7, 0.6) 0.86 
Sex Female          0 0.31 
Male -0.5 (-1.6, 0.5)  
Age (**) - 0.5 (0.2, 0.8)   0.003 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
205 
 Category Coefficient (95% CI) P-value 
Leg Right         0 0.03 
Left 0.7 (-0.6, 2.0)  
Both 1.7 (0.4, 2.9)  
Obese (BMI > 30) No          0 0.59 
Yes 0.3 (-0.9, 1.5)  
Previous VV surgery No           0 0.01 
Yes 1.6 (0.4, 2.7)  
Vein treated LSV         0 0.08 
SSV 1.3 (-0.2, 2.7)  
Smoking status Non-
smoker 
        0 0.90 
Smoker -0.2 (-2.9, 2.6)  
(*)   Coefficient reported for a 5-unit increase in predictor variable 
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results suggest that, when each variable was examined separately, the VCSS 
score at baseline, CEAP, age, leg and previous surgery were significantly associated 
with values at 6 months.  There was also some evidence of an association with the 
outcome for vein treated, but this result was not quite statistically significant. 
 
Higher VCSS scores at baseline were associated with higher scores at 6 months.  A 
10-unit increase in the score at baseline was associated with a 0.3 unit increase in 
scores at 6 months. 
 
The CEAP score results suggested little difference between those with a score of 3 
and those with a score of 0-2.  However, patients with a score of 4-6 had increased 
values, on average 1.7 units higher than those with a score of 0-2.  
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Older patients had higher scores at 6 months, as did patients in the both leg group.  
Higher scores were also observed in patients with previous surgery, on average 1.6 
units higher than patients with no previous surgery. 
 
The second stage in the analysis was to examine the joint association between the 
variables and VCSS scores at 6 weeks in a multivariable analysis. A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the results are summarised in Table 21. 
 
Table 21:  Results of Backwards Selection for VCSS at 6 months 
 Category Coefficient (95% CI) P-value 
CEAP 0-2            0   0.003 
3 -0.4 (-1.7, 0.9)  
4-6 1.4 (0.2, 3.0)  
Age (**) -   0.3 (0.0, 0.6) 0.05 
Previous VV surgery No             0 0.01 
Yes 1.4 (0.3, 2.5)  
Vein treated LSV            0 0.04 
SSV 1.3 (0.0, 2.5)  
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results of the multivariable analysis indicated some evidence that CEAP score, 
age, previous VV surgery and vein treated were independently associated with the 
VCSS score at 6 months. After adjusting for these variables, there was no additional 
effect of VCSS score at baseline or leg upon the 6 month scores. 
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As in univariable analyses patients with CEAP scores of 4-6, older patients, and 
those with previous surgery all had higher VCSS scores. 
 
Vein treated was not quite significant in the univariable analyses. However, after 
adjusting for the other variables in the multivariable analysis, this variable was 
now statistically significant. Patients with a SSV vein treated had higher scores at 
6 months, on average 1.3 units higher. 
 
The regression coefficients from the final model can also be obtained, and used to 
write down a predictive model for the VCSS score at 6 months. This can be 
expressed as follows: 
 
VCSS 6 months = -0.38 - 0.42 if CEAP 3 + 1.36 if CEAP 4-6 + 0.032 x age 
                  + 1.42 if previous surgery + 1.29 if vein SSV 
 
The R2 value from the final model is 0.32 (or 32%). This suggest that 32% of the 
variation in the VCSS scores at 6 months due to the three variables in the final 
model.  
6.6.2.2.4.	  VCSS	  at	  12	  months	  
The final analysis examined factors associated with the VCSS score at 12 months.  
A summary of the univariable analysis results is given in Table 22. 
 
Table 22:  Results of Univariable comparison for VCSS at 12 months. 
 Category Coefficient (95% CI) P-value 
VCSS baseline (**) - 0.3 (0.0, 0.6) 0.04 
CEAP 0-2         0 0.04 
3 -0.3 (-2.4, 1.8)  
4-6 1.7 (-0.1, 3.5)  
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 Category Coefficient (95% CI) P-value 
Vein diameter (*) - -0.4 (-1.3, 0.4) 0.29 
Sex Female          0 0.25 
Male 0.8 (-0.6, 2.2)  
Age (**) - 0.7 (0.2, 1.2) 0.01 
Leg Right         0 0.03 
Left 0.1 (-1.5, 1.8)  
Both 2.0 (0.3, 3.8)  
Obese (BMI > 30) No          0 0.24 
Yes 1.0 (-0.7, 2.6)  
Previous VV surgery No           0   0.007 
Yes 2.2 (0.6, 3.7)  
Vein treated LSV         0 0.35 
SSV 1.0 (-1.2, 3.1)  
Smoking status Non-smoker         0 0.38 
Smoker -1.5 (-5.0, 1.9)  
(*)   Coefficient reported for a 5-unit increase in predictor variable 
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results suggested that, when each variable was examined separately, the VCSS 
score at baseline, CEAP, age, leg and previous VV surgery were significantly 
associated with values at 12 months.  The remaining variables were not found to be 
associated with VCSS values at 12 months. 
 
Higher VCSS scores at baseline were associated with higher scores at 12-months.  A 
10-unit increase in the score at baseline was associated with a 0.3 unit increase in 
scores at 12-months. 
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The CEAP score results suggested that patients with a score of 4-6 had higher 
outcome values compared to those with lower scores. 
 
Older patients had higher VCSS scores at 12 months, with a 10-year increase in age 
associated with a 0.7 unit increase in score.  
 
There was little difference in outcome between the left and right leg group. 
However, the both leg group had higher values, 2.0 units higher than the right leg 
group. 
 
Patients with previous VV surgery had VCSS scores at 12 months that were, on 
average, 2.2 units higher than the group having no surgery. 
 
The second stage in the analysis was to examine the joint association between the 
variables and VCSS scores at 12 months in a multivariable analysis. A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the results are summarised in Table 23. 
 
Table 23:  Results of Backwards Selection for VCSS at 12 months 
 Category Coefficient (95% CI) P-value 
CEAP 0-2            0 0.03 
3 -1.0 (-2.8, 00.9)  
4-6 1.0 (-0.6, 2.7)  
Age (**) -   0.6 (0.1, 1.1) 0.01 
Previous VV surgery No             0 0.02 
Yes 1.7 (0.3, 3.2)  
(**) Coefficient reported for a 10-unit increase in predictor variable 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
210 
 
The results of the multivariable analysis indicated that CEAP score, age and 
previous VV Surgery were independently associated with the VCSS score at 12 
months.  After adjusting for these variables, VCSS score at baseline and leg were 
not found to be additionally statistically significant. 
 
 The results for CEAP score again suggested highest values in group with a score of 
4-6.  As in the univariable analyses, older patients and those with previous surgery 
also had higher scores. 
 
The regression coefficients from the final model can also be obtained, and used to 
write down a predictive model for the VCSS score at 6 weeks, which is: 
 
VCSS 12 months = -1.90 - 0.97 if CEAP 3 + 1.03 if CEAP 4-6 + 0.060 x age + 1.72 if 
previous surgery 
 
The R2 value from the final model is 0.39 (or 39%).  This suggest that 39% of the 
variation in the VCSS scores at follow-up is due to the three variables in the final 
model.  
6.6.3.	  Overall	  Quality	  Of	  Life	  Benefit	  
The final component to outcomes assessment of varicose vein treatment, after 
disease specific symptom effect and disease specific clinical score is the outcome for 
the overall well-being of the patient - the generic QOL assessment.  These were 
assessed using the EQ-5D QOL and EQ-VAS assessment tools. 
 
Using the methods from the assessment of the symptomatic benefit modelling 
process, this was repeated for the EQ-5D QOL and EQ-VAS outcomes for the 6 
week, 6 month and 12 month time points, with a view to create a predictive model 
from baseline data. 
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6.6.3.1.	  EQ-­‐5D	  QOL	  
6.6.3.1.1.	  Statistical	  Methods	  
An examination of the follow-up values indicated that there was little variation in 
the scores between the follow-up time periods.  As a result it was chosen to consider 
a single analysis for all time-points.  Data from all follow-up time-points was 
treated as the outcome values in the analysis, with the patient characteristics at 
baseline considered to be the predictor variables. 
 
As all time-points were considered in a single analysis, there are up to three 
measurements from each subject in the analysis.  It is likely that two values from 
the same patient are more similar than values from different patients, which 
violates the assumption of many statistical methods (Goldstein et al. 2002; 
Goldstein 2011).  To allow for this multilevel statistical methods were used for the 
analysis, which can account for multiple responses from each patient (Goldstein et 
al. 2002; Goldstein 2011).  Two level models were used with individual results 
nested within patients. 
 
The EQ-5D QOL scores were measured on a continuous scale, and as a result 
multilevel linear regression was used for the analysis.  An examination of the 
distribution of the values suggested that these had a negatively skewed 
distribution.  It is difficult to transform such data to be more normally distributed.  
However, the assumptions of the statistical methods were met despite this 
distribution, and therefore the distribution was not transformed. 
 
The analysis was performed in two stages.  Firstly the separate association between 
each variable and the outcome was assessed separately in a series of univariable 
analyses.  Subsequently the joint association between the variables and the EQ-5D 
QOL score was assessed in a multivariable analysis.  To reduce the number of 
variables in this stage of the analysis, only those variables showing some evidence 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
212 
of an association with the outcome in the univariable analyses (p<0.02) were 
considered for this stage of the analysis.  The final model was produced by using a 
backwards selection procedure.  This involves removing non-significant values one 
at a time, until all remaining variables were statistically significant. 
 
Again there is no independent data on which to test the fit of a predictive model, 
and therefore the R2 statistic was again used as measure of the model's fit. 
6.6.3.1.2.	  Results	  
The scores at the three follow-up time-points were examined, and summaries of the 
scores at each time-point are given in Table 24.  The figures reported are the mean 
and standard deviation, as well as the median and inter-quartile range. 
 
Table 24:  Overall EQ-5D QOL Values 
Time EQ-5D QOL Mean (SD) EQ-5D QOL Median (IQR) 
6 weeks 0.82 (0.21) 0.84 (0.75, 1.00) 
6 months 0.82 (0.19) 0.84 (0.74, 1.00) 
12 months 0.84 (0.17) 0.84 (0.74, 1.00) 
 
The results suggested almost identical values at the three follow-up timepoints.  As 
a result, the data from all timepoints was analysed together. 
 
Initially the separate association between each of the patient characteristics and 
the EQ-5D scores was examined in a series of univariable analyses.  The results are 
summarised in Table 25.  This shows the regression coefficients.  For the categorical 
variables, this gives the difference in QOL values in each category and the values in 
a baseline category.  For the continuous variables the change in QOL score is 
reported for a given increase in each variable. 
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Table 25:  Results of Univariable comparison for EQ-5D QOL 
 Category Coefficient (95% CI) P-value 
QOL score baseline (†) - 0.05 (0.03, 0.06) <0.001 
CEAP 0-2      0 0.21 
3 -0.09 (-0.19, 0.01)  
4-6 -0.05 (-0.14, 0.04)  
Vein diameter (*) - 0.01 (-0.04, 0.05) 0.76 
Sex Female       0 0.06 
Male 0.07 (0.00, 0.14)  
Age (**) - -0.02 (-0.04, 0.00) 0.08 
Leg Right       0 0.27 
Left -0.05 (-0.15, 0.03)  
Both -0.07 (-0.17, 0.02)  
Obese (BMI > 30) No       0 0.09 
Yes -0.06 (-0.014, 0.01)  
Previous VV surgery No        0 0.14 
Yes -0.06 (-0.15, 0.02)  
Vein treated LSV       0 0.10 
SSV -0.08 (-0.18, 0.01)  
Smoking status Non-smoker      0 0.99 
Smoker 0.00 (-0.14, 0.14)  
(†)   Coefficient reported for a 0.1-unit increase in predictor variable 
(*)   Coefficient reported for a 5-unit increase in predictor variable 
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results suggest that, when each variable was examined separately, only the 
EQ-5D QOL score at baseline was strongly associated with values at follow-up. 
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However, there was some evidence that sex, age, obesity and vein treated showed a 
trend towards significance, although results for these variables were not quite 
statistically significant.  The remaining variables were not found to be associated 
with QOL values at follow-up. 
 
Higher QOL scores at baseline were associated with higher scores at follow-up.  A 
0.1-unit increase in the score at baseline was associated with a 0.05 increase in 
scores at follow-up. 
 
The gender differences suggested higher scores for males relative to females.  Scores 
for males were 0.07 units higher, on average, for males than for females.  
 
QOL decreased with increased age.  A 10-year increase in age was associated with a 
0.02 unit decrease in QOL scores at follow-up. 
 
Obese patients also had a lower quality life scores, on average 0.06 units lower than 
for non-obese patients.  Patients whose SSV vein was treated also had lower quality 
of life at follow-up. 
 
Patients with previous VV surgery had higher scores at 6 weeks, on average 86% 
higher than those with no previous surgery. 
 
The second stage in the analysis was to examine the joint association between the 
variables and QOL scores at follow-up in a multivariable analysis.  A backwards 
selection procedure was used to retain only the statistically significant variables, 
and the final model is summarised in Table 26.  
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Table 26:  Results of Backwards Selection for EQ-5D QOL 
 Category Coefficient (95% CI) P-value 
QOL score baseline (†) - 0.05 (0.04, 0.06) <0.001 
Age (**)  -0.02 (-0.04, 0.00) 0.02 
Vein treated LSV         0 0.07 
SSV -0.07 (-0.15, 0.01)  
(†)   Coefficient reported for a 0.1-unit increase in predictor variable 
 (**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results of the multivariable analysis indicated some evidence that QOL score at 
baseline, age and vein treated were independently associated with the QOL score at 
follow-up.  The results for vein treated were not quite statistically significant, but it 
was chosen to retain these variables in the final model.  As in the univariable 
analyses, patients with higher baseline values had higher values at follow-up, 
whilst older patients and SSV patients had lower quality of life scores. 
 
The regression coefficients from the final model can also be obtained, and used to 
write down a predictive model for the QoL score.  This can be expressed as follows: 
 
EQ-5D QOL follow-up = 0.62 + 0.50 x EQ-5D baseline - 0.0023 x Age - 0.074 if SSV 
 
The R2 value from the final model is 0.29 (or 29%), suggesting that 29% of the 
variation in the EQ-5D QOL scores at follow-up is due to the three variables in the 
final model.  This suggests that whilst the variables have some predictive ability, 
there is a lot of variation (71%) which is unexplained by the model.  Therefore the 
model is unlikely to give extremely reliable predictions of QOL score at follow-up. 
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6.6.3.2.	  EQ-­‐VAS	  
The final outcome considered was the EQ-5D VAS scores.  An examination of the 
follow-up values indicated that there was little variation in the scores between the 
follow-up time periods.  As a result it was chosen to consider a single analysis for all 
timepoints.  Data from all follow-up timepoints was treated as the outcome values 
in the analysis, with the patient characteristics at baseline considered to be the 
predictor variables.  As all timepoints were considered in a single analysis, the 
analysis was performed using multilevel linear regression, as described 
previously(Goldstein et al. 2002; Goldstein 2011). 
 
An examination of the distribution of the outcome was assessed.  Although these 
were not perfectly normally distributed, the assumptions of the regression methods 
were met in all analyses. 
 
The scores at the three follow-up timepoints were examined, and summaries of the 
scores at each timepoint are given in Table 27.  The figures reported are the mean 
and standard deviation, as well as the median and inter-quartile range. 
 
Table 27:  Overall EQ-VAS Values 
Time EQ-VAS Mean (SD) EQ-VAS Median (IQR) 
6 weeks 79.5 (15.8) 80 (70, 90) 
6 months 79.1 (16.8) 85 (70, 90) 
12 months 78.0 (24.9) 85 (70, 96) 
 
The results suggested similar values at the three follow-up timepoints.  As a result, 
the data from all timepoints was analysed together. 
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Initially the separate association between each of the patient characteristics and 
the EQ-5D VAS scores was examined in a series of univariable analyses.  The 
results are summarised in Table 28 as the regression coefficients.  For the 
categorical variables, this gives the difference in VAS values in each category and 
the values in a baseline category.  For the continuous variables the change in VAS 
score is reported for a given increase in each variable. 
 
Table 28:  Results of Univariable comparison for EQ-VAS 
 Category Coefficient (95% CI) P-value 
VAS score baseline (**) - 6.6 (5.0, 8.1) <0.001 
CEAP 0-2      0 0.03 
3 -13.3 (-23.2, -3.4)  
4-6 -6.1 (-14.8, 2.6)  
Vein diameter (*) - -3.3 (-7.7, 1.0) 0.14 
Sex Female       0 0.32 
Male 3.6 (-3.5, 10.7)  
Age (**) - -0.3 (-2.7, 2.0) 0.79 
Leg Right       0 0.79 
Left -2.3 (-11.4, 6.8)  
Both -3.2 (-12.4, 6.0)  
Obese (BMI > 30) No       0 0.38 
Yes -3.8 (-12.2, 4.6)  
Previous VV surgery No        0 0.68 
Yes -1.8 (-10.3, 6.7)  
Vein treated LSV       0 0.62 
SSV 2.5 (-7.4, 12.4)  
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 Category Coefficient (95% CI) P-value 
Smoking status Non-smoker      0 0.79 
Smoker -2.0 (-17.0, 12.9)  
(*)   Coefficient reported for a 5-unit increase in predictor variable 
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results suggested that, when each variable was examined separately, only the 
EQ-5D VAS score at baseline and CEAP were significantly associated with values 
at follow-up.  The remaining variables were not found to be associated with VAS 
values at follow-up. 
 
Higher VAS scores at baseline were associated with higher scores at follow-up.  A 
10-unit increase in the score at baseline was associated with a 6.6 unit increase in 
scores at follow-up. 
 
The CEAP score results suggested a slightly inconsistent picture.  Patients with a 
score of 3 at baseline had the lowest values, with those with a score between 0 and 2 
the highest values.  Those with scores of 4-6 had values in the middle of the two 
other groups.  Values for patients with a score of 3 were, on average, 13 units lower 
than those for patients with a score of 0-2. 
 
The second stage in the analysis was to examine the joint association between the 
variables and VAS scores at follow-up in a multivariable analysis.  A backwards 
selection procedure was used to retain only the statistically significant variables.  
The results of two different models are presented in Table 29.  The first considers 
CEAP score as three categories.  However, due to the lack of a consistent trend, the 
analysis was repeated categorising the patients into only two CEAP groups, and 
this revised analysis is seen in the second part of Table 29. 
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Table 29:  Results of Backwards Selection for EQ-VAS.  Analysis 1 and 2. 
 Category Coefficient (95% CI) P-value 
Analysis 1    
VAS score baseline (**) - 6.3 (4.8, 7.8) <0.001 
CEAP 0-2           0 0.02 
3   -9.8 (-16.9, -2.8)  
4-6 -3.4 (-9.3, 2.6)  
    Analysis 2    
VAS score baseline (**) - 6.2 (4.7, 7.8)  
CEAP 0-2           0 0.07 
3-6 -5.4 (-11.2, 0.5)  
(**) Coefficient reported for a 10-unit increase in predictor variable 
 
The results of the multivariable analysis indicated some evidence that VAS score at 
baseline and CEAP score were independently associated with the VAS score at 
follow-up. The results for CEAP score not quite statistically significant when 
considered in two categories, but it was chosen to retain this variable in the final 
model. As in the univariable analyses, patients with higher baseline values had 
higher values at follow-up, whilst those with higher CEAP scores had lower values 
at follow-up. 
 
The regression coefficients from the final model can also be obtained, and used to 
write down a predictive model for the VAS score. Considering CEAP score in two 
categories, this can be expressed as follows: 
 
EQ-VAS follow-up = 36.4 + 0.62 x EQ-VAS baseline – 5.4 if CEAP≥3 
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The R2 value from the final model is 0.41 (or 41%), suggesting that 41% of the 
variation in the EQ-VAS quality scores at follow-up is due to the two variables in 
the final model.  
6.6.4.	  Discussion	  
This study has assessed the predictive ability of a standardised proforma (see 
Appendix 1) to predict the outcome of varicose vein treatment, when measured 
using patient reported outcome measures (PROMS - AVVQ, EQ-5D QOL and EQ-
VAS) and when measured by clinicians (VCSS).  Previous work by Carradice et al. 
(Carradice et al. 2011) demonstrated the complexity of venous disease and 
illustrated that increasing clinical severity led to worsening QOL, in the context of 
primary unilateral single trunk venous incompetence.  The key finding from the 
different models created is that the most important factor in delineating outcome 
was the symptom or clinical score pre-operatively.  Whilst patients with higher 
symptom score or clinical score pre-operatively have the greatest potential to 
benefit, to do so those patients also had to have the greatest improvement, from a 
standardised treatment.  The evidence from this study shows that these patients 
fare worse, symptomatically (AVVQ), with post-operative scores increasing 
exponentially with pre-operative scores.  Despite an larger actual reduction in 
AVVQ score, the proportion improvement is decreased.  It is likely that this 
represents increasingly persistent symptomatology - i.e. Worse symptoms are more 
difficult to resolve.  This exponential increase is not seen in the VCSS and EQ-5D 
QOL and EQ-VAS models, indicating a linear relationship, with worse clinical 
scores or generic quality of life leading to an increased improvement (but a constant 
proportion).  This variance may be explained by two main reasons - firstly, that the 
treatment resolves the anatomical situation and as is seen in symptom studies the 
anatomical data does not correlate well with symptomatology (Bradbury et al. 1999; 
Campbell et al. 2007; Conway et al. 2011; Gibson et al. 2012).  The second reason is 
that the generic quality of life measure may not be sufficiently sensitive to detect 
the persistence of disease symptoms that the AVVQ can detect. 
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This study used 461 individual patient data sets pre-operatively and 227 post-
operatively to produce models that showed a fit of between 30 and 41%.  No model 
was able to explain >41% of the variability seen in the outcomes with the data 
collected pre-operatively.  This underlines the difficulty found in previous studies 
(Bradbury et al. 1999; Campbell et al. 2007) - varicose veins are difficult to quantify 
and explain with anatomical or physical data poorly correlating with 
symptomatology (Conway et al. 2011; Gibson et al. 2012). 
 
Some authors are suggesting that patient reported outcome measures could be used 
as a rationing or triage tool (Staniszewska et al. 2013; Ward et al. 2013).  This is a 
flawed approach as not only does it lead to manipulation of the scores by patients 
(Fayers & Machin 2007) and is subject to selection bias (Rupp et al. 2002), it also 
ignores the fact that symptomatic benefit and symptoms themselves worsen with 
time (Carradice et al. 2011; Rabe et al. 2010; Robertson et al. 2013).  Additionally, 
recent work by Black et al. has shown that increasing the number of procedures (i.e. 
the reverse of rationing) does not lead to a significant reduction in symptom severity 
pre-operatively (Black et al. 2013).  This indicates that the NHS is not fully treating 
the affected population, and that treatment numbers should be increased.  The 
study supports this viewpoint with increased symptomatology having a relatively 
worse outcome. 
 
The principle aim of this study was to attempt to create a predictive model from a 
comprehensive data set.  The model which has been created provides a first 
predictive model for varicose vein outcomes.  Unfortunately this model is of limited 
accuracy and the predictive model requires further work with an increased number 
of variables collected to try and identify the key variables that drives outcomes. 
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The major limitations are firstly the lack of 100% follow-up of the cohort, which 
impairs the creation of the model, and prevented formal testing on independent 
data, due to low number of independent data points.  To enable formal testing, a 
new cohort of patients must be collected and analysed.  This would also allow for a 
refinement and extension of the data collected and improvement of the model, and 
cover the second major limitation - the initial baseline dataset is inadequate to fully 
explain the outcome.  This could not have been avoided prospectively, and will help 
to guide further prospective cohort data collection. 
6.6.5.	  Conclusion	  
This study demonstrates the complexity and individuality of varicose veins, and 
provides the first predictive model of varicose vein treatment outcomes in the 
context of endovenous ablation under local anaesthetic.  The model is limited in 
accuracy, and needs further refinement with independent data provided by a 
further prospective cohort.  Interestingly, it has unveiled further evidence that 
varicose vein symptomatology is difficult and non-linear, which should hopefully 
guide future work. 
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7.1.	  Introduction	  
Adjunctive procedures in the treatment of varicose veins are the treatment of non-
truncal varicosed veins - the small tortuous dilated veins that are commonly 
referred to as varicose veins by the lay public.  These are treated with either 
sclerotherapy or phlebectomy (avulsion). 
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7.2.	  Systematic	  Review	  of	  the	  Use	  of	  Adjunctive	  Procedures	  	  
7.2.1.	  Introduction	  
Traditional treatment of varicose veins involved general anaesthetic, SFJ ligation 
and stripping of the GSV.  At this point phlebectomies or multiple stab avulsions 
were completed to remove the varicosities present.  This enabled complete 
treatment of the pathological venous system in one sitting and became the standard 
of care. 
 
Figure 68:  The target of Adjunctive Procedures 
7.2.1.1.	  Local	  anaesthesia	  and	  patient	  choice	  
With the advent of minimally invasive endoluminal procedures, treatment 
pathways have changed with patient comfort and experience coming to the fore 
(Gandhi et al. 2010; Shepherd, Gohel, Lim, Hamish & Davies 2010b; Shepherd, 
Gohel, Lim, Hamish & Davies 2010a).  However, the majority of interventional 
treatments still remove the incompetent GSV or SSV, with either physical removal, 
ablation, sclerosant or occlusion (Lane et al. 2011). 
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Tumescent local anaesthesia has allowed extensive venous treatments with patients 
awake but comfortable (Do & Kelley 2007; Lane et al. 2011).  This has led to a move 
from the operating theatre into the procedure room (McLafferty 2006).  Procedure 
rooms may not have the facility for phlebectomy treatment, and historically 
phlebectomies were felt to be too painful for local anaesthetic treatment.  With the 
emergence of tumescent local anaesthesia this consensus is changed and the 
ASVAL technique and its variants offer excellent evidence of acceptability of local 
anaesthetic phlebectomies (Pittaluga et al. 2009; Onida et al. 2012).  Additionally 
studies have shown the safety of foam sclerotherapy during endovenous ablation 
(Yilmaz et al. 2011). 
Previous work has assessed patient preference for hernia repair showed 47% of 
patients opted for general anaesthetic, compared to 33% for local (Gnanalingham & 
Budhoo 1998), however, in the context of varicose veins patients preferred local 
anaesthetic treatment (71%) and single session treatment (63%) (Shepherd et al. 
2010). 
7.2.1.2.	  Reflux/Varicosities	  
The clinician therefore has a choice - to treat the varicosities at the first sitting or to 
arrange two treatment session, and consequently has led to debate over the 
treatment of the varicosities left behind (Mowatt-Larssen 2010; Passman 2011).  
Following the removal of the feeding truncal vein, the varicosities should from 
descending haemodynamic theory shrink down and become asymptomatic due to 
reduced flow, however recurrence may evolve despite technical success (Perrin et al. 
2000).  For some patients, the initial treatment is sufficient, but not for others.  
Recent evidence has shown that even techniques with robust occlusion and success 
rates can incur early recurrence (Lattimer et al. 2012; Kalodiki et al. 2012), which 
effects long term treatment needs. 
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7.2.1.3.	  Study	  Aim	  
This study aims to systematically review and perform a meta-analysis of the 
literature regarding the timing adjunctive procedures for the treatment of varicosed 
tributaries in the context of incompetent truncal vein ablation. 
7.2.2.	  Methods	  
7.2.2.1.	  Search	  Strategy	  
A search of the published literature was performed according to Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Liberati et 
al. 2009).  The searches were performed by two authors (T.L. and S.O).  The 
Medline and EMBASE online databases were searched from 1948 to July 2013 
using the OVID online portal.  In cases of dispute a third review was asked to 
independently assess the article (AHD). 
Search terms used were: 
• Varicose veins (MeSH Search Term) AND Phlebectomies OR Avulsions OR 
Secondary Interventions 
• Concomitant AND Phlebectomies OR Avulsions OR Secondary Interventions 
7.2.2.2.	  Search	  Criteria	  
Inclusion criteria were 
• Studies assessing the timing and outcome of phlebectomies in the context of 
ablation of the GSV for the treatment of varicose veins. 
Exclusion criteria were: 
• Those studies with no clear phlebectomy selection procedure 
• Those studies where all patients were treated with either simultaneous or 
delayed adjunctive procedures. 
• Those studies which did not compare phlebectomy timing in the context of 
varicose vein treatment 
• Those studies not related to varicose veins 
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No limits, filters or language exclusions were applied. Case reports, review articles 
and letters were excluded if they did not meet the inclusion criteria. 
Additional hand-searching of reference lists from full-text included publications was 
undertaken. 
7.2.2.3.	  Study	  Analysis	  
After title and abstract screening, full-text articles were assessed independently for 
clinical heterogeneity and methodological quality by two reviewers (T.L., S.O.), 
assessing according to the Consolidated Standard of Reporting Trials (CONSORT) 
(Moher et al. 2010), and the Cochrane Collaboration assessment tools (Revman v5, 
Cochrane Collaboration, Oxford, UK). 
Data was extracted into Comprehensive Meta-Analysis v 2.2.064 (Biostat, 
Englewood, USA) and OpenMetaAnalyst for statistical analysis (TL) using the 
Fixed Effects Inverse Variance Meta-Analysis model. 
7.2.3.	  Results	  
7.2.3.1.	  Search	  Outcomes	  
Search outcomes are shown in Figure 69.  Few studies investigated the principle 
study question of varicosity treatment timing, excluding many well-conducted 
trials.  Studies included are described in Table 30 and risk of bias is demonstrated 
in Figure 70. 
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Figure 69:  PRISMA diagram for phlebectomies review.  Three clinical questions were identified 
from the literature search - need for further procedure, QOL and rate of DVT. 
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7.2.3.2.	  Risk	  of	  bias	  summary	  
 
Figure 70:  Risk of bias summary: review authors' judgements about each risk of bias item for each 
included study.  Green dots equate to low risk of bias, red dots equate to high risk of bias, blank 
spaces indicate unknown risk of bias.  
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7.2.3.3.	  Included	  Study	  Summary	  Table	  
Table 30:  Included Study Characteristics.  Phleb = Phlebectomy.  EVLA = Endovenous laser 
ablation.  UGFS = Ultrasound Guided Foam Sclerotherapy.  RCT = Randomised Clinical Trial.  DVT 
= Deep Vein Thrombosis.  QOL = Quality of Life 
Study Study 
Type 
Participants 
(Simultaneous / 
Delayed) 
Follow-
Up 
Duration 
(Weeks) 
Intervention 
Anaest
hesia 
Outcomes 
Assessed 
Carradice 
(2009) 
{Carradice:20
09dr} 
RCT 50 (25/25) 
52 
EVLA ± 
Phlebectomies 
LA 
Phleb/QOL/D
VT 
Theivacumar 
(2008) 
{Theivacuma
r:2008ed} 
RCT 68 (22/46) 12 EVLA ± UGFS LA 
Phleb/QOL/D
VT 
Kim (2009) 
{Kim:2009ix} 
Case Series 265 (132/133) 104 
EVLA ± 
Phlebectomies 
GA/LA Phleb/DVT 
Knipp (2008) 
{Knipp:2008h
s} 
Case Series 456 (186/279) 28 
EVLA ± 
Phlebectomies 
GA/LA DVT 
Puggionni 
(2009) 
{Puggioni:200
9js} 
Case Series 293 (90/203) 7 
EVLA ± 
Phlebectomies 
GA/LA DVT 
Marsh (2010) 
{Marsh:2010c
d} 
Case Series 2820 (2470/350) 1 
EVLA ± 
Phlebectomies 
GA/LA DVT 
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7.2.3.4.	  Need	  for	  further	  procedures	  
Only four studies were eligible for analysis based on study methodology - these were 
the only studies to have separate groups based on phlebectomy timing.  Two studies 
were formal randomised controlled trials investigating adjunctive intervention 
delay in the context of laser ablation with either phlebectomy (n=50) (Carradice et 
al. 2009) or foam sclerotherapy (n=68) (Theivacumar et al. 2008).  Two studies were 
retrospective cohort studies assessing the need for secondary interventions after 
endovenous ablation with either radiofrequency (n=184) (Welch 2006) or laser 
(n=265) (Kim et al. 2009).  However, whilst Welch's 2006 study included both 
groups, 177 were delayed and only 7 were simultaneous, it was therefore excluded.  
Kim et al. Described a large study with even groups of 132 patients (simultaneous) 
and 133 patients (delayed) with 12 and 11 patients requiring further treatment 
respectively.  Carradice et al. is the only randomised clinical trial (RCT) assessing 
the timing of varicosity treatment in the context of endovenous ablation.  This study 
had 64% of patients in the delayed group needing further treatment, compared to 
4% in the simultaneous arm.  Theivacumar et al. was a RCT assessing the outcome 
of differing treatment protocols for the below knee GSV in the context of EVLA.  46 
patients received EVLA alone, with 18 (39%) requiring further treatment, compared 
to 22 patients receiving EVLA and UGFS combined, with 8 (36%) requiring further 
treatment. 
 
The subsequent forest plot of three studies assessing need for further procedure is 
demonstrated in Figure 71, and publication bias in Figure 72. 
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Figure 71:  Forest plot of Need for Further Procedures.  Sim = Simultaneous Phlebectomy, Del = 
Delayed Phlebectomy.  Fixed Effects Inverse Variance Model.  Odds Ratio=0.734, Z-Value=-0.957, 
p=0.339.   I2=81.45, p=0.005 
 
Figure 72:  Funnel Plot of Need for further procedure studies 
These figures show that there is no significant difference in need for further 
procedure, although the statistical heterogeneity is high at 81%.  This statistical 
variability provides a large confidence interval surrounding the Odds Ratio of 0.734.  
Isolating the randomised clinical trials produces a more clinically homogenous 
group, but due to the different findings of the trials, the statistical heterogeneity 
increases as shown in Figure 73. 
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Figure 73:  Forest plot of RCTs only concerning need for further procedures.  Sim = Simultaneous 
Phlebectomy, Del = Delayed Phlebectomy.  Fixed Effects Inverse Variance Model.  Odds Ratio=0.443, 
Z-Value=-1.687, p=0.092.  I2=88.63, p=0.003. 
 
However, there is a trend (p=0.092) towards simultaneous treatment offering a 
reduced Odds Ratio (0.443) of needing further treatment, though this is not 
statistically significant. 
7.2.3.5.	  Quality	  Of	  Life	  Outcomes	  
Both of the randomised trials assessed quality of life at 6 and 12 weeks post 
treatment.  The forest plot of the QOL outcome at 6 weeks is displayed in Figure 74.  
Carradice et al. found a much improved AVVQ at 6 weeks in the simultaneous 
compared to Theivacumar et al.  This may be secondary to the differences in 
number of patients requiring further treatment. 
 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
235 
 
Figure 74:  Forest plot of QOL outcomes at 6 weeks. Sim = Simultaneous Phlebectomy, Del = Delayed 
Phlebectomy.  Fixed Effects Inverse Variance Model.  Odds Ratio=0.460, Z-Value=-2.177, p=0.029.  
I2=84.89, p=0.010. 
The pooling of the data shows that there is a significant improvement in AVVQ at 6 
weeks for the simultaneous group, with an Odds Ratio of 0.460 (p=0.029). 
 
AVVQ outcomes at 12 weeks, after all further treatments are concluded, is shown in 
Figure 75. 
 
 
Figure 75:  Forest plot of QOL outcomes at 12 weeks. Sim = Simultaneous Phlebectomy, Del = 
Delayed Phlebectomy.  Fixed Effects Inverse Variance Model.  Odds Ratio 0.688, Z-Value=-1.073, 
p=0.283.  I2=18.70, p=0.267. 
This data shows no significant difference between simultaneous and delayed 
varicosity treatment by 12 weeks (Odds Ratio 0.688, p=0.283). 
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8.2.3.6.	  Incidence	  of	  DVT	  or	  EHIT	  
Three studies have examined the role of combined phlebectomy and venous ablation 
on the incidence of deep venous thrombosis (DVT).  All are retrospective analyses of 
changing practice from operating theatre to procedure room, and from general 
anaesthetic (GA) to local anaesthetic (LA) (Puggioni et al. 2009; Marsh et al. 2010; 
Knipp et al. 2008). 
 
The first study of 293 limbs by Puggioni et al (Puggioni et al. 2009) showed a 
significantly increased occurrence of thrombotic events in the combined 
phlebectomy and radiofrequency ablation group, of 22% (20/90) versus 9% (18/203) 
(overall incidence of 38/293 = 13%).  Of these thrombotic events, 5% were DVTs 
(2.5% calf vein and 2.5% common femoral vein), with 8% more correctly termed 
endovenous heat induced thrombosis (EHIT) (Kabnick et al. 2006) with extension 
into but not occlusion of the Sapheno-Femoral junction. However, the combined 
phlebectomy group procedures were all performed under general anaesthetic, with 
the delayed procedures under local anaesthetic.  Neither groups received 
pharmaceutical DVT prophylaxis.  This study also does not report on the number of 
procedures required after the initial treatment. 
 
Other studies have indicated a much lower incidence of DVT after endovenous 
ablation (Anwar et al. 2012; Dexter et al. 2012), including the second study by 
Knipp et al (Knipp et al. 2008) which examines DVT in the context of combined and 
non-combined procedures. 
 
This study represents 456 limbs, with an overall DVT incidence of 0.7% (3/456) and 
an EHIT incidence of 7% (32/456).  177 procedures were completed under GA, 107 
with pharmaceutical DVT prophylaxis and 74 without.  There were 4 treatment 
failures which were not analysed.  321 limbs were treated with EVLA alone and 135 
had combined EVLA and phlebectomy.  DVT and EHIT rates were not significantly 
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different between GA and LA or between prophylaxis groups.  When assessing the 
combined EVLA and phlebectomy group with the EVLA solely groups, it was found 
that rates of DVT increased with phlebectomy (2.2% versus 0%) but EHIT was 
unchanged (5.9% versus 7.8%, p=0.554).  This gave a DVT or EHIT rate of 12/135 in 
the concomitant group and 23/321 in the delayed group. 
 
Finally Marsh et al. (Marsh et al. 2010) retrospectively assessed 2820 endovenous 
procedures, 2470 RFA under GA with concomitant phlebectomies and 350 EVLA 
under LA with delayed phlebectomies.  All patients received pharmacological DVT 
prophylaxis.  An overall DVT or EHIT rate of 0.7% was described (21/2820), with 17 
post RFA(7%) and 4 post EVLA (1%).  There was no significant difference between 
treatment groups.  However, in 567 RFA GA procedures short saphenous ligation 
was performed simultaneously with ablation and phlebectomies.  These cases 
accounted for 7/21 of the thrombotic events.  If these cases are excluded, the 
appropriate comparison would be 7/1903 (0.37%) versus 4/350 (1.14%).  In this 
study the EHIT categories were 2-4 (Kabnick et al. 2006), which would classify 
them as DVT.  Overall, the rate of any thrombotic event was extremely low 
throughout. 
 
These studies are pooled in Figure 76 and Figure 77. 
 
Figure 76:  Forest plot of DVT incidence studies.  DVT = Deep Venous Thrombosis, EHIT = 
Endovenous Heat Induced Thrombosis.  Fixed Effects Inverse Variance Model, Odds Radio=1.519, 
p=0.078 (Odds Ratio >1 favours Delayed Treatment).  I2=80, p=0.007. 
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Figure 77:  Funnel plot of DVT incidence studies 
This indicates no significant difference in risks of DVT or EHIT between 
simultaneous and delayed phlebectomy treatment strategies (Odds Ratio 1.519, 
p=0.078), though there is a trend in favour of delayed varicosity treatment.  
Statistical heterogeneity is extremely high at 80, and indeed clinical heterogeneity 
between groups (but not studies) is also high, with combined procedures under GA 
and endovenous only under LA.  Fernandez et al (Fernández et al. 2008) found a 
DVT rate of 0.13% after 1985 combined EVLA and phlebectomy procedures under 
LA.  This may indicate that the increased risk found in the other studies is as a 
consequence of the GA approach rather than the actual procedure itself, with the 
three studies above reporting a rate of 7-22% under GA. 
 
The three studies looking at need for further procedures post endovenous ablation 
identified no DVT's in either group (0/250), with Carradice et al. and Theivacumar 
et al. both performing treatment under local anaesthetic only and Kim et al. 
offering general anaesthetic, regional spinal anaesthetic or local anaesthetic.  If 
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these three studies are added into the meta-analysis the resulting analysis is 
obtained (Figure 78). 
 
 
Figure 78:  Forest plot of DVT incidence studies.  DVT = Deep Venous Thrombosis, EHIT = 
Endovenous Heat Induced Thrombosis.  Fixed Methods Inverse Variance.  Odds Ratio=1.508, 
p=0.077 (Odds Ratio > 1 favours Delayed Treatment).  I2=50, p=0.076 
With the addition of these further cases, the statistical heterogeneity is reduced to 
50 (non-significant, p=0.076), and there remains no significant difference in rate of 
EHIT or DVT between simultaneous or delayed varicosity treatment (Odds Ratio of 
1.508, p=0.077, Odds Ratio > 1 favours Delayed Treatment). 
7.2.4.	  Discussion	  
This review of the literature has shown that despite extensive work assessing the 
impact of endovenous treatments on varicose vein outcomes from both a technical 
occlusion viewpoint and a patient centred quality of life outlook, little literature 
exists on the technicality of secondary interventions.  The evidence that does exist, 
whilst including level 2 evidence (Carradice et al. 2009; Theivacumar et al. 2008) 
only serves to fuel the controversy.  There is a non-significant trend towards 
simultaneous phlebectomies in the context of avoiding secondary procedures and 
early quality of life improvements.  However, this is limited by the low numbers 
available in the literature, and the fact that both treatment groups offer good and 
equivalent QOL and disease improvement at one year. 
 
The technique described in Theivacumar et al is catheter directed foam 
sclerotherapy to the distal GSV rather than direct varicosity treatment (with either 
phlebectomy or needle injection).  This may limit the applicability of its results in 
comparing delayed and simultaneous varicosity treatment.  However, due to the 
Studies
Carradice 2009
Theivacumar 2008
Kim 2009
Puggioni 2009
Knipp 2008
Marsh 2010
Overall (I^2=50% , P=0.076)
Estimate (95% C.I.)
1.000 (0.019,  52.362)
2.067 (0.040, 107.560)
1.008 (0.020,  51.152)
2.937 (1.468,   5.876)
1.264 (0.610,   2.620)
0.319 (0.093,   1.097)
1.508 (0.956,   2.380)
EHIT or DVT / Simultaneous
0/25          
0/22          
0/132         
20/90          
12/135         
7/1903        
39/2307        
EHIT or DVT / Ablation Only
0/25           
0/46           
0/133          
18/203          
23/321          
4/350          
45/1078         
0.02 0.04 0.1 0.19 0.38 0.95 1.51 3.82 9.55 19.1 38.2 95.49
Odds Ratio (log scale)
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dispersing nature of foam sclerotherapy and the average length of vein treated 
(19cm), tributaries of treated vein will have received foam sclerotherapy treatment, 
as has been shown in other studies (Williamsson et al. 2012).  Additional 
treatments were either repeat injection via catheter or direct injection 
(Theivacumar et al. 2008). 
 
Interestingly this review has found large retrospective single-centre studies 
showing that combined phlebectomy and ablation and delayed phlebectomy 
treatment pathways have similar risks of DVT or EHIT.  Another study suggested 
that the VT risk may be greater in patients treated with concomitant phlebectomy, 
although the use of general anaesthetic and the lack of thromboprophylaxis may 
have also significantly influenced this study’s DVT rates. 
 
Modern day practice facilitates vein procedures to be performed under LA unless 
there are specific patient concerns and this is evidenced by the excellent results 
gathered in randomised trials (Rasmussen et al. 2011; Rasmussen et al. 2010; 
Rasmussen et al. 2013).  These trials include phlebectomies or foam sclerotherapy of 
varicosities.  With tumescent anaesthesia now widespread and accepted at levels of 
up to 35-55 mg/kg (Do & Kelley 2007), it is clear that multiple extensive procedures 
are acceptable and well-tolerated under local anaesthetic. 
 
In light of the lack of clear answer in the literature regarding the optimal treatment 
pathways, the recent NICE guidelines (Marsden et al. 2013) for the management of 
varicose veins have posed as a research topic whether or not adjunctive procedures 
are required for the optimal patient treatment pathway.  Before clear evidence is 
obtained the guidelines also recommend that clinicians should consider offering 
patients simultaneous treatment. 
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7.2.4.1.	  Limitations	  
This review of the literature and summary of outcomes is limited by the paucity of 
studies assessing a crucial component of varicose vein treatment.  The randomised 
studies available provide level 2 evidence, but only cover 118 procedures.  Many 
studies were identified that assessed various treatment methods for truncal veins 
however very few assessed the need for phlebectomies in their work.  This leads to 
concerns regarding the generalizability of this analysis. 
 
The larger non-randomised retrospective studies are limited by their methodology, 
but offer good procedure numbers.  These studies have a confounding factor of a 
change from GA to LA procedure, reflecting the change in venous practice.  This 
may have affected the outcomes, and so the analysis outcome should be approached 
with caution.  However, with such low rates of thrombotic events found, the need for 
large registry style data is required to investigate the clinical question in the era of 
full tumescent anaesthesia. 
7.2.5.	  Conclusion	  
This study has shown that evidence guiding varicose vein adjunctive procedure 
timelines is sparse, with no significant difference in need for further procedure 
between combined ablation and varicosity treatment and ablation alone.  QOL 
outcomes after treatment is improved in both groups, but significantly higher with 
simultaneous varicosity treatment at 6 weeks, though this is not maintained 
through to 12 weeks.  Rates of DVT are low in both settings with no significant 
difference seen between treatment strategies. 
 
Larger randomised clinical trials investigating the role of phlebectomies in local 
anaesthetic ambulatory vein treatment (such as AVULS -  ISRCTN76821539) are 
needed to provide evidence to guide clinicians in the future.  These may or may not 
support the previous work by Carradice et al. and Theivacumar et al. (Carradice et 
al. 2009; Theivacumar et al. 2008). 
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With the advent of venous registries (European Venous Forum et al. 2012; 
American Venous ForumAmerican Venous Forum 2012) and many centres moving 
to predominantly local anaesthetic procedures, large patient series assessing the 
role of phlebectomies in the modern era should be available, with outcomes 
including QOL, need for further procedures and complications key to improvements. 
 
Patient preference must also be taken into account - many patients prefer one-stop 
treatment, a trend that has persisted for over a decade (Campbell et al. 1998; 
Shepherd et al. 2010).  This limits the generalizability of sequenced treatment trial 
data due to patients opting out. 
 
Overall, there is not conclusive evidence for or against combined venous ablation 
and varicosity treatment and so clinician judgement in combination with clinician 
and patient preference is the key to formulating satisfactory venous treatment 
pathways. 
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7.3.	  Ambulatory	  Varicosity	  avUlsion	  Later	  or	  Synchronised	  (AVULS):	  A	  
Randomised	  Clinical	  Trial	  
7.3.1.	  Introduction	  
With the advent of techniques described earlier in this manuscript, the treatment of 
the incompetent truncal veins has been intensively investigated with multiple 
studies showing benefit (Rasmussen et al. 2011; Carradice et al. 2012; Shepherd et 
al. 2010).  This has led to clinicians moving away from surgical ligation of the 
saphenofemoral junction and stripping of the great saphenous vein, towards less 
invasive options.  However the issue of residual varicosities has not been 
conclusively investigated and remains a matter of debate (Mowatt-Larssen 2010). 
 
Varicosities can be treated at the same sitting as truncal veins, either with 
phlebectomy or foam sclerotherapy; alternatively treatment of varicosities can be 
delayed for 6-12 weeks, when, in a number of patients the need for treatment will 
be reduced following truncal vein treatment. 
 
The proportion of patients who are adequately treated with solely truncal vein 
treatment is unclear, and the additional benefit of simultaneous treatment of 
varices in the context of radiofrequency ablation has not been investigated in depth. 
 
There are two schools of thought with regard to treating varicosities in those 
patients undergoing truncal vein ablation. The first suggests simultaneous truncal 
treatment and phlebectomy as a single procedure (Mekako et al. 2006; Theivacumar 
et al. 2008). The second advises delayed phlebectomy after monitoring for varicosity 
regression. If still present, these varicosities or REVAS (REsidual Varicosities After 
Surgery) can be addressed with either ambulatory phlebectomies or foam 
sclerotherapy (Monahan 2005). 
Previous work in laser ablation has shown that approximately 40% of patients with 
delayed phlebectomies require a second procedure, which was matched in a non-
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randomised cohort study in radiofrequency ablation (Carradice et al. 2009; 
Monahan 2005).  Both studies present similar data, however this is used to support 
different positions.  Carradice et al. showed that there was no difference in long-
term QOL outcome between the delayed or simultaneous varicosity treatment. 
 
Advocates of the first option suggest that immediate treatment of surface 
varicosities is advantageous in that it ensures patients are treated in a single 
session and reduces the varicosity reservoir. However, this may increase operative 
time (Carradice et al. 2009), and could be over-treating patients whose varicosities 
may regress. 
 
Those in favour of delayed phlebectomies claim that this treatment is shorter, 
saving operative time. However, a variable number of patients do come back with 
troublesome residual varicosities, which require secondary procedures. 
The evidence of the timing for phlebectomy is at best confusing. Carradice et al.'s 
2009 study showed that while there was no sustained difference in QOL measures 
between delayed and simultaneous phlebectomy in the context of EVLA treatment, 
66% of patients in the truncal ablation only group required secondary interventions 
(Carradice et al. 2009). Monahan et al. suggested that after RFA, 13% of patients 
had spontaneous varicosity regression and 41% of patients did not require further 
treatment, suggesting that monitoring for regression is the best option (Monahan 
2005). 
 
This appears confusing and contradictory, but both EVLA and RFA truncal ablation 
have been shown to save 30 – 40% of patients from having needless phlebectomies. 
Part of the issue is that the literature is very heterogeneous, making comparisons 
between studies challenging (Thakur et al. 2010).  Variations exist in the reporting 
standards for surgical versus EVLA/RFA or foam sclerotherapy both in terms of 
vein classification, as well as length to follow-up, objective assessments and 
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questionnaires. Studies looking at specifically immediate versus delayed 
phlebectomies are few in number (Mekako et al. 2006; Carradice et al. 2009; 
Monahan 2005).  Most randomised studies into catheter type or modality to date 
have used standardized delayed or simultaneous phlebectomies across their study 
groups, with no clear definition of the trigger to varicosity treatment. This makes 
comparison difficult. 
 
Furthermore, there are a number of variables that confound the picture.  Patient 
factors such as age, body habitus and mobility will influence the result of any 
intervention on the venous system. Patient preference and expectations, as well as 
operator experience, may have an effect on patient and operator satisfaction. Pain 
levels experienced have been assessed only in Carradice's study, which showed no 
statistical difference in pain or return to normal activities (Carradice et al. 2009). 
 
Finally the anatomy of the venous system and its preoperative haemodynamic state 
(Cappelli et al. 2004; Cappelli et al. 2006) will also influence the outcome of any 
intervention, as will the condition of the patient and the venous calf pump. These 
factors need to be considered when considering treatment options, with the 
appreciation that any alteration in the venous tree will lead to haemodynamic 
changes (Blomgren et al. 2005).  Indeed the ASVAL technique solely removes 
varicosed tributaries, leaving incompetent truncal veins in situ.  This has also be 
shown to produce good results and implies a significant factor is the incompetence 
venous reservoir found in each patient (Pittaluga et al. 2009). 
 
Ultimately, the aim of procedures for residual venous disease is to provide the 
maximum symptomatic relief for as long as possible. An ideal treatment would be 
minimally invasive, safe, effective from a functional and cosmetic point of view, 
have low recurrence rates and be cost-effective. However, the goal of ambulatory 
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minimally invasive treatment should not preclude the full management of the 
disease. 
Recent studies have shown that radiofrequency ablation has equivalent closure 
rates to laser ablation and has a reduced pain profile (Shepherd et al. 2010; 
Rasmussen et al. 2011). 
7.3.2.	  Aim	  
The aim of this study was to ascertain the outcomes of delayed or simultaneous 
phlebectomy in the context of truncal vein ablation. 
7.3.3.	  Methods	  
AVULS is a single centre randomised controlled trial recruiting 240 patients into 2 
equal sized groups – one with simultaneous local anaesthetic treatment of truncal 
veins with endovenous ablation and varicosity treatment with phlebectomy; and the 
other with delayed varicosity avulsion. 
7.3.3.1.	  Ethical	  Approval	  and	  Trial	  Registration	  
Ethical approval has been granted for the AVULS Trial by Brighton Research 
Ethics Committee Reference Number 11/H1107/3. 
 
The trial was registered with Current Controlled Trials - ISRCTN76821539 (Lane 
2011). 
7.3.3.2.	  Patient	  Selection	  
Consecutive patients presenting with symptomatic primary varicose veins due to 
reflux in the great saphenous vein (GSV), or small saphenous vein (SSV) were 
invited to participate.  The study was set in the Department of Vascular Surgery at 
Charing Cross Hospital.  Patients were followed up for 12 months post-procedure, 
with repeated quality of life measures at 6 weeks, 6 and 12 months and technical 
success appraisal at 6 months. 
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Patients were eligible if they had treatable single truncal vein incompetence and 
visible varicosities in the distribution of the target vein. 
 
Patients were consented and complete a quality of life questionnaire incorporating 
the AVVQ, EQ-5D 5L and VAS, CES-D and SF-12.  The consenting clinician 
completed the VCSS, CEAP, VDS and also estimated the number of avulsions 
required. 
7.3.3.3.	  Power	  Calculations	  
7.3.3.3.1.	  Aberdeen	  Varicose	  Vein	  Questionnaire:	  
Based on previous randomised clinical trials, an improvement of 10 points is 
predicted at 6 weeks with a standard deviation of 10 in patients who have 
concomitant phlebectomies.  A difference of 5 points at 6 months is considered 
clinically significant. 
 
At 90% power and 5% significance, 64 patients per arm would be required. 
Allowing for loss to follow-up and protocol violation, target recruitment was set at 
120 per arm, or 240 in total. 
7.3.3.4.	  Reasons	  for	  declining	  AVULS	  
Patients who did not want to participate in the AVULS study were invited to offer a 
reason for not entering into the study. 
7.3.3.5.	  Randomisation	  
Following consenting and recruitment patients were randomised into concomitant 
or delayed phlebectomy groups on the day of treatment. 
 
Randomisation was via computerised allocation at a remote location provided by a 
randomisation service (Sealed Envelope, London, UK).  
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7.3.3.6.	  Treatment	  
Treatment was then performed according to standardised endovenous thermal 
ablation using radiofrequency ClosureFAST catheters under tumescent local 
anaesthetia using standard Covidien Venefit procedure (Creton et al. 2010) and 
multiple stab phlebectomies according to treatment arm. 
 
Number of phlebectomies and length of treatment were recorded. 
 
The treatment was non-blinded as the use of phlebectomies cannot be hidden from 
either the practitioner or patient.  Patients then received standardised compression 
hosiery for 2 weeks post-operatively. 
7.3.3.7.	  Follow-­‐up	  
Patients were seen in the research clinic at 6 weeks, 6 months and 1 year post-
operatively.  At each clinic visit, clinical review was completed as were complete the 
quality of life questionnaires. 
 
At the 6 week visit, the patient was assessed for the need for further intervention 
by independent clinicians unaware of the initial treatment group.  This was offered 
as either foam sclerotherapy or multiple stab phlebectomies under local anaesthetic.  
However, as patients had healing scarring after phlebectomies this was not full 
blinding.  All further treatments were completed as soon as possible after the 6 
week visit and all before the 6 month visit. 
 
At the 6 month follow-up a certified duplex ultrasound scan was completed to 
ensure closure of the treated truncal vein.  This is categorised as fully occluded, 
predominantly occluded, predominantly patent and fully patent.  The duplex was 
performed by an independent vascular scientist who is blinded to the treatment 
allocation. 
 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
249 
7.3.3.8.	  Primary	  Endpoint	  
The primary endpoint of this study was disease specific quality of life improvement 
at 6 months post procedure assessed by the AVVQ 
7.3.3.9.	  Secondary	  Endpoints	  
• The need for further procedures over the 6 month period 
• Clinical disease severity assessed using the Venous Clinical Severity Score 
(VCSS) 
• Generic quality of life assessed using the EQ-5D 
• Anatomical success assessed with colour duplex at 6 months 
• Level of depression assessed using CES-D  
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7.3.3.10.	  AVULS	  Throughput	  Diagram	  
 
Figure 79:  AVULS Thoughput Diagram 
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7.3.3.11.	  Statistical	  Methods	  
All data was entered into a bespoke database created in Microsoft Access version 14 
(Microsoft, Redmond, Washington, USA).  Statistical analysis was performed on 
SPSS version 22 (IBM, Armonk, New York, USA), Prism version 6 (Graphpad, La 
Jolla, California, USA) and Wizard Pro version 1.3.5 (Evan Miller, Chicago, Illinois, 
USA). 
7.3.4.	  Results	  
From April 2011 until November 2012, 393 consecutive patients presenting to the 
Charing Cross Local Anaesthetic Varicose Vein Unit for treatment were screened 
for inclusion in the AVULS trial.  221 patients were suitable for the trial.   
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Figure 80:  AVULS Trial Consort Diagram 
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The 172 patients ineligible for the trial included those with no visible varicosities 
but truncal reflux (88 = 23%), patients with visible varicosities but no truncal reflux 
(71 = 19%), and patients with mixed truncal disease with venous anatomy 
unsuitable for endovenous treatment. 
 
Of the 221 patients eligible, 101 patients consented to randomisation.  Of those 
refusing to participate in the trial, 95% gave wanting single sitting treatment as the 
reason for declining. 
 
 
Figure 81:  Reasons given for refusing trial participation 
 
The final trial sample was 26% of the screened population and 46% of the suitable 
population. 
 
The baseline demographics are shown below in Table 31, and as can be seen the 
groups were well-matched, with no significant differences: 
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Table 31:  AVULS Baseline Demographics 
 Overall Delayed Simultaneous 
Patients (n) 101 50 51 
M:F 44:57 22:28 22:29 
Age 52.9 53.9 52.0 
BMI > 30 24% 26% 22% 
BMI 28.28 29.13 27.52 
CEAP (Median) 4 4 4 
Maximal Vein Diameter 9.04 8.97 9.11 
AVVQ Baseline 22.52 21.80 23.20 
VCSS Baseline 7.56 7.80 7.30 
EQ-5D QOL Baseline 0.691 0.695 0.688 
EQ-5D VAS Baseline 75.68 74.76 77.30 
CES-D Baseline 11.68 12.26 11.14 
 
Treatment characteristics are shown below in Table 32.  No differences were seen 
between groups.  All treatments were completed as per protocol. 
 
Table 32:  AVULS Completed Treatment Details 
 Overall Delayed Simultaneous 
Patients (n) 101 50 51 
Trunks Treated (Median) 1.10 (1) 1.08 (1) 1.11 (1) 
Cycles Completed (Median) 6.71 (7) 6.93 (7) 6.49 (6) 
Vein Length Treated (Median) 46.97 (49) 48.51 (49) 45.43 (42) 
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 Overall Delayed Simultaneous 
Pre-Operative Estimated 
Phlebectomies (Median) 
9.00 (8) 9.76 (10) 8.24 (6) 
Phlebectomies Completed (Median) 6.84 (6) - 6.84 (6) 
Further Phlebectomies (Median) 7.33 (9) 7 (9) 10 (10) 
7.3.4.1.	  Primary	  Outcome	  -­‐	  AVVQ	  
Mean AVVQ decreased following treatment as shown by Figure 82.  The mean 
baseline AVVQ was 22.54 (standard deviation, SD, 12.40), decreasing to 13.57 
(12.04) at 6 weeks, 11.19 (10.08) at 6 months and 8.56 (7.83) at 1 year, which 
represents an symptomatic improvement of 62%. (p<0.001). 
 
 
Figure 82:  Aberdeen Varicose Vein Questionnaire (AVVQ) over the course of treatment. 
Mean change at 6 weeks, 6 months and 12 months was -8.86 (11.30), -10.00 (10.24) 
and -11.54 (7.76) respectively (negative change equates to an improvement in 
symptoms). 
 
Both groups showed a significant improvement in symptoms from baseline at all 
time points (p<0.0001).  There was a significant difference seen at 6 weeks, with the 
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simultaneous group showing a 5.48 point improvement (p=0.029).  However there 
was no significant difference at 6 months or 12 months.  Table 33 demonstrates the 
AVVQ values. 
 
Table 33:  AVVQ Results between groups 
AVVQ Overall Delayed Simultaneous Difference P Value 
Baseline 22.54 (12.40) 22.69 (11.67) 22.39 (13.17) 0.30 0.908 
6 Weeks 13.57 (12.04) 16.34 (12.62) 10.86 (10.91) 5.48 0.029 
6 Months 11.19 (10.08) 12.93 (11.05) 9.46 (8.80) 3.47 0.120 
12 Months 8.56 (7.83) 9.48 (9.61) 7.60 (5.43) 1.88 0.387 
 
This is shown in Figure 83 and Figure 84. 
 
Figure 83:  Aberdeen Varicose Vein Questionnaire (AVVQ) over the course of treatment showing 
delayed and simultaneous groups. 
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Figure 84:  Aberdeen Varicose Vein Questionnaire (AVVQ) over the course of treatment showing 
delayed and simultaneous groups. 
When assessed between patients who did not need any further treatment after 6 
weeks there was no significant difference seen between the groups at any time point 
as shown in Figure 85, Figure 86 and Table 34. 
 
Table 34:  AVVQ outcomes when no further treatment is required. 
AVVQ Delayed & No 
Further 
Treatment 
Simultaneous & 
No Further 
Treatment 
Difference P Value 
Baseline 21.62 (10.97) 22.37 (13.31) 0.75 0.795 
6 Weeks 13.78 (11.36) 10.85 (11.04) 2.93 0.279 
6 Months 11.47 (11.19) 9.40 (8.91) 2.07 0.405 
12 Months 8.75 (9.00) 7.60 (5.43) 1.15 0.605 
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Figure 85:  Comparison of AVVQ between delayed and simultaneous groups when no further 
treatment required. 
 
Figure 86:  Comparison of AVVQ between delayed and simultaneous groups when no further 
treatment required. 
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When comparing the groups who did and did not need further treatment a large 
significant difference of 8.1 AVVQ points was found at 6 weeks (p=0.004).  Though 
those requiring Further Treatment remained at higher symptom scores throughout, 
this difference was not statistically significant at 6 months or 12 months and is 
demonstrated by Figure 87 and Figure 88 and Table 35.  Further treatment was 
completed before the 6 month review. 
 
Table 35:  AVVQ for no further treatment needed and further treatment needed groups. 
AVVQ 
No Further 
Treatment 
Needed 
Further 
Treatment 
Needed 
Difference P Value 
Baseline 22.08 (12.38) 24.70 (12.63) 2.62 0.937 
6 Weeks 11.97 (11.18) 20.07 (13.53) 8.1 0.010 
6 Months 10.24 (9.86) 15.48 (10.26) 5.24 0.069 
12 Months 8.05 (6.98) 10.73 (10.96) 2.68 0.335 
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Figure 87:  Comparison of AVVQ between further treatment required and further treatment not 
required. 
 
Figure 88:  Comparison of AVVQ between further treatment required and further treatment not 
required. 
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The final comparison for the AVVQ quality of life score was between those in the 
delayed group who needed further treatment compared to the simultaneous group.  
This showed a large significant difference at 6 weeks and 6 months in favour of 
simultaneous treatment.  This is shown in Table 36, Figure 89 and Figure 90. 
 
Table 36:  AVVQ values for the Delayed and requiring further treatment group and the 
simultaneous group 
AVVQ 
Delayed & Further 
Treatment Needed 
Simultaneous Difference P Value 
Baseline 24.76 (13.04) 22.39 (13.17) 2.37 0.534 
6 Weeks 20.56 (13.77) 10.86 (10.91) 9.7 0.005 
6 Months 15.74 (10.59) 9.46 (8.80) 6.28 0.033 
12 Months 10.73 (10.96) 7.60 (5.43) 3.13 0.258 
 
 
Figure 89:  Comparison of AVVQ between Simultaneous Group and Delayed Group Further 
Treatment Required. 
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Figure 90:  Comparison of AVVQ between Simultaneous Group and Delayed Group Further 
Treatment Required. 
7.3.4.2.	  Secondary	  Outcomes	  
7.3.4.2.1.	  Need	  for	  Further	  Procedure	  
There was a significant difference in need for further treatment between the 
delayed and simultaneous groups - 18 (36%) required further treatment in the 
delayed group compared with 1 (2%) in the simultaneous group (p<0.001). 
The odds ratio and relative risk of patients in the delayed group requiring further 
varicosity treatment were 27.78 and 18.36 respectively (p<0.0001). 
There was no difference between estimated number of multiple stab phlebectomies 
required prior to intervention (9.76 vs 8.24, p=0.171) in the patient groups and 
there was no significant difference between the number of phlebectomies estimated 
as necessary prior to intervention and the number performed in patients requiring 
further treatment (9.0 vs 7.33, p=0.3479). 
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All procedures were completed as soon as feasible after the 6 week review and no 
further procedures were needed after 6 months or 1 year. 
7.3.4.2.2.	  Technical	  Success	  
At 6 months, 93.75% of patients had truncal vein treatment success, termed as 
complete venous ablation and absence of any flow on colour duplex or predominant 
venous ablation with small areas of isolated colour flow (<5cm). 
 
6.25% of patients had partially treated veins with >5cm of colour flow.  No patient 
needed truncal retreatment and no cases of complete patency and reflux were 
found. 
 
There was no difference in treatment success between groups (p=0.849). 
7.3.4.2.3.	  Generic	  Quality	  of	  Life	  
There was a significant improvement in generic quality of life as measured by the 
EQ-5D  QOL from baseline to 6 weeks (0.691 to 0.820, p<0.0001) but not as 
measured by the EQ-VAS (76.24 to 79.45, p=0.157).  The significant improvement in 
EQ-5D QOL was maintained through to 12 months however there were no further 
significant differences seen between time groups.  This improvement equates to a 
21% improvement in QOL.  This is shown in Figure 91. 
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Figure 91:  EQ-5D QOL for total cohort over follow-up. 
 
Overall, EQ-5D results showed the same trends as found for the primary outcome of 
AVVQ. 
 
Between treatment groups there was a significant difference in EQ-5D QOL at 6 
weeks (Delayed 0.773, Simultaneous 0.866, p=0.033) but this difference was lost as 
the follow-up progressed, as shown in Figure 92 and Figure 93.  There was no 
significant difference seen between groups for the EQ-VAS score, as shown in 
Figure 94. 
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Figure 92:  EQ-5D Generic Quality of Life Outcomes for Simultaneous and Delayed Groups 
 
Figure 93:  EQ-5D Generic Quality of Life Outcomes for Simultaneous and Delayed Groups 
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Figure 94:  EQ-VAS Generic Quality of Life Outcomes for Simultaneous and Delayed Groups 
For those patients not requiring further treatment, there was no significant 
differences seen between treatment arms as shown in Table 37, Figure 95 and 
Figure 96. 
 
Table 37:  EQ-5D QOL outcomes when no further treatment is required. 
EQ-5D QOL Delayed & No 
Further Treatment 
Simultaneous & No 
Further Treatment 
Difference 
P 
Values 
Baseline 0.689 (0.248) 0.689 (0.221) 0.00 0.995 
6 Weeks 0.807 (0.189) 0.870 (0.201) 0.63 0.191 
6 Months 0.825 (0.151) 0.830 (0.212) 0.005 0.917 
12 Months 0.846 (0.147) 0.850 (0.142) 0.004 0.929 
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Figure 95:  EQ-5D QOL Outcomes for patients requiring no further treatment for Simultaneous and 
Delayed Groups. 
 
Figure 96:  EQ-5D QOL Outcomes for patients requiring no further treatment for Simultaneous and 
Delayed Groups. 
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Comparing those requiring further treatment to those not requiring further 
treatment showed a significant difference at 6 weeks, with those needing further 
treatment having a significantly worse QOL (0.719 vs 0.846, p=0.018).  This 
difference was not seen at 6 months or 12 months and is shown in Figure 97 and 
Figure 98. 
 
Figure 97:  EQ-5D QOL Outcomes for patients comparing no further treatment with further 
treatment required. 
 
Figure 98:  EQ-5D QOL Outcomes for patients comparing Further Treatment Required and No 
Further Required 
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Comparing those in the delayed group who required further treatment to the 
simultaneous group shows a similar picture - a significant difference at 6 weeks in 
favour of simultaneous treatment (0.720 vs 0.866, p=0.024) however this difference 
in QOL was not seen at 6 months or 12 months.  This is shown in Figure 99 and 
Figure 100. 
 
 
Figure 99:  EQ-5D QOL Outcomes for patients comparing Further treatment in the delayed group 
and the Simultaneous Groups. 
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Figure 100:  EQ-5D QOL Outcomes for patients comparing Further treatment in the delayed group 
and the Simultaneous Groups. 
7.3.4.2.4.	  Clinical	  Disease	  Severity	  
7.3.4.2.4.1.	  CEAP	  
CEAP is a non-reactive clinical staging measure, however, it does provide an 
overview of the cohort. 
 
Median CEAP at baseline was 4 (inter-quartile range 3-4), decreasing to 2 (2-4) at  6 
weeks, 2 (1-4) at 6 months and 1(1-3) at 12 months.  This was a significant 
improvement from baseline (p<0.0001), and is shown in Figure 101. 
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Figure 101:  Overall CEAP status of the treated cohort. 
This represents an improvement in clinical signs from venous eczema to thread 
veins at 1 year. 
 
When looking at the simultaneous and delayed groups, there was a significantly 
higher CEAP score at 6 weeks (p=0.006) and 6 months (p=0.003), however by 1 year 
this was no longer significantly different (p=0.117).  This is shown in Figure 102. 
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Figure 102:  CEAP for the Delayed and Simultaneous Treatment Arms. 
This represents an improvement for the delayed group from venous eczema to 
varicosities, compared to from venous eczema to thread veins in the simultaneous 
group. 
7.3.4.2.4.2.	  VCSS	  
Treatment led to a significant reduction in VCSS from a baseline of 7.368 (2.556) to 
3.011 (2.193) at 6 weeks, 2.557 (2.319) at 6 months and 1.978 (2.390) at 12 months 
(p<0.0001) (Figure 103).  This represents a 73% decrease in clinical score. 
 
Table 38:  VCSS Outcomes over duration of follow-up. 
VCSS Overall Delayed Simultaneous Difference P Value 
Baseline 7.32 (2.55) 7.65 (2.59) 7.00 (2.50) 0.65 0.212 
6 Weeks 2.99 (2.191) 3.76 (2.18) 2.26 (1.96) 1.50 <0.001 
6 Months 2.56 (2.356) 3.20 (2.45) 1.90 (2.09) 1.30 0.012 
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VCSS Overall Delayed Simultaneous Difference P Value 
12 Months 1.90 (2.234) 2.62 (2.46) 1.14 (1.72) 1.48 0.011 
 
 
Figure 103:  VCSS Scores for whole cohort 
Treatment groups were well matched at baseline (Delayed 7.696 versus 
Simultaneous  7.061, p=0.229) and showed a significant difference in VCSS levels at 
all follow-up points as shown in Figure 104 and Figure 105 (p=0.001 at 6 weeks, 
p=0.012 at 6 months and p=0.011 at 12 months). 
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Figure 104:  Mean VCSS in Delayed and Simultaneous Treatment Groups 
 
Figure 105:  Mean VCSS in Delayed and Simultaneous Treatment Groups 
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When comparing those patients who needed no further treatment, a significant 
difference between the delayed and the simultaneous groups was again seen at 6 
weeks (3.72 vs 2.22, p=0.004), 6 months (3.21 vs 1.90, p=0.022) and 12 months (2.83 
vs 1.14, p=0.013), again in favour of the simultaneous group.  This is shown in 
Figure 106 and Figure 107. 
 
 
Figure 106:  Mean VCSS in Delayed and Simultaneous Groups not requiring any further treatment 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
276 
 
Figure 107:  Mean VCSS in Delayed and Simultaneous Groups not requiring any further treatment 
 
Assessing those patients who did and did not require further treatment, no 
statistical difference was seen at any follow-up time-point.  At 6 weeks the further 
treatment group scored 3.82 vs 2.8 (p=0.082), at 6 months scored 3.07 vs 2.34 
(p=0.371) and at 12 months scored 2.27 vs 1.80 (p=0.537).  This is shown in Figures 
Figure 108 and Figure 109. 
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Figure 108:  Comparison of VCSS between those that needed further treatment and those who do 
not. 
 
Figure 109:  Comparison of VCSS between those that needed further treatment and those who do 
not. 
 
Finally, assessing the group of the delayed arm that required further treatment 
versus the simultaneous arm, a significant difference in favour of the simultaneous 
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arm was found at 6 weeks (3.81 vs 2.26, p=0.006), but at 6 months (3.15 vs 1.90, 
p=0.080) and 12 months (2.27 vs 1.14, p=0.088) this was no longer significant 
(p=0.080 and p=0.088).  This is demonstrated in Figure 110 and Figure 111. 
 
Figure 110:  Comparison of VCSS between the Simultaneous Group and Delayed Group requiring 
Further Treatment 
 
Figure 111:  Comparison of VCSS between the Simultaneous Group and Delayed Group requiring 
Further Treatment 
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7.3.4.2.5.	  Depressive	  Symptoms	  -­‐	  CES-­‐D	  
CES-D results are tabulated in Table 39  There was no significant difference seen 
between baseline and 6 weeks for the CES-D score, though there was a 24% 
reduction (p=0.0636).  There was a significant improvement between baseline and 6 
months (24%, p=0.0199).  However at 12 months this difference had reduced and 
was not significant (17%, p=0.2657). 
 
No significant difference was seen during follow-up in the delayed group.  There 
was a significant improvement at 6 weeks in the simultaneous group (p=0.0361) but 
this was no longer significant by 6 months (p=0.0796) or 12 months (p=0.6600). 
No significant difference was seen between groups at any time point during follow-
up. 
 
Table 39:  CES-D Scores during Follow-up. 
CES-D Overall Delayed Simultaneous Difference P Value 
Baseline 11.68 (10.32) 12.26 (11.41) 11.14 (9.29) 1.12 0.598 
6 Weeks 8.85 (10.14) 10.81 (10.53) 7.02 (9.53) 3.79 0.082 
6 Months 8.22 (9.07) 8.82 (8.96) 7.65 (9.26) 1.17 0.574 
12 Months 9.66 (10.02) 9.32 (8.16) 9.96 (11.58) 0.64 0.829 
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Figure 112:  CES-D Scores during follow-up. 
 
Figure 113:  CES-D Scores during follow-up for Delayed and Simultaneous Groups 
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7.3.4.3.	  Complications	  
Two episodes of superficial venous thrombosis occurred, one in each group.  No 
other complications were reported by patients. 
7.3.5.	  Discussion	  
Endovenous management of varicose veins in the outpatient setting is a successful 
and safe procedure with increasing uptake (Anon 2013; McLafferty 2006).  This 
study provides further evidence of excellent results with endovenous ablation at up 
to 1 year after treatment in both clinical (73% improvement) and disease specific 
QOL (62% improvement) scoring systems.  Additionally generic QOL scores 
improved by 21%.  Both simultaneous phlebectomy and delayed phlebectomy groups 
showed excellent overall improvements.  Minimal complications were seen, with 
only two SVT episodes observed, one in each group.  This study provides further 
evidence that both simultaneous and delayed treatment pathways are safe and 
feasible. 
 
The main finding of this study is that simultaneous treatment of incompetent 
truncal veins and varicosed tributary veins provides improved clinical outcomes 
which persist up to one year after treatment.  Quality of life values are improved at 
6 weeks in both disease specific and generic scoring systems.  These changes 
normalise by 6 months after adjunctive treatment was completed.  The 
simultaneous group showed an improved VCSS score out to 1 year compared to the 
delayed group and even when comparing only those patients who did not require 
further treatment.  Understandably, no significant difference was seen in the QOL 
tools, as these patients were happy with their outcome.  Most interesting is how the 
"under-treated" group fared - those in the delayed group who underwent further 
treatment.  In these 18 patients whilst the clinical score was no longer significantly 
different to the simultaneous arm after further treatment (p=0.080 at 6 months and 
0.088 at 12 months), the AVVQ remained significantly worse until 1 year. 
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Depression screening scores (CES-D) improved overall at 6 months by 24%, before 
regressing to 17% improvement, a non-significant improvement on pre-treatment 
values.  Interestingly, delayed patients displayed no significant difference in scores 
at the time points, with simultaneous patients only improved at 6 weeks.  This may 
indicate that patients experience a greater mental-health "bounce" from a larger 
procedure, and the improvement offered by delayed treatment is too gradual to be 
assessed with the numbers achieved in this study. 
 
Patients undergoing delayed treatment in this study had a significantly higher rate 
of further intervention (36% vs 2%, Relative Risk 18.36).  Advocates of delayed 
phlebectomies cite "over-treatment" as a prime concern (Welch 2006), however in a 
time of austerity (Lane et al. 2013) one must also consider "under-treatment" and 
its sequelae as shown by this study's worse outcomes in those patients needing 
further treatment.  With recent long term cohort data indicating that superficial 
venous disease has a progressive nature (Schultz-Ehrenburg & Reich-Schupke 
2009; Rabe et al. 2010; Robertson et al. 2013), and good outcomes from ascending 
theory evangelists (Pittaluga et al. 2009), the fact that patients receive both better 
clinical outcomes and the treatment that they prefer with simultaneous treatment 
may become a key driver to better healthcare. 
 
This study provides further evidence that simultaneous treatment of truncal veins 
and varicosities leads to improved early disease specific quality of life with 
improved clinical status as found by Carradice et al in the previous randomised 
study specifically addressing this question (Carradice et al. 2009).  That study of 50 
patients using laser ablation found that clinical severity (as assessed by VCSS) was 
not significantly different at 1 year, but did show early improvement in favour of 
simultaneous treatment.  Our present study replicates these outcomes with early 
QOL improvement but adds extended clinical improvement. 
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The odds ratio of patients undergoing adjunctive procedures in the delayed 
phlebectomy group in the Carradice trial was 16.67 (66% in delayed group vs 4% in 
simultaneous group) with a relative risk of 16.67, which is in keeping with the risk 
profile seen in our current study.  In our study, patients who underwent delayed 
treatment had an Odds Ratio of 28.125 (p<0.0001) and Relative Risk of 18.360 
(p<0.0001) of requiring further treatment, with 36% requiring further treatment 
compared to 2% in the simultaneous group.  It is interesting that despite a decrease 
in overall percentage requiring re-intervention the risk statistics are in fact 
increased.  The patient demographic reported by Carradice et al had a far lower 
disease burden than that reported in this study (AVVQ 13 vs 23 and VCSS 4 vs 7.4).  
This may be secondary to change in referral practice in the intervening 5 years or a 
different burden of disease in our local geographical area. 
 
This study was powered to detect a 5 point difference in AVVQ at 6 months between 
groups, and thus required a recruitment target of 128 patients with 100% follow-up.  
Allowing for loss to follow-up, target recruitment was 240.  81% of recruited 
patients were follow-up up to the primary endpoint at 6 months.  A significant 
limitation of this study is the failure to reach target recruitment over the 18 month 
recruitment period.  The target was not achieved due to patient preference for 
single sitting treatment despite equipoise from the researchers and careful 
consenting for both the trial and the procedure - >50% of the suitable population 
refused randomisation due to a preference for simultaneous treatment.  At 6 weeks 
the difference in AVVQ was 5.48 and at 6 months 3.47.  It is possible therefore that 
this lack of significance is a Type 2 error.  Alternatively, as all patients requiring 
further treatment would have both received and recovered from the second 
intervention by 6 months, it may not be possible to achieve this difference.  A 
clearer picture may have been found if a further review at 6 weeks post re-
intervention had been undertaken.  Carradice et al. also set their reintervention 
review at 6 weeks, with this trial using a similar protocol, however using 3 months 
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as a further intervention decision point may have offered better differentiation 
between groups. 
 
No specific assessment of operating time or efficiency was completed in this study, 
however all patients participating in the trial were scheduled as ± phlebectomies 
and booked onto standardised morning lists in single slots.  The morning day case 
lists catered for a maximum of 6 patients per session, based on one surgeon 
completing all tasks (consent, positioning, preparation and treatment including 
ultrasonography).  Those undergoing adjunctive procedures were booked into 
similar single slots, however previous work on anaesthetic time reduction in general 
anaesthetic cases has found that large reductions in treatment time are required to 
allow extra case throughput (Dexter et al. 1995; Dexter & Macario 1999), due to the 
logistical time involved in moving, positioning and preparing the patient.  This is 
even more vital in the context of local anaesthetic procedures where the patient 
must not feel rushed. 
 
Initial adjunctive procedures were not completed with foam sclerotherapy, though 
this is standard in some centres (King et al. 2009; Yilmaz et al. 2011).  This may 
provide a more time-efficient option, especially as tumescentless ablation 
techniques become more accepted and commonplace, as phlebectomies would render 
the major selling point of the techniques obsolete. 
7.3.6.	  Conclusion	  
This study lends further weight to the argument that one stage treatment is not 
only the patient’s preference but also in their best interests with improved early 
quality of life and prolonged improved clinical status.  The clinical improvement is 
upheld even in those in the delayed group who do not need further varicosity 
treatment. 
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This study would therefore suggest that simultaneous treatment of truncal veins 
and varicosities represents the optimal management of patients with symptomatic 
varicose vein disease.  However, larger scale studies are required to confirm these 
results, and this may be difficult due to patient preference. 
 
Further work into cost-effectiveness, operating time and pain profile would allow 
clear guidance on not only the patient's ideal treatment pathway, but also the most 
efficient. 
 
Crucially the final decision on treatment pathway remains with the clinician and 
the patient as both simultaneous and delayed pathways offer good outcomes overall 
with excellent complication profiles. 
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Chapter	  8:	  Assessing	  New	  Technologies	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8.1.	  Introduction	  
With the advance of technology, the evidence base must move with it.  Efficacy and 
safety are assessed first, followed by long-term reliability and patient experience.  
Over time the endpoints of treatment move from technical and objective measures 
(Lurie et al. 2005) to quality of life and patient assessment (Rasmussen et al. 2011). 
 
New techniques are driven by new devices and vice versa.  The target of bloodless, 
painless varicose vein surgery remains elusive, however minimally invasive 
techniques are becoming more common and more advanced (Lane et al. 2011; 
McBride 2011; Onida et al. 2013).  In order to truly examine each device many 
outcome measure need to be assessed, from initial clinical safety assessments and 
technical success to long-term occlusion and QOL results. 
 
Varicose veins pose a difficult disease question as progression and recurrence are 
relatively common, and may not be related to the treatment modality used.  
Therefore RCTs between different modalities and "gold standards" are required.  
However, the pace of development often outstrips the follow-up required in these 
trials.  This can easily be seen in the EVLA modality with the multiple different 
wavelengths being developed at rapid intervals (Ash & Moore 2010; Massaki et al. 
2013). 
It is also important to fully investigate previous generations of devices, those that 
are in common use at present, as concerning features are often not visible until long 
term follow-up and generalised acceptance is available.  Additional theories 
concerning complications seen in other modalities need further exploration to assess 
their generalisability and occurrence under different circumstances. 
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8.2.	  Echocardiography	  during	  Radiofrequency	  Ablation	  of	  Varicose	  Veins	  
8.2.1.	  Introduction	  
Chronic venous insufficiency presents with lower limb varicosities, ankle swelling, 
skin changes and in severe cases venous ulceration (Callam 1994). Over the last 15 
years, the practice of treating varicose veins has moved towards minimally invasive 
endovenous techniques, which can be performed under local anaesthetic in an 
ambulatory, outpatient based setting (Nael & Rathbun 2009; Lane et al. 2011). 
Two commonly used endovenous modalities of varicose vein treatment are foam 
sclerotherapy and endothermal ablation, which have been described before.  Modern 
ultrasound guided foam sclerotherapy (UGFS) has good technical efficacy, low cost 
and low morbidity (Coleridge Smith 2009; Bradbury et al. 2010) and is a generally 
accepted treatment modality for varicose veins.  Endothermal ablation is now also a 
mainstay of clinical practice (van den Bos & Proebstle 2013).  The thermal energy 
causes damage of the venous wall leading to fibrosis and occlusion of the refluxing 
vein, however, the exact mechanism is still unclear (Van Den Bos et al. 2009; 
Malskat et al. 2013). 
 
Both UGFS and endothermal ablation are associated with few complications 
(Anwar et al. 2012; Dexter et al. 2012; Cavezzi & Parsi 2012), however, neurological 
events ranging from auras and headaches to transient ischaemic attacks and 
strokes have been reported in association with UGFS in approximately 2% of 
patients (Hartmann et al. 2009; Regan et al. 2011; Rathbun et al. 2012).  
Sarvananthan et al. (2011) (Sarvananthan et al. 2012) stated that the mechanism 
behind such adverse events was unclear and, there may potentially be more than 
one cause. 
 
One of the principal hypotheses is the migration of bubbles (Bush et al. 2008; Picard 
et al. 2010; Parsi 2011), which are introduced as part of the foam sclerosant, to the 
brain, possibly by passing through a patent foramen ovale.  These bubbles may be 
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responsible for cerebral vessel occlusion working as emboli.  However, studies with 
carbon dioxide bubble formation has shown varied results with a reduced incidence 
of cerebral symptoms in one study, but not another, when compared to conventional 
air based foam (Parsi 2011).  Significant bubble migration has been shown through 
a variety of imaging modalities during sclerotherapy and some bubbles are able to 
reach the middle cerebral artery, as detected by Morrison et al. (Morrison et al. 
2008) through the use of transcranial Doppler studies.  Bubbles have also been 
found in the middle cerebral artery of patients who did not suffer from neurological 
complications. 
 
A principle theory behind the mechanism of action of endothermal ablation is heat 
transfer by bubble formation.  It has been shown previously that endothermal 
ablation produces steam bubbles at the tip of the catheter (Proebstle, Lehr, et al. 
2002a; Proebstle, Sandhofer, et al. 2002b). However, there have been no reported 
incidences of neurological complications (Anwar et al. 2012) nor have there been 
any investigations into whether the bubbles dissipate or are able to persist 
throughout the circulation in a fashion akin to those produced in foam sclerotherapy 
(Guex et al. 2010). 
8.2.2.	  Aim 
The aim of this safety study was to determine whether microemboli present at the 
catheter tip during endothermal ablation of varicose veins are seen in the right side 
of the heart. 
8.2.3.	  Methods	  
8.2.3.1.	  Study	  Design	  and	  Size	  
Research Ethics Committee approval was sought and obtained (11/LO/1358) and all 
patients gave written informed consent.  Ethical approval had initially been 
obtained for the investigation of up to 32 patients allowing the prevalence to be 
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calculated to the nearest 3%, however, it was deemed both unnecessary and 
unethical to proceed after the first 16 patients were scanned. 
Patients undergoing elective endothermal ablation of the great saphenous vein 
under local anaesthesia using a VNUS ClosureFast Catheter (VNUS Medical 
Technologies, San Jose, USA) took part in the study.  Only those undergoing long 
saphenous vein ablation were considered as they would be in the appropriate supine 
position. Those undergoing an ablation of the short saphenous vein are positioned in 
the prone position in our institution and therefore were unable to undergo 
transthoracic echocardiography. 
8.2.3.2.	  Inclusion	  and	  Exclusion	  Criteria	  
Consecutive patients over 18 years of age presenting for endothermal ablation of the 
long saphenous vein were invited to take part in the study.  
The following patients were excluded: 
• Those unable to consent. 
• Those undergoing other venous procedures 
• Those with recurrent varicose veins (especially with prior high-tie) 
8.2.3.3.	  Training	  Phase	  
Transthoracic echocardiography provides a sensitive, well validated method to 
identify and quantitatively grade the presence of microbubbles in the right atrium 
and ventricle, as evidenced by its common use in the diagnosis of a patent foramen 
ovale (Attaran et al. 2006). Prior to scanning the patient population of the study, a 
sonographer was observed performing bubble echocardiography on four patients by 
the independent consultant cardiologist. The model used was a Philips iU22 system 
with an X3 curvilinear echo transducer.  
8.2.3.4.	  Main	  Study	  Phase	  
Consecutive patients undergoing elective endothermal ablation of varicose veins 
under local anaesthetic underwent intra-procedural echocardiographic monitoring 
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from March 2012 to May 2012. A B-mode apical four chamber view was acquired 
throughout the procedure.  The settings for the ultrasound machine were as follows: 
 
• Mechanical index: 1.1 
• Compression: 72 
• Persistence: Off 
• Focal depth set to visualise right atrium (12±2cm) 
• Gain optimised to ensure blood appeared black 
 
The GSV was successfully cannulated, catheter advanced to 2cm distal to the SFJ 
and tumescent local anaesthetic instilled as standard protocol for endovenous 
ablation (Creton et al. 2010).  Several, standardised loops of footage were saved for 
each patient: 
• A loop of 30 seconds of the patient's heart prior to the start of the procedure 
serving as a negative control (no microemboli present)  
• A 30 second loop of footage captured as a 10ml saline flush was introduced 
through the sheath at the site of cannulation to serve as a positive control 
• A third loop of 30 seconds prior to commencement of heating to confirm no 
circulating bubbles remained after the flush. 
• Radiofrequency ablation was commenced at a 2 minute interval after 
flushing, and only after no remaining bubbles were present.  Loops taken 
during endovenous ablation itself were then recorded.  The number of loops 
captured was dependent on the number of heating cycles performed (usually 
three or four cycles per procedure).  
• Finally, one minute after the ablative treatment had ended, a loop of footage 
was captured.  It was deemed unethical to perform a Valsalva procedure as 
this may have induced symptoms.  Phlebectomies were then completed as 
clinically indicated.  The patient was monitored for an hour post procedure 
for neurological phenomena. 
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The raw DICOM data was exported as AVI format. The AVI loops were then 
independently scored for quality and presence of bubbles at a later date by an 
independent consultant cardiologist. The grading system (Figure 114) used was a 
modification from the International Consensus Criteria grading guidelines (Lao et 
al. 2008) used to assess the bubble density seen in a cardiac shunt test. 
 
Figure 114:  A visual depiction of the grading scale that was devised. The numbers indicate the 
grade assigned to each particular presence of microbubbles in the right heart.  Grade 0 = no 
detectable bubbles, grade 1=solitary bubbles, grade 2=stream of bubbles, grade 3=opacification of 
right heart 
8.2.4.	  Results	  
16 patients consented to the study during the recruitment period of March 2012-nay 
2012.  However, 2 declined to proceed during the procedure itself, as detailed in the 
Standards for Reporting of Diagnostic Accuracy Studies (STARD) diagram (Figure 
115), and the scans of 3 patients were deemed to be non-diagnostic, as both the 
right ventricular walls and the mitral valve were not clearly visible throughout the 
procedure. 
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The mean age of the patients scanned was 49 years old (SD = 14) and the cohort 
was predominantly female (8 Females to 3 Males, 73%:23%).  No adverse events 
were noted in any of the cohort during the procedures themselves or after a one 
hour period of observation in the unit.  
 
Figure 115:  Standards for Reporting of Diagnostic Accuracy Studies (STARD) diagram 
 
Microbubbles were absent in the pre-procedure scan in all the 11 patients scanned.  
However in the heating phase, 5 patients (45±9%) had acoustic reflectors, moving 
from the right atrium into the right ventricle.  As shown in Table 40, 4 patients had 
solitary microbubbles visible, and 1 patient had a visible stream of microbubbles. 
 
Figure 116 represents a still image from a video loop from patient #2.  Bubbles were 
noted to persist from 20 seconds to up to 5 minutes after the ablation had begun, 
however, this varied widely between patients.  No patient reported any neurological 
symptoms. 
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Table 40:  Baseline demographics, visualised bubbles and the occurrence of neurological 
complications 
Patient ID 
 
Age Gender 
Diagnostic 
Bubble Grade 
Neurological symptoms 
at 1 hour 
1 56 M 0 Nil 
2 43 M 2 Nil 
3 39 F 1 Nil 
4 68 F 0 Nil 
5 28 F 1 Nil 
6 36 F 0 Nil 
7 51 F 1 Nil 
8 43 F 1 Nil 
9 62 M 1 Nil 
10 72 F 1 Nil 
11 57 F 0 Nil 
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Figure 116:  Still taken from an echocardiography of Patient #2 during the heating phase of 
treatment which demonstrates the presence of a stream of bubbles in the right side of the heart. 
The bubbles are circled in red. The chambers are also marked (RV: Right Ventricle, RA: Right 
Atrium, LV: Left Ventricle, LA: Left Atrium) 
8.2.5.	  Discussion	  
This study provides the first documented presence of microbubbles in the right 
atrium and ventricle during endothermal ablation of varicose veins.  Despite the 
fact that this was a common finding s no neurological complications ensued. These 
results suggest that the presence of microbubbles in the right heart may be an 
incidental finding. 
 
Ceulen (2008) (Ceulen et al. 2008) cast doubt on the theory that microbubbles play a 
major role in the development of neurological complications as he showed that 100% 
of the 33 patients who had underwent UGFS had bubbles present in the right side 
of the heart, but it was noted that only 7% of their cohort suffered from neurological 
complications.  If transient bubbles are the primary causative agent in the 
pathogenesis of the neurological complications, one would, in theory, expect to see 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
296 
neurological complications quickly arise in every patient with a PFO, which is 
estimated to have a prevalence of approximately 17% in the general population 
(Schwerzmann et al. 2005). This, however, is not the case and therefore suggests 
that these neurological complications may be either unrelated to the sole presence 
of bubbles or are part of a multi-factorial aetiological process.  In addition, patients 
undergoing investigation for the presence of a PFO have agitated saline with air 
bubbles injected into a peripheral vein.  There is some controversy as to whether 
neurological complications occurring during the test can be attributed to the 
bubbles (Romero et al. 2009), but during a large multi-centre study no neurological 
complications were reported and it is routinely carried out for the investigation of a 
right to left cardiac shunt (Tsivgoulis et al. 2011). 
 
It is likely that there are inherent differences between the micro-emboli witnessed 
in this study and the bubbles seen in the systemic circulation of patients 
undergoing foam sclerotherapy.  For example, bubbles formed by foam 
sclerotherapy may be more stable, or more likely to coalesce than the bubbles 
formed by endothermal ablation, due to the presence of the sclerosant detergent.  
Epstein and Plesset initially suggested that air bubbles in dynamic biological 
systems do not usually have the potential to persist for extended periods of time 
(Epstein & Plesset 1950; Plesset & Sadhal 1982) and work by Peterson and 
Goldman has shown that the half-life of foam bubbles was 25-28 seconds and 86-91 
seconds using carbon dioxide and room air respectively (Peterson & Goldman 2011).  
However, bubbles produced by foam sclerotherapy have the potential to persist for 
up to 32 minutes beyond the commencement of treatment (Regan et al. 2011). This 
prolonged persistence may have a role to play in the neurological complications. 
 
An alternative hypothesis currently gaining momentum is that the action of the 
sclerosant on the endothelium leads to the production of Endothelin 1 (ET1), which 
is able to initiate many pathogenic pathways, including those related to migraines 
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and auras.  Frullini et al (Frullini et al. 2011; Frullini et al. 2012) showed there is 
an increased production of ET1 following UGFS in murine models, and that levels 
correlate closely with the severity of the neurological events experienced. Initial 
recent human work has also shown that increased ET1 levels are found in patients 
who have undergone UGFS.  However, ET1 levels have yet to be measured in 
patients post endothermal ablation for comparison.  It may be that thermal ablation 
technique destroys any endothelin produced during treatment, or that thermal 
ablation does not cause the release of endothelin.  These results may shed light on 
why neurological complications are almost exclusive to foam sclerotherapy.  
8.2.6.	  Conclusion	  
This study demonstrates that microemboli are commonly found in the right heart 
during endothermal ablation of the GSV but without immediate neurological 
sequelae, and may therefore be an incidental finding.  This evidence suggests that 
that neurological complications experienced after foam sclerotherapy are not solely 
due to microemboli, but may be due to differing bubble stability or the production of 
endothelin. 
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8.3.	  Clarivein	  -­‐	  Mechanochemical	  Ablation	  
8.3.1.	  VNUS	  Versus	  Clarivein	  for	  Varicose	  Veins	  -­‐	  A	  Randomised	  Clinical	  Trial	  
8.3.1.1.	  Background	  
Varicose veins are characterised by dilated, tortuous superficial veins in the legs 
and affect approximately 25% of men and women in the United Kingdom (Callam 
1994; Evans et al. 1999; Robertson et al. 2008).  
 
The introduction of minimally invasive endovenous techniques has resulted in a 
rapid increase in their use throughout the UK and worldwide (Lane et al. 2011).  Of 
the 27, 000 procedures,  of which over 9,000 (36%) were endovenous ablation a 
change from 15% of procedures in 2008-2009 (Edwards et al. 2009; Shepherd et al. 
2010). 
 
Advantages of endovenous techniques including thermal (laser, radiofrequency or 
steam) and chemical ablation (foam sclerotherapy) include the fact that they are 
routinely performed under local anaesthesia in an outpatient setting (Darwood & 
Gough 2009) and result in less post procedural discomfort and allow a more rapid 
recovery compared to traditional surgery (Darvall et al. 2009; Rasmussen et al. 
2011) with low complication rates, they are therefore highly desirable for patients 
and clinicians.  Efficacy has been shown to be equivalent between all treatment 
modalities (Rasmussen et al. 2013). 
 
Covidien Venefit is the most frequently used radiofrequency device world-wide and 
allows rapid thermal ablation of truncal veins (Proebstle et al. 2011). Treatments 
are performed under tumescent local anaesthesia (Klein 1996) to provide a heat 
sink for the thermal energy around the vein, to compress the vein around the 
catheter, reducing the energy requirements and provides anaesthesia for the 
patient, and allowing the use of the outpatient setting (Bisang et al. 2012).  This 
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technique can be performed under general anaesthetic, but still requires the 
instillation of local anaesthetic.   
 
Clarivein is a relatively new device which combines mechanical and chemical 
ablation to achieve vein closure (Elias et al. 2013). Potential advantages include the 
fact that no tumescent anaesthesia is required, reducing the discomfort experienced 
by the patient and the time to perform the procedure. It also reduces risk of skin or 
nerve damage as can be encountered with thermal ablation therapies (Dexter et al. 
2012; Anwar et al. 2012).   
 
In addition, the combination of chemical sclerosant and mechanical abrasion of the 
vein wall has been shown to achieve closure rates comparable to those achieved 
with thermal ablation (Elias & Raines 2012). Early results have shown 6 month 
occlusion rates to be 96% in all studies, 94% at 1 year (Boersma et al. 2013) in one 
study and 96% in the original study (Elias et al. 2013).  These results are therefore 
comparable with thermal ablation results - 93% at 3 years (Rasmussen et al. 2013). 
 
Each endovenous technique has specific advantages and disadvantages, the ideal 
therapy would provide long term success rates at a competitive cost, it should be 
quick and simple to perform with minimal discomfort to the patient. At present 
there is limited data comparing endovenous treatment modalities and this study 
proposes to compare Clarivein with RFA. By eliminating the need for tumescent 
anaesthesia, is it thought that Clarivein will be significantly less painful than RFA 
to perform, due to a reduction of tumescent anaesthesia injections counter-balanced 
by the feeling of the Clarivein device. 
8.3.1.2.	  Methods	  
Patients referred for treatment of symptomatic varicose veins who are found to have 
primary great or small saphenous vein reflux on colour duplex imaging will be 
studied. In patients with bilateral disease, the leg which is most symptomatic 
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according to the patients will be randomised and both legs will receive the same 
treatment.  
8.3.1.2.1.	  Inclusion	  Criteria	  
Adults over 18 years of age 
Symptomatic long or short saphenous vein reflux < 0.5 seconds on colour duplex. 
8.3.1.2.2.	  Exclusion	  Criteria	  
• Current DVT 
• Recurrent Varicose Veins 
• Arterial disease (ABPI<0.8) 
• Veins less than 3mm in diameter 
• Hypercoagulability 
• Patients who are unwilling to participate 
• Inability or unwillingness to complete questionnaires 
8.3.1.2.3.	  Patient	  allocation	  and	  randomisation	  
Two potential allocations are available: 
1. VNUS Closure FASTTM 
2. ClariveinTM 
 
Patients will be randomised to receive one of the possible treatment options. 
Treatments will be completed local anaesthetic with concomitant phlebectomy if 
necessary. Randomisation will be via an internet randomisation service (Sealed 
Envelope, London, UK).  
8.3.1.2.4.	  Measurement	  of	  outcomes	  
8.3.1.2.4.1.	  Primary	  outcome	  
The primary outcome of pain during the procedure will be measured using a 
validated patient reported Visual Analogue Score (VAS) (Appendix 2) 
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8.3.1.2.4.2.	  Secondary	  Outcomes	  
• Improvement in the AVVQ score at 30 days and 6 months compared to 
baseline (Appendix 1) 
• Improvements in generic quality of life measured using the EQ-5D at 30 days 
and 6 months (Appendix 1) 
• Technical success/saphenous vein occlusion at 30 days and 6 months 
measured using colour duplex by an accredited vascular scientist 
• Clinical success at 30 days and 6 months according to the VCSS 
• Number of days taken to resume work and normal activities 
• Cost effectiveness of the treatment regimes in terms of quality adjusted life 
years  
8.3.1.2.5.	  Operative	  details	  
The length of the specific vein ablated, the amount of local anaesthesia used and the 
number of phlebectomies performed will be recorded at the time of operation.  
Patients are treated under local anaesthetic with standard mechanochemical 
ablation protocol via a 4 French sheath (Elias et al. 2013) or with standard 
radiofrequency ablation protocol with tumescent anaesthesia via a 7 French sheath 
(Creton et al. 2010). 
8.3.1.2.6.	  Recruitment	  
Eligible patients who have been referred by their GP with primary symptomatic 
varicose veins will be identified at their first out patient appointment by the clinical 
team. They will be informed of the study and provided with an information sheet. 
Willing patients will sign a consent form agreeing to participate in the trial. 
8.3.1.2.7.	  Participating	  Sites	  
The study was initially approved as a one site study - Charing Cross Hospital in 
London (Imperial College Heathcare NHS Trust) and was then expanded into a 
three site study incorporating Northwick Park and Central Middlesex Hospitals in 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
302 
London (North West London Hospitals NHS Trust) and Addenbrookes Hospital in 
Cambridge (Cambridge University Hospitals NHS Trust). 
8.3.1.2.8.	  Proposed	  sample	  size	  
Power calculations were based on the primary outcome measure of pain during the 
procedure and were based upon detection of a 20mm difference in maximum pain 
score with a standard deviation of pain score of 20mm, which was considered to be a 
significant clinical difference. 
To attain 90% power at the 5% significance level, a minimum target sample size of 
47 legs per group was required. 
This figure was increased to allow for loss to follow up or protocol violation. This 
resulted in an overall target recruitment of 170 patients (85 per group). 
 
The trial protocol is below. 
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Figure 117:  VVCVV Trial Protocol 
8.3.1.2.9.	  Ethical	  Approval	  
Ethical approval was sought and gained from the National Research Ethics Service 
Committee London-Chelsea, identifier 12/LO/0570.  This was initially approved as a 
one site study then amended to a three site study with local NHS Research and 
Development approval locally at Imperial College NHS Trust and North West 
London Hospitals NHS Trust (Imperial College NHS Trust approval identifier 
JRC0HH0431 and North West London Hospitals NHS Trust approval identifier 
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RD13/032).  Cambridge University Hospitals NHS Foundation Trust local approval 
is pending. 
The trial is registered at Current Controlled Trials with the identifier 
ISRCTN06552809 (ISRCTN Register 2012). 
8.3.1.3.	  Interim	  Results	  
After one year of recruitment, 85 patients (50% of target) have been successfully 
randomised over 2 sites since January 2013.  As 50% of the recruitment has been 
achieved an interim analysis has been performed to ensure data quality and patient 
safety. 
 
85 patients (46% male) with a mean age of 51 years have been recruited and 
treated, with 43 Clarivein procedures completed.  1 protocol violation occurred due 
to intolerance of the VNUS procedure, which necessitated conversion to Clarivein 
treatment. 
 
Initial primary outcome results indicate that there is currently a significant 
difference in maximum intraoperative discomfort and average intraoperative 
discomfort scores between Clarivein and VNUS treatments (Maximum: 13.9 mm vs 
33.7 mm, p<0.001; Average 9.6 mm vs 22.4 mm, p=0.002) as shown in Figure 118 
and Figure 119.  Median numerical pain score values were also significantly 
different between mechanochemical and radiofrequency ablation for both maximum 
and average intraoperative discomfort (Maximum 2 vs 4, p<0.001; Average 1 vs 3, 
p=0.005). 
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Figure 118:  Visual Analogue Scale (VAS) scores in millimetres for maximal discomfort experienced.   
 
Figure 119:  Visual Analogue Scale (VAS) scores in millimetres for average pain experienced 
VASMaxLPXP'LVFRPIRUWmP
ClariveiQYHUVXVVNUS
&ODULYHLQ 13.871 ± 4.852
9186 33.69 ± 9.694
VASAveUDJH'LVFRPIRUWmm
ClariveinYHUVXVVNUS
&ODULYHLQ 9.59 ± 3.987
9186 22.362 ± 7.224
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Figure 120:  Mean days taken to return to normal activities 
 
 
Figure 121:  Mean days taken to return to work 
No significant difference has thus far been seen between Clarivein and VNUS 
groups for the time taken to return to normal activities (3.6 days vs 4.8 days, 
p=0.417, Figure 120) and to return to work (4.1 vs 5.4, p=0.435, Figure 121).  
Additionally, no difference has been seen for disease specific or generic QOL tools at 
30 days (AVVQ – 14.8 vs 14.3, p=0.897; EQ-5D - 0.80 vs 0.79, p=0.902). 
 
No thromboembolic complications (SVT, DVT or PE) have been reported nor have 
any local complications (infection, nerve injury or skin burns). 
TimeToReturnTo1ormalActivities'D\V
Clarivein9HUVXVVNUS
&ODULYHLQ 3.643 ± 2.008
9186 4.833 ± 2.466
TimeToReturnToWorN'D\V 
ClariveinYHUVXVVNUS
&ODULYHLQ 4.077 ± 2.473
9186 5.364 ± 2.536
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
307 
 
The first patients recruited are beginning to complete follow-up.  It is anticipated 
that recruitment will be completed by June 2014, with the trial completed by 
December 2014. 
8.3.1.4.	  Discussion	  
These early outcomes from this ongoing study lend further weight to previous 
evidence that treatment with the Clarivein mechanochemical ablation device is safe 
and efficacious.  The primary outcome of this study is to demonstrate the differing 
pain profiles of radio frequency and mechanochemical ablation.  Interim analysis 
has shown that mechanochemical ablation has a significantly lower maximum 
intraoperative discomfort score, both statistically and clinically.  Average 
perioperative discomfort was also significantly reduced in the mechanochemical 
ablation group. 
 
Recent work in the Netherlands on 68 patients has shown that post-operative pain 
after GSV treatment is significantly improved for mechanochemical ablation 
compared to radiofrequency ablation (van Eekeren et al. 2013).  Interestingly, the 
peri-operative discomfort score seen in the two groups was 22mm (Clarivein) and 
27mm (radiofrequency) (van Eekeren et al. 2013), with the same group obtaining a 
20mm average peri-operative discomfort for SSV mechanochemical ablation and the 
early safety study from the same group for GSV mechanochemical ablation 
produced a mean pain score of 4/10  (van Eekeren et al. 2011).  Our study’s values 
show an reduced pain score for the Clarivein mechanochemical technique, compared 
to relatively static radiofrequency pain scores.  This indicates that with the 
maturation of the technique and increased familiarity improved procedural 
outcomes can be obtained.  This stable level of peri-operative pain for 
radiofrequency ablation is likely to be due to the tumescent anaesthesia application, 
with technique having reached a plateau. 
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8.3.1.5.	  Conclusion	  
Completion of this study should provide level 1 evidence to guide clinicians on 
improving their patient's experience and pathway during endovenous treatment. 
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8.4.	  Sapheon	  -­‐	  Cyanoacrylate	  Ablation	  
8.4.1.	  European	  Sapheon	  Closure	  System	  Observational	  ProspectivE	  Study	  
8.4.1.1.	  Introduction	  
The Sapheon Cyanoacrylate Closure System is a new device that treats incompetent 
truncal veins by instillation of cyanoacrylate into the treated vein.  It builds on the 
experience of using thermal and mechanochemical ablation techniques (Proebstle et 
al. 2005; Lohr & Kulwicki 2010; Elias et al. 2013).  This "arms race" aims to 
simplify the endovenous treatment paradigm and reduce complications such 
thermal injury and reduce the need for protective tumescent anaesthetic (Dexter et 
al. 2012; Anwar et al. 2012). 
 
This has led to the production of the Sapheon Closure System as shown in Figure 
122 and Figure 123. 
 
Figure 122:  Sapheon Closure System 
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Figure 123:  Sapheon Cyanoacrylate 
The kit consists of a proprietary glue and a proprietary catheter system.  The 
cyanoacrylate glue is a tissue adhesive which is used extensively in other 
applications and has been modified for superficial venous treatment (Morrison 
2013).  The cyanoacrylates rapidly polymerise on contact with water or blood 
(Kamer & Joseph 1989). 
 
The superficial venous treatment system requires no tumescent anaesthesia and no 
compression.  In theory this should provide a reduced pain experience for patients 
undergoing treatment, in line with other modality advancements and studies 
assessing previous technologies and other tumescentless treatments(Nordon et al. 
2011; Shepherd et al. 2010). 
 
This study attempts to treat and observe the first large cohort of treated patients 
across 7 different participating sites and clinical teams. 
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8.4.1.2.	  Methods	  
This observational study recruited symptomatic C2-C4 chronic venous disease 
patients from multiple sites in the UK and Europe from March-June 2012.  
Imperial College London and Imperial College Healthcare NHS Trust was the lead 
UK centre and only NHS centre, responsible for ethical approval, NHS Research 
and Development approval and trial registration.  Additionally the first UK 
Sapheon cases were performed at Charing Cross Hospital in the training phase of 
the study. 
 
Patients were suitable for recruitment if they had primary incompetent long 
saphenous veins, with a reflux time of >0.5 seconds on colour duplex 
ultrasonography. 
 
Patients were treated with the standard Sapheon Venaseal cyanoacrylate treatment 
pathway as previously published (Almeida et al. 2011; Lane et al. 2013).  Standard 
endovenous Seldinger technique is used for access via a 5 French sheath and then 
the patient is placed in the standard reverse-Trendelenburg position.  The catheter 
is passed to 5 cm distal to the saphenofemoral junction.  Compression is applied at 
the saphenofemoral junction using the ultrasound probe in cross-section 
(transverse).  Then one injection using the catheter system is completed before the 
catheter is withdrawn 1 cm and the second injection completed.  The catheter is 
withdrawn a further 3 cm and 3 minutes of light compression is applied to the 
treated area.  Then further injections with 3 cm withdrawals and 30 seconds of 
compression are completed.  The compression times allow for polymerisation of the 
glue.  Occlusion is confirmed on duplex ultrasound. 
 
Patients were reviewed at 48-72 hours, 1 month, 3 months, 6 months, 12 months, 24 
months and 36 months with a duplex ultrasound and a standardised questionnaire 
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including AVVQ and EQ-5D QOL and EQVAS.  A pain diary was completed for the 
first month.  2 year and 3 year follow-up is ongoing. 
 
No additional procedures were completed at the initial treatment, and were only 
allowed after the 3-month review. 
8.4.1.2.1.	  Number	  of	  Study	  Sites	  and	  Subjects	  
This multi-centre study consisted of 7 centres that specialize in the diagnosis and 
treatment of peripheral venous disease: 
1. Private Clinic Proebstle in Mannheim, Germany 
2. Charing Cross Hospital, Imperial College London and Imperial College 
Healthcare NHS Trust, London, UK - Lead UK Centre and NHS site. 
3. Vein Center, Ouderkerk, Netherlands 
4. The Danish Vein Center, Naestved, Denmark 
5. The Whiteley Clinic, Guildford, UK 
6. Vein Solutions, Spire Cheshire, UK 
7. Dermatoligikum, Hamburg, Germany 
8.4.1.2.2.	  Study	  Outcomes	  
8.4.1.2.2.1.	  Primary	  Outcomes	  
• Vein closure at 1 year as assessed by duplex ultrasound - defined as no 
patent segments >10 cm. 
8.4.1.2.2.2.	  Secondary	  Outcomes	  
• Venous Clinical Severity Score 
• Quality of life and pain 
⁃ Specific QOL – AVVQ 
⁃ Generic QOL - EQ-5D 
⁃ Pain during the procedure, diary (VAS) on use of analgesics 
⁃ Pain reported during the first 30 days by patient diary VAS 
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8.4.1.2.3.	  Inclusion	  Criteria	  
• Age ≥18 years and ≤ 70 years of age 
• Symptomatic primary GSV incompetence diagnosed by clinical 
symptoms, with or without visible varicosities, and confirmed by 
duplex ultrasound imaging 
• CEAP classification of C2, C3 or C4 
• Ability to walk unassisted 
• Ability to attend follow-up visits 
• Ability to understand the requirements of the study and to provide 
written informed consent 
• GSV on standing pre-procedure Doppler US ≥3mm and ≤10mm 
(maximum diameter) 
8.4.1.2.4.	  Exclusion	  Criteria	  
• Life expectancy < 1 year 
• Regular pain medication 
• Anticoagulation including Heparin or Warfarin 
• Previous DVT 
• Previous superficial thrombophlebitis in GSV 
• Previous venous treatment on target limb 
• Known Hyper-coagulable disorder 
• Conditions which prevent routine vein treatment like: 
- Acute disease 
- Immobilization or inability to ambulate 
- Pregnancy 
- Tortuous GSV, which in the opinion of the Investigator will limit 
catheter placement (no 2 primary access sites allowed) 
- Incompetent ipsilateral small saphenous or anterior accessory great 
saphenous vein 
- Known sensitivity to the cyanoacrylate (CA) adhesive 
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-Current participation in another clinical study involving an 
investigational agent or treatment, or within the 30 days prior to 
enrollment 
8.4.1.2.5.	  Ethical	  Approval	  
Ethical approval was obtained in the United Kingdom for NHS sites (sites 2, 5 and 
6) from the NHS Lothian South East Scotland Research Ethics Committee 02 with 
the unique identifier of 12/SS/0028.  The study is registered with ClinicalTrials.gov 
with the record number: NCT01570101.  Local site specific approval was gained 
from NHS Research and Development Offices (Imperial College NHS Trust 
Approval Number: JR0HH0356) and local private hospital approval offices. 
8.4.1.3.	  Results	  
69 patients have been recruited throughout Europe, with 6 month data and early 12 
month data available. 
3 (4%) patients have been recruited from Charing Cross Hospital Venous Unit.  All 
3 have shown excellent results with good vein closure and reduction in symptoms at 
1 years post-treatment. 
The three patients baseline demographics and outcomes are presented in Table 41. 
 
Table 41:  Imperial College eSCOPE Participants Demographics and Outcomes 
 Patient 1 Patient 2 Patient 3 Mean 
Baseline       
Age 53 27 46 42 
Sex F F F  
Leg Right Right Right  
GSV Maximal 
Diameter (mm) 
10.0 6.3 5.4 7.23 
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 Patient 1 Patient 2 Patient 3 Mean 
CEAP 4 3 3 3 (Median) 
VCSS 7 5 5 5.67 
AVVQ 15.55 13.45 24.31 17.77 
EQ-5D QOL 0.837 0.837 0.837 0.837 
EQ-5D VAS 99 95 95 96.33 
 Patient 1 Patient 2 Patient 3 Mean 
30 Day F/Up     
CEAP 1 2 2 2 (Median) 
VCSS 1 1 2 1.33 
AVVQ 15.92 8.34 16.13 13.46 
EQ-5D QOL 1.000 1.000 0.837 0.946 
EQ-5D VAS 100 98 98 98.67 
Vein Occluded Y Y Y 100% 
3 Month F/Up     
CEAP 1 2 2 2 (Median) 
VCSS 0 2 1 1 
AVVQ 2.98 11.05 19.34 11.12 
EQ-5D QOL 1.000 0.837 0.837 0.891 
EQ-5D VAS 100 100 99 99.67 
Vein Occluded Y Y Y 100% 
6 Month F/Up     
CEAP 1 1 2 1 (Median) 
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 Patient 1 Patient 2 Patient 3 Mean 
VCSS 0 0 2 0.67 
AVVQ 3.26 10.46 12.03 8.58 
EQ-5D QOL 1.000 1.000 0.837 0.946 
EQ-5D VAS 100 98 99 99 
Vein Occluded Y Y Y 100% 
12 Month F/Up     
CEAP 1 1 1 1 (Median) 
VCSS 
0 0 0 
0 
(-5.67 = 100% 
improvement) 
AVVQ 
0 16.93 13.65 
10.19 
(-7.58 = 43% 
improvement) 
EQ-5D QOL 
1 0.837 1.000 
0.946 
(+0.109 = 13% 
improvement) 
EQ-5D VAS 
100 100 100 
100 
(+3.66 = 3.81% 
improvement) 
Vein Occluded Y Y Y 100% 
 
These three patients showed excellent and persisting improvement in symptoms 
and disease status. 
 
Two patients (66%) required treatment of persisting symptomatic varicosed 
tributaries performed between the 3-month and 6-month follow-up.  Both patients 
underwent foam sclerotherapy.  No complications were encountered. 
PhD Thesis - Apr 2014/Lane TRA      Outcomes in Varicose Vein Disease 
317 
This small sample is part of the eSCOPE study, with the 6-month results displayed 
below. 
8.4.1.3.1.	  eSCOPE	  Results 
70 GSVs in 70 patients have been treated, with a median follow-up of 3 months.   6-
month complete vein occlusion figures are satisfactory at 93.75%, indicating 
technical success in 45/48 cases, with partial recanalisation seen by 3 months in 2 
cases and by 6 months in the third case.  No complete treatment failures have been 
seen to date.  Figure 124 shows the Kaplan Meier Curve with occlusion rates of 95% 
at 3 months (Confidence Interval 88.5-100%) and 90% at 6 months (78.9%-100%).   
 
Figure 124:  Kaplan-Meier curve showing vein closure rates for the Sapheon Venaseal device 
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The clinical outcomes have shown good improvements.  Figure 125 shows 
improvement in VCSS scores after treatment from a baseline of 4.4 (SD 2.3) to 1.8 
(1.6) at 1 month and to 0.2 (2.2). 
 
Figure 125:  VCSS Outcomes for the eSCOPE Study 
 
6 cases (8.7%) of phlebitis were reported during follow-up, which were treated with 
non-steroidal anti-inflammatories for 7 days.  One case (0.7%) of thrombus 
extension beyond the SFJ into the common femoral vein was reported.  This was 
treated with anticoagulation and resolved without intervention. 
8.4.1.4.	  Discussion	  
As can be seen from both the local and European results, the Sapheon Venaseal 
cyanoacrylate occlusion device shows a good efficacy and safety profile.  This will 
need to be examined with further randomised comparative trials in the future and 
long-term follow-up of this initial cohort of patients is ongoing.  This will be key in 
describing the long-term effect of glue instillation for the treatment of varicose 
veins. 
 
The benefits of the technique are patient experience - no tumescent injection and no 
compression hosiery.  However, with combined truncal ablation and varicosity 
phlebectomy under local anaesthetic a common procedure, the benefits may not be 
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as obvious as initially thought.  The compatibility of the cyanoacrylate device with 
foam sclerotherapy has yet to formally investigated, although delayed adjunctive 
procedures have been performed without complication thus far. The high unit cost 
of the proprietary cyanoacrylate will hinder adoption, especially in developing 
countries. 
 
A randomised study between all 5 truncal ablation techniques (radiofrequency, 
laser, steam, Clarivein and Sapheon) would be the optimum outcome to provide the 
evidence base for device differentiation.  The first randomised study - the VeClose 
study in the USA, has recruited 242 patients, comparing Sapheon Venaseal with 
Covidien ClosureFAST (Sapheon Inc 2013).  This study has completed recruitment 
and is in follow-up, and should report in Spring 2014.  Total follow-up duration of 
the VeClose trial is planned at 3 months. 
8.4.1.5.	  Conclusion	  
Cyanoacrylate glue appears to be a safe, feasible option with promising initial 
ablation success.  It provides a further modality for treatment, but requires further 
longer term follow-up and randomised trials to confirm these initial results.  The 
VeClose study allows initial success assessment and comparison with the current 
gold standard, but further long-term studies and repetition is required prior to 
blanket adoptance of the technique. 
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9.1.	  Final	  Discussion	  
The world of venous disease and treatment has changed significantly since the start 
of the 21st Century, in terms of understanding of pathophysiology and 
haemodynamics, and of investigation and management.  The emergence of duplex 
ultrasound imaging has been pivotal in guiding the development of the surgeon's 
armamentarium and their understanding of an superficially simple but 
significantly complex disease (Labropoulos et al. 1997; García-Gimeno et al. 2009).  
With the knowledge and concepts introduced, ultrasound assessment of varicose 
veins has paved the way for refinements to surgical treatments (Smith et al. 2002; 
Blomgren et al. 2005), the birth of the endovenous revolution (Navarro et al. 2001; 
Lohr & Kulwicki 2010) and the evolution of vascular trainees education and 
expectations (Scurr et al. 2011; Karthikesalingam et al. 2012). 
 
The endovenous revolution has led to a predominantly local anaesthetic based 
treatment for varicose veins, increasing the pool of patients suitable for treatment.  
It has also enabled clinicians to select different options for their patients, safe in the 
knowledge that all interventions offer good outcomes with good improvements in 
symptomatology (Rasmussen et al. 2011; Rasmussen et al. 2013).  A body of 
evidence is beginning to form examining the long-term outcomes of venous disease, 
which is shining the light on the consequences of under-treatment.  However, 
despite this burgeoning literature base, it is clear that non-vascular specialists are 
yet to be carried forth on the endovenous wave (Lane et al. 2013) with many 
continuing to deem varicose veins of little import (Audit Commission 2011) despite 
the morbidity experienced.  The knowledge and understanding of the options for 
local services by GPs (now Clinical Commissioning Groups) is relatively poor, and 
cost is held as the reason for rationing treatment in many cases.   It is hoped that 
the new NICE guidance (National Institute for Health and Care Excellence 2013) 
will improve this education level.  These guidelines expound the future of venous 
treatment with minimally invasive treatments to the fore and endothermal 
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treatment first line due to it's lower level of complications with similar efficacy 
(Biemans et al. 2013).  With evidence existing for the past decade of the benefits of 
endovenous techniques, it is surprising that it is not universally-offered in the NHS 
(Lees et al. 1999; Subramonia & Lees 2007; Edwards et al. 2009).  This may be due 
to the generational effect seen previously with laparoscopic surgery, and as the 
procedures become more widespread in senior clinicians then trainee experience 
and NHS uptake will follow outside of cutting-edge centres. 
 
A difficulty interpreting research into varicose veins and its treatment has been the 
multiplicity of different assessment tools, both clinician derived and patient 
reported.  Since the international consensus regarding CEAP and VCSS 
classification (Eklöf et al. 2004; Vasquez et al. 2010; Gloviczki et al. 2011), reporting 
standards have improved in clinical trials, making comparisons easier and more 
reliable.  This allows meta-analyses to be more significant and robust.  Currently 
the PROM outlook remains less clear, with differing countries preferring specific 
questionnaires.  Fortunately, as our study demonstrates, well-constructed 
questionnaires show a high correlation and allow relative ease of comparison.  This 
may enable easier comparison in the future, especially as the advent of tablet 
computers and smart-phones allow for easy entry of data online.  This reduces the 
workload for analysis, however is limited by difficulty with electronic drawing 
(Ward et al. 2013; Lane et al. 2013).  With different PROM tools requiring differing 
input methods such as the CIVIQ, an optimum option might be to use this tool in 
preference to the AVVQ, with previous scores converted.  Alternatively, with 
progress in software, the AVVQ may remain a viable option with patient completed 
online drawings, as is completed in some trials currently underway (Sapheon Inc 
2013). 
 
With this progression of reporting standards, PROMs have become the key outcome 
of interest in most studies.  This is partly due to equivalent technical outcomes with 
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most treatments in experienced hands, but also due to the understanding that even 
partial technical "failure" may lead to an improved and satisfactory outcome for one 
patient, and a complete technical "success" may be of zero benefit for another 
patient (Brake et al. 2013).  This variability has led to many studies trying to isolate 
the principle cause of the symptomatology.  The venous disease cohort and 
modelling work presented in this thesis shows that currently collected data 
(demographic, clinical and symptoms) is only a part of the cause.  More extensive 
demographic data needs to be collected in further research cohort studies in order to 
tease out the key variables, which can then streamline data collection for registry 
entry.  With national publication of surgeon level data on abdominal aortic 
aneurysms and carotid endarterectomies (Vascular Services Quality Improvement 
Programme et al. 2013), it is only a matter of time until funding groups and 
patients will expect all outcomes to be published at local levels as opposed to 
national levels with the Hospital Episode Statistics programme (Anon 2013).  The 
American Venous Forum has already created a modular registry (American Venous 
ForumAmerican Venous Forum 2012), based on previous work for the International 
Venous Registry (European Venous Forum et al. 2012) and has begun to link it to 
the pre-existing Society for Vascular Surgery's Vascular Quality Initiative registry 
(Society for Vascular SurgeryAmerican Venous Forum 2013).  This collaborative 
effect will lead to large cohort data evidence, but this is only of use if the data 
quality is good and the data collected is appropriate.  At present our work suggests 
that this standard demographic data collected needs to be expanded to enable good 
outcome prediction with these population sized cohorts. 
 
Previous work on the timing of varicosity treatment has been sparse, as shown by 
Chapter 7.  The previous work available has shown a significant early improvement 
in quality of life after simultaneous treatment, but heterogenous findings with 
respect to re-intervention, and similar rates of deep venous thrombosis.  This may 
explain the lack of widespread adoption of simultaneous treatment despite excellent 
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outcomes from the single randomised clinical trial explicitly examining the timing 
question.  The AVULS trial showed early symptomatic benefits and persistent 
clinical benefits.  Additionally, the group of patients in the delayed treatment arm 
that required further treatment suffered from symptoms out to 6 months from 
initial treatment.  Finally, patients undergoing delayed procedures were 
significantly more likely to need further intervention (Odds Ratio 16).  Recruitment 
for AVULS study was less successful than expected with only 46% of those eligible 
participating over the 18 month recruitment window.  Follow-up was within 
expectations, with 80% at 6 months (primary endpoint).  12 month follow-up was 
below expectations (56%) but within the bounds of previous trials (Nordon et al. 
2011).  The total population examined in the AVULS trial was 26% of the screened 
population.  To reach minimum target recruitment of 128 it is likely to have 
required a further 6 months of recruitment, and to reach 240 it would have required 
some 28 further recruitment months.  This highlights the difficulty encountered in 
generalising trial results into the wider population - the sample may not be a truly 
random constituent of the target population.  The data from the Hospital Episode 
Statistics (Anon 2013)suggest that our patients were slightly more symptomatic 
than the general population, and much more symptomatic than the population 
assessed by Carradice et al. (Carradice et al. 2009).  This is reassuring that our 
results are applicable to the National Health Service generally.  Many institutions 
do not have the logistical support to allow for combined phlebectomy and 
endovenous truncal ablation, and though foam sclerotherapy of the varicosities is an 
appropriate alternative, the evidence base for that approach is sparse.  This leads to 
many clinicians being unable to offer combined treatment in the public sector 
despite the evidence base and public preference.  Further work is needed to compare 
the outcomes of foam sclerotherapy in the endovenous ablation context.  
 
The advance of technology has led to the emergence of tumescent-less techniques 
and these devices once again alter the geography of treatment (Lawson et al. 2013; 
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Elias et al. 2013).  Indeed, some may suggest that they have rendered the question 
of adjunctive treatment moot as whilst phlebectomy can easily be performed during 
ablation (as in the VVCVV trial (ISRCTN Register 2012)), the need for further 
anaesthetic reduces the benefits offered by these new devices.  Additionally, the use 
of foam sclerotherapy and mechanochemical ablation may be limited due to 
sclerosant safety limits; whilst there is no published data describing the use of 
cyanoacrylate and sclerosant simultaneously.  These safety concerns allied to the 
lack of extensive long-term data limit the applicability of the newer devices outside 
of the research environment.  Long-term evidence of equivalence of the different 
endothermal modalities is beginning to emerge (Rasmussen et al. 2013; Proebstle et 
al. 2011) and ex vivo work is explaining the differences in complications whilst 
reassuring that there is a similar method of action (van den Bos & Proebstle 2013; 
Malskat et al. 2013).  The new devices must satisfy the conditions of equivalence to 
current techniques that the endothermal devices have achieved previously with 
surgery. 
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9.2.	  Conclusion	  
Endovenous ablation has revolutionised the treatment of varicose veins allowing 
virtually all patients appropriate treatment.  With improved techniques and 
technology and long-term follow-up, endovenous treatment is now the "gold 
standard" against which other treatments must be compared.  This is not due to 
improved technical outcomes but improved pain profiles, reduced logistical 
requirements and improved complication rate.  These benefits also make 
endovenous ablation a cheaper solution overall, with a much preferred patient 
experience, despite higher initial equipment costs.  The differing thermal ablation 
devices available all offer excellent treatments, and work is now focussed on the 
final 1-2% of treatment optimisation.  The development of non-thermal ablation 
systems offers further refinement and improvement of the patient pathway. 
 
Primary care management of venous diseases is severely behind this forefront of 
venous treatment, which is understandable from a generalists viewpoint.  However, 
with the advent of Clinical Commissioning Groups, these very primary care 
physicians are the key decision makers.  With the release of the first National 
Institute for Health and Care Excellence guidance on varicose vein management it 
is hoped that this deficit in understanding will be reduced.  
 
Patient reported outcome measures have been accepted as the key tool for 
assessment of success, with technical achievement almost a secondary aim.  
Management and treatment of the patient rather than the anatomy has become the 
target for venous specialists.  Previously studies have reported disease specific 
quality of life with differing scales causing confusion in interpretation.  Fortunately, 
the two most commonly used scales have been shown to have excellent correlation, 
and therefore interpretations can be made confidently.  Anatomical data has 
classically been a focus point for surgeons dealing with varicose veins, with the 
belief that the largest veins cause the most problems, which has been shown to be 
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inaccurate, with symptomatology being poorly associated with vein diameter.  This 
leads to a more patient centred consultation with management of expectations key. 
 
Simultaneous treatment of varicosities during truncal vein ablation leads to 
significantly improved and persistent clinical outcomes with significantly improved 
early quality of life.  Delayed treatment leads to a significantly increased risk of 
further treatments, and those delayed treatment patients requiring further 
intervention have a significantly worse outcome.  In large retrospective studies 
delayed and simultaneous treatments have been shown to have equivalent rates of 
deep venous thrombosis or endovenous heat induced thrombosis. 
 
Modelling of varicose vein outcomes remains a complex and difficult field with many 
key variables currently unclear.  The isolation of those patients who will have the 
best outcomes is still elusive, however, it is clear that worsened symptoms equate to 
worse outcomes, and so by inference early treatment is key.  Further careful work to 
identify further key variables is necessary to provide robust and accurate predictive 
models.  The varicose vein population is extensive and disparate, and some of the 
multiple variables needed to explain the variation in symptomatology may remain 
hidden until further population scale cohorts studies are undertaken. 
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10.1.	  Future	  Work	  in	  Treatment	  Devices	  
As part of ongoing assessment of different treatment devices, the currently running 
VVCVV trial is assessing the peri-procedural pain profile of the mechanochemical 
ablation and radiofrequency thermal ablation (ISRCTN Register 2012).  The 
eSCOPE trial is also in long-term follow-up (Sapheon Inc 2012). 
 
Following this study, long term studies comparing mechanochemical ablation, 
thermal ablation (using modern laser and radiofrequency devices) and chemical 
occlusion are planned to provide detailed experience of the safety and efficacy of the 
devices.  This would provide robust data to complement that by recently published 
comparing UGFS, EVLA, RFA and open surgery (Rasmussen et al. 2011; 
Rasmussen et al. 2013). 
 
Assessment of microemboli seen in other mechanochemical ablation (which uses 
detergent sclerosant) is a further study to be completed as this would allow possible 
identification of equivalent bubble propagation to foam sclerotherapy.  This would 
be completed using the previous protocol for standardisation (Sounderajah et al. 
2012). 
10.2.	  Future	  Work	  in	  Simultaneous	  Treatment	  
The AVULS trial (Lane 2011) examined the timing of adjunctive treatments in the 
context of endothermal ablation of truncal venous incompetence.  However, due to 
patient preference this trial under-recruited.  Additionally the recommendation of 
simultaneous treatment may not be feasible due to local treatment pathways.  
Further evidence would be needed to provoke change, as local centres have 
preferred methods of operation, which often have not changed with recent evidence. 
 
To this end, a further study AVULS 2 is planned with multi-centre recruitment.  
This would extend follow-up to 2 years post treatment to allow for assessment of 
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progression and recurrence.  The study would aim to recruit in the region of 500 
patients from 8 separate clinical institutions to provide extensive and reliable data 
for further modelling work and pathway optimisation.  In order to be able to proceed 
with this study, a grant to the Health Technology Assessment Programme of the 
National Institute for Health Research is in the initial stages, as it is anticipated 
that the study will cost in the region of £2, 000, 000 to complete. 
10.3.	  Further	  Work	  in	  Venous	  Education	  
The recent publication of the NICE guidelines (National Institute for Health and 
Care Excellence 2013) for the management of varicose veins aim to improve the 
baseline knowledge of clinicians regarding varicose veins.  This will need to 
investigated and assessed for effectiveness.  It is therefore proposed that a 
repetition of the GP survey (Lane et al. 2013) assessing management of varicose 
veins should be completed 1 year after the publication of the guidelines, to allow for 
assimilation into clinical practice. 
 
A survey of vascular surgeons to assess current venous treatment and surgical 
practice would be appropriate following the launch of the Vascular Surgery 
speciality in 2013.  This would ideally be completed in 2015 to allow for initial 
trainees to commence and for settling of the new speciality.  This would then be 
compared to previous work (Shepherd et al. 2010), and compared to the outcome of 
a recently published survey of vascular trainees (Karthikesalingam et al. 2012). 
 
10.4.	  Further	  Work	  in	  Venous	  Cohort	  and	  Modelling	  
The venous cohort data is planned to be repeated and expanded with a new cohort 
of patients, with further demographic details recorded at baseline.  The aim of this 
work is to improve the predictive model created from the current venous patient 
cohort and reduce the unexplained variance.  It would also allow the independent 
testing of long-term modelling. 
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Of great importance is discovering the minimally important clinical difference 
(Revicki et al. 2008), and so as part of this work, a patient satisfaction 
questionnaire will be completed to discover how much of an improvement in QOL 
scores is clinically significant.  This will greatly help both the predictive model and 
interpretation of future trial results. 
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Appendix	  5.	  CIVIQ-­‐14	  
 
 
C I V I Q-14 
SELF-QUESTIONNAIRE PATIENTS 
In English language for UK 
 
 
 
 1 
 
Many people complain of leg pain. We would like to find out how often these leg 
problems occur and to what extent they affect the everyday lives of those who suffer 
from them. 
 
Below you will find a list of symptoms, sensations or types of discomfort that you 
may be experiencing and which may make everyday life hard to bear to a greater or 
lesser extent. For each symptom, sensation, or type of discomfort listed, we 
would like you to answer in the following way: 
 
Please indicate if you have experienced what is described in each sentence, and if 
the answer is ‘yes’, how intense it was. There are five possible answers, and we 
would like you to circle the one which best describes your situation. 
 
 
 
Circle 1 if you feel the symtom, sensation of discomfort described 
does not apply to you 
 
Circle 2, 3, 4 or 5  if you have felt it to a greater or lesser extent 
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C I V I Q-14 
SELF-QUESTIONNAIRE PATIENTS 
In English language for UK 
 
 
 
 2 
 
QUALITY OF LIFE WITH VENOUS INSUFFICIENCY 
 
 
1)  During the past four weeks, have you had any pain in your ankles or legs, and how 
severe has this pain been? 
Circle the number that applies to you. 
 
No  
pain 
Slight  
pain 
Moderate 
pain 
Considerable 
pain 
Severe 
pain 
     
1 2 3 4 5 
     
 
 
 
 
2)  During the past four weeks, how much trouble have you experienced at work or 
during your usual daily activities because of your leg problems? 
Circle the number that applies to you. 
 
No trouble Slight trouble Moderate trouble Considerable trouble Severe trouble 
     
1 2 3 4 5 
     
 
 
 
 
3)  During the past four weeks, have you slept badly because of your leg problems, and 
how often? 
Circle the number that applies to you. 
 
Never Rarely Fairly often 
Very  
often 
Every 
night 
1 2 3 4 5 
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C I V I Q-14 
SELF-QUESTIONNAIRE PATIENTS 
In English language for UK 
 
 
 
 3 
 
 During the past four weeks, how much trouble have you experienced 
carrying out the actions and activities listed below because of 
your leg problems? 
For each statement in the table below, indicate how much trouble you 
have experiened by circling the number chosen. 
 
 No trouble Slight trouble Moderate trouble 
Considerable 
trouble 
Could not  
do it 
4)  Climbing several 
flights of stairs 1 2 3 4 5 
5)  Crouching, 
Kneeling down 1 2 3 4 5 
6)  Walking at a 
brisk pace 1 2 3 4 5 
7)  Going out for 
the evening, going 
to a wedding, a 
party, a cocktail 
party… 
1 2 3 4 5 
8)  Playing a sport, 
exerting yourself 
physically 
1 2 3 4 5 
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C I V I Q-14 
SELF-QUESTIONNAIRE PATIENTS 
In English language for UK 
 
 
 
 4 
 
  Leg problems can also affect your mood. How closely do the following 
statements correspond to what you have felt during the past four 
weeks? 
 For each statement in the table below, circle the number that applies 
to you. 
 
  
Not at all 
 
A little 
 
 
Moderately 
 
A lot 
 
Completely  
 
9)  I have felt 
nervous/tense 1 2 3 4 5 
10)  I have felt I 
am a burden 1 2 3 4 5 
11)  I have felt 
embarrassed about 
showing my legs 
1 2 3 4 5 
12)  I have become 
irritated easily 1 2 3 4 5 
13)  I have felt as if 
I am handicapped 1 2 3 4 5 
14)  I have not felt 
like going out 1 2 3 4 5 
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Appendix	  6.	  Management	  of	  varicose	  veins	  in	  the	  community	  survey	  
 
Survey of Superficial Venous Disease Management in 
Primary Care 
Superficial Venous Disease (Varicose Veins) is a common condition with a varied presentation. Many 
treatment options are available. The purpose of this survey is to look at referral patterns for the treatment 
varicose vein disease in the community. 
 
The below questionnaire is a service evaluation/audit of current practice in primary care. The aim is to 
identify what GPs think of chronic venous insufficiency (and varicose veins), what the level of knowledge 
is regarding new advancements in varicose vein treatment. This information will be utilised to improve the 
co-ordination of primary and secondary care. In the current era of proposed GP commissioning it is vital 
that such co-ordination is as efficient and up to date as possible, in both directions. We aim to provide an 
extensive primary care viewpoint which will be disseminated to both primary care and secondary care. 
* How many patients do you see on average per year with Superficial Venous Disease (Varicose Veins)? 
  < 10   10-50 
  51-100   101-200 
  > 200  
Reset 
* Do you manage or treat Superficial Venous Disease (Varicose Veins) in the community (e.g. compression 
hosiery or injection sclerotherapy)? 
  Yes 
  No 
Reset 
If yes, how? 
  
* If you do refer patients with Superficial Venous Disease (Varicose Veins),  to whom do you refer? 
(please select all that apply) 
  Vascular Surgeon   General Surgeon 
  Dermatologist   Vascular Nurse Specialist 
Reset 
Other, Please specify 
  
* What presenting symptoms would you refer to a specialist (please select all which apply) 
  Prominent varicose veins   Bleeding veins 
  Leg swelling   Thrombophlebitis 
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  Skins Changes   Active Venous Ulcers 
  Healed Venous Ulcers   Leg aching or pain 
  Cellulitis   Itching 
  Patient request   Cosmesis 
Reset 
* What treatments options do you discuss with your patients for the management of varicose veins? 
  
* Which of the following treatment options are available for your patients in your area? (please select all 
which apply) 
  Compression hosiery   Compression bandaging 
  Sclerotherapy   Endovenous radiofrequency ablation 
  Endovenous laser ablation   Open tradition vein stripping surgery 
  Do not know  
Reset 
* Are you aware of NICE Guidelines for the referral of Superficial Venous Disease (Varicose Veins) to 
specialist care? 
  Yes 
  No 
Reset 
If yes, do you follow them? 
  
* Are you aware of Local PCT Guidelines for the referral of Superficial Venous Disease (Varicose Veins) 
to specialist care? 
  Yes, and I agree with them 
  Yes, but I do not agree with them, please specify 
  No 
Reset 
Please outline PCT guidelines 
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* Are you aware of NICE Treatment Guidelines for the management of Superficial Venous Disease 
(Varicose Veins)? 
  Yes 
  No 
Reset 
If yes, do you follow them? 
  
* Are you aware of Local PCT Treatment Guidelines for the management of Superficial Venous Disease 
(Varicose Veins)? 
  Yes, and I agree with them 
  Yes, but I do not agree with them, please specify 
  No 
Reset 
If yes, please outline 
  
* Are you aware of any clinical scoring systems for Superficial Venous Disease (Varicose Veins)? 
  Yes 
  No 
Reset 
If so, which? 
  
* Below are a number of treatment options (A-F), how would you treat the following patients if they 
presented to your GP surgery? 
 Reassurance 
Compression 
Hosiery, Please 
Specify which class 
or type 
Compression 
Bandaging Sclerotherapy 
Referral to 
a specialist 
Other, 
please 
specify 
A patient with 
non-painful but 
visible varicose 
veins? 
            
A patient with 
painful visible 
varicose veins?             
A patient with 
leg swelling?             
A patient with 
varicose veins             
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& leg swelling 
A patient with 
varicose veins, 
leg swelling, & 
pain? 
            
A patient with 
venous skin 
changes?             
A patient with 
a venous ulcer?             
Reset 
Any Specific Comments? 
  
* In the above cases, do you think there is a role for operative/invasive/endovenous management? 
 Yes No Don't Know 
A patient with non-painful but visible varicose veins?       
A patient with painful visible varicose veins?       
A patient with leg swelling?       
A patient with varicose veins and leg swelling       
A patient with varicose veins and leg swelling, and pain?       
A patient with venous skin changes?       
A patient with a venous ulcer?       
Reset 
Any specific reasoning or comments? 
  
* Do you think that mild Superficial Venous Disease (Varicose Veins) will progress over time to more 
severe disease unless treated? 
  Yes, but can be managed conservatively   Yes and needs invasive treatment 
  No   Don't Know 
Reset 
If yes, what percentage roughly per year? 
  
* Do you think that by treating Superficial Venous Disease (Varicose Veins) you will improve a patient's 
quality of life? 
  Yes, but can be managed conservatively   Yes and needs invasive treatment 
  No   Don't Know 
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Reset 
Any comments? 
  
* Do you think that treatment of Superficial Venous Disease (Varicose Veins) is a cost-effective use of 
NHS resources? 
  Yes, but can be managed conservatively   Yes and needs invasive treatment 
  No   Don't Know 
Reset 
Any comments? 
  
* In the following cases, do you think all treatment should be provided free-of-charge by the NHS? 
 Yes No Don't Know 
A patient with non-painful but visible varicose veins?       
A patient with painful visible varicose veins?       
A patient with leg swelling?       
A patient with varicose veins and leg swelling       
A patient with varicose veins and leg swelling, and pain?       
A patient with venous skin changes?       
A patient with a venous ulcer?       
Reset 
Any specific comments? 
  
* If a patient has had invasive treatment, are you: 
  Happy to provide the aftercare 
  Feel that aftercare should be provided by the specialist 
  Feel no aftercare is required 
Reset 
* If you had Superficial Venous Disease (Varicose Veins) how would you like them treated? 
  
What best describes your medical practice 
  Single-handed GP   Salaried GP 
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  GP Partner   Locum GP 
  Hospital Physician   Hospital Surgeon (General) 
  Hospital Surgeon (Vascular)   Other, please specify 
Reset 
Other Please Specify 
  
Where is your medical practice located? (please tick all that apply) 
  Rural   Urban 
  South West   South East 
  London   Wales 
  West Midlands   East Midlands 
  East of England   North West 
  Yorkshire and the Humber   North East 
  Scotland   Northern Ireland 
Reset 
Do you have any comments on aspects of care that have not been covered or you would like to make the 
researchers aware of? 
  
If you would like further information with results of the survey please provide your e-mail address below 
(this will not be used for any other purposes nor released to third parties) 
 
For further information please refer to the Royal Society of Medicine's Venous Forum Recommendations 
  
 
Thank you very much for considering and participating in our survey. We appreciate the time you have 
spent on it. All results are held confidentially, and are not identified to individuals. If you have submitted 
your e-mail address as part of the survey, this will only be used for dissemination of the survey results. It is 
not obligatory. The e-mail address and the survey answers are not linked and your responses are not 
personally identifiable. 
 
If you would like any further information, including the recently published RSM Venous Forum 
Guidelines, or recent study publications, please contact me at tristan.lane@imperial.ac.uk. 
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Appendix	  7.	  Management	  of	  superficial	  venous	  thrombosis	  in	  primary	  and	  
tertiary	  care	  survey	  
 
21/08/2012 19:36FreeOnlineSurveys.com
Page 1 of 7http://freeonlinesurveys.com/app/papersurvey.asp
The Management of Superficial Venous
Thrombophlebitis Survey in Primary and Secondary
Care
Dear colleague,
Many thanks for visiting our survey.  This is a replacement survey which has been made on a
new server following the collapse of our previous host.  If you have previously completed the
survey then thank you very much.
We are investigating the management and care of patients with superficial venous thrombosis or
superficial venous thrombophlebitis (SVT).
This is a 20 question survey which should not take more than 10 minutes to complete.
We would be grateful for your help in completing this survey.  Please help to disseminate this
survey to GP and vascular consultant colleagues.
Kind Regards,
Tristan
tristan.lane@imperial.ac.uk
Tristan Lane, Kaji Sritharan, Mr Ian Franklin and Professor Alun Davies
Academic Section of Vascular Surgery, Imperial College London
1) Are you a:
GP  
GP Trainee  
Consultant Vascular Surgeon  
Vascular Trainee  
Other (Please Specify):
 
 
 
2) Which country do you practice in?
UK  
Europe  
Other (Please Specify):
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3) How many patients do you see each year with superficial thrombophlebitis?
< 5  
6 - 10  
11 - 20  
21 - 30  
> 30  
 
4) When you encounter a patient with superficial thrombophlebitis, do you:
Treat the patient yourself  
Refer ALL patients elsewhere  
Refer select cases  
Other (Please Specify):
 
 
 
5) If you refer the patient, who do you refer to? (Please select all which apply)
Vascular Surgeon  
Dermatologist  
General Physician  
Haematologist  
Nurse-Led DVT Clinic  
Do Not Refer On  
Other (Please Specify):
 
 
 
6) Do you think there is an association between superficial thrombophlebitis and deep vein
thrombosis (DVT)?
Yes  
No  
Don't Know  
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7) If yes, what percentage of patients with superficial thrombophlebitis in your experience have
a co- existing deep vein thrombosis (DVT) at presentation?
< 5%  
10%  
25%  
50%  
75%  
All patients  
Don't Know  
 
8) If yes, what percentage of patients with superficial thrombophlebitis in your experience will
develop a deep vein thrombosis (DVT) at 3 months?
< 5%  
10%  
25%  
50%  
75%  
All patients  
Don't Know  
 
9) Do you think there is an association between superficial thrombophlebitis and the following?
 Yes No Don't Know
Pulmonary Embolus (PE)    
Varicose Veins (VV)    
Deep Venous Incompetence    
Cancer    
Infection    
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10) In your assessment of the patient, which of the following would you perform? (Please
select all which apply)
Thrombophilia Screen  
Venous Duplex  
CT Venography  
MR Venography  
Conventional Venography  
None of the above  
Other (Please Specify):
 
 
 
11) How would you treat a patient with superficial thrombophlebitis? (Please select all which
apply)
No treatment required  
Compression Hosiery  
NSAIDs  
Antibiotics  
Topical Heparinoids  
Low Molecular Weight Heparin  
Fondaparinux  
Warfarin  
Leg Elevation  
Bed Rest  
Surgery  
Other (Please Specify):
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12) If Low Molecular Weight Heparin (LMWH) is commenced, for what duration?
2 weeks  
4 weeks  
6 weeks  
3 months  
Depends on specialist advice  
Varies according to care  
Other (Please Specify):
 
 
 
13) Would your management be different if the patient had recurrent (more than one episode)
thrombophlebitis?
No  
Don't Know  
Yes, How?
 
 
 
14) In your experience what proportion of patients experience recurrent episodes of
thrombophlebitis?
< 5%  
10%  
25%  
50%  
75%  
All patients  
Don't know  
 
15) Would the distribution (i.e. SSV or Above Knee or Below Knee GSV) of the superficial
thrombophlebitis influence your treatment?
No  
Don't Know  
Yes, How?
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16) How do you follow-up patients with superficial thrombophlebitis?
No follow-up is performed  
Follow-up only in selected cases  
Weekly  
Fortnightly  
Monthly  
Other (Please Specify):
 
 
 
17) At follow-up do you perform any imaging?
No follow-up undertaken  
No, no imaging performed  
Yes, venous duplex  
Yes, CT venography  
Yes, MR venography  
Yes, Other (Please Specify):
 
 
 
18) If surgery is performed, what are the indications? (please select all of those which apply)
Don't know - would take specialist advice  
Persistent pain  
Cosmesis  
Failure of conservative/medical measures  
Propagation of thrombus  
Thrombus in close proximity to the deep venous system - please specify minimum acceptable
distance from junction if this is one of your criteria
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19) In your personal experience, is there a seasonal variation in the incidence of superficial
thrombophlebitis?
No  
Don't Know  
Yes, (Please Specify):
 
 
 
20) Is there anything else that you would like to tell us?
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Abstract 
 
Objective The use of Inferior Vena Cava (IVC) filters for prevention of Venous Thromboembolism (VTE) in bariatric surgery is a contentious issue. We aim to review the evidence for the use of IVC filters in bariatric surgical patients, describe trends in practice and discuss challenges in developing evidence-based guidelines.   
 
Summary Background Data The incidence of VTE in modern bariatric procedures with traditional methods of thromboprophylaxis, such as sequential calf compression devices and perioperative low molecular weight heparin, is approximately 2%. 
 
Methods A systematic review of the literature was conducted according to PRISMA 
guidelines.	  We	  searched	  Medline	  up	  until	   July	  2013	  with	  the	  terms	  ‘bariatric	  filter’	  and	  
‘gastric	   bypass	   filter’.	   Two	   investigators	   independently	   screened	   search	   results	  according to an agreed list of eligibility criteria.   
Results 18 studies were included. There were no randomised controlled trials. Data from controlled cohort studies suggest that those who undergo IVC filter insertion pre-operatively may be at higher risk of developing DVT and PE. A small cohort of patients with multiple risk factors for VTE benefitted from reduced PE-related mortality following pre-operative IVC filter insertion. Data from twelve case series reporting VTE outcomes from a total of 497 patients who underwent pre-operative IVC filter insertion demonstrated DVT rates of 0-20·8% and PE rates ranging from 0-6·4%. 
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Conclusions Published data reporting the safety and efficacy of IVC filter use in bariatric surgical patients is highly heterogeneous. There is no evidence to suggest that the potential benefits of IVC filters outweigh the significant risks of therapy.      
 
Mini-Abstract Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in the bariatric surgical population. Although most would agree that there is a role for both pre- and post-operative pharmacoprophylaxis, the use of Inferior Vena Cava (IVC) filters remains a contentious issue. In this systematic review we summarise evidence for the insertion of pre-operative IVC filters to prevent pulmonary embolism in patients undergoing bariatric surgery.              
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Background  The World Health Organisation (WHO) estimates that there are more than 500 million obese individuals worldwide.1 Morbid obesity, defined as a body mass index (BMI) >40kg/m2, is associated with significant co-morbidities including cardiovascular disease, obstructive sleep apnea, an increased risk of cancer and the metabolic syndrome.2-4 This population is at high risk of developing venous thromboembolism (VTE). Indeed risk of VTE may be directly proportional to BMI.5  Bariatric surgical procedures have been shown to be the most effective treatment modality for morbid obesity and its co-morbid conditions.6, 7 Procedures include laparoscopic or open Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable gastric banding (LAGB) and laparoscopic sleeve gastrectomy (LSG). They are thought to work through the so-called	   ‘BRAVE’	   effects: (Bile flow alteration; Reduction of gastric size; Anatomical gut rearrangement and altered flow of nutrients; Vagal manipulation; and Enteric gut hormone modulation).4 Bariatric procedures are increasingly performed worldwide and there is growing evidence that they may represent a sustainable cost-effective long-term solution for the treatment of morbid obesity.8  Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in the bariatric surgical population.9 Historically, the incidence of symptomatic VTE in open bariatric surgery has been reported as high as 3.4%.10 In modern practice with the use of perioperative thromboprophylaxis and pneumatic calf compression devices, VTE may still occur in greater than 2% of all open procedures.11 Those undergoing revisional surgery are potentially at greater risk still. The introduction of laparoscopic bariatric 
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surgery has been associated with reduced rates of VTE. A recent meta-analysis of published literature demonstrated that the overall incidence of symptomatic VTE in modern laparoscopic bariatric procedures is less than 1% with a further 1% thought to have subclinical disease.12 These figures suggest that conventional methods of thromboprophylaxis such as the use of sequential calf compression devices and perioperative low molecular weight heparin may be adequate for the bariatric surgical population as a whole. However in many cases this approach is seen to be inadequate due to the presence of multiple risk factors for VTE or the presence of a contraindication to pharmacological prophylaxis. This has led to the increased use of inferior vena-caval filters in modern bariatric surgical practice.  Currently there is a lack of consensus on the most effective strategy for prevention of venous thromboembolism in patients undergoing bariatric surgery. A recent survey of predominantly North American surgeons suggests that more than 92% of bariatric surgeons routinely use preoperative pharmacological prophylaxis. The majority of surgeons prescribe sequential compression devices in high-risk patients (96·3%) and pharmacological prophylaxis is used post-operatively by 97% however the duration and dose of therapy is highly variable. In patients perceived to be high risk, routine use of IVC filters is reported by 28·1% of surgeons, with more than half of these patients receiving additional pharmacoprophylaxis on discharge.13 At present there is no cross-sectional data available to describe strategies employed in other parts of the world. In the United Kingdom the National Institute of Clinical Excellence (NICE) recommends mechanical prophylaxis with 5-7 days of pharmacological therapy after bariatric surgery however the role of IVC filters is not discussed.14 Although most would agree that there is a role 
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for both pre- and post-operative pharmacoprophylaxis, the use of IVC filters remains a contentious issue among bariatric surgeons worldwide.   To date there are no randomised trials investigating the role of IVC filters for prevention of venous thromboembolism in bariatric surgical patients. We aim to review the evidence for the use of IVC filters in bariatric surgical patients, describe trends in practice and discuss challenges in developing evidence-based guidelines.   Methods 
 A systematic review of the literature was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.15 We searched Medline up until July 2013 with	  the	  terms	  ‘bariatric	  filter’	  and	   ‘gastric	  bypass	  
filter’	  and	  reviewed	  reference lists to identify additional publications. Two investigators separately assessed search results according to an agreed list of eligibility criteria. Articles were eligible for inclusion if they described rates of venous thromboembolism in patients who had undergone IVC filter insertion before bariatric surgery and were written in English. We excluded duplicate articles, review articles, case studies, editorials, and letters. Two investigators independently assessed the methodological quality of each study using the QUADAS-2 tool.16 Where there were differences in ratings a joint assessment was performed in order to reach a consensus. Data was extracted systematically under the following headings: Study Design (eg. Randomised Controlled Trial, Registry Review, Cohort study etc.), Study Population (Dates of recruitment, Number of patients, Age, Sex, BMI), Indications for IVC filter insertion, Pharmacological prophylaxis, Surgical Procedure, Operative Time, Filter insertion time, Type of Filter, and 
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Follow-up Period. Outcomes data was collected to assess rates of pulmonary embolism (PE), deep vein thrombosis (DVT), PE-related mortality, all-cause mortality, filter related complications, as well as rates and timings of filter removal.       
 Results 
 Figure 1 summarises results from our systematic review of the literature. The search 
terms	  ‘bariatric	  filter’	  and	  ‘gastric	  bypass	  filter’	  returned	  39	  and	  29	  results	  respectively.	  Following exclusion of duplicates 46 titles were screened leaving 41 abstracts for review. Six further results were excluded on abstract screening leaving 35 manuscripts for full review. 18 manuscripts were found to contain outcomes data for patients who had undergone bariatric surgery with pre-operative insertion of IVC filter and were included in this systematic review. Quality assessment using the QADAS-2 tool demonstrated at least a low risk of bias in at least one domain in all included studies. A high risk was of bias was found in more than one domain in several studies. 
 There were no randomised controlled trials evaluating the benefit of IVC filters for prevention of venous thromboembolism in obese patients undergoing bariatric surgery. Table 1 summarises data from controlled cohort studies. There were two large registry reviews reporting VTE outcomes in patients with IVC filter and no IVC filter.17, 18 In a study of prospectively collected data from 1077 patients with an equal number of propensity-matched controls Birkmeyer et al. reported that both PE (0·84% vs 0·46%) and PE-related mortality (0·37% vs 0%) tended to be higher in patients who had pre-operative placement of IVC filter than those who did not, although results were not statistically significant.18 Rates of DVT (1·20% vs 0·37%) and serious complications 
 IVC Filters in Bariatric Surgery 
7 
(5·8% vs 3·8%) also tended to be higher in the IVC filter cohort, but again were not statistically significant. Li et al. reported VTE outcomes from a retrospective registry review of 97, 218 patients, of which 322 had pre-operative filter insertion.17 IVC filter patients had a higher incidence of DVT (0·93% vs 0·12 %; p<0·001) and tended to suffer from PE more frequently (0·31% vs 0·12%), although this was not statistically significant. Death from suspected PE was also higher in the IVC filter cohort (0·31% vs 0·03%; p=0·003). In this study patients in the IVC filter cohort had a greater pre-operative risk of VTE due to higher rates of previous VTE, impairment of functional status, lower extremity oedema, obstructive sleep apnea, and pulmonary hypertension. Patients in the IVC filter cohort were also more likely to be male, had a higher BMI, and more frequently underwent open surgery with a longer operative time. Statistical analysis was performed using a multivariate logistic regression model to address the aforementioned differences in VTE risk factors.    There were 3 further controlled cohort studies describing VTE outcomes in patients who had pre-operative IVC filter insertion.19-21 Obeid et al. reported symptomatic DVT rates of 1·21%	  in	  a	  cohort	  of	  246	  ‘high	  risk’	  patients	  who	  had pre-operative IVC filter insertion. DVT rates of 0·8% were found in the remaining bariatric surgical population (n=1848), who acted as unmatched controls.19 PE rates were higher in the IVC filter cohort (0·8% vs 0·6%) however differences were not statistically significant. In a prospective cohort study of 330 patients Overby et al. reported DVT numbers identified by duplex screening at 6-weeks follow-up.20 DVT rates were again higher in the IVC filter cohort (3·13% vs 2·35%; p=0·744) however those without an IVC filter more frequently suffered from pulmonary embolism (2·94% vs 0·63%; p=0·216). A cohort of non-IVC filter patients were again more likely to suffer from PE in a prospective study by Gargiulo et al. (28% vs 
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0%; p<0·05).21 PE related mortality was less than 1% in these three studies with the exception of Gargiulo et al who reported rates as high as 11% in certain subgroups.21 National Survival outcomes have been estimated for bariatric surgical patients with and without IVC filter who developed VTE. According to the Nationwide Inpatient Sample, which captures around 20% of US non-federal short-term hospitals, mortality in patients who developed DVT in hospital was lower in those who had undergone IVC filter insertion (0/510) compared to those who did not (80/5970; p=0·009).22 No significant difference in PE-related mortality was found between the two cohorts.   Table 2 summarises observational data describing population demographics and rates of venous thromboembolism in patients who had undergone prophylactic IVC filter insertion prior to bariatric surgery.23-34 Data presented is largely from retrospective series and as a result there is significant heterogeneity in both patient demographics and thromboprophylaxis protocol. Carmody et al. report the largest series of 145 patients with data collected over a 24-year period.33 Patients had a mean BMI of 57 kg/m2 and mean age of 47 years with a 2·1% PE rate. This was the only series to report PE related mortality in a patient who had pre-operative IVC filter insertion (1/145 patients). Piano et al. reported VTE outcomes from a cohort of 58 patients who had a Gunther–Tulip filter placed before undergoing Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) or Duodenal switch.28 There was a mean age of 43 years and mean BMI of 61 kg/m2 with 17% male population. PE occurred at a rate of 1·7% with no DVT identified on routine lower limb duplex scanning performed prior to filter retrieval at a mean of 63 days post-operatively. The highest rates of PE were reported as 6·4% and 4·2% in cohorts of 31 and 24 patients respectively who had Gunther-Tulip filter insertion prior to either open or laparoscopic Roux-en-Y Gastric Bypass surgery.24, 29 These cohorts were followed-up for a mean of 
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262 days and 16 months respectively. Symptomatic DVT rates were also relatively high, reported as 20·8% and 3·1% respectively. In the remaining eight observational studies results from 239 patients were reported with no PE.23, 25-27, 30-32, 34 DVT rates in these studies were less than 5% with the exception of the study by Vaziri et al. which reported a rate of 21% in a cohort of 29 patients who were followed up for a mean of 16 days following insertion of an Optease filter prior to LRYGB (16), LAGB (9), or open RYGB (4).     
 Our search identified three published case series describing outcomes specifically after Laparoscopic Roux-en-Y Gastric Bypass surgery.30, 31, 34 There were two retrospective cohort studies and one prospective study. 81 patients underwent LRYGB between December 2004 and July 2009 with mean follow-up of 16, 204 or 356 days according to the series in question. Types of IVC filters utilised included Gunther Tulip, Bard G2, and Optease. These were used in combination with subcutaneous heparin, sequential calf compression devices, and early ambulation. Pharmacoprophylaxis was not continued after discharge. Mean operative time was highly variable ranging from 93 minutes to 175 minutes. There was no reported incidence of pulmonary embolism but a minimum of five examples of deep vein thrombosis. There was one minor complication of IVC filter insertion (haematoma). Filter retrieval rates were not reported.  There was one case series identified describing procedure specific rates of venous thromboembolism after open RYBG surgery in morbidly obese patients who underwent insertion of IVC filter.23 58 patients underwent surgery with IVC filter insertion at a single institution between 1999 and 2007. This represented 10% of all morbidly obese patients undergoing open RYGB. In the IVC filter cohort there was a mean age of 37 years with 38% males. Mean BMI was 62kg/m2. There were 35 TrapEase filters, 9 
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Simon-Nitinol, 2 Greenfield, and 12 Bard Recovery filters placed with an average additional operating time of 20+/-5 minutes. In addition all patients received sequential calf compression, subcutaneous heparin therapy (50units/Kg) pre- and post-operatively twice daily until ambulating four hours per day.  All patients underwent pre-operative and post-operative venous duplex examination as a screening test for DVT. After a mean follow-up of 65±12 months there were no examples of pulmonary embolism and two cases of DVT, one fatal. Only one IVC filter was removed and this was at one year post-operatively with no reported filter-related complications. There were no case series reporting procedure specific data for patients who underwent adjustable gastric banding or sleeve gastrectomy with placement of prophylactic IVC filter. Table 3 summarises published literature detailing DVT, PE and PE related mortality rates in patients who underwent IVC filter insertion before laparoscopic vs open RYGB.   IVC filter-specific complications, not including failure to retrieve, occurred at a rate of 0-11·1%. (Table 4) There was one report of a DVT forming at the insertion site of the IVC filter and another report of PE occurring secondary to thrombus formation within the filter itself. Other major complications included device migration requiring cardiac valve replacement, development of contrast induced nephropathy, and haemopericardium.18, 
19 Minor complications included haematoma formation (three), malposition (three), cellulitis (one) and severe pain (one). In five of the twelve case series there were no filter-specific complications reported. Planned filter retrieval was attempted in ten of the twelve studies with retrieval rates reported in six of these. In the largest study to report retrieval rates 90% of filters were removed from 58 patients at a mean of 63 days post-operatively.28 In all cases failure to retrieve was due to technical difficulties secondary to 
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filter tilt. In this series a further six retrievable filters were converted to permanent filters due to patient preference. Halmi et al. demonstrated that a retrieval rate of 96·3% can be achieved, indeed only one filter remained due to an unrelated illness.26 High retrieval rate (100%) was also demonstrated to be possible in a small UK study of five patients.32 Schuster et al. and Vaziri et al. reported 83% and 72% filter retrieval respectively with one filter in each cohort remaining in place due to technical failure in retrieval.29, 34 The lowest filter retrieval rate was reported as 68·3% by Vaziri et al. in a cohort of 29 patients.30 This series also reported the longest time to filter removal (mean 204 days). There were no technical failures during retrieval. Of those patients who did not have their IVC filter retrieved, two refused, three were advised against retrieval due to DVT, and one patient had died from an unrelated cause.    Discussion 
 This systematic review of the literature describing VTE outcomes in bariatric surgical patients with and without IVC filter demonstrated a heterogeneous dataset comprising of controlled and un-controlled cohort studies. There were no randomised controlled trials. Data from controlled cohort studies suggest that those who undergo IVC filter insertion pre-operatively may be at higher risk of developing DVT and PE. A small cohort of patients with multiple risk factors for VTE may have benefitted from reduced PE-related mortality following pre-operative IVC filter insertion. However there is no evidence at present to suggest that this potential benefit outweighs the significant risks associated with IVC filter use. Data from twelve case series reporting VTE outcomes from a total of 497 patients who underwent pre-operative IVC filter insertion demonstrated 
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DVT rates of 0-20·8% and PE rates ranging from 0-6·4%. PE-related mortality however was rare with only one reported case. Of these twelve series there were three studies reporting LRYGB specific outcomes with no PE-related mortality.  In recent years the use of IVC filters for prevention of VTE has been limited by safety concerns, which have been described in detail by a 2010 report from the United States Food and Drug Administration.35 Serious complications include filter migration and embolisation, thrombosis and occlusion of the filter, IVC perforation, and filter fracture. Much of the available data is from case reports and there is a paucity of data describing filter-specific complications in the bariatric population. The risk of radiation and contrast exposure during filter insertion and removal must also be considered. In our study filter related complications were rare however the authors recognise that publication bias may have influenced our findings. Data from the aforementioned 2010 FDA report suggests that there may be significant under-reporting of complications in the medical literature. Further, complications of therapy are often described as case reports, a format that is not captured by the systematic review process. Serious complications of IVC filter occurred most frequently in patients with prolonged filter exposure, which may occur when patients are lost to follow-up or where there is technical failure during retrieval. We recommend filter retrieval at the earliest possible opportunity in order to reduce risk of complications. This recommendation is supported by recent evidence suggesting increased risk of technical failure during retrieval when the first attempt is delayed.36 Until evidence based protocols are available the risks and benefits of filter retrieval should be considered on a case-by-case basis.  
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Given the risks of IVC filter insertion, bariatric surgeons only consider their use in patients believed to be at increased risk of venous thromboembolism.13 Within the published literature factors consistently believed to increase risk of VTE include a history of prior VTE or deep vein thrombosis, pulmonary hypertension, personal or family history of coagulopathy, chronic severe immobility, and evidence of pre-operative lower limb venous stasis.17-20 The presence of obstructive sleep apnea is considered an independent risk factor by some bariatric surgeons.29 Those with the highest BMI are considered to be at increased risk of VTE in all case series to date however there is apparent disagreement between surgeons regarding the level at which raised BMI should be deemed as an independent risk factor. BMI of 50kg/m2, 55kg/m2, 60kg/m2 have each been used as cut-off points.24, 28, 31 According to analysis of retrospective data at a single institution those with a BMI >55 may have significantly increased risk of venous thromboembolism (relative risk 10·2) compared to those with BMI <55 kg/m2.21 It should be noted that this recommendation is based on data obtained from patients who underwent open bariatric surgery, which has been largely superseded by minimally invasive techniques in modern bariatric surgical practice. However the findings by Gargiulo et al. may still be relevant to those undergoing revisional surgery, which may often be performed via an open approach.11 A survey of 385 surgeons from the United States reported that 44% consider the presence of one risk factor as an indication for IVC filter insertion. 54·7% believed that at least two risk factors are required before IVC filter insertion and 47·4% require the presence of three risk factors.13 Finks et al. have demonstrated that individual risk factors may have unequal significance in bariatric surgical patients, suggesting that an empirically based risk calculator may be the most appropriate method of risk stratification.37 Such an approach has been applied successfully in other cohorts of patients.38 A recent statement by the ASMBS has 
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suggested that IVC filters should be considered only in high-risk patients, however there continues to be a lack of consensus regarding risk stratification for morbidly obese patients and indications for IVC filter.39  Development of evidence based guidelines for use of IVC filter in bariatric surgical patients is challenging given the significant heterogeneity in published series. In current series thromboprophylaxis regimen are not standardised40 and a wide range of IVC filter models have been employed. It should be noted that much of the published data describes VTE outcomes after open surgery. Laparoscopic bariatric surgery, now considered gold standard, is associated with shorter operative time and reduced rates of VTE.41 Physicians should also consider that in published series IVC filters have been used exclusively in subjects deemed to be at relatively high risk of VTE.  Without randomized controlled trial study design it is not possible to assess outcomes if IVC filters had not been inserted in these high risk groups.  Whilst investigators have attempted to address this issue by the inclusion of propensity matched controls and statistical correction for example, it cannot be excluded that experienced clinicians in fact correctly predicted those at highest risk, and that the outcome might have been much worse had no filter been inserted. Such factors are important when considering whether the benefits of therapy outweigh the significant risks associated with IVC filters. Further evidence is required to evaluate the risks of VTE and IVC filter use in modern bariatric units. Whilst randomised controlled trials provide the ideal evidence source the issue may be more successfully addressed with non-randomised large multicentre prospective trials with well-defined patient cohorts. Such trials should include long-term follow-up in order to identify complications of therapy. Until such evidence is available, data from well-maintained national registries may provide a basis for future recommendations.22, 42 
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Given the lack of evidence to demonstrate any significant benefit of IVC filter use over alternative approaches, it could be argued that appropriate national or local guidance for surgical thromboprophylaxis may represent the safest option.  Indeed it has been demonstrated that extended pharmacological therapy with early ambulation and perioperative sequential calf compression can all but eliminate the risk of VTE in some bariatric surgical cohorts.43  Conclusions  Published data reporting the safety and efficacy of IVC filter use in bariatric surgical patients is highly heterogeneous and lacks randomized controlled trial evidence. Given the shift towards laparoscopic surgery and ongoing developments in filter technology current evidence may not be directly applicable to modern bariatric surgical practice. At present we would recommend that pre-operative IVC filter insertion should only be considered for prevention of VTE in high-risk bariatric surgical patients. It is important to consider the potential for significant harm resulting from IVC filter insertion. The benefits of therapy are unlikely to outweigh the risks unless there are multiple risk factors for VTE, which may include super-morbid obesity, previous VTE, pulmonary hypertension, a history of coagulopathy, chronic severe immobility, obstructive sleep apnea, or evidence of pre-operative lower limb venous stasis. Where IVC filters are used there is evidence to suggest that early retrieval will increase technical success and reduce long-term complications. Given the significant challenges in performing a randomised controlled trial in this population, large multicentre prospective trials with well-defined patient cohorts should be designed to investigate the role of IVC filters in modern bariatric surgery.  
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 Legends.   Figure 1. PRISMA Literature Search Results  Table 1. Controlled cohort studies describing venous thromboembolism after bariatric surgery with and without pre-operative IVC filter insertion. (NS=Not Specified; RYGB=Roux-en-Y Gastric Bypass; LRYGB=Laparoscopic Roux-en-Y Gastric Bypass; AGB=Adjustable Gastric Band; LGB=Laparoscopic Gastric Band; GB=Gastric Band; DS=Duodenal Switch; SG=Sleeve Gastrectomy; IVCF=Inferior Vena Cava Filter; Hx=History; DVT=Deep vein thrombosis; PE=Pulmonary Embolism; HTN=Hypertension; BMI=Body Mass Index; LMWH=Low molecular weight heparin; SCD=Sequential Compression Device)   Table 2. Case series describing venous thromboembolism after bariatric surgery with pre-operative IVC filter insertion. *Garigiuolo 2010 reports long-term Follow-up data from cohort by Gargiulo et al. 2006, presented in Table 1. (NS=Not Specified; RYGB=Roux-en-Y Gastric Bypass; LRYGB=Laparoscopic Roux-en-Y Gastric Bypass; LGB=Laparoscopic Gastric Band; DS=Duodenal Switch; LSG=Laparoscopic Sleeve Gastrectomy; BMI=Body Mass Index; LMWH=Low molecular weight heparin; SCD=Sequential Compression Device)   Table 3. Summary of published literature detailing DVT, PE and PE related mortality rates in patients who underwent IVC filter insertion before Laparoscopic 30, 34 vs Open23, 
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s for IVC 
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Procedure Cohort No. 
Patie
nts 
Age 
(Mean 
Years) 
Male Sex 
% 
BMI PE DVT 
(Screened 
or 
Symptoma
tic?) 
PE related 
mortality 
Mortality All 
Cause (%) 
Thromboproph
ylaxis 
Anticoa
gulatio
n post-
dischar
ge 
Follow-
Up 
Birkmey
er et al. 
2013 
Propensity-matched cohort study 
NS AGB 15%, SG 12%, RYGB 73%, DS 0.7% 
IVCF 1077 48 32 58 0.80% 1.2% (NS) 0.37% 0.70% Pre-Op Heparin: 36% unfractionated, 60% LMWH. Post-op Heparin: unfractionated 7%, LMWH 70% 
72% 30 days 
    NS AGB 17%, SG 13%, RYGB 69%, DS 0.8% 
No IVCF 1077 49 31 57 0.50% 0.4% (NS) NS 0.09% Pre-Op Heparin: 38% unfractionated, 54% LMW. Post-op Heparin: unfractionated 10%, LMWH 68% 
66% 30 days 
Gargiulo 
et al. 
2006 
Retrospective Cohort Hx DVT or PE, pulmonary HTN, BMI>55kg/m2 not an indication 
Open RYGB IVCF 8 NS NS NS  0 NS 0 0 SCD, thromboembolic devices (TEDs), and weight-adjusted subcutaneous heparin (50 U/kg) injections before surgery and every 12 hours after surgery until ambulating more than 4 hours per day. 
NS 2.5 years (1-42 months) 
  Retrospective Cohort   Open RYGB No IVCF 185 NS NS NS 2.20% NS 1.60% 1.60% As Above NS 2.5 years (1-42 months) 
  Prospective Cohort BMI>55, Hx DVT, PE, Pulmonary HTN 
Open RYGB IVCF 33 NS NS NS NS NS NS   As Above NS 2.5 years (1-42 months) 
  Prospective Cohort   Open RYGB No IVCF 148 NS NS NS NS NS NS NS As Above NS 2.5 years (1-42 months) 
7DEOH
  Prospective Cohort Patient Choice. BMI>55, Hx DVT, PE, Pulmonary HTN 
Open RYGB IVCF 17 NS 17.6 63 0 NS 0 NS As Above NS 2.5 years (1-42 months) 
  Prospective Cohort   Open RYGB No IVCF 18 NS 16.7 63 28% NS 11% NS As Above NS 2.5 years (1-42 months) 
Obeid et 
al. 2007 
Retrospective Cohort Poor mobility, Hx DVT, BMI>60, lower limb venous disease, personal or FHx or thrombophilia. (Data only available for 36% of cohort.) 
LRYGB (12); Open RYGB (234); Lap GB (0) 
IVCF 246 46.6 23.6 60 0.80% 1.2% (Symptomatic) NS 0.81% SCD, enoxaparin, 1mg warfarin/day  NS 30 days 
      LRYGB (132); Open RYGB (1689); Lap GB (27) 
No IVCF 1848 44.7 14 38.8 0.60% 0.6% (Symptomatic) NS 4.00% SCD, enoxaparin NS 30 days 
Overby 
et al. 
2009 
Prospective Cohort Evidence of thrombophilia (all patients underwent full screening), poor ambulation, severe venous disease, pulmonary HTN, severe OSA, obesity hypoventilation 
RYGB (NS) IVCF 162 NS NS NS 0.63% 3.13% (Screened) 0 NS SCD, S/C Heparin 5000-7500U2 TDS. No 6 weeks 
syndrome, patients with central obesity and BMI>60, history of DVT/PE 
      RYGB (NS) No IVCF 168 NS NS NS 2.94% 2.35% (Screened) 0.61% NS SCC, S/C Heparin 5000-7500U2 TDS No 6 weeks 
Li et al. 
2012 
Retrospective Cohort Comparative Database Review 
Variable LRYGB 179 (55.59%); Open RYGB 69 (21.43%); LGB 74 (22.98); 0 
IVCF 322 47 31.4 45.3 0.31% 0.93% NS 0.31% Variable NS 90 days 
      LRYGB 51,648 (53.35%); Open RYGB 4580 (4.73%); LGB 40538 (41.88%); Open GB 40 (0.04%) 
No IVCF 96806 46 21.1 44.5 0.12% 0.12% NS 0.03% Variable NS 90 days 
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*Gargiul
o et al. 
2010 
Open RYGB 58 37 38 62 NS NS 0 3.40% (Screened) 0 20+/-5 SCD, Subcut Heparain 50u/kg pre op and post-op BD until ambulating 4hrs per day 
NS 65+/-12mths 
Kardys 
et al. 
2008 
LRYGB (8); Open RYGB (23) 
31 43 8.3 71 NS NS 6.40% 3.10% 0 NS Pre-op: 5000u Heparin. Post-op: SCD, Enoxaparin 40mg BD Day 1, Enoxaparin for 2/52 if BMI>60 
Only if BMI>60 262+/-38 days 
Trigilio 
Black et 
al. 2007 
LRYGB (14/41); Open RYGB (20/41); LGB (1); LSG (5/41); Open Jej-ileal bypass (1)  
41 47.3 29.2 64.2 Not retrieved, by design 
172.3+/-45 0 2.40% 0 34.3+/-9 Pre-op: LMWH, Post-Op Lovenox 30mg S/C 
No Mean 16 months 
7DEOH
Halmi et 
al. 2007 
Mini' RYGB (Open) 27 47 33.3 48.7 18-21 days NS 0 0 0 NS Pre-op: Heparin 5000u or Lovenox 40mg S/C 1 hr before surgery continued post-op 8 and 12hry respectively. High Risk: 3 weeks of Lovenox with the IVC 
Only for High Risk 15-21 days 
Brent 
Keeling 
et al. 
2005 
LRYGB=11; Open RYGB=3 
14 49.1 14.3 56.5 NS NS 0 0 0 NS Heparin (NS), SCD. For BMI 40-60: 40U Lovenox OD. For BMI>60: 30U BD. 
NS 11months 
Piano et 
al. 2007 
LRYGB or DS (NS) 58 43 17 61 63+/-30 days NS 1.70% 0 (Screened) NS NS SCD, Intraop Heparin infusion 500U/Hr in BMI<50, 750U/Hr BMI>50. LMWH 1 week post-op. 
Yes for 1 week 63+/- 30 days 
Schuste
r et al. 
2007 
RYGB (NS) 24 50 58 57 NS NS 4.20% 20.80% 0 NS SCD, S/C Hep NS 16+/-7.6 months 
Vaziri et 
al. 2011 
LRYGB 41 48 29.3 58 200+/-131 days 106+/-22 0 4.88% (Screened) 0 NS 5000U S/C Hep Preop, Post-op: S/C Heparin TDS. SCD. 
No Mean FU 204+/-160 days 
Escalant
e- 
Tattersf
ield et 
al. 2008 
LRYGB 24 NS NS NS NS 93 0 NS 0 NS 5000u SCH on induction, repeated 8hrly for initial 24hrs post-op, then 40mg enoxaparin sodium BD until discharge. SCD intraoperatively and until patient fully mobile.  
No 2, 8, 12, 24 and 52 weeks 
Chan et 
al. 2013 
NS - Lap 5 NS NS NS 5-6 weeks NS 0 0 0 NS Tinzaparin 50 U/kg/40–80 mg Enoxaparin (dose according to weight) OD 1 day before surgery 2 weeks post surgery. SCD. 
Yes for 2 weeks NS 
Carmod
y et al. 
2006 
Various 145 47 NS 57 NS NS 2.10% NS 0.70% NS 40mg Enoxaparin OD. No NS 
Vaziri 
2009 et 
al. 
LRYGB (16), LAGB (9), Open RYGB (4) 
29 49 41 49 NS 165+/-65 0 20.70% (Screened) 0 NS 5000U unfractionated heparin S/C pre-op then TDS post-op, SCD until ambulatory. 
No 16+/-18 days 
 
 DVT (Screened) PE PE related Mortality Laparoscopic Roux-en-Y Gastric Bypass 30, 34 
7.0%   (4/57 patients) 
0% 0% 
Open Roux-en-Y Gastric Bypass 23, 34 6.7%  (4/60 patients) 
0% 0% 
 
7DEOH
Reference Type of IVC Filter 
Device related 
Complications  
Technical 
failure to 
retrieve 
% Filters 
removed 
Gargiulo et al. 2010 
TrapEase=35, Simon-
Nitinol=9, Greenfield=2, 
Bard Recovery=12 0 NS 1.72% 
Kardys et al. 2008 NS 
6.4% 
(Malposition) NS NS 
Trigilio Black et al. 2007 
9 Optease (retrievable); 31 
Greenfield (non-
retrievable); 1 Gunther-
Tulip (retrievable) 0 N/A 
Not retrieved, by 
design 
Halmi et al. 2007 Gunther Tulip Cook 
11.1% 
(Haematoma (2), 
cellulitis (1)) 0 
96.3% (1 not 
retrieved due to 
unrelated 
illness) 
Brent Keeling et al. 
2005 
13 Greenfield, 1 VenaTech 
LGM 0 NS NS 
Piano et al. 2007 Gunther Tulip Cook 0 
9.3% (5/54 
Filter Tilt) 
90% (6 patient 
refused) 
Schuster et al. 2007 Gunther Tulip Cook 
4% (1 PE from 
thrombus in 
filter) 4% 83% 
Vaziri et al. 2011 Gunther Tulip/Bard G2 
4.8% (pain, 
malposition) 0 68.30% 
Escalante- 
Tattersfield et al. 2008 NS 
4.2% 
(Haematoma) NS NS 
Chan et al. 2013 NS 0 0 100% 
Carmody et al. 2006 NS NS NS NS 
Vaziri 2009 et al. Optease 
3.4% (DVT at 
device insertion 
site) 3.40% 72%  
7DEOH
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The Disparate Management of Superficial Venous Thrombosis in Primary and 
Secondary Care 
Tristan R A Lane*, Kaji Sritharan*, J Ros Herbert§, Ian J Franklin*, Alun H Davies* 
*Academic Section of Vascular Surgery, Imperial College London 
§ Department of Primary Care and Public Health Faculty of Medicine, Imperial College London 
Abstract: 
Objectives 
Superficial Venous Thrombosis (SVT) is common and traditionally considered a benign condition requiring 
only symptomatic treatment.  Recent evidence however advocates more aggressive management.  
Extensive guidance is available but actual practice is unknown. This study aimed to assess the 
management of SVT by General Practitioners (GPs; primary care physicians) and Vascular Surgeons. 
Methods 
A 19 question validated electronic survey was created and circulated by e-mail to GPs and Vascular 
Surgeons in the United Kingdom.  The survey evaluated presentation, investigation and treatment of SVT. 
Results 
369 surveys were returned from 197 vascular surgeons and 172 GPs.  Most clinicians saw < 20 cases a 
year, with 40% of clinicians not performing any investigations.  Venous duplex was the investigation of 
choice in over 55%.  Treatment with anti-inflammatory drugs was widespread, but anticoagulation and 
compression were seldom prescribed.  Follow-up and treatment duration were disparate. 
Discussion 
The management of SVT varies widely despite good levels of evidence and guidance.  Investigation and 
treatment of SVT shows marked differences both between and within groups.  Improvements in 
education are required to optimise the treatment pathway and advance patient care. 
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The Disparate Management of Superficial Venous Thrombosis in Primary and 
Secondary Care 
Tristan R A Lane*, Kaji Sritharan*, J Ros Herbert§, Ian J Franklin*, Alun H Davies* 
 
*Academic Section of Vascular Surgery, Imperial College London 
§ Department of Primary Care and Public Health Faculty of Medicine, Imperial College London 
Introduction 
Superficial venous thrombophlebitis or more correctly superficial venous thrombosis (SVT) is 
thrombus formation within a superficial vein, associated with inflammation within the 
surrounding tissue. It typically presents with pain, tenderness, induration, and/or erythema 
extending along the vein. In addition, there is often a palpable cord which suggests the presence 
of thrombus.  SVT is a common disease that has traditionally been regarded as benign and until 
recently, its pathophysiology has been poorly characterised. 
 
It has an estimated prevalence of between 3% and 11% [1-7], and thus it is more common than 
deep vein thrombosis (DVT) [8]. Moreover, SVT has been shown to be a significant risk factor in 
the development of DVT and consequently PE with an Odds Ratio of 4.3 [9,10].  Between 6% and 
44% of patients with a SVT have a concomitant DVT [2], and up to 30% have a concomitant 
asymptomatic pulmonary emboli (PE) [10,11]; 2% to 13% have a symptomatic PE.   
 
Despite this association, the literature in the past has advocated conservative management [12].  
This is compounded by the belief that treating varicose veins is of low value [13]. Varicose veins 
are a risk factor for SVT and an independent risk factor for DVT [7,8]. 
 
Clear guidance regarding the management of SVT is provided by a recently revised Cochrane 
review [3,5,14]. Despite this, post-graduate teaching on the management of SVT is anecdotally 
sparse. This may be because SVT falls between the stools of multiple specialities which include 
vascular surgery, medicine and general practice.   
 
The aim of our study was to assess the investigation and management of SVT by both GPs and 
vascular surgeons in the UK. 
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Methods 
A 19 question electronic survey was created which assessed SVT management, investigation and 
treatment pathways (Appendix 1).  This did not require Ethical Approval as it is termed Service 
Evaluation by the United Kingdom National Research Ethics Service. 
 
The questionnaire was tested and validated for content and validity by GPs and vascular 
surgeons, with internal, external and independent assessors as previously described [15-17]. 
 
In England there are approximately 34,101 GPs and 456 members of the Vascular Society in the 
UK.  456 Consultant Vascular Surgeons, 290 vascular trainees and 1,000 GPs (including GP 
Registrars) were contacted. 
 
Invitations to complete the survey were sent via e-mail to potential participants (url = 
http://kwiksurveys.com?u=Thrombophlebitis and subsequently url = 
http://freeonlinesurveys.com/s.asp?sid=hql8rbxblw7i8h387978) using local and national mailing 
lists.  
 
Responses were collated by the survey server (KwikSurveys, Dover, UK and FreeOnlineSurveys, 
UK) over a 6-month period and results were analysed using Microsoft Excel 2011 (Microsoft 
Corporation, Redmond, USA) and IBM SPSS (v21, IBM Software, Armonk, USA). 
 
Results 
369 completed responses have been received, from 165 vascular consultants (36% response 
rate), 172 GPs or GP trainees (17% response rate) and 32 vascular trainees (11% response rate). 
 
Most clinicians see fewer than 20 cases per year of SVT, with vascular surgeons seeing more 
cases compared to their GP colleagues (See Figure 1). 
 
The overwhelming majority of clinicians (though significantly different proportions, p=0.007) 
believed there to be an association between SVT and DVT. There was however a disparity 
between this view and the treatment offered – Table 1.  The belief of a relationship between 
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SVT and other conditions is also varied. Clinicians consistently across all groups felt there was an 
association between SVT and varicose veins.  Beliefs of a relationship between SVT and PE, Deep 
Venous Incompetence, Cancer or Infection were significantly different between GPs and VCs. 
   
The majority of clinicians performed a venous duplex as their main investigation, but 40% 
performed no investigations at all (See Figure 2).  
 
A large disparity was shown in the treatment offered for patients with SVT.  Almost 10% offered 
no treatment at all for this painful and potentially serious condition. Moreover, complete bed 
rest was advocated by a few clinicians for this thrombotic disease. The majority opted for non-
steroidal anti-inflammatory drugs (NSAIDs) but only 25% treated with anticoagulation. The 
duration of anticoagulation was widely disparate as (p<0.001). Even fewer (<20%) prescribed 
compression hosiery (See Figure 3).  
 
Finally, the approach to follow-up was variable (p<0.001) and inconsistent as shown in Figures 4, 
with 23.8% of GPs and 13.3% of VCs providing no follow-up at all; and 57% of GPs and 39% of 
VCs providing follow-up in select cases only.  
 
Discussion 
This study demonstrates that the management of SVT is disparate despite good level 2 evidence 
indicating that NSAIDs, LMWH and compression hosiery are effective and reduce the incidence 
of DVT [5].  This is likely to be due to the continued misconception amongst GPs and VCs that 
SVT is a benign self-limiting disease [18].  
 
The number of cases seen per year (on average <20) appears at odds to the estimated 3-11% 
reported prevalence of SVT. This should equate to 200-700 cases per year given the average list 
size of a GP, and 7,500 cases per year for a VC [2,19].  The discrepancy in prevalence and cases 
seen, may be due to failure of these patients to present to their doctor, or more likely due to 
poor recognition or a low level of understanding of both the condition and its relative 
importance in the context of venous thromboembolism.   
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Whilst the majority of clinicians believed there to be an association between SVT and DVT, a 
fifth of all clinicians believed there to be no association at all despite the increasing literature 
base to the contrary [2,6]. Moreover, the majority of clinicians (40% GPs vs 57% VCs) who did 
believe in an association between DVT and SVT, significantly underestimated that risk. This once 
again highlights the need for focussed postgraduate education into this condition. 
 
Venous disease has been shown to have a low level of public exposure in previous work from 
the our unit, and SVT is likely to suffer from  a similar under-exposure [17].  A concerning feature 
from our study,  is the low level usage of compression hosiery which is a simple, symptom 
relieving measure that is poorly utilised. Moreover, the use of compression hosiery in SVT has 
been shown to significantly reduce SVT progression and is associated with lower rates of VTE.  
 
Antibiotics were prescribed by approximately 20% of clinicians. The use of antibiotics for the 
treatment of a sterile inflammation leads to no symptomatic improvement for the patient, 
misdiagnosis and potentially antibiotic resistance [20]. However, their use is perhaps not 
surprising given the belief held by 72% of GPs and 48% of VCs, of an association between 
infection and SVT. 
 
SVT and DVT share similar predisposing factors, once again suggesting a similar or linked 
pathophysiology. Despite this, less than 20% of clinicians performed a thrombophilia screen as 
part of their work-up.  In addition, a third of clinicians did not perform any imaging at 
presentation. Baseline imaging would have usefully excluded a concomitant DVT and allow for 
objective assessment of thrombus propagation.  
 
No national guidelines exist for the management of SVT, however robust level 1 and 2 evidence 
exist to guide clinicians. The goal of management is not only geared towards symptom control, 
but also aimed at prevention of thrombus propagation, reduction in SVT recurrence and venous 
thromboembolism (VTE) prevention. The latter is the key driver for more aggressive and 
standardised  treatment [5,21].  The use of guidelines to help construct an optimal patient 
pathway should in theory be of benefit, but evidence from other conditions has shown that 
guideline formulation does not lead to significant changes or improvements in practice in both a 
first and third world setting [17,22-28].  Education regarding the full gamut of VTE and venous 
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disease would provide holistic improvements in treatment pathways, however, this would be 
costly and time consuming, and would be difficult to achieve.  Intensive methods in 
cardiovascular medicine have led to improved guideline adherence over a period of 9 years [29]. 
 
Conclusion 
The treatment and understanding of SVT is disparate and unclear in the UK. If the potentially 
devastating thromboembolic sequelae of SVT are to be avoided, better awareness of the 
pathophysiology of SVT and education regarding its management is mandatory. The creation of 
Guidelines and the development of clearer referral pathways would both give SVT a higher 
clinical profile and over time improve patient care.   
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Table 1: Is there an association between SVT and DVT, what percentage of 
patients suffer from DVT and association between SVT and other conditions split 
amongst speciality 
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Table 2: Follow-up for SVT table 
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Original Article
Retrograde mechanochemical ablation
of the small saphenous vein for the
treatment of a venous ulcer
Hayley M Moore, Tristan RA Lane, Ian J Franklin and
Alun H Davies
Abstract
We present the first case of retrograde ablation of the small saphenous vein to treat active venous ulceration. A 73-
year-old gentleman with complicated varicose veins of the left leg and a non-healing venous ulcer despite previous
successful endovenous treatment to his left great saphenous vein underwent mechanochemical ablation of his small
saphenous vein with the ClariVein! system, under local anaesthetic, using a retrograde cannulation technique. Post-
operatively the patient had improved symptomatically and the ulcer size had reduced. This report highlights that patients
with small saphenous vein incompetence and active ulceration can be treated successfully with retrograde mechano-
chemical ablation.
Keywords
ClariVein, varicose veins, endovenous ablation, mechanochemical ablation, ulcer
Introduction
Venous ulceration is generally treated with compression
therapy, but work by Gohel et al.1 showed that surgical
intervention was eﬀective at preventing ulcer recur-
rence. More recent evidence from Kulkarni et al.2 and
Pang et al.3 demonstrated that ultrasound-guided foam
sclerotherapy improved ulcer healing rates compared to
historical data. Mechanochemical superficial vein abla-
tion using the ClariVein! (Vascular Insights LLC of
Madison, CT, USA) catheter does not require tumes-
cent anaesthesia and has good treatment outcomes.4
Twenty two percent of patients with venous ulcer-
ation have small saphenous vein (SSV) incompetence.5
In the presence of active ulceration, open surgery and
distal endovenous ablation techniques requiring cannu-
lation and tumescent anaesthesia may risk the introduc-
tion of infection. The use of ultrasound-guided foam
sclerotherapy has been described, however ablation
rates are variable.2,6–8
In this report, we present the first case of retrograde
ablation of the SSV to treat active venous ulceration.
Case report
A 73-year-old gentleman presented to the clinic at
Charing Cross Hospital with complicated varicose
veins of the left leg, with a non-healing 4-cm diameter
venous ulcer present for more than 1 year. He had a
Clinical Etiological Anatomical Pathological (CEAP)
score of C6bS Ep Asd Pr, an Aberdeen Varicose Vein
Questionnaire (AVVQ) score of 23.85,9 an EQ-5D
0.666, EQ-VAS 7010 and a VCSS of 16.11 He had a
history of type II diabetes mellitus and a past history
of prostate cancer, which had been treated with radio-
therapy. A venous duplex ultrasound revealed refluxing
(>0.5 seconds reflux time) disease of both the great
saphenous vein (GSV) and SSV as well as an incompe-
tent deep venous system. The GSV was 7.2 millimetres
in maximal diameter and the SSV maximal diameter
was 12 millimetres in maximal diameter. He underwent
endovenous treatment to his left GSV, following which
his pain improved and the size of the ulcer reduced
from 4 cm to 2 cm diameter. However, after 6 months
of adequate compression with the three-layer banda-
ging technique, the ulcer had failed to fully heal and
his symptoms worsened. A repeat venous duplex scan
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demonstrated occlusion of the GSV and persisting
reflux in the SSV and the femoral and popliteal veins.
The patient underwent mechanochemical ablation of
his SSV under local anaesthetic in August 2012. The
procedure was as follows:
The SSV was cannulated under ultrasound guidance
at the SSV fascial curve in the popliteal fossa and the
ClariVein! catheter was passed distally using standard
Seldinger technique in a prone reverse Trendelenberg
position. The patient angle was then flattened. Using
standard mechanochemical ablation technique4 and
4ml 2% Fibrovein! (sodium tetradecyl sulphate),
20 cm of the SSV was ablated. The puncture site was
closed with a Steri-Strip dressing (3M, St. Paul, Minn)
and a cannulation site plaster (Mepore; Mo¨lnlycke
Health Care, Gothenburg, Sweden) without sutures.
A schematic of the technique is demonstrated by
Figure 1, with a clinical photo of the equipment in
Figure 2. Adequate compression with the three-layer
bandaging technique was continued until ulcer healing.
At 3-month follow up, subjectively, he had experi-
enced no post-operative pain or inflammation. The
patient had improved symptomatically, increasing his
daily activities due to a reduction in the pain from his
ulcer. The ulcer size had reduced to 3mm with evidence
of granulating tissue at the base. His AVVQ had not
improved – 24.82 (5% deterioration) – however, the
EQ-5D 0.735 (10% improvement) and EQ-VAS of 80
(14% improvement) were both markedly improved and
his VCSS score was improved to 12 (25% improve-
ment). Repeat venous duplex ultrasound at 3 months
showed successful SSV occlusion and a competent deep
venous system.
Figure 1. Schematic of retrograde ClariVein procedure.
Figure 2. Clinical picture of ClariVein mechanochemical
ablation device in use.
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Discussion
In this report, we demonstrate that retrograde venous
ablation using a non-thermal modality is feasible with a
catheter-based technique such as the ClariVein! device.
A mechanochemical catheter device allows distal treat-
ment without the risk of nerve damage due to thermal
injury. This retrograde technique ensures that the can-
nulation site is distant from the site of ulceration, which
may reduce the risk of infection, with the added benefit
that no additional skin punctures are required for tumes-
cent anaesthesia. However, the current rate of infection
during ablation runs at 0.3% and so the improvement
will beminor. Historic infection rates of 4–8%have been
reported in the context of general anaesthetic with sim-
ultaneous adjunctive phlebectomies12–14 and the one
notable report of sepsis after endovenous treatment
was treatment of an ulcer with endovenous ablation
and phlebectomies under general anaesthetic.15
The segment of vein underlying the area of ulcer-
ation can also be treated using this technique, meaning
a longer segment of vein can be ablated. The technique
could also be applied to treat both the distal GSV in the
presence of ulcerations and in the future may allow
precise access to problematic incompetent veins extend-
ing under active ulceration.
Further patients have also been treated with this
approach with good closure rates and improvements
in symptomatology and ulcer status. The normalisation
of deep venous reflux on treatment of superficial reflux
has been previously described after surgery.16,17
Use of the ClariVein! device for retrograde treat-
ment has a good margin of safety as the amount of
liquid sclerosant used is small and the active treatment
area is 2 cm distant to the cannulation site to prevent
skin damage. Coupled with a vein in spasm and a cath-
eter impeding flow, proximal passage of sclerosant into
the deep venous system before deactivation by blood is
highly unlikely.
Conclusion
This report highlights the expanding possibilities for
treatment of venous ulceration. Patients with SSV
incompetence and active ulceration can be treated suc-
cessfully with retrograde mechanochemical ablation
whilst maintaining sterility.
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Abstract Varicose veins are common and cause extensive
morbidity; however, the value of treatment is under-
appreciated. Many procedures allow the treatment of varicose
veins with minimal cost and extensive literature supporting
differing minimally invasive approaches. In this article, we
investigate the current literature regarding treatment options,
clinical outcome and the cost-benefit economics associated
with varicose vein treatment. The practice of defining clinical
outcome with quality of life (QOL) assessment is explained to
provide valid concepts of treatment success beyond occlusion
rates.
Keywords QOL .QALY .Varicoseveins .Cost-effectiveness
Varicose veins are an extremely common and affect over 25%
of the population with the majority of patients presenting with
varicose veins being young and otherwise systemically well
[1, 2].
There are widespread misconceptions held by both the
general public and primary care physicians with regards to
varicose veins; the public fear that there is an increased
likelihood of DVT, or that chronic venous changes are a
common cause of limb amputation [3], whilst primary care
physicians are often mistaken in believing that varicose veins
are merely a cosmetic concern and so, leading to a reduced
rate of referral for treatment, and even the skin changes of
chronic venous insufficiency (a precursor to ulceration) are
often deemed inconsequential [4, 5]. Additionally, knowledge
on current treatment methods in the primary care sector is
poor, leading to denial of referral for treatable patients [4, 6].
Health-care costs are spiralling; in the UK, they have
doubled over the last decade to £126 billion annually [7], with
a similar picture seen in the USAwhere spending is now $1.2
trillion/year [8], equivalent to over 8 % GDP, a value seen
throughout Europe as well [9, 10].
Whilst costs and value for money have always had a role in
the decision-making processes, these increasing financial
pressures at the hospital, regional and national levels have
caused hospital managers to look at ways to cut costs at all
levels. Varicose veins have been labelled as a “procedure of
low clinical value” due to the low mortality rates associated
with this benign disease, leading to a reduced rate of referral
for treatment [5]. Varicose vein surgery in the National Health
Service is an obvious target for exclusion to reduce costs, as
some may see this surgery as not essential.
Varicose vein assessment
Varicose vein symptoms are often vague and non-specific but
include aching, discomfort, pruritus and muscle cramps [11];
however, there are more obvious and objective symptoms
which include varicose eczema, pigmentation, bleeding and
ulceration [12]. There is a wealth of evidence which demon-
strates that venous disease significantly impairs quality of life.
Patients with varicose veins have been shown to have lower
scores than UK population norms for domains relating to pain
and physical function and an increased prevalence of depres-
sion [13–19].
There are many definitions of quality of life and as many
ways to measure it, including instruments completed by the
patient or physician. For a quality of life instrument to be a
valuable measure of what is intended, it must be reliable and
valid, and probably most importantly, it must also be practical.
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Quality of life instruments include both generic and
disease-specific surveys. Generic surveys assess global states
of well-being and provide a subjective measure of treatment
efficacy, whilst disease-specific surveys focus on elements
associated with particular disease processes and treatment
effects [20–22]. These instruments are helpful when
attempting to determine cost-effectiveness in an era of limited
resources.
Patient reported outcome measures are intended to provide a
direct measure of the success of medical interventions, as judged
by patients, to enable clinical teams to benchmark their perfor-
mance and research the success of different treatment options.
The results of the returned questionnaires will be available to the
public on the NHS choices website allowing comparison be-
tween centres from a patient perspective [23–28].
CEAP classification
Varicose veins have often not been adequately defined and
have variously been described as being visible subcutaneous
veins, to dilated palpable subcutaneous veins generally larger
than 3 mm in the upright position. Due to this lack of consen-
sus in the reporting and classification in the published litera-
ture, the clinical severity, aetiology, anatomy and pathophys-
iology (CEAP) classification for chronic venous disorders
(CVD) was developed in 1994 by an international ad hoc
committee of the American Venous Forum, endorsed by the
Society for Vascular Surgery, and this classification became
incorporated into “Reporting Standards in Venous Disease” in
1995, with further refinements made to it in 2004 [29]. This
classification has become universally adopted and so allows a
direct comparison between studied modalities.
This is a clinician-implemented categorisation tool. The
clinical component indicates disease severity, ranging from 0
points, for completely asymptomatic patients, up to 6 points for
active ulcers. The etiologic component denotes the venous
disease as congenital, primary or secondary in nature. The
anatomic classification pinpoints the veins involved as superfi-
cial, deep or perforating. The pathophysiological classification
identifies the presence of reflux in the superficial, communicat-
ing or deep systems, as well as the existence of outflow ob-
struction. The CEAP classification is doctor-driven and high-
lights the cause of the underlying venous abnormality; howev-
er, it is not sensitive enough to track progressive changes.
Venous Clinical Severity Score (VCSS)
The VCSS is a clinician-completed tool, which includes nine
hallmarks of venous disease, each scored on a severity scale
from 0 to 3. In order to generate a dynamic score, VCSS
categories are scored individually. These include skin changes
and pigmentation, inflammation and induration, and ulcers
(including number, size and duration). In 2007, an interna-
tional ad hoc working group was created to revise the VCSS to
update the terminology, simplify the application and clarify
ambiguities, which was completed in 2010 [30].
The value of the VCSS is its ease of use along with an
emphasis on the most severe manifestations of venous disease
which are likely to show the greatest response to therapy
allowing tracking and quantification of improvement (or de-
terioration) [12].
Disease-specific assessment—Aberdeen Varicose Vein
Questionnaire (AVVQ)
The AVVQ is a 13-question patient-completed survey ad-
dressing multiple elements of varicose vein disease, first de-
veloped in 1993 [31]. It is designed for patient self-completion
with a timescale of 2 weeks.
Physical symptoms along with social issues, including
pain, ankle oedema, ulcers, compression therapy use and
limitations on daily activities are examined, as well as the
cosmetic effect of varicose veins. The questionnaire is scored
from 0 (no effect) to 100 (severe effect).
Disease-specific assessment—Venous Insufficiency
Epidemiological and Economic Study Quality of Life
and Symptom Severity Questionnaires
(VEINES-QOL/Sym)
The VEINES-QOL/Sym is a 26-question patient-completed
survey developed in 2003, which addresses symptoms, daily
life limitations, change in condition and psychological impact
of the venous disease. Responses are rated on two-point to
seven-point response scales of intensity, frequency or agree-
ment. The time frame for questions is the previous 4 weeks.
The raw scores are then translated into a standardised scale for
comparison [32].
Disease-specific assessment—Chronic Venous
Insufficiency Quality of Life Questionnaire (CIVIQ)
The CIVIQ is a 20- or 14-question survey developed in 1996
and then refined in 2011 [33, 34], which again assesses
patient-reported symptoms and the impact of chronic venous
disease on quality of life. It has four principal domains and a
maximum score of 100, with lower scores indicating a better
quality of life.
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Disease-specific assessment—Specific Quality of Life
and Outcome Response–Venous (SQOR-V)
The SQOR-V is a 45-item survey for patient completion,
which assesses physical and psychosomatic symptoms pro-
viding a score out of 100 for each category. Each item is
scored from 1 to 5 and grouped into 1 of 5 subcategories with
normalisation to a maximum score of 20 per subcategory. A
quality of life due to venous disease improves the score
decreases [35, 36].
Disease-specific assessment—Assessment of Burden
in Chronic Venous Disease (ABC-V)
Recently developed, this 39-point survey assesses the burden
of venous disease opposed as the specific quality of life due to
venous disease. It has a scale of 0 (best)–90 (worst). The tool
is aimed primarily at population scale assessment [37].
Generic assessment—Short Form Health Survey (SF-36,
SF-12, SF-8)
A widely used and well-validated generic health quality of
life assessment tool is the Short Form Health Survey
(QualityMetric, Lincoln, RI, USA), developed over time with
questions in physical and mental health. These two categories
have been broken down into eight domains that include phys-
ical and social functioning, role limitations due to physical or
emotional problems, mental health, pain, vitality and health
perception. The survey generates a score ranging from 0 to
100, with higher scores indicating better general health per-
ception with a time coverage of 4 weeks.
Generic assessment—EuroQOL 5 Domain (EQ-5D)
The EuroQOL 5 Domain survey (Euroqol, Rotterdam, The
Netherlands) is an alternative validated patient-completed ge-
neric health quality of life questionnaire that measures mobility,
self-care, usual activities, pain and anxiety domains at the time
of questioning. The domains generate a unique quality of life
outcome between −0.594 and 1, with 1 being perfect health.
It also provides a separate visual analogue scale (VAS)
rendering of global health status, from 0 to 100, with higher
scores indicating better health [21, 38].
Treatment of varicose veins
The treatment of patients with superficial venous reflux
has changed in recent years following the widespread
acceptance of minimally invasive, endovenous modalities
including ultrasound-guided foam sclerotherapy (UGFS),
radiofrequency ablation (RFA) and endovenous laser ablation
(EVLA) [6, 39]. Recent thermal and non-thermal modalities
have emerged in the past 2 years including steam ablation,
mechanochemical ablation (ClariVein) and pharmacological
occlusion (Sapheon) [40–42]. All endovenous interventions
are aimed at principally abolishing truncal reflux and then
removing or occluding any incompetent varicosities. Many
open techniques exist such as traditional sapheno-femoral
ligation (crossectomy) with or without vein stripping [43],
cryostripping [44, 45], varicosity avulsion (ASVAL) [46]
and haemodynamic correction (CHIVA) [47]. Traditional
open surgery remains the gold standard against which other
modalities must be measured [6, 48, 49].
Endovenous ablation
In the past decade, the introduction of minimally invasive
endovenous ablation therapy has revolutionised the treatment
of varicose veins.
Endovenous laser ablation (EVLA) treatment is designed
to cause thermal damage to the vein lining. During laser
activation, light energy is transmitted through an optical fibre
to the tip, usually producing a fine beam within the vein. This
beam either exits the fibre at the end (end firing) or from the
side of the fibre tip (radial firing).
Lasers used for EVLA may be either diodes or solid-state
neodymium-doped yttrium aluminium garnet (Nd:YAG) la-
sers and are available in a number of wavelengths (i.e. 810,
940, 941, 1,064, 1,320 and 1,470 nm) to target different
absorbing molecules. Diode lasers are numerically the most
common laser type.
The active material in a diode laser is a small semiconduc-
tor chip powered by injected electric current. Diode lasers
have the advantage of being small in size, may be desktop-
or trolley-mounted or stored in a cupboard, producing less
heat than Nd:YAG and requiring minimal maintenance for
reliable operation.
In a Nd:YAG laser, there are two main components. The
active laser medium is a solid rod of the crystal YAG which
has been “doped” or artificially contaminated byNd. The laser
medium is optically pumped with energy by a diode laser or
flash tube, and the laser process amplifies the energy input by
using the neodymium ion. The process causes significant heat
production and therefore a cooling system is incorporated in
the device. The laser is floor standing and so requires suitable
storage space. Nd:YAG and diode lasers may also be used for
other cosmetic, aesthetic or dermatological applications and
cost-effectiveness will increase if they have multiple uses and
if treatment is funded.
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Diode lasers that produce infrared wavelengths are com-
mon as these wavelengths match an energy absorption peak in
both oxyhaemoglobin and deoxyhaemoglobin. At these wave-
lengths, laser energy is preferentially absorbed by the blood,
causing rapid heating and coagulation.
Laser energy at longer wavelengths is preferentially
absorbed by water, so both water within the blood and the
vein wall lining directly absorb the laser energy. The 1,470-
nm diode laser has a reduced post-operative pain profile in one
study [50], though previous studies have shown excellent
results with the “old-fashioned” 810-nm laser [51].
EVLT delivers laser energy directly into the vein lumen, but
the mechanism of action bywhich this brings about destruction
of the vein wall is debated [52]. The laser energy causes the
blood inside the vein to boil, and it may be the diffusion of the
superheated steam bubbles to the vein wall that actually de-
stroys the vein architecture [53]. Other authors argue that the
heat generated by the steam bubbles is not sufficient to destroy
the vein wall, and that this requires direct contact with the laser
energy itself [54]. With either theory, the final common path-
way is the same as the heating of the vein wall, resulting in
collagen contraction and destruction of endothelium.
The use of lasers requires minor modifications to the room
(fitting window blinds, warning notices), the wearing of safety
glasses by all in the room, appointment of one of the team as
laser protection supervisor, written safety procedures and
safety training for all staff.
Radiofrequency ablation (RFA) uses electrical energy to
heat the vein wall. The vein wall is exposed to high-frequency
alternating current by direct contact of the catheter with the
endothelium of the vein wall. Tissue destruction is precise
with loss of vessel wall architecture and disintegration of the
vessel. This technique also requires the injection of tumescent
anaesthesia to minimise pain and reduce the risk of skin burns
during the procedure.
Current RFA technology includes the VNUS ClosureFAST
catheter and the Olympus Celon RFiTT catheter. Both require
radiofrequency generators which are compact and portable.
& The VNUS ClosureFast catheter uses radiofrequency en-
ergy to achieve temperatures between 95 and 120 °C in a
7-cm-long heating element. The temperature is monitored
by a thermocouple within the catheter tip.
& The Celon RFiTT catheter comprises two concentric bi-
polar electrodes, one at the tip and the other several
millimetres down the catheter shaft. An electrical current
at 470 kHz is conducted through the adjacent blood and
vein wall. The generator monitors electrical impedance,
which rises as the blood and the vein wall heat up to 85 °C.
A continuous audible signal indicates that ablation is
complete.
Extensive evidence is available to support the use of RFA,
and indeed, direct comparisons between RFA and EVLA have
resulted in the knowledge that RFA and EVLA have similar
occlusion rates with RFA having a reduced side-effect profile
[55–57].
Steam ablation is a new modality, currently in the early
stages of development with few published studies. It utilises
pressurised steam to thermally ablate the walls of the vein in a
similar method to EVLA and RFA [41, 58].
Non-thermal techniques, such as mechanochemical abla-
tion using the ClariVein device and pharmacological occlu-
sion using the Sapheon device [40, 42], have recently come to
prominence due to allowing treatment without tumescent
anaesthesia. These devices are still in the early stages of
clinical evaluation but show promising results and glimpses
of the future.
Cost-effectiveness
Despite being one of the most commonly performed surgical
procedures, few cost-effectiveness evaluations have been
calculated.
Ratcliffe et al. conducted a randomised trial compar-
ing open surgery with conservative management [59].
The surgical group was a heterogeneous collection of
unilateral and bilateral procedures performed under gen-
eral anaesthesia as a day case; the conservative group
was treated with compression hosiery or bandaging.
Not only did they demonstrate that open surgery was
cost-effective using £20,000 QALY level, but a third of
patients allocated to the conservative group dropped out
to undergo surgery before the trial had finished.
This led to the development of the Randomised and Eco-
nomic Assessment of Conservative and Therapeutic Interven-
tions for Varicose Veins (REACTIV) study whose aim was to
investigate the clinical and cost-effectiveness of varicose vein
treatments [60].
Patients were split into three groups:
Group 1 (n =34) minor varicose veins below the knee
without truncal reflux
randomised to conservative or
sclerotherapy treatment
Group 2 (n =77) moderate varicose veins below the knee
with truncal reflux
randomised to standard
surgery or sclerotherapy treatment
Group 3 (n =246) significant varicose veins above and
below the knee with truncal reflux
randomised to conservative treatment
or standard surgery
Once again, a significant number of patients allocated to a
conservative management path became dissatisfied and
dropped out of the study, so that they could undergo surgery.
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Although numbers were small in some groups, this study
further demonstrated the economic value in treating patients
with symptomatic varicose veins.
Subramonia and Lees performed a study comparing
surgery and RFA [61] which incorporated cost analysis
into the design [62]. This study randomised 88 patients
into RFA (VNUS ClosurePlus™) and conventional sur-
gery (RFA 47, surgery 41) under general anaesthetic.
RFA was found to be significantly more expensive
(£1,276 vs. £559); however, the RFA group returned
to work at an average of 1 week earlier (10 vs.
18.5 days), at a cost of £8.14 per additional working
hour gained. However, this study utilised the VNUS
ClosurePlus™ catheter, which is six times slower than
the current VNUS ClosureFAST™ catheter (0.05 vs.
0.33 cm/s) and requires a constant pullback technique.
The cost difference was due to increased theatre time
(83.6 vs. 55.7 min, additional cost of £171.01) and
catheter cost (£550).
Gohel et al. produced a Markov model to evaluate
the cost-effectiveness of traditional and endovenous
treatments for patients with unilateral primary great
saphenous varicose veins [63]. Day-case open surgery
under general anaesthetic or endovenous ablation using
EVLA or RFA under local anaesthetic and foam sclero-
therapy performed as an outpatient were shown to be
the most likely cost-effective treatment strategies for
patients with primary unilateral GSV reflux requiring
treatment. This is supported by a study in the USA
[64]. It should be expected that bilateral treatment and
open surgery under local anaesthetic would also be cost-
effective.
A recent work by Rasmussen et al. showed equivalence
between all available modalities in a direct comparison trial of
580 legs [56]—125 patients were treated with open surgery,
RFA, EVLA and UGFS. All procedures were under local
anaesthetic, and treatment time was 19–32 min. RFA was
shown to be associated with less post-operative pain leading
to a faster return to work and therefore a better cost-
effectiveness analysis compared to open surgery or laser ab-
lation. Catheter costs were set at £307 for EVLA and £371 for
RFA. Two separate lasers were used, 14 % 980 nm and 86 %
1,470 nm. Foam sclerotherapy remained the cheapest option
but was associated with a significantly higher recurrence rate
at 1 year (16 vs. 5–6 %).
Overall, this trial suggests that all modalities of venous
intervention have comparable efficacy and cost-effectiveness.
Importantly, the study allows a direct comparison of the 1,470-
nm laser with VNUS ClosureFAST, as though there were two
separate wavelengths used, the vast majority of laser patients
were treated with the 1,470-nm laser. Similar efficacy profiles
were demonstrated, but RFA had a reduced post-operative pain
profile, allowing earlier return to work.
Conclusion
Endothermal ablation has enabled clinicians to provide easy
access to treatment that improves quality of life and reduces
the societal and personal burden of venous disease. Minimally
invasive treatment with endothermal techniques results in
high-quality treatment at low cost. Surely, this is the way of
the future. Further studies using advancing technology will no
doubt confirm this position.
References
1. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D (2005) The
epidemiology of chronic venous insufficiency and varicose veins. Ann
Epidemiol 15(3):175–184. doi:10.1016/j.annepidem.2004.05.015
2. Maurins U, Hoffmann BH, Lösch C, Jöckel K-H, Rabe E, Pannier F
(2008) Distribution and prevalence of reflux in the superficial and
deep venous system in the general population—results from the
Bonn Vein Study, Germany. J Vasc Surg 48(3):680–687. doi:10.
1016/j.jvs.2008.04.029
3. Blaettler W, Amsler F, Mendoza E (2012) The relative impact on leg
symptoms of fears of getting varicose veins and of great saphenous
vein reflux. Phlebology 28(7):347–52. doi:10.1258/phleb.2012.
011158, Venous Forum of the Royal Society of Medicine
4. Lane TRA, Sritharan K, Herbert JR, Franklin IJ, Davies AH (2013)
Management of chronic venous disease by primary care. Phlebology:
J Venous Dis 28(6):299–304
5. Commission A (2011) Reducing spending on low clinical value
treatments. Health briefing. Audit Commission, London
6. Lane TRA, Pandey VA, Davies AH (2011) Superficial venous dis-
ease treatment—is there still a role for open surgery in 2011? Acta
Chir Belg 111(3):125–129
7. Treasury HM (2011) HM treasury budget 2011, vol HC 836. HM
Treasury, London
8. United States Government (2011) Fiscal year 2012 budget of the US
Government. US Government Printing Office, Washington
9. Przywara B (2010) Projecting future health care expenditure at
European level: drivers, methodology and main results. Eur
Comission Econ Pap 417:1–85. doi:10.2765/42844
10. Rabe E, Pannier F (2010) Societal costs of chronic venous disease in
CEAP C4, C5, C6 disease. Phlebology 25(Suppl 1):64–67. doi:10.
1258/phleb.2010.010s09
11. Bradbury A, Evans C, Allan P, Lee A, Ruckley CV, Fowkes FG
(1999) What are the symptoms of varicose veins? Edinburgh vein
study cross sectional population survey. BrMed J 318(7180):353–356
12. Vasquez MA, Munschauer CE (2012) Revised venous clinical sever-
ity score: a facile measurement of outcomes in venous disease.
Phlebology 27(Suppl 1):119–129. doi:10.1258/phleb.2012.012S16
13. Sritharan K, Lane TRA, Davies AH (2012) The burden of depression
in patients with symptomatic varicose veins. Eur J Vasc Endovasc
Surg 43(4):480–484. doi:10.1016/j.ejvs.2012.01.008
14. Bachoo P (2009) Interventions for uncomplicated varicose veins.
Phlebology 24(Suppl 1):3–12. doi:10.1258/phleb.2009.09s002
15. Beresford T, Smith J, Brown L, Greenhalgh R, Davies A (2003) A
comparison of health-related quality of life of patients with primary
and recurrent varicose veins. Phlebology 18(1):35
16. Franks PJ,Wright DD, Fletcher AE,Moffatt CJ, Stirling J, Bulpitt CJ,
McCollum CN (1992) A questionnaire to assess risk factors, quality
of life, and use of health resources in patients with venous disease.
Eur J Surg Acta Chir 158(3):149–155
Lasers Med Sci
17. Kaplan RM, Criqui MH, Denenberg JO, Bergan J, Fronek A (2003)
Quality of life in patients with chronic venous disease: San Diego
population study. J Vasc Surg 37(5):1047–1053. doi:10.1067/mva.
2003.168
18. Kurz X, Lamping DL, Kahn SR, Baccaglini U, Zuccarelli F,
Spreafico G, Abenhaim L,VEINES Study Group (2001) Do varicose
veins affect quality of life? Results of an international population-
based study. J Vasc Surg 34(4):641–648. doi:10.1067/mva.2001.
117333
19. Shepherd AC, Gohel MS, Lim CS, Davies AH (2011) A study to
compare disease-specific quality of life with clinical anatomical and
hemodynamic assessments in patients with varicose veins. J Vasc
Surg 53(2):374–382. doi:10.1016/j.jvs.2010.09.022
20. Dolan P, Gudex C, Kind P,Williams A (1996) Valuing health states: a
comparison of methods. J Health Econ 15(2):209–231
21. Gudex C, Dolan P, Kind P, Williams A (1996) Health state valuations
from the general public using the visual analogue scale. Qual Life
Res: Int J Qual Life Asp Treat, Care Rehab 5(6):521–531
22. Romney DM, Evans DR (1996) Toward a general model of health-
related quality of life. Qual Life Res: Int J Qual Life Asp Treat, Care
Rehab 5(2):235–241
23. Greenhalgh J (2009) The applications of PROs in clinical practice:
what are they, do they work, and why? Qual Life Res: Int J Qual Life
Asp Treat, Care Rehab 18(1):115–123. doi:10.1007/s11136-008-
9430-6
24. Guex JJ (2012) Importance of patient-reported outcomes in chronic
venous disorders. Phlebology 27(Suppl 1):136–138. doi:10.1258/
phleb.2012.012S20
25. Kahn SR, M’lan CE, Lamping DL, Kurz X, Bérard A, Abenhaim
LA, Group VS (2004) Relationship between clinical classification of
chronic venous disease and patient-reported quality of life: results
from an international cohort study. J Vasc Surg 39(4):823–828. doi:
10.1016/j.jvs.2003.12.007
26. Lurie F, Kistner RL (2011) Trends in patient reported outcomes of
conservative and surgical treatment of primary chronic venous dis-
ease contradict current practices. Ann Surg 254(2):363–367. doi:10.
1097/SLA.0b013e31821d4a5f
27. Nesbitt C, Wilson WRW, Lees TA, Stansby G (2011) Interpretation
of patient-reported outcome measures for varicose vein surgery.
Phlebology. doi:10.1258/phleb.2011.011013
28. Ousey K, Cook L (2011) Understanding patient reported outcome
measures (PROMs). Br J Community Nurs 16(2):80–82
29. Eklof B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P,
Kistner RL, Meissner MH,Moneta GL, Myers K, Padberg FT, Perrin
M, Ruckley CV, Smith PC, Wakefield TW, AVFIAHCfRotC Classi-
fication (2004) Revision of the CEAP classification for chronic
venous disorders: consensus statement. J Vasc Surg 40(6):1248–52,
Paper presented at the Journal of Vascular Surgery: official publica-
tion, the Society for Vascular Surgery [and] International Society for
Cardiovascular Surgery, North American Chapter
30. Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA,
Gillespie D, Meissner MH, Rutherford RB, Group AVFAHOW
(2010) Revision of the venous clinical severity score: venous out-
comes consensus statement: special communication of the American
Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg
52(5):1387–1396. doi:10.1016/j.jvs.2010.06.161
31. Garratt AM, Macdonald LM, Ruta DA, Russell IT, Buckingham JK,
Krukowski ZH (1993) Towards measurement of outcome for patients
with varicose veins. Qual Health Care 2(1):5–10
32. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L (2003)
Evaluation of outcomes in chronic venous disorders of the leg:
development of a scientifically rigorous, patient-reported measure
of symptoms and quality of life. J Vasc Surg 37(2):410–419. doi:
10.1067/mva.2003.152
33. Launois R, Le Moine JG, Lozano FS, Mansilha A (2011) Construc-
tion and international validation of CIVIQ-14 (a short form of
CIVIQ-20), a new questionnaire with a stable factorial structure. Qual
Life Res : Int J Qual Life Asp Treat, Care Rehab. doi:10.1007/
s11136-011-0008-3
34. Launois R, Reboul-Marty J, Henry B (1996) Construction and vali-
dation of a quality of life questionnaire in chronic lower limb venous
insufficiency (CIVIQ). Qual Life Res : Int J Qual Life Asp Treat,
Care Rehab 5(6):539–554
35. Guex JJ, Zimmet SE, Boussetta S, Nguyen C, Taïeb C (2007)
Construction and validation of a patient-reported outcome dedicated
to chronic venous disorders: SQOR-V (specific quality of life and
outcome response - venous). J Mal Vasc 32(3):135–147. doi:10.
1016/j.jmv.2007.05.004
36. Guex JJ, Zimmet SE, Boussetta S, Taieb C (2010) SQOR-V: a
patient reported outcome specifically dedicated to chronic
venous disorders. In: Preedy V, Watson R (eds) Handbook
of disease burdens and quality of life measures. Springer,
New York, pp 161–177
37. Guex J-J, Rahhali N, Taïeb C (2010) The patient’s burden of chronic
venous disorders: construction of a questionnaire. Phlebology 25(6):
280–285. doi:10.1258/phleb.2010.010039
38. Dolan P (1997) Modeling valuations for EuroQol health states. Med
Care 35(11):1095–1108
39. van den Boezem PB, Klem TMAL,Wittens CHA, d’Armandville EC
(2011) Themanagement of superficial venous incompetence. BrMed
J 343:d4489. doi:10.1136/bmj.d4489
40. Elias S, Raines JK (2012) Mechanochemical tumescentless
endovenous ablation: final results of the initial clinical trial. Phlebol-
ogy 27(2):67–72. doi:10.1258/phleb.2011.010100
41. van den Bos RR, Milleret R, NeumannM, Nijsten T (2011) Proof-of-
principle study of steam ablation as novel thermal therapy for saphe-
nous varicose veins. J Vasc Surg 53(1):181–186. doi:10.1016/j.jvs.
2010.06.171
42. Almeida JI, Javier JJ, Mackay EG, Bautista C, Proebstle T (2012)
Cyanoacrylate glue great saphenous vein ablation: preliminary 180-
day follow-up of a first-in-man feasibility study of a no-compression-
no-local-anesthesia technique. J Vasc Surg 55(1):297. doi:10.1016/j.
jvs.2011.11.008
43. Perkins JMT (2009) Standard varicose vein surgery. Phlebology
24(Suppl 1):34–41. doi:10.1258/phleb.2009.09s004
44. Breuninger H (2001) Cryostripping of the long saphenous vein with a
percutaneously guided probe. Dermatol Surg 27(6):545–548. doi:10.
1046/j.1524-4725.2001.00194.x
45. Disselhoff BCVM, Buskens E, Kelder JC, der Kinderen DJ, Moll FL
(2009) Randomised comparison of costs and cost-effectiveness of
cryostripping and endovenous laser ablation for varicose veins: 2-
year results. Eur J Vasc Endovasc Surg 37(3):357–363. doi:10.1016/
j.ejvs.2008.11.013
46. Pittaluga P, Chastanet S, Locret T, Barbe R (2010) The effect of
isolated phlebectomy on reflux and diameter of the great saphenous
vein: a prospective study. Eur J Vasc Endovasc Surg 40(1):122–128.
doi:10.1016/j.ejvs.2010.03.031
47. Oriol Parés J, Juan J, Tellez R, Mata A, Moreno C, Quer FX, Suarez
D, Codony I, Roca J (2010) Varicose vein surgery: stripping versus
the CHIVA method: a randomized controlled trial. Ann Surg 251(4):
624–631. doi:10.1097/SLA.0b013e3181d0d0a3
48. Gohel MS, Davies AH (2008) Choosing between varicose vein
treatments: looking beyond occlusion rates. Phlebology 23(2):51–
52. doi:10.1258/phleb.2008.081000
49. Gohel MS, Davies AH (2008) Varicose veins: highlighting the con-
fusion over how and where to treat. Eur J Vasc Endovasc Surg 36(1):
107–108. doi:10.1016/j.ejvs.2008.03.010
50. Doganci S, Demirkilic U (2010) Comparison of 980 nm laser and
bare-tip fibre with 1470 nm laser and radial fibre in the treatment of
great saphenous vein varicosities: a prospective randomised clinical
trial. Eur J Vasc Endovasc Surg 40(2):254–259. doi:10.1016/j.ejvs.
2010.04.006
Lasers Med Sci
51. Carradice D, Mazari FAK, Mekako A, Hatfield J, Allgar V, Chetter
IC (2010) Energy delivery during 810 nm endovenous laser ablation
of varicose veins and post-procedural morbidity. Eur J Vasc
Endovasc Surg 40(3):393–398. doi:10.1016/j.ejvs.2010.04.010
52. Fuller WR, Raiti M, Bush RG (2011) Modelling of heat conduction
along vein walls in endovenous laser treatment. Internet J Bioeng 5(1)
53. van der Geld CWM, van den Bos RR, van Ruijven PWM, Nijsten T,
Neumann HAM, van Gemert MJC (2010) The heat-pipe resembling
action of boiling bubbles in endovenous laser ablation. Lasers Med
Sci 25(6):907–909. doi:10.1007/s10103-010-0780-2
54. Fan C-M, Rox-Anderson R (2008) Endovenous laser ablation: mech-
anism of action. Phlebology 23(5):206–213. doi:10.1258/phleb.
2008.008049
55. Shepherd AC, Gohel MS, Brown LC, Metcalfe MJ, Hamish M,
Davies AH (2010) Randomized clinical trial of VNUS ClosureFAST
radiofrequency ablation versus laser for varicose veins. Br J Surg
97(6):810–818. doi:10.1002/bjs.7091
56. Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklöf
B (2011) Randomized clinical trial comparing endovenous laser
ablation, radiofrequency ablation, foam sclerotherapy and surgical
stripping for great saphenous varicose veins. Br J Surg 98(8):1079–
1087. doi:10.1002/bjs.7555
57. Nordon IM, Hinchliffe RJ, Brar R, Moxey P, Black SA, Thompson
MM, Loftus IM (2011) A prospective double-blind randomized
controlled trial of radiofrequency versus laser treatment of the great
saphenous vein in patients with varicose veins. Ann Surg 254(6):
876–81. doi:10.1097/SLA.0b013e318230af5a
58. Lane TRA, Shepherd AC, Davies AH (2012) It matters not a jot or
tittle which method is used to thrombose the superficial varicose vein
by heat—the result is the same. In: Greenhalgh RM (ed) Vascular and
endovascular controversies update, 34th edn. BIBA Medical, Lon-
don, pp 546–552
59. Ratcliffe J, Brazier JE, Campbell WB, Palfreyman S, MacIntyre JB,
Michaels JA (2006) Cost-effectiveness analysis of surgery versus
conservative treatment for uncomplicated varicose veins in a ran-
domized clinical trial. Br J Surg 93(2):182–186. doi:10.1002/bjs.
5263
60. Michaels JA, Campbell WB, Brazier JE, Macintyre JB, Palfreyman
SJ, Ratcliffe J, Rigby K (2006) Randomised clinical trial, observa-
tional study and assessment of cost-effectiveness of the treatment of
varicose veins (REACTIV trial). Health Technol Assess 10(13):1–
196, iii-iv
61. Subramonia S, Lees T (2010) Randomized clinical trial of
radiofrequency ablation or conventional high ligation and stripping
for great saphenous varicose veins. Br J Surg 97(3):328–336. doi:10.
1002/bjs.6867
62. Subramonia S, Subramonia S, Lees T, Lees T (2010) Radiofrequency
ablation vs conventional surgery for varicose veins—a comparison of
treatment costs in a randomised trial. Eur J Vasc Endovasc Surg
39(1):104–111. doi:10.1016/j.ejvs.2009.09.012
63. Gohel MS, Epstein DM, Davies AH (2010) Cost-effectiveness
of traditional and endovenous treatments for varicose veins.
Br J Surg 97(12):1815–1823. doi:10.1002/bjs.7256, discussion
1823–1814
64. Eidson JL, Atkins MD, Bohannon WT, Marrocco CJ, Buckley CJ,
Bush RL (2011) Economic and outcomes-based analysis of the care
of symptomatic varicose veins. J Surg Res 168(1):5–8. doi:10.1016/j.
jss.2010.12.027
Lasers Med Sci
Original article
Management of chronic venous disease
by primary care
T R A Lane*, K Sritharan*, J R Herbert†, I J Franklin* and A H Davies*
*Academic Section of Vascular Surgery, Division of Surgery and Cancer, Imperial College School of Medicine,
Charing Cross Hospital; †Department of Primary Care and Public Health Faculty of Medicine, Imperial College,
London, UK
Abstract
Objective: To assess the patterns of referral for chronic venous disease (CVD).
Method: General practitioners (GPs) were invited by an email to complete a validated online
survey evaluating the referral and community management of CVD.
Results: A total of 138 participants were recruited. Most GPs (85%) saw fewer than 50
patients with CVD a year. Thirty-one percent were aware of National Institute for Clinical
Excellence referral guidelines for CVD and 36% were aware of and agreed with local
referral guidelines. Eleven percent were aware of clinical venous scoring systems. Sixty-
three percent believed mild CVD would progress and 84% believed treatment would
improve the quality of life. Sixteen referred C3 disease, 43% C4, 37% C5 and 65% C6
disease. Forty-one percent would refer on request. Pain symptoms increased referral in C2
disease. Endothermal ablation was believed available to 33% and traditional stripping to
62% and 27% were unaware of the treatment options. Forty-five percent were happy to
provide postoperative care.
Conclusions: Despite national guidelines, the management of CVD in the UK is variable.
Keywords: varicose veins; referral patterns; primary care; chronic venous disease
Introduction
Chronic venous disease (CVD) is extremely
common, affecting 25–50% of the population.1–3 It
is associated with a high level of morbidity and
socioeconomic cost, and accounts for 2% of the
National Health Service (NHS) budget per year.4
Ulceration is the endpoint of venous disease and
alone consumes 1% of the NHS budget. Varicose
vein intervention is common and over 37,000 treat-
ments are performed each year in the NHS.5
Symptoms from varicose veins can vary widely;
however, significant swelling, prominent varicos-
ities, itching and pain are common.6 The treatment
of varicose veins has advanced considerably in the
past 15 yearswith the advent of endovenous ablation,
regional or local anaesthetic for open surgery and an
increased interest in foam sclerotherapy.7,8–10 Exten-
sive work has shown the cost-effective nature of
intervention11,12 and a poor compliance of patients
with stockings, which ranges between 18% and
25%.13,14 Minimally invasive treatments now can
provide large quality of life improvements at a
low cost.7,11
General practitioners (GPs) are the gatekeepers to
secondary care in the UK. Standard GP training,
however, does not include any formal teaching on
CVD and GPs have variable exposure to the surgical
specialties during their medical training.15 GP
traineesdo thoughundergo an extensive apprentice-
ship with GP trainers and will cover such topics
during this period. Interestingly, work by Chassany
et al.16 demonstrated the disparity between patient-
reported and GP-reported symptom severity with
GPs routinely reporting lower levels of pain and
quality-of-life impairment compared with patients.
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Conway et al.17 have also shown that patient reported
symptoms are unreliable compared with standar-
dized questionnaires due to the subjectivity of symp-
toms.
In order to aid GPs in the management and refer-
ral of CVD, extensive guidelines have been devel-
oped in the UK by the National Institute for
Clinical Excellence (NICE)18 and more recently by
the Royal Society of Medicine’s Venous Forum.19
In the USA, guidelines on management of CVD
patients have also been created.20 In order to stratify
CVD, various clinical scoring systems have also
been developed and validated, such as VCSS
(Venous Clinical Severity Score).21,22 Despite the
existence of guidelines and scoring systems, the
treatment of varicose veins has been classified and
is viewed of low clinical value,23 leading to the cre-
ation of disparate and confusing local guidelines
and these are often in contention with national
guidelines.
GPs are now also expected to perform routine
postoperative follow-up for surgical procedures,
such as varicose veins and hernia repairs,24
without appropriate remuneration or support. Pre-
vious work25 surveying patients, GPs and surgeons
after postoperative outpatient attendance found
that in the context of benign general surgical
disease, 95% of patients found follow-up specialist
consultations useful, and only 49% would prefer
to see their GP. Importantly, management was
changed by the specialist in 44% of cases. Preference
for specialty follow-up was mirrored in a similar
study by Frew et al.26 in cancer patients.
The aim of this study was to assess patterns of
referral and the management of CVD in primary
care in the UK.
Methods
Following ethical review and categorization as
service evaluation by the local ethical subcommit-
tee, a 23-question electronic survey was created
which assessed different aspects of CVD manage-
ment and treatment pathways. The questionnaire
was tested and validated for content and construct
by GPs and vascular surgeons, with internal, exter-
nal and independent assessors as previously
described by other authors.27 In England there are
approximately 34,101 GPs. Invitations to complete
the survey were sent via email to an estimated 300
GPs throughout England (http://kwiksurveys.
com?u=gpvaricoseveins), at random using local
and national mailing lists. Please see Appendix 1
for the complete survey. Responses were collated
by the survey server (KwikSurveys, Dover, UK)
over a six-month period and results were analysed
using Microsoft Excel 2011 (Microsoft Corporation,
Redmond, WA, USA) and GraphPad Prism (Graph-
Pad Software Inc., La Jolla, CA, USA) software.
Results
A total of 138 completed responses were received,
representing a response rate of 46%. All received
surveys were analysed and none were excluded.
Cases seen
The vast majority of GPs (85%, P, 0.001) stated
that they saw less than 50 patients with varicose
veins per annum, which is an average of less than
one per week. Seventy-eight percent managed
CVD patients conservatively in the community,
with one providing treatment with sclerotherapy.
If specialist care was required most GPs (78%, P,
0.001) referred to a vascular surgeon, 10% to a
general surgeon and 11% to a vascular nurse
specialist.
Reasons for referral
In all, 40% of GPs would refer a patient at their
request and 10% for cosmesis, 43% for venous
skin changes and 58% for pain (see Figure 1).
Available treatments
Figure 2 demonstrates which treatments GPs
believe are available to their patients. Thirty-three
percent believed that endovenous treatments were
available in their locality, but a surprisingly low
Figure 1 Reasons for referral from primary care (% of GPs). GP,
general practitioner
Original article T R A Lane et al. Referral patterns for chronic venous disease
300
Phlebology 2013;28:299–304
figure of 60% believed traditional open surgery to
be available as a treatment option, despite its
usually universal availability (P, 0.001).
Guidelines and scoring systems
Only one-third of GPs (31% versus 69%, P, 0.001)
were aware of the NICE Referral Guidelines (pub-
lished in 2001) for CVD. Sixty-one percent were
aware of local Primary Care Trust (PCT) referral
guidelines, but only 36% agreed with these guide-
lines. Twenty-six percent of GPs said that they
were aware of NICE Treatment Guidelines;
however, these guidelines do not actually exist.
Local PCT guidelines do exist and 41% of GPs
were aware of these, although again only 26%
agreed with them. Eleven percent were aware of
clinical scoring systems and 89% were not (P,
0.001).
How to manage CVD
Overall, for patients with varicose veins, 62% of all
treatment was conservative with reassurance (15%),
compression hosiery (38%) or compression banda-
ging (10%). Twenty-nine percent of patients would
be referred to a specialist and 8% would undergo
further investigation prior to referral. One GP
would treat varicose veins with sclerotherapy in
the community. Fifty-three percent of GPs would
refer active ulceration (C6), and 41% venous skin
changes (C4). Pain symptoms would increase the
referral rate for CEAP (clinical, aetiological, ana-
tomical and pathological elements) clinical stage
C2 disease from 2% to 24% (P, 0.001) and from
20% to 55% for C3 disease (P, 0.001). Pain is not
a discriminator in national guidelines.
Role of intervention
Figure 3 illustrates how GPs determined whether
there was a role for intervention using sample
cases. Pain appeared to be the most important
factor in this decision with 16% agreeing that
CEAP class C2a (asymptomatic) warranted inter-
vention but with pain (C2s) the referral rate
increased to 71% (P, 0.001). In patients with leg
swelling and varicose veins (C3), 42% of GPs felt
that pain-free patients should have treatment com-
pared with 83% if patients also had pain (P,
0.001). Interestingly, only 62% of GPs believed that
venous skin changes warranted intervention. More-
over, only 78% believed venous ulceration required
Figure 2 Interventions believed available (% of GPs). GP, general
practitioner; RFA, radiofrequency ablation; EVLA, endovenous laser
ablation
Figure 3 Role of intervention in example cases (% of GPs). GP, general practitioner
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intervention compared with 8% who did not and
14% were unsure (P, 0.005).
Progression, quality of life and cost-effectiveness
Sixty-four percent of GPs believed that mild CVD
would progress to severe disease, compared with
36% who did not (P, 0.001). Eighty-four percent
of GPs thought that treating varicose veins would
improve a patient’s quality of life, and only 26%
felt that it was not a cost-effective use of NHS
resources. The majority (75%) believed that CVD
for the purpose of improving quality of life could
be managed conservatively.
Free of charge treatment
Figure 4 shows which treatments GPs felt should be
provided free of charge on the NHS. Interestingly
11% of GPs believed that CEAP class C2a (visible
but asymptomatic veins) should be treated free of
charge and 8% were unsure. As CEAP class
increased the proportion favouring free treatment
also increased. Once again the onset of pain vastly
increased the favour for free treatment.
Follow-up and ‘Me Too’?
Forty-five percent of GPs were happy to provide
aftercare for varicose vein intervention, and 8%
felt that no follow-up was required.
In the ‘Me Too’ question, 71% of GPs stated they
would like invasive treatment if they have varicose
veins, with none wanting traditional open surgery.
Discussion
The management of CVD is a common scenario
encountered in general practice. The important
aim of treatment is to avoid ulceration. From our
results, it is evident that there is no clear consensus
on the management of CVD in the community.
While the majority of patients are no doubt
treated appropriately, there is a reticence of
primary care fund holders to allow referral for inva-
sive treatment and consequently the burden of
disease remains widespread. From our study, the
treatment options also appear not to be universally
available and in addition, there is patchy GP aware-
ness of their availability.
Interestingly, GPs saw relatively few patients
with CVD – with a 25–50% prevalence the
average GP practice should have 1600–3200
patients with the condition.28 This is likely due to
a combination of public and medical ignorance of
the benefits of treatment.
What has become clear from this survey is that
the CVD knowledge base of GPs is limited due to
both a lack of exposure to the condition in their
training and recent treatment progress. The
number of GPs unaware of classification criteria,
local and national guidelines, and the treatment
options available demonstrates this. A substantial
portion of GPs were also unsure of the benefits of
treatment on a patient’s quality of life (11%),
disease progression (23%) or on cost-effectiveness
of treatment (34%), despite extensive literature
published on these areas in the last two decades.
Our results would also suggest that follow-up
should be with the treating physicians, and 92%
of GPs felt that this was required, with only
45% were happy to provide postoperative care
themselves.
National advice for referral for patients with CVD
recommends referral to a specialist if there is
quality-of-life detriment from prominent varicos-
ities, not for cosmetic reasons or pain specifically.
A key finding of the study is that pain is the main
discriminator for patients being referred to second-
Figure 4 Should treatment be free of charge on the NHS? (% of GPs). GP, general practitioner; NHS, National Health Service
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ary care. While this is unsurprising, as patients will
not attend without symptoms, our study also
demonstrates that only about one third of GPs
were aware of the NICE Referral Guidelines and
that among them only about one-third agreed
with these guidelines. Crucially, 71% of GPs felt
that C2 disease with pain (prominent varicose
veins) should have intervention compared with
63% (NS) who thought that venous skin changes
warranted treatment. This is concerning as the treat-
ment of C4 disease is vital in the prevention of
venous ulceration. Moreover, CVD intervention is
far quicker and cheaper than ulcer treatment.
In an era of austerity and primary and secondary
care commissioning, there must be improved dis-
course between venous specialists and primary
care physicians. This must include mutual edu-
cation sessions in order to disseminate recent
advances. Surgical exposure in GP training is
limited and topics such as venous disease are
taught during an 18-month mentorship with GP
trainers. It would therefore be prudent to encourage
careful updating of these experienced GP trainers
by the specialists to whom they refer.
This study is limited by two main factors –
numbers and participants. There are approximately
34,101 GPs in England. It was not feasible to contact
all GPs and therefore a representative sample of
approximately 300 GPs was sought. The study
additionally suffers from responder-bias, as those
GPs willing to respond to the study are likely to
be more engaged with local PCTs and commission-
ing services. They are also more likely to
keep abreast of current treatments. Despite this
the disparity between guidelines and practice was
significant.
Conclusion
Despite clear national guidance and advice, referral
and treatment patterns are extremely hetero-
geneous. This is the driving force behind the formu-
lation of the various guidance documents available.
CVD education is also lacking from GP training
programmes despite CVD being a common
condition, and venous specialists should aim to
aid the lifelong learning needs for new and
mature GP colleagues. For the benefit of our
patients improved communication with GPs will
lead to better patient care. We suggest that this
should be sought at a local level with the develop-
ment of clearer lines of feedback between primary
and secondary care.
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Original Article
Comparison of disease-specific quality of
life tools in patients with chronic venous
disease
Mong-Loon Kuet, Tristan RA Lane, Muzaffar A Anwar and
Alun H Davies
Abstract
Objectives: Quality of life (QoL) is an important outcome measure in the treatment for chronic venous disease. The
Aberdeen Varicose Vein Questionnaire (AVVQ) and the ChronIc Venous Insufficiency quality of life Questionnaire
(CIVIQ-14) are two validated disease-specific QoL questionnaires in current use. The aim of this study is to evaluate
the relationship between the AVVQ and the CIVIQ-14 to enable better comparison between studies and to compare
these disease-specific QoL tools with generic QoL and clinician-driven tools.
Methods: Adults attending our institution for management of their varicose veins completed the AVVQ, CIVIQ-14 and
EuroQol-5D (EQ-5D). Clinical data, CEAP classification and the Venous Clinical Severity Score (VCSS) were collected.
The relationship between the AVVQ and CIVIQ-14 scores was analysed using Spearman’s correlation. The AVVQ and
CIVIQ-14 scores were also analysed with a generic QoL tool (EQ-5D) and a clinician-driven tool, the VCSS.
Results:One hundred patients, mean age 57.5 (44 males; 56 females), participated in the study. The median AVVQ score
was 21.9 (range 0–74) and the median CIVIQ-14 score was 30 (range 0–89). A strong correlation was demonstrated
between the AVVQ and CIVIQ-14 scores (r¼ 0.8; p< 0.0001). Strong correlation was maintained for patients with C1-3
disease (r¼ 0.7; p< 0.0001) and C4-6 disease (r¼ 0.8; p< 0.0001). The VCSS correlated strongly with the AVVQ and
CIVIQ-14 scores (r¼ 0.7; p< 0.0001 and r¼ 0.7; p< 0.0001, respectively). Both the AVVQ and CIVIQ-14 scores
correlated well with the EQ-5D score (r¼"0.5; p< 0.0001 and r¼"0.7; p< 0.0001, respectively).
Conclusions: This study demonstrates that there is good correlation between two widely used varicose vein specific
QoL tools (AVVQ and CIVIQ-14) across the whole spectrum of disease severity. Strong correlation exists between
these disease-specific QoL tools and generic and clinician-driven tools. Our findings confirm valid comparisons between
studies using either disease-specific QoL tool.
Keywords
Varicose veins, chronic venous disease, patient-reported outcome measures, quality of life, Aberdeen Varicose Vein
Questionnaire, Chronic Venous Insufficiency Quality of life Questionnaire
Introduction
The introduction of endovenous treatments has her-
alded new advances in the management of chronic
venous insuﬃciency over the past decade.1 Key to
understanding the burden of venous disease and the
long-term eﬃcacy of newer endovascular approaches
is the use of outcome measures relevant to the func-
tional status of the patient.
Traditional objective measures of disease severity
that focus on the morbidity and mortality of venous
disease, whilst readily quantifiable, do not necessarily
correlate with the functional status of the patient. To
meaningfully capture outcomes in venous disease, the
full biopsychosocial consequence of the disease must
also be established.2 As the role for patient-centred
care in venous disease increases, the assessment of qual-
ity of life (QoL) in venous disease is becoming
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increasingly important. Currently, there are a wide
variety of validated outcome measures in use and
these can be divided into generic and disease-specific
QoL tools.
Generic QoL instruments permit a patient’s overall
functional status to be measured regardless of their spe-
cific disease state and thus have the advantage of allow-
ing comparison across diﬀerent studies of diﬀerent
diseases. The EuroQol 5 Domain score (EQ-5D) is a
well-validated generic QoL score.3 Disease-specific QoL
tools directly assess attributes related to a particular
disease. They are increasingly becoming utilized in the
study of varicose veins as they are more sensitive for
assessing venous disease outcomes. The Aberdeen
Varicose Vein Questionnaire4 (AVVQ) and the
ChronIc Venous Insuﬃciency quality of life
Questionnaire5 (CIVIQ) are two validated disease-spe-
cific QoL questionnaires most commonly used. Other
examples of disease-specific QoL tools include the
Charing Cross Venous Ulceration Questionnaire
(CXVUQ),6 the Venous Insuﬃciency Epidemiological
and Economic Study instrument (VEINES)7 and the
Specific Quality of Life and Outcome Response-
Venous questionnaire (SQOR-V).8
In a joint statement by the American Venous Forum
and the Society of Interventional Radiology, the use of
both disease-specific and generic QoL tools in conjunc-
tion with clinician-driven assessment is recommended
in all clinical trials investigating venous insuﬃ-
ciency.9,10 There are significant diﬀerences in the
choice of QoL tools amongst studies, making it challen-
ging for the clinician to make direct comparisons
between studies.11 Therefore, the correlation between
diﬀerent QoL tools is of huge significance if clinicians
are to make valid comparisons between studies.
However, at present the relationship between the vari-
ous QoL tools has not been fully characterized. The
aim of this study is to evaluate the relationship between
two disease-specific QoL tools; the extensively validated
AVVQ and more recently validated CIVIQ-14, to
enable better comparison between studies and to com-
pare these tools with generic QoL tools and clinician-
driven tools.12
Methods
Patient selection
Adult patients attending the vascular surgery out-
patient clinic at our Institution for management of
their varicose veins were prospectively invited to par-
ticipate in this study. Patients were recruited over a
four-month period, from August 2012 to December
2012 in a consecutive manner. Demographic data
including patient age and gender were collected.
All participants were asked to complete the two dis-
ease-specific QoL tools, the AVVQ and CIVIQ-14,
prior to their outpatient appointment. The AVVQ con-
sists of 13 questions addressing various biopsychosocial
attributes of chronic venous disease, including specific
signs and symptoms, use of compression stockings and
daily functional impact.13 The overall score ranges
from 0 to 100, with a higher score denoting greater
burden of disease. The CIVIQ-14 is a revised version
of the well-validated CIVIQ-20 instrument and has
been shown to be valid in studies of patients across
diﬀerent countries.2,5 The CIVIQ-14 contains 14 ques-
tions covering three QoL dimensions: physical, pain
and psychological and is scored from 0 to 100, with a
higher score denoting a lower QoL.
Patients also completed the EuroQol-5D question-
naire (5-level version of the EQ-5D, EuroQoL Group,
Rotterdam, the Netherlands).3,14 The EQ-5D measures
the biological, psychological and social aspects of a dis-
ease state to generate an overall score.
The clinical severity of venous disease for each patient
was stratified by a single clinician using the following clin-
ician-driven tools: the Clinical Etiologic Anatomic
Pathophysiologic (CEAP) score15 and the revised
Venous Clinical Severity Score12 (VCSS). The VCSS com-
prises nine characteristics of venous disease and each com-
ponent is scored independently on a scale from 0 to 3.
Statistical analysis
Outcomes were scored for each patient. In cases of
bilateral venous disease, scores were recorded for each
leg and the score of the worst leg was used. Statistical
analysis was performed using Prism 5.0a (GraphPad
Software, Inc, La Jolla, CA). The relationship between
the AVVQ and CIVIQ-14 scores was analysed using
Spearman’s correlation for nonparametric data.
Correlation was also analysed separately for patients
with less severe (C1-3) disease and more severe (C4-6)
disease.
The AVVQ and CIVIQ-14 scores were analysed
against the EQ-5D and EQ-VAS. Both the AVVQ
and CIVIQ-14 were analysed against the VCSS.
Spearman’s correlation was used to assess the relation-
ship for each analysis, and p values less than 0.05 were
considered statistically significant.
Results
Patient demographics
Over a four-month period between August 2012 and
December 2012, fully complete questionnaires were col-
lected for 100 patients. There were 44 males (44%) and
56 females (56%). The mean age of participants was
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57.5 years (range 22–84 years); 50% of patients were
aged 65 years and over. The median AVVQ score was
21.9 (range 0–74; IQR 13.3–30.7) and the median
CIVIQ-14 score was 30 (range 0–89; IQR 17.6–46).
Relationship between disease-specific QoL tools
(AVVQ and CIVIQ-14) and EQ-5D
The EQ-5D score demonstrated a strong negative cor-
relation with both the AVVQ (Figure 1(a)) and CIVIQ-
14 scores (Figure 1(b)) (r¼"0.5; p< 0.0001 and
r¼"0.7; p< 0.0001, respectively).
Relationship between disease-specific QoL tools
(AVVQ and CIVIQ-14) and VCSS
There was a strong positive correlation between
the VCSS and both the AVVQ (Figure 2(a)) and
CIVIQ-14 scores (Figure 2(b)) (r¼ 0.7; p< 0.0001 and
r¼ 0.7; p< 0.0001, respectively).
Relationship between the AVVQ and CIVIQ-14
Strong positive correlation was seen between the
AVVQ and CIVIQ-14 scores (r¼ 0.8; p< 0.0001)
(Figure 3(a)). Strong correlation was maintained
for patients with C1-3 disease (r¼ 0.7; p< 0.0001)
(Figure 3(b)) and C4-6 disease (r¼ 0.8; p< 0.0001)
(Figure 3(c)).
Discussion
Measurement of QoL is now common place in studies
of chronic venous disease. Over the past decade, there
has been increasing recognition amongst phlebologists
that disease-specific QoL tools provide a more
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Figure 2. Graphs demonstrating the relationship between the VCSS and: (a) the AVVQ score (r¼ 0.7; p< 0.0001); (b) the CIVIQ-14
score (r¼ 0.7; p< 0.0001).
VCSS: venous clinical severity score; AVVQ: Aberdeen varicose vein questionnaire; CIVIQ: chronic venous insufficiency quality of life
questionnaire.
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Figure 1. Graphs demonstrating the relationship between the EQ-5D score and: (a) the AVVQ score (r¼"0.5; p< 0.0001);
(b) the CIVIQ-14 score (r¼"0.7; p< 0.0001).
AVVQ: Aberdeen varicose vein questionnaire; CIVIQ: chronic venous insufficiency quality of life questionnaire.
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meaningful correlate of a patent’s functional status
than objective anatomical or haemodynamic outcome
measures.16,17 Reporting guidelines published by the
American Venous Forum now recommend the use of
disease-specific and generic QoL tools along with clin-
ician-driven outcome measures in studies of chronic
venous disease.9,10 In 2005, a review commissioned by
the United Kingdom Department of Health recom-
mended the routine use of patient-reported outcome
measures after intervention for venous disease.18,19
The choice of disease-specific QoL questionnaire is
crucial to permit both the evaluation of the eﬃcacy of
current endovenous treatments and valid comparison
of results from diﬀerent trials. Currently, there are a
number of diﬀerent disease-specific and generic QoL
tools and clinician-driven tools being utilized in studies
of chronic venous disease.11,20 The AVVQ and CIVIQ-
14 were chosen for evaluation in this study. The AVVQ
is a commonly used validated disease-specific QoL tool
that has been shown to be sensitive in assessing func-
tional outcome after treatment for chronic venous dis-
ease.21 The CIVIQ-14 was recently developed as a more
stable version of the CIVIQ-20 instrument, which itself
has been commonly used and validated since 1996.2,5,22
This study has established that a strong correlation
exists between the two disease-specific QoL tools
selected for evaluation, the AVVQ and CIVIQ-14, fur-
ther demonstrating that these disease-specific question-
naires are useful tools in the assessment of QoL in
chronic venous disease. The findings from this study
show that the relationship between the AVVQ and
CIVIQ-14 scores are predictable, thereby supporting
the validity of making comparisons between studies
regardless of whether the study has utilized the
CIVIQ-14 or AVVQ QoL tool. The AVVQ diﬀers in
several aspects from the CIVIQ-14 questionnaire. In
comparison with the CIVIQ-14, the AVVQ assigns a
greater proportion of questions to the physical aspects
of chronic venous disease. The CIVIQ-14 is validated
for the entire spectrum of chronic venous disease,5
except venous ulcers, whilst the AVVQ specifically tar-
gets varicose veins and includes ulceration.4 Despite
these diﬀerences, the current study shows that the two
QoL tools closely correlate, and the correlation is main-
tained across the spectrum of disease severity, from less
severe (C1-3) to more severe disease (C4-6).
Our findings have expanded on the findings of
Shepherd et al.16 who found that the AVVQ correlated
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Figure 3. Graphs demonstrating the relationship between AVVQ and CIVIQ-14 scores for: (a) CEAP 1-6 disease (r¼ 0.8;
p< 0.0001); (b) CEAP 1-3 disease (r¼ 0.7; p< 0.0001) and (c) CEAP 4-6 disease (r¼ 0.8; p< 0.0001).
AVVQ: Aberdeen varicose vein questionnaire; CIVIQ: chronic venous insufficiency quality of life questionnaire; CEAP: clinical etiologic
anatomic pathophysiologic.
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strongly with another disease-specific QoL tool, the
SQOR-V questionnaire. The degree of correlation
(Spearman coeﬃcient 0.702) was similar to our findings
(Spearman coeﬃcient 0.8). Both the SQOR-V8 and
CIVIQ-14 place a greater emphasis on patient-reported
symptoms rather than physical signs and this may in
part explain the comparable degree of correlation.
Other types of outcome measures utilized to assess
chronic venous disease were also shown in this study to
correlate with the AVVQ and CIVIQ-14 QoL tools.
The study evaluated a generic QoL questionnaire, the
EQ-5D, which was shown to correlate strongly with
both of the disease-specific QoL tools. This is in con-
trast to findings from previous studies, which have
compared diﬀerent generic QoL questionnaires with
disease-specific QoL questionnaires. Shepherd et al.16
found that the AVVQ only correlated weakly with a
generic QoL tool, the Short Form-12 (SF-12) question-
naire. The reasons for the diﬀerences in our findings are
not immediately clear, but may be attributed to the
diﬀerence in construction of health profile-based ques-
tionnaires (Short Form series) and preference-based
questionnaires (EQ-5D).23
This study also evaluated a clinician-completed
assessment tool (VCSS) against the AVVQ and
CIVIQ-14. A very strong correlation was found
between the clinical scoring system and both of the
disease-specific QoL tools. This relationship highlights
the sensitivity of the AVVQ and CIVIQ-14 towards the
physical aspects of QoL in chronic venous disease. Our
results strongly reinforce the findings by Carradice
et al.24, which also found that increasing venous disease
severity was associated with poor disease-specific and
generic QoL scores as measured by the AVVQ and EQ-
5D, respectively.
The lack of consensus on which disease-specific QoL
tool to use for measuring outcomes in chronic venous
disease has contributed to an inconsistency in the choice
of the QoL tool used in studies of venous disease.11,25
The need to make comparisons between studies using
diﬀerent outcome measures has highlighted the import-
ance of understanding the relationship between these
disease-specific QoL tools as well as the relationship
with generic QoL and clinician-driven tools.
A limitation of this study was the relatively small
number of participating patients with C1 disease. This
may limit the generalizability of our findings. The
number of patients with C1 disease treated in secondary
care is restricted due to the limitation of referrals from
primary care under the United Kingdom National
Healthcare System. In the current study, the patient
selection was performed in a consecutive manner, and
not randomized. This would have been unlikely to
impact on the results as the primary purpose of this
study was ascertain the correlation between the
CIVIQ-14 and AVVQ QoL tools rather than to com-
pare the outcomes between interventions. What
remains to be seen is the relationship of the responsive-
ness between the disease-specific QoL tools, generic
QoL tools, and clinician-completed outcome measures
several weeks post-procedure. It will be important to
see if changes in post-procedure AVVQ scores correlate
with respective changes in CIVIQ-14 scores and this
will contribute further to our understanding of these
QoL tools relative to one another. Further data
points are required to generate a reliable conversion
formula.
Conclusion
This study demonstrates that there is a strong and sig-
nificant linear correlation between two of the main dis-
ease-specific QoL tools for varicose veins (AVVQ and
CIVIQ-14) across the whole spectrum of disease sever-
ity. Strong correlation also exists between these disease-
specific QoL tools and the generic EQ-5D QoL tool as
well as the clinician-driven VCSS tool. Our findings
support the validity of comparisons of results between
studies using either the CIVIQ-14 or AVVQ disease-
specific QoL tool.
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CASE REPORTS
Cyanoacrylate glue for the treatment of great
saphenous vein incompetence in the anticoagulated
patient
Tristan R. A. Lane, MBBS, MRCS, Damian Kelleher, MBBS, FRCS, Hayley M. Moore, MBBS, MRCS,
Ian J. Franklin, MS, FRCS, and Alun H. Davies, DM, FRCS, FEBVS, FHEA, London, United Kingdom
The Sapheon Venaseal Closure System (Sapheon Inc, Santa
Rosa, Calif), using cyanoacrylate glue, has provided a new
modality of treatment, with patients treated without both
tumescent anesthesia and postoperative compression. We
present the ﬁrst case of great saphenous vein occlusion
performed using glue while the patient was fully anticoagulated
with warfarin. This was tolerated well, and the treated vein
showed complete early occlusion at 8 weeks; however at 6
months, extensive recanalization was demonstrated on duplex
imaging. (J Vasc Surg: Venous and LymDis 2013;1:298-300.)
Varicose vein treatments have advanced signiﬁcantly
during the past 10 years.1 With the development of endove-
nous ablation techniques, procedures to treat varicose veins
have become available to most patients under local anes-
thesia. These techniques offer good technical and symptom-
atic beneﬁt and reduce the risk of nerve and skin damage.2
Previously, patients with long-term anticoagulation pre-
sented a difﬁcult scenario; however, endovenous thermal
ablation and foam sclerotherapy offer minimally invasive
treatment, which is not affected by anticoagulation.3-9
Recently, new techniques have been developed that do
not require tumescent anesthesia.10,11 We present the ﬁrst
case of endovenous pharmacologic occlusion using cyano-
acrylate glue via the Sapheon Venaseal Closure System
(Sapheon Inc, Santa Rosa, Calif) while the patient was
therapeutically anticoagulated using warfarin.
CASE REPORT
A 73-year-old man presented to the Charing Cross Varicose
Vein clinic with complicated varicose vein disease of the right
leg, with recurrent bleeding from extensive varicosities. He had
a CEAP12 score of C4bS Ep As Pr, an Aberdeen Varicose Vein
Questionnaire (AVVQ)13 score of 15.44, and a Venous Clinical
Severity Score (VCSS)14 of 14. His medical history included atrial
ﬁbrillation treated with warfarin and pre-existing use of compres-
sion hosiery for varicose vein symptom control. A venous duplex
ultrasound scan revealed an incompetent deep venous system,
saphenofemoral junction (SFJ), and great saphenous vein (GSV).
The maximum diameter of the GSV was 15 mm just distal to
the SFJ.
The patient underwent right leg GSV endovenous occlusion
in March 2012 with the newly developed Sapheon Venaseal
Closure System using standard procedure as follows: The patient
was advised not to stop his warfarin anticoagulation. The interna-
tional normalized ratio at treatment was 2.3. Under local anes-
thetic, the GSV was cannulated at the knee level and a guidewire
passed into the vein. A standard 7F sheath was passed using the
Seldinger technique into the vein.
The Sapheon outer catheter was fed into the vein and placed 5
cm distal to the SFJ. The inner glue catheter was primed, leaving
a 3-cm air gap at the end of the catheter, and connected to the
application gun. The catheter was fed into the outer catheter,
and as the glue catheter reached 5 cm from the SFJ, the outer cath-
eter was withdrawn to expose the glue catheter at 5 cm from the
SFJ, and the catheters were locked together.
The proximal GSV was then occluded using transverse probe
placement 2 cm distal to the SFJ. One full 3-second activation of
the glue applicator was completed; then, the catheters were with-
drawn 1 cm, and a further application was completed without
moving the transverse probe occlusion. The catheter was with-
drawn a further 3 cm, and light minimal compression was applied
as the initial curing time of 3 minutes was completed using a stop-
watch. The rest of the GSV was treated with one application, a 3-
cm pullback, and a 30-second minimal compression time. This was
repeated to treat 35 cm of GSV.
The woundwas closed with a Steri-Strip dressing (3M, St. Paul,
Minn) and a cannulation-site plaster (Mepore; Mölnlycke Health
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Care, Gothenburg, Sweden) without sutures. The total procedure
took 20minutes, from the ﬁrst local anesthetic injection to the appli-
cation of the wound plaster, and was well tolerated by the patient.
The patient was advised to continue with class II compression
hosiery in the long term due to pre-existing mild deep venous
incompetence. There was no perioperative bleeding. Completion
duplex imaging showed GSV occlusion.
On postoperative clinical and duplex ultrasound review at 8
weeks, the GSV was occluded from the point of entry for treat-
ment to the point of compression, 2 cm distal to the SFJ. The
mild deep venous incompetence had resolved. The patient’s symp-
toms were much improved, with no further episodes of bleeding
varicosities. His lower leg varicosities had shrunk in size, and he
wanted no further treatment. Subjectively, he had experienced
no postoperative pain and no inﬂammation. His VCSS was 7
and AVVQ was 4.64, a reduction of >10 points.
At the 6-month follow-up, his VCSS was 10 and AVVQ was
25.53. His varicosities had not returned; however, signiﬁcant
edema and symptoms had recurred. On repeat venous
duplex imaging, the GSV was recanalized and incompetent
(Supplemental Video, online only), with a maximal diameter of
7.2 mm at the SFJ (Figs 1-3). Two 2-cm sections of the GSV in
the midthigh remained completely occluded. The deep venous
incompetence remained absent. Repeat treatment of the GSV
with foam sclerotherapy was arranged.
DISCUSSION
This report demonstrates the ﬁrst case of cyanoacrylate
glue GSV occlusion while a patient was formally anticoagu-
lated with warfarin. Early technical success and symptom
resolution, unfortunately, led to reopening of the treated
vein. Despite an increase in venous symptoms and an
incompetent GSV, this patient’s varicosities remained in
remission.
Because the cyanoacrylate occlusion process is separate
to the coagulation cascade, it is likely that this treatment
failure was secondary to the large vein diameter and the
learning curve associated with new procedures.15 Other
techniques have shown early-to-midterm occlusion failures,
despite experience,16-20 with previous studies highlighting
the risks of track neovascularization.21
CONCLUSIONS
This case report highlights the need for thorough
follow-up for new technologies and an understanding
that isolated cases of recanalization can occur after initial
success.
We thank Sapheon Inc for providing the Sapheon Vena-
seal Closure Device for evaluation.
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Editorial
Inferior vena cava filters: when, where, why?
Inferior vena cava (IVC) filters are believed by
many to be an effective method of preventing clot
from a lower extremity deep vein thrombosis
(DVT) travelling centrally and causing a pulmonary
emobolism (PE).1 Prior to the development of per-
cutaneous devices, open ligation/clip placement
was utilized for PE prevention.2 The potential role
of the IVC filter has been diminished by the effec-
tiveness and lowmorbidity of systemic anticoagula-
tion.3–5
The complications of vena cava filter insertion
can be significant with a mortality rate of 0.12%
reported. The common complications include
DVT, vena cava perforation, filter migration, total
occlusion due to clot despite anticoagulation and
PE despite filter placement.5,6 In the USA, IVC
filters are placed in up to 15% of all DVTs, and
indeed in 2008 over 65,000 filters were placed (20
per 100,000 population).1,4,7 In the UK, Hospital
Episode Statistics reveal that 1173 IVC filters were
placed in 2011 (2 per 100,000 population), an
increase from 532 in 2006 (1 per 100,000 popu-
lation).8,9
It is estimated that there are 466,000 cases of DVT
and 296,000 cases of PE per annum in the European
Union, with 370,000 fatal cases (150, 95 and 120 per
100,000, respectively).10 In the USA, there are an
estimated 900,000 venous thromboembolism cases,
with 300,000 fatalities from PE alone (290 and 97
cases per 100,000, respectively).11
Little evidence governs their insertion and even
less for their effectiveness.2,12 This has led to
extreme discordance between guidelines and prac-
tice.1,3,13 A disconcerting feature of the literature is
the poor rate of randomized controlled trials –
only two studies were methodologically sound
enough to be included in Young et al.’s2 Cochrane
review.
The only indications for insertion with guideline
recommendation are for cases of DVT where antic-
oagulation is contra-indicated or where there is
recurrent PE despite adequate anticoagulation.3,13
Most concerning of all is the poor rate of retrieval
of so-called ‘temporary’ filters (also known as
optional filters).This is despite the evidence that
anticoagulation need not be stopped for safe retrie-
val,14 and the development of new filter designs
which allow removal safely after some months.
Importantly, technique of insertion to achieve
accurate centre-lining is vital for removal and
haemodynamic flow.15,16
The USA data show that only 1.5–2.1% of tem-
porary filters were removed in 20081 with even pro-
spective studies displaying disappointing removal
figures of 10–70%.17–19
In the UK, the retrieval rate has improved from
13% in 2006 to 26% in 2011, though this remains
poor.9 The rate of IVC thrombosis ranges from 6–
30%. The rate of IVC thrombosis without anticoagu-
lation has been found to be as low as 0% in one
study, with the large eight-year PREPIC study
finding a rate of 13%, with only 35% of the IVC
filter undergoing long-term anticoagulation. Those
advocating placement must accept responsibility
for removal.
Trauma is a field where there is great interest in
the placement of IVC filters. Trauma patients are
often immobile and often have contraindications
to anticoagulation due to ongoing bleeding. This
has led to the development of insertion under ultra-
sound guidance at the bedside.20 However, even
here the evidence is conflicting at best: initial trials
highlight the problems with retrieval.21 and
further studies have shown the inconsistencies
with US treatment.22 Indeed, a recent study of cost-
effectiveness questioned the use of IVC filters even
in this highly selected group.23
IVC filter placement in the context of cancer
patients has been advocated in some circles,
especially when IVC manipulation is required;
however, a recent review of patients with renal
cell carcinoma undergoing resection recommended
that filters should not be placed unless the con-
ditions of contra-indicated anticoagulation or con-
tinued PE despite anticoagulation are met.24 IVC
filters are also a hazard in this and similar groups
of patients due to possibility of incorporation in
tumour thrombus and technical difficulty in
surgery secondary to the filter.
Prophylactic use of IVC filters during bariatric
surgery has also gathered interest despite studies
showing no reduction in rates of PE.25 Caution
should be used in the interpretation of small scale
studies in favour of the procedure.26,27
Thrombophilic patients remain a difficult group,
with little evidence to guide decision-making, due
to the complex nature of coagulation. There is a sig-
nificantly increased risk of IVC filter thrombosis.28
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The recent implementation of the UK Inferior
Cava Filter Registry in conjunction with the
British Society of Interventional Radiology29 has
led to improved treatment and guideline adherence
– in the latest report spanning 2008–2010, 1255 IVC
filters were placed, with 25% overall retrieval rate
(41% of temporary filters).30 This is mirrored by
work on trauma patients in the USA.
Overall it is clear that IVCfilters remain a favoured
procedure despite limited evidence of its benefits
and poor retrieval of the implanted filters. Further
high-quality randomized studies are required to
inform us of the benefits or detriments to placing
filters. Currently, the practice is unguided despite
decades of filter insertion, which it is vital to
improve.
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Varicose veins and their
management
Sarah Onida
Tristan RA Lane
Alun H Davies
Abstract
Varicose veins are a common condition, affecting up to a quarter of the UK
population. They have been shown to negatively impact on patients’ qual-
ity of life and are an important cause of morbidity. The management of
varicose veins may be conservative (including lifestyle changes and
compression hosiery) or surgical. Operative treatment aims to disconnect
the superficial and deep venous systems at the sites of venous incompe-
tence; traditionally saphenofemoral and saphenopopliteal junction liga-
tion with or without stripping were the mainstay of treatment. In the
last decade surgical treatment has been moving towards minimally inva-
sive endovascular techniques, including thermal ablation (by means of
radiofrequency, laser technology, steam), cryoablation and mechano-
chemical ablation. These are less invasive than open surgery and may
be done under local anaesthesia.
This article discusses the epidemiology, diagnosis and management of
varicose veins, including the latest endovascular and targeted open surgi-
cal techniques such as haemodynamic surgery and variceal ablation.
Keywords Ablation; cyanoacrylate; endovenous; haemodynamic; laser;
mechanochemical; radiofrequency; sclerotherapy; surgery; varicose veins
Definition
Varicose veins are a common condition affecting up to one in
four patients1; they cause significant morbidity, including
depression, and have a negative impact on patients’ quality of
life.2 They are a manifestation of chronic venous disease (CVD)
and are characterized by tortuous, dilated superficial veins more
than 3 mm in diameter. The condition can occur anywhere in the
body where there is poor venous return; however, they are most
often associated with the lower limb.
Epidemiology
Venous disease is extremely common, with similar incidences
worldwide; spider veins (fine, dilated intradermal venules
approximately 1 mm in diameter) affect up to 80% of the pop-
ulation1 and the reported incidence of varicose veins is variable,
ranging from 20 to 64%.
Risk factors associated with venous disease include previous
deep venous thrombosis (DVT), obesity, pregnancy, family his-
tory and posture (e.g. standing for long periods of time).
Although rarely life-threatening varicose veins are highly
prevalent; their treatment accounts for approximately 2% of the
total NHS budget and in 2001 an estimated £20e£25 million
(excluding non-hospital costs) was spent on varicose veins.
Varicose veins are a manifestation of CVD; in this condition
venous return is impaired secondary to reflux, obstruction or calf
muscle-pump failure. The exact aetiology is unclear. What is
known is that there is an increase in the venous pressure distally,
which leads to the cutaneous changes typical of the disease.
Primary varicosities are due to incompetence in the superficial
veins, often located at connections between the deep and superficial
systems (saphenofemoral junction (SFJ), saphenopopliteal junction
(SPJ) or perforating veins). This leads to enlarged, thin-walled veins
with incompetent valves. They most commonly occur in the great
saphenous vein (GSV) and/or small saphenous vein (SSV) distri-
bution (Figure 1), however surface examination can be misleading.
Secondary varicosities arise as a result of pathology (often in
the deep venous system) that has led to venous hypertension in
the superficial system. Examples are DVT, deep venous
incompetence, pressure on the pelvic veins from an intra-
abdominal mass, or simply obesity. The underlying pathology
is best investigated by venous duplex and ultrasound abdomen/
pelvis.
Diagnosis
Varicose veins are a significant cause of morbidity, affecting pa-
tients’ quality of life.2 Symptoms include pain, heaviness,
swelling, aching, restless legs, cramps and itching. These correlate
well with the clinical severity of the disease,2 however varicose
vein diameter does not correlatewith symptoms and quality of life.
Symptoms are exacerbated by standing stationary or long
periods sedentary and may be worse towards the end of the day.
Leg elevation helps reduce the associated swelling, whilst
walking significantly improves the symptoms, due to calf-pump
action reducing the venous pressure.
When assessing these patients, it is important to rule out other
diagnoses that may account for similar symptoms, including
arterial, neurological and musculoskeletal disease. A history of
DVT, previous leg trauma, venous surgery and a family history of
DVT and hypercoagulable states are important.
Examination
When examining the patient with varicose veins, it is important
to assess for significant complications of this disease process,
such as progressive skin changes, superficial thrombophlebitis
and bleeding varicosities.
Skin changes consist of venous eczema, lipodermatosclerosis,
haemosiderin deposition, ulceration and atrophie blanche
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(scarring at sites of previous ulceration) (Figure 2). These are
most commonly found around the malleolar, or gaiter, area.
Superficial thrombophlebitis is inflammation of the vein,
which thromboses, becoming tender and erythematous. This is
treated with non-steroidal anti-inflammatory drugs.
Large, prominent varicosities may be prone to bleeding, either
spontaneously or as a result of trauma. Rarely, this can result in
fatal haemorrhage.
The patient should be assessed initially standing, allowing the
veins to fill. A full neurovascular examination should be carried
out, paying particular attention to the assessment of the arterial
vascular system. Hand-held Doppler (HHD) may be used as an
adjunct in the clinical examination, to assess for the presence and
level of incompetence. However, it is not an accurate tool and
cannot be depended upon- at the SFJ and SPJ the reported
sensitivity has been as low as 56% and 23% respectively.
The CEAP (Clinical, Etiology, Anatomy, Pathophysiology)
classification was developed in 1994 to describe the severity and
aetiology of lower-limb venous disease. The adoption of this
system has allowed a standardized approach, enabling correla-
tion between different studies and units. (Table 1).
The venous clinical severity score (VCSS) and Aberdeen
varicose vein questionnaire are both assessment tools of venous
disease. The VCSS is clinician-completed, scoring nine hallmarks
of venous disease in order of severity from 0 to 3. The Aberdeen
questionnaire is a patient-completed quality of life (QoL)
assessment tool comprising 13 questions ranging from physical
symptoms to social effect and cosmesis. Other assessment tools
include the Chronic Venous Insufficiency Questionnaire-20
(CIVIQ-20), the Venous Insufficiency Epidemiological and Eco-
nomic Study (VEINES) Symptom and QoL assessments, the Short
Form Health Survey (SF-36, SF-12, SF-8) and the EuroQoL-5
domain survey.
Imaging
The gold-standard imaging technique is colour duplex ultra-
sound. This non-invasive dynamic imaging modality allows
assessment of the deep and superficial venous systems,
Figure 1 Varicose veins in the (a) long saphenous vein and (b) short saphenous vein distribution.
Figure 2 Venous ulceration over the medial malleolus (gaiter area).
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indicating the level of incompetence. Guidelines of the Society for
Vascular Surgery (SVS) and the American Venous Forum (AVF)
recommend that patients with varicose veins should all have
preoperative duplex ultrasound scanning.3 Venography should
be used only in cases with inconclusive duplex results.
Magnetic resonance venography (MRV) and computed
tomographic venography (CTV) are used to assess the abdominal
and pelvic veins in complex cases where the site of venous
incompetence is not in the lower limbs.
Treatment
The National Institute for Health and Clinical Excellence (NICE)
guidelines for the diagnosis and management of varicose veins
will be published in July 2013. Current guidelines recommend
NHS treatment for patients with significant complications of
varicose veins (progressive skin changes, bleeding, recurrent
thrombophlebitis) or if the symptoms are significantly affecting
their quality of life.
Over the last decade, major advances have been made in the
treatment of varicose veins, with a shift from the open tech-
niques towards minimally invasive outpatient procedures. An
ideal treatment for varicose veins should be effective, cheap,
safe, performed in day surgery, with low recurrence rates and
good clinical outcomes.
Compression hosiery
The first-line of treatment for patients with symptomatic venous
disease is compression hosiery; this has been reported in the
literature since the 1950s although compression therapy has been
used since biblical times.
The technique works by applying graded external pressure to
the skin (i.e. greatest at the ankle and reducing at the calf and
thigh) and therefore to the superficial venous system, thereby
reducing the venous reservoir in the dilated veins. Compression
also increases venous flow in the lower limbs, reducing venous
stasis and reflux. This reduction in venous pressure allows
improved capillary pressure differentials and an improved arterial
inflow. The combination of physiological effects translates into a
reduction in the symptoms of CVD and prevention of deterioration
of the skin changes associated with venous hypertension.
In the UK, there are three grades of compression hosiery with
general indications. European standard stockings utilize the RAL
testing standard and therefore provide more reliable compression
levels. There is no formula for the amount of pressure needed for
a specific symptom; however, generally the more severe the
clinical picture the higher the Class of stockings used (Table 2).
Class-II and -III compression have been shown to confer
maximum benefit in patients with varicose veins and Class-II
below-knee stockings are the most commonly prescribed.
There is, however, a lack of high-quality evidence regarding
the effect of compression hosiery on varicose veins. Studies are
heterogeneous, using different types of stockings in different
patient groups with unclear methodology. A 2009 systematic
review concluded that the evidence for the benefit of compres-
sion hosiery was equivocal.4
There is some evidence that compression hosiery may reduce
the rates of ulcer recurrence although again, comparison be-
tween studies is difficult.
Patients do report symptomatic relief after wearing compres-
sion hosiery. However, this is very subjective and the effect is
limited to the period during which the stocking is worn. In
addition, patients often find them uncomfortable, difficult to
apply and remove and cosmetically unsightly; non-adherence
rates are as high as 33%.
Importantly, good-quality stockings are expensive (£50e100 per
pair), and require the patient to wear them every day for life, with
replacements at 3e6-monthly intervals. With the average patient
attending in their 50s, this translates into a huge long-term cost.
The advantage of compression hosiery is that it has few side
effects. Risks include skin necrosis in poorly fitted stockings,
CEAP (Clinical, Etiology, Anatomy, Pathophysiology)
classification of lower venous disease
Clinical classification
C0: no visible or palpable signs of venous disease
C1: telangiectasia or reticular veins
C2: varicose veins
C3: oedema
C4a: pigmentation or eczema
C4b: lipodermatosclerosis or atrophie blanche
C5: healed venous ulcer
C6: active venous ulcer
S: symptomatic, including ache, pain, tightness, skin irritation,
heaviness, muscle cramps
A: asymptomatic
Aetiological classification
Ec: congenital
Ep: primary
Es: secondary (post thrombotic)
En: no venous cause identified
Anatomical classification
As: superficial veins
Ap: perforator veins
Ad: deep veins
An: no venous location identified
Pathophysiological classification
Pr: reflux
Po: obstruction
Pr,o: reflux and obstruction
Pn: no venous pathophysiology identifiable
Table 1
European classification of compression hosiery
Class I e 14e17 mmHg (light)
C Indication: varicose veins; mild oedema
Class II e 18e24 mmHg (medium)
C Indication: severe varicose veins; mild oedema; prevention of
ulcer recurrence
Class III e 25e35 mmHg (strong)
C Indication: severe varicose veins; post-phlebitic limb;
prevention of ulcer recurrence; chronic venous insufficiency
Table 2
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particularly in patients with diabetes or peripheral vascular dis-
ease; compression hosiery should not be used in patients with an
ankle brachial pressure index (ABPI) less than 0.9.
Despite the lack of high-quality evidence on their role in
varicose veins, these are non-invasive and cost-effective and are
advised by the SVS and AVF as initial treatment options, but
should not be used as a rationing tool.3
Sclerotherapy
The practice of sclerotherapy involves inserting a small volume
of sclerosant into a vein and applying compression, resulting in
occlusive fibrosis without clot formation. There are three kinds of
sclerosants:
! chemical irritants (chromated glycerine)
! osmotic (hypertonic saline)
! detergent (sodium tetradecyl sulphate (STS) and polido-
canol (PD)).
In the UK STS (1e3%) and PD (0.5e3%) are more widely used,
particularly for small reticular or spider veins.
Sclerotherapy was initially used in its liquid form (LS), via the
‘air-block’ technique. However, as sclerosant is deactivated by
blood contact, liquid sclerotherapy suffered poor occlusion rates
due to rapid protein binding. The practice went out of fashion
with the publication of randomized controlled studies showing
poor long-term results compared to surgery.
The advent of foam sclerotherapy (FS) has reintroduced this
practice.FSstill utilizesSTSorPDbut converts it fromits liquidphase
to foambymixing it with air. Two syringes are connected by a three-
way tap with liquid sclerosant and air (ratio 1:4). The mixture is
oscillated between them until foam is produced (Tessari technique).
The advantage of FS is increased potency of the sclerosant
(allowing smaller volumes to be used), as the foam ‘displaces’
blood in the vein (increasing the contact area between foam and
vein wall, increasing fibrosis and reducing thrombosis). This
allows the treatment of truncal veins and large varicosities.
FS is more effective than LS with a similar side-effect profile
and can be delivered accurately under ultrasound guidance. Re-
ports comparing its effectiveness to open surgery are contradic-
tory with some stating it is less effective and other randomized
controlled trials suggesting it is just as effective as surgical
stripping with high-ligation on 2-year follow-up.5
Complications of foam sclerotherapy include anaphylaxis,
DVT, skin pigmentation and tissue necrosis, particularly in
cases of extravasation. Neurological complications are rare but
when present can be serious, in the form of cerebrovascular
accident (CVA), transient ischaemic attack (TIA), blurred vision
or migraine. CVA and TIA have been reported in extremely low
numbers. These are more likely to occur in patients with a right-
to-left cardiac shunt, and may be due to small particles of
sclerosant entering the cerebral circulation through said shunt
or to air embolism.6 An alternative explanation is that the
production of endothelin at the treatment point is the causative
factor.6
The guidelines from the SVS and AVF recommend FS to treat
tributaries and as an option for the treatment of the incompetent
saphenous vein.3 Current NICE guidelines advise that ultra-
sound-guided FS (UGFS) is efficacious in the short term and
should be performed under local (or no) anaesthetic. After the
procedure compression bandaging should be used and the
patient can have further treatment if, upon follow up, the vari-
cosities have not resolved.
Contraindications are allergy to the sclerosant and DVT
without recanalization.
Thermal ablation
Radiofrequency ablation (RFA)
RFA is a technique that employs radiofrequency waves to deliver
thermal energy, reaching temperatures of 85e120 C. The heat
generated damages the venous endothelium, sealing the incom-
petent vein. RFA of the GSV was described by Goldman in 20007
using the VNUS Closure Plus! catheter (San Jose, CA, USA).
Since then the newer VNUS ClosureFast! device has been
developed, now known as the Venefit! catheter since Covidien
(Mansfield, MA, USA) acquired VNUS in 2009. The Olympus
Celon RFITT! is another kind of radiofrequency catheter.
The vein is cannulated under ultrasound guidance using the
Seldinger technique and a bipolar catheter wire is inserted to
approximately 2 cm from the junction between the superficial
and deep systems (Figure 3a). Tumescent anaesthesia is instilled
under ultrasound guidance (Figure 3b) with the aim of sur-
rounding the vein, separating it from the surrounding structures
in order to avoid thermal injury. Crucially it compresses the vein
onto the catheter, increasing the energy transfer and reducing
power requirements and also provides pain relief. Treatment
without tumescence has shown poor technical outcomes.
Once adequate coverage is obtained and the temperature at
the probe tip is reduced (25"C) the VNUS system can be activated
and treatment started.
The patient should be placed in the Trendelenburg position
and extrinsic compression can be used to ensure vein wall/
catheter apposition to maximize treatment efficacy.
The Venefit! catheter’s tip is active during treatment, heating
a 7-cm segment of vein over 20 seconds at temperatures of 120"C.
This allows a treatment rate of 0.35 cm/second, with visual and
auditory feedback once the 20 seconds are complete. The catheter
has an inbuilt feedback mechanism that enables delivery of
consistently high temperatures and ongoing ablation by adjusting
energy delivery. Usually two rounds of treatment are given in the
segment closest to the junction to ensure adequate seal. Subse-
quently, the catheter is pulled back after each treatment.
The original ClosurePlus! system required continuous pullback
at a rate of 3 cm/minute resulting in a treatment rate of 0.05 cm/
second,making it a longer procedurewith potentially less consistent
ablation as the rate of drawback may be difficult to gauge. The new
generationClosureFast! catheters are superior to theClosurePlus!
with respect to the rate of DVTs and obliteration of the GSV.
A meta-analysis comparing open and endovascular treatment
of varicose veins found that at 3 months there was no significant
difference in recurrence rates between open surgery, EVLT or
VNUS, although endovenous ablation conferred a faster return to
work.8 Prospective randomized studies also revealed that RFA
has comparable results to high-tie and stripping with regards to
recurrence both in the short, mid and long-term.5 RFA was better
tolerated by patients and associated with a quicker recovery
period and improved quality of life scores.5 RFA has been shown
to be a minimally invasive, safe and effective procedure for the
treatment of varicosities; 3-year data confirm its durability.
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When consenting patients for this procedure, they must be
warned of the risk of bleeding, infection, nerve damage (due to
direct thermal injury to the saphenous/sural nerve) and DVT.
Risks specific to VNUS are difficulty with cannulation, guidewire
passage and catheterization through tortuous segments, super-
ficial burns, pigmentation and phlebitis.
Bipolar radiofrequency induced thermotherapy (Olympus Celon
RFITT!) is an alternative to VNUS. The main differences are that it
heats the vein to lower temperatures (85!C) and similarly to the
ClosurePlus! system it requires a continuous pull-back technique.
Its efficacy has been demonstrated in the incompetent saphenous
veins, particularly when performed by a skilled operator. Studies
comparing VNUS to RFITT are yet to be published.
Endovenous laser ablation (EVLA)
Introduced in 2001,9 EVLA uses laser (light amplification by
stimulated emission of radiation) and fibreoptic catheter tech-
nology to generate thermal energy. It acts by heating the vein
wall and blood, reaching temperatures of up to 800!C; this is not
dependent on the laser wavelength itself but on the speed of
pullback and on the power supplied. Unlike RFA, the catheter
does not have a feedback mechanism to maintain a constant
temperature. To prevent under or over-treatment it is important
to maintain constant pullback at a rate of 1 cm every 5 seconds
(0.2 cm/second); using 14W power the energy delivery is 70 J/
cm. The procedure for EVLA is the same as for RFA in terms of
vein catheterization and use of tumescent anaesthesia.
EVLA has been shown to be effective for saphenous vein sur-
gery, with impressive clinical outcomes that are at least compa-
rable, if not better10 than open surgery. As with RFA, patients tend
to prefer the endovenous option, with better satisfaction, reduced
postoperative pain and quicker return to work. Two-year follow-
up has revealed durable results. EVLA short-term outcomes are
equivalent to high-tie and ligation, with reduced postoperative
pain and bruising. RFA and EVLA have similar outcomes, with
more than 90% GSV occlusion rates.10 EVLA can be used in the
GSV and SSV, as well as for branch varicose veins.
Complications of EVLA include bruising, induration, numb-
ness, thermal burns and superficial thrombophlebitis. It is more
expensive than conventional surgery, requiring additional
equipment in the form of eye goggles, fibreoptic catheters,
micropuncture kit and a protected room. The catheters are very
small (0.5e1 mm diameter) and can be difficult to navigate up a
tortuous vein. The rate of postoperative DVT is 0.5%.
Steam therapy (Steam Varicose System!)
In steam ablation a catheter delivering pulsated steam reaching
temperatures of 120!C causes endothelial destruction and
fibrosis. An original pilot study revealed satisfactory results with
65% occlusion rate at 6 months and the remaining 35% showing
small-segment recanalization that was not clinically relevant.
Large, long-term studies are required to further assess this
method, with the first case-series in publication.
Cryoablation
Cryoablation combines open and endovascular techniques. The
SFJ is divided via a groin incision and a cryoprobe is inserted into
the GSV to the knee. The tip position is confirmed by ultrasound.
Liquid nitrogen or carbon dioxide are released from the cryo-
probe tip, reaching temperatures of "85!C for 10e15 seconds,
freezing the GSV to the cryoprobe; the vein is then stripped by
removal of the probe. Studies have shown that cryosurgery is as
effective as conventional stripping and EVLA,11 in terms of
recurrence, neovascularisation and quality of life measures.
Mechano-chemical endovenous ablation
ClariVein" (Vascular Insights, Madison, CT, USA), developed for
saphenous incompetence, is a hybrid between endovenous
ablation and sclerosant treatment. It does not use heat energy,
thus obviating the need for tumescent anaesthesia.
The procedure is performed under local anaesthetic with
percutaneous puncture under ultrasound guidance. The basic
SFJ
a
b
catheter tip
Figure 3 Ultrasound images of endovenous ablation. (a) Longitudinal view
of endovenous catheter placement at the saphenofemoral junction (SFJ).
Note the junctionon the left side of the image. TheGSV canbe seendraining
into the common femoral vein with the hyperechoic, linear catheter posi-
tioned 2 cm away from the junction. (b) Transverse view of the GSV after
instillation of tumescent anaesthesia. The hyperechoic catheter is sur-
roundedbyhypoechoicfluid, collapsing the veinonto the catheter itself and
separating away the surrounding structures.
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principles are as for endovenous ablation, with venous cannu-
lation via Seldinger technique and catheter insertion up to 2 cm
from the SFJ.
The ClariVein! device causes local mechanical damage via a
wire placed at its tip, which rotates at 3500 rpm, abrading the
intima of the vein, causing venospasm. Liquid sclerosant (STS or
PD) is infused through an opening at the catheter tip, close to the
rotating wire and the catheter is pulled back at a rate of 1e2 mm/
second. Closure rates at 8 months have been reported as high as
96.7%.12
The complication/side-effect profile appears to be more
favourable than standard endovenous ablation, this includes
minor bruising at the puncture site and superficial phlebitis. Larger
studies with prolonged follow-up are needed to assess its efficacy.
Sapheon" Venaseal Closure System
The Sapheon" Venaseal Closure System (Sapheon Inc, Santa
Rosa, CA, USA) uses the same principle as endovenous ablation,
with ultrasound-guided catheterization. A proprietary glue and
ongoing manual compression are used to occlude the vein, which
fibroses. Initial first in-man studies and preliminary data from the
ongoing European Sapheon Closure system Observational Pro-
spectivE study (ESCOPE) have been presented but longer-term
results are awaited.
Open surgery
Open surgery has been the gold-standard treatment for varicose
veins since the late 1800s, when Friedrich von Trendelenburg
performed a mid-thigh open ligation of the LSV in a patient with
an incompetent SFJ. With recent advances in minimally invasive
surgery, endovenous ablation is fast-becoming the treatment of
choice, with the proportion of open surgery performed dropping
from 83% in 2006 to 44% in 2012.13
Surgery for varicose veins can be performed under general,
local or regional anaesthesia and should be a day-case procedure
in all but special cases.
The basic principle is disconnection of the refluxing superfi-
cial venous system from the deep system.
Saphenofemoral junction ligation (SFJL)
SFJL for LSV incompetence was described by John Homans in
1916. It consists of a groin incision and dissection down to
the SFJ. Tributaries are identified, isolated and divided
beyond secondary branch points. The LSV should be ligated
flush with the common femoral vein via a transfixion suture
or double tie.
Despite addressing the main point of reflux in cases of SFJ
incompetence, duplex studies have revealed ongoing reflux in
the remaining segment of LSV. Winterborn et al14 recommended
stripping the LSV in combination with SFJL, due to a 60%
reduction in re-intervention after 11 years.
The risks of open ligation þ/" stripping include bleeding,
infection, haematoma formation, recurrence and damage to the
saphenous nerve. The incidence of nerve lesions may be as high
as 40% in full stripping; a significant reduction has been reported
when partial stripping (to the knee) is performed. According to
the Hospital Episode Statistics, the rate of DVT in open high-tie
and stripping is 0.54%.
Saphenopopliteal junction ligation (SPJL)
SPJL follows the same principles of SFJL. An incision is made in
the popliteal fossa and dissection is performed to the junction,
which is ligated or transfixed. SPJL is less successful than SFJL,
with high recurrence and complication rates, particularly
regarding common peroneal nerve damage resulting in foot drop,
which is a cause of litigation. Endovenous ablation is a suitable
option for SSV treatment.
Ambulatory conservative haemodynamic management of
varicose veins (CHIVA)
The French acronym CHIVA (Cure Conservatrice et
H!emodynamique de l’Insuffisance Veineuse en Ambulatoire) is a
minimally invasive, saphenous-sparing strategy for the treatment
of varicose veins first described in 1988 by Franceschi and col-
leagues. Haemodynamic surgery is based on the premise that
varicose veins arise secondary to a pathological venovenous
shunt, which allows reflux between the superficial and deep
systems. The aim of CHIVA is to disrupt this shunt by inter-
rupting the refluxing venous outlets without compromising the
saphenous vein. The technique relies on precise preoperative
anatomical and haemodynamic duplex mapping of the areas of
reflux, allowing the operator to identify specific areas to ligate
that will enable disconnection of the venovenous shunt and
fragmentation of the hydrostatic pressure column which forms in
the incompetent superficial venous system upon standing. By
ligating the origin of the incompetent venous segment, separating
targeted areas and sparing perforators, the superficial system can
still drain into the competent deep venous system. The procedure
can be performed under local anaesthetic in day surgery.
In experienced hands CHIVA is more effective than saphenous
stripping, with reduced long-term recurrence. Studies comparing
CHIVA to EVLT reported significantly reduced pain scores,
bruising and residual varicosities in the CHIVA group. There are
currently no studies comparing CHIVA with RFA and it remains
the preserve of specialist centres.
Ambulatory selective varices ablation under local
anaesthesia (ASVAL)
ASVAL removes the venous reservoir by targeting superficial
varicosities as opposed to the main refluxing saphenous vein. Via
this technique, described by Pittaluga and colleagues,15 multiple
phlebectomies are performed on varices without intervening on
the refluxing saphenous veins. Their retrospective study revealed
a postoperative reduction in saphenous vein reflux, improvement
in symptoms and up to 88.5% of patients were free from variceal
recurrence on 4-year follow up.15 Isolated phlebectomies appear
to improve venous haemodynamics by reducing LSV reflux
duration, peak velocity and diameter.15
Conclusion
The earliest Pubmed-indexed text titled “Observations on the
treatment of Varicose Veins of the Legs” was published in 1816.
Since then countless research has been performed on a common
and troublesome condition. It is exciting that two centuries later
new developments are still being presented. Open high-tie and
stripping has truly become a procedure of the past, with the new
generation of endovenous treatments offering effective, mini-
mally invasive and safe treatment.
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Interestingly, a 2009 survey revealed that only 14% of
vascular surgeons offered endovenous treatment; this should be
compared to the fact that in 2012 only 44% of procedures are
open surgery.13 The paradigm shift in the treatment of varicose
veins is on the way but the universal adoption of new techniques
in everyday practice is yet to be achieved. With the current ad-
vances in minimally invasive treatment it is imperative that new
vascular trainees are fully trained in these techniques. A
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Short-term gain for long-term pain? Which patients
should be treated and should we ration?
T R A Lane, B Dharmarajah, D Kelleher, I J Franklin and A H Davies
Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London,
Charing Cross Hospital, London, UK
Abstract
Objectives: Treatments of common conditions which do not affect mortality often become
sidelined in the drive to improve efficiency and reduce costs. The rationing of patients is a
divisive but crucial component to universal health care. How should this be accomplished?
Methods and Results: In this article we examine the outcomes of various rationing methods
in varicose veins.
Conclusions: No method is perfect and treatment of symptoms and complications should
remain the target for all physicians.
Keywords: varicose veins; rationing; treatment
Background
Varicose veins are currently the source of intense
debate and is a common condition worldwide,1,2
with increasing prevalencewith age.1 Despite exten-
sive work on clinical and quality-of-life (QOL)
outcomes after treatment,3 it has been classified as
a ‘treatment of limited clinical value’.4 Indeed, the
UK Audit Commission classifies varicose veins as
‘potentially cosmetic’, against the evidence.5 This
reinforces the common misperception that varicose
veins are not a significant condition.6
This definition has not kept pace with epidemio-
logical research progress2,7,8 and device develop-
ment.9–12 By some it is used to enable the concept
of rationing.
Treatment of all patients with varicose veins is
unfeasible and indeed unnecessary, as not all
patients experience symptoms or complications.2,7,13
As with many conditions, selecting the patients
who would most benefit from intervention is extre-
mely difficult14 and prone to socioeconomic bias.15
This article aims to review the evidence for different
rationing methods employed.
In the UK, Primary Care Trusts (PCTs) are the
current funding bodies for National Health Service
(NHS) treatment, and they have applied criteria
for funding,16 which limits treatment to those with
permanent damage which may well lead to higher
long-term costs – ‘short term gain for long term
pain’.17 Only 68% of PCTs fund symptomatic vari-
cose veins, compared with 90% of complicated
cases.18 This is despite funding underspends19
and the complexities of such rationing.20 This
setting is made even more difficult by the disparate
management and training on chronic venous
disease in the primary care setting,21 and leads to
complex health disparities between public and
private care.18
In addition, with the ever-increasing centraliza-
tion of care, rationing has become a crucial com-
ponent, as it is becoming evident that far from
improving care, mergers lead to worse financial
and care outcomes.22
Interestingly, patients with varicose veins are
accepting waiting lists23 and delays in excess of
the standard NHS 18-week pathway for diagnosis
and treatment24 – while ideally they would like to
be treated within 12 weeks of consultation and
listing for the procedure, patients are willing to
Correspondence: T R A Lane MBBS BSc MRCS, Academic
Section of Vascular Surgery, Department of Surgery and
Cancer, Imperial College London, Charing Cross Hospital,
Fulham Palace Road, London W6 8RF, UK.
Email: tristan.lane@imperial.ac.uk
Accepted November 2012
# The Author(s), 2013. Reprints and permissions:
http://www.sagepub.co.uk/journalsPermissions.nav
Phlebology 2013;28 Suppl 1:148–152. DOI: 10.1177/0268355513476815
wait up to 26 weeks and this does not have an effect
on their QOL.25–27 However, patients who wait
longer show progression of disease,8 which in
other fields leads to worse outcomes.28
Many treatment criteria have been investigated
to assess their suitability for treatment. Here we
outline their impact.
Rationing methods
Stocking treatment
Treatment with conservative measures includes the
use of compression hosiery, which has been shown
to provide effective relief for subjective symptoms
of aching and pain.29–31
However, the stockings available take many
forms and the evidence is extremely heterogenous
in nature.32 Stockings are expensive, costing up to
£200–300 per year per patient. In addition, compli-
ance is moderate, with one-third of patients in a
trial setting not wearing their stockings,33 increas-
ing to two-thirds in a non-trial setting.34 This is
partially due to difficulty in application.35,36
Varicose veins lead to increased leg volume,37
and physiological assessment has shown a signifi-
cant reduction in leg volume with compression
hosiery, with varicose vein patients benefiting
more with higher compression levels.38
Post ulceration there is significant evidence that
long-term use of compression hosiery reduces
recurrence by half,39 in addition to aiding healing
of those ulcers.40
Intriguingly, while stockings do improve symp-
toms, they do not prevent the emergence of varicos-
ities in pregnancy, which may be extrapolated to
indicate long-term progression.41
The additional cost of intervention has been
shown to be modest (,£400 over 2 years), with a
significant improvement in QOL for those under-
going open surgery.42
Waiting list
Waiting lists have always been the simplest of
rationing tools – with clinician input, the most
urgent cases are performed earlier, and more elec-
tive procedures are done in due course. Patients
are familiar and comfortable with such a
process.23,25,43 However, there is evidence to
show that long term the simplest cases continue
to be pushed back without the aid of a waiting
list limit, and in extremes never get per-
formed at all.44 In addition, ‘wastage’ of cases
occurs – patients pay to undergo private treatment,
patients die and patients move, all of which remove
the burden from the waiting list. It has also been
shown that reducing waiting lists with increased
resources does not lead to increased demand, indi-
cating that extending waiting times will have a
limited effect on reducing demand.45 However,
the hospital load does not reduce, as it is replaced
by alternative procedures.46
Vein diameter
Vein diameter has been shown to be significantly
positive correlated with venous haemody-
namics47–49 and the clinical stage of disease48,50–52
using the clinical aetiological anatomical pathologi-
cal (CEAP) scoring system.53 There is also evidence
to show worsening clinical scores using the venous
clinical severity score (VCSS)54 with increasing vein
diameter.50,55
Interestingly, despite this extensive work
showing an anatomical and haemodynamic corre-
lation, this does not apply to patient symptomatol-
ogy. The presence of symptoms and their
significance to the patient are independent of size
or rate of reflux in the veins.50,55,56 This work indi-
cates that as with pain,57,58 symptom thresholds
vary from patient to patient.
Complications
Rationing by limiting treatment to those who
already have complications of the disease is an
attractive method in principle – those patients
who never suffer significant long-term damage
will not be treated unnecessarily. It can lead to a
large reduction in the waiting list and load on
treatment.59–61 However, this reactive process
unfortunately does not prevent disease and allows
permanent change to occur and is out of step with
today’s evidence and practice of preventative medi-
cine. Once patients have developed skin changes
(CEAP C4) then lifelong compression hosiery is
indicated at considerable cost.62 Indeed with the
evidence now emerging from studies such as the
Bonn Vein Study indicating that varicose veins do
progress up the clinical scale at about 5% per year
per class, suggesting such reactive action is flawed.8
Waiting until the appearance of skin changes, or
worse ulceration, leads to extensive QOL impair-
ments and significant societal cost.63–65
Recent work into superficial venous thrombosis
has shown that it is a significant risk factor for
deep vein thrombosis, and additionally, varicose
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veins themselves are a four fold risk factor for deep
vein thrombosis if present under the age of 45.66,67
Clinical stage (CEAP)
Rationing by CEAP53 criteria has been suggested
with some areas only those patients with CEAP
class 4 and above being treated – complicated var-
icose veins. The problems with this approach are
detailed above, including the higher societal costs.
However, crucially the CEAP classification is rela-
tively insensitive to change, and does not correlate
well with symptomatic problems.68 Patients with
increasing CEAP do have worse QOL measures;
however, improvement post-treatment is not sig-
nificantly different between classes, leaving patients
with higher CEAP classes worse off.56 This indi-
cates that permanent damage has been done,
leading to a longstanding QOL impairment.
Symptoms
Extensive work has been completed showing the
QOL impairment caused by varicose vein sympto-
matology.56,69,70 Patients experience a constellation
of symptoms, ranging from aching and heavy legs
to restless legs.71 These can be difficult to unpick
but extensive studies have shown improvements
in OQL post-treatment,3,56,72,73 which is now routi-
nely performed under local anaesthetic.11
A crucial symptom is pain, which leads to a
large number of referrals from primary to second-
ary care;21 however, this is extremely variable
patient-to-patient 57,58 and can be difficult to
quantify.71,74 Previous work in the 1990s showed
significant dissatisfaction with varicose vein inter-
vention;75 however, with treatment advances, satis-
faction is currently high.76
There is no current literature utilizing QOL tools
to ration treatment, and doing so would bias the
questionnaires due to the possibility of gaming by
patients to influence their desired outcome.
Conclusion
Rationing is not an ideal starting point, however,
due to the prevalence of venous disease it is a neces-
sity. No method is perfect, however the relief
of symptoms and prevention of disease should
always remain the main aim of any physician.
Therefore, treatment on symptomatic grounds
with QOL assessment for service evaluation pur-
poses should be our rationing tool of choice. This
allows the greatest benefit in the most cost-effective
manner, before permanent chronic change is
evident.
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The European burden of primary varicose veins
H M Moore, T R A Lane, A Thapar, I J Franklin and A H Davies
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Abstract
Background: The treatment of varicose veins has been demonstrated to improve quality of
life, alleviate symptoms of depression and treat the complications of venous disease. This
study aims to show the studies which contain information regarding the prevalence and
distribution of venous disease. Then using the population and prevalence data for venous
disease, and considering the cost of treating varicose veins, this study aims to analyse the
treatment of varicose veins and assess whether there is a disparity between European
countries.
Methods: Relevant papers regarding the prevalence or incidence of venous disease were
identified through searches of PubMed (1966 to October 2010). The search terms
‘prevalence OR incidence’ AND ‘varicose veins or venous disease’ were used. Population
data, prevalence data and the number of varicose vein procedures performed in each
country was obtained for 2010.
Results: Four studies were included. From calculated values comparing the predicted and
actual number of patients requiring treatment for venous disease, the UK, Finland and
Sweden are potentially not treating all patients with C2 disease. In contrast to this, all
other European countries represented are treating more patients, suggesting that they may
be treating additional patients. There was up to a four-fold difference in the numbers of
procedures per million population that were performed for varicose veins in different
European countries.
Conclusion: There is a marked disparity across Europe between the predicted number of
patients with varicose veins requiring treatment and the actual care given. The factors
influencing this need more detailed investigation.
Keywords: varicose veins; healthcare burden; treatment
Introduction
Venous disease is common in the UK.1 Although
prevalence data are highly variable, other European
cohorts report comparable prevalence data.2–4 The
majority of patients with venous disease have
superficial venous reflux alone with clinical mani-
festations including telangiectasia, varicose veins,
oedema and venous ulceration. Superficial venous
disease does not pose an immediate threat to life;
however, the treatment of varicose veins has been
demonstrated to improve quality of life,5 alleviate
symptoms of depression6 and treat the compli-
cations of venous disease.7 Patients with superficial
venous reflux and varicose veins have benefitted
from recent advances, particularly the use of endo-
thermal technologies to ablate superficial veins.8 All
treatment modalities have been shown to improve
patients’ quality of life in national non-selected
patient-reported outcome measures9 and in the
UK, all treatment modalities have been shown to
be cost-effective in terms of quality-adjusted life-
years gained relative to conservative treatment.10
In the UK, the National Institute for Clinical
Excellence referral advice document, published
in 2001, recommends referral by the general
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practitioner (GP) for specialist advice if patients
have ‘troublesome symptoms attributable to their
varicose veins, and/or they and their GP feel that
the extent, site and size of the varicosities are
having a severe impact on quality of life’ as well
as patients who have healed or active ulceration
or bleeding varicosities.11 However, despite this,
individual primary care trusts (National Health
Service [NHS] funding bodies) are commonly
recommending, and indeed will only reimburse
treatment if patients have severe skin changes and
have failed a six-month trial of compression, or if
the patient has leg ulceration, chronic continuous
pain or severe oedema.12 If patients are treated
in the earlier clinical stages of disease, then pro-
gression, estimated to be approximately 2% per
year from C2 to C3–C6 disease,13 may be halted.
In the long term, to prevent the more costly severe
clinical stages of venous disease, it may prove to
be more cost-effective to treat early symptomatic
disease, although larger studies are needed.
Is this management strategy reflected across the
rest of Europe? How many procedures for varicose
veins are performed and is there a difference be-
tween countries? Which clinical stages of disease
are being treated and is there consistency? Impor-
tantly, what are the potential treatment costs of per-
forming these procedures and can they be justified?
This study aims to show the studies which
contain information regarding the prevalence and
distribution of venous disease. Then using the
population and prevalence data for venous
disease, and considering the cost of treating vari-
cose veins, aims to analyse the treatment of varicose
veins and assess whether there is a disparity
between European countries.
Methods
Relevant papers regarding the prevalence or inci-
dence of venous disease were identified through
searches of PubMed (1966 to October 2010).
The search terms ‘prevalence OR incidence’ AND
‘varicose veins or venous disease’ were used.
Article titles and abstracts were screened for
inclusion. A manual reference list search was also
carried out for further appropriate studies to be
considered for inclusion. Articles regarding
cardiac or coronary disease, cancer and throm-
boembolism were excluded. Relevant full-text
articles were scrutinized and all studies reporting
the distribution of venous disease in a representa-
tive sample population, that is not those seeking
specific treatment for venous disease, were
included. The relevant data including the preva-
lence of venous disease in the population and the
distribution of clinical disease severity within that
population were included.
For the subsequent calculations, prevalence data
were obtained from the Bonn Vein Study (BVS).14
In this study 3072 people were selected at random
from a population register and screened for venous
disease. This included a full history, clinical assess-
ment, completion of a quality-of-life questionnaire
and venous duplex ultrasound examination. The
severity of venous disease for each subject was
given by the CEAP (clinical, aetiological, anatomical
and pathological elements) classification.
Population data were obtained from the UK
Office for National Statistics UKONS and Eurostat,
the statistical office of the European Union, Luxem-
bourg. The number of inhabitants aged between 15
and 79 years of age was obtained. This age range
was selected as some of the data grouped patients
from age 15 to 79 and also this represents the age
range in which the majority of patients with
venous disease would be offered a procedure in
all countries. These data-sets were used to calculate
the numbers within the population and the actual
numbers that would fall into each of the clinical
stages of disease.
The number of varicose vein procedures per-
formed in each country was obtained from the Hos-
pital Episode Statistics (HES) for the UK and from
the Millennium Research Group for continental
European countries for 2010. These data were com-
pared with the predicted number of patients that
were previously calculated that would require an
intervention for varicose veins, that is, the predicted
numbers of patients with C2–C6 disease.
Data regarding the cost of treating varicose veins
were obtained from HES online in the UK and for
continental European countries from health econ-
omic analyses.15,16 These data-sets were used to
estimate the cost of treating these patients with
superficial venous disease. Venous experts in each
of the European countries were contacted if infor-
mation regarding the cost of varicose vein interven-
tions could not be found in the literature. In these
cases the reimbursement fees for each of the pro-
cedures were used for each country if available.
Results
Epidemiology of venous disease
The initial search strategy yielded 4896 results.
After title and abstract screening, 11 full-text articles
were examined. Seven were excluded as either the
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sampled populations consisted of patients present-
ing with venous disease so were not considered to
be representative of the general population, or the
population selected could not be classified by
disease class as insufficient information was avail-
able, or if the selected population was restricted.
The results from the four included studies regard-
ing the prevalence and distribution of clinical
disease class severity are shown in Table 1. Each
study determined the prevalence of venous
disease by a different consideration. Bihari et al.17
considered the presence of venous disease in any
patient with a visible varicosity including reticular
or spider veins. Evans et al.4 did not use the
CEAP classification and considered patients with
C1 disease in the ‘no disease’ category. Rabe
et al.18 selected a large population; however, the re-
sults regarding clinical severity have not yet been
correlatedwith the presence of reflux, so the number
of patients with treatable disease is not known.
Chiesa et al.19 and Evans et al.4 both assessed for
the presence of reflux in the general population;
however, there was selection bias in the study by
Chiesa et al.19 as patients were selected by advertis-
ing, so it was not a representative of the general
population. Rabe et al,14 however, although they
note a high prevalence of C1 disease and above,
over 90%, they also correlate this with reflux
measurements, and therefore potentially treatable
disease can be calculated. The prevalence data
from all of these studies are shown in Table 1.
Prevalence of venous disease across Europe
Population data were obtained from the UK Office
for National Statistics UKONS and Eurostat, the
statistical office of the European Union, Luxem-
bourg. The number of inhabitants aged between
15 and 79 years of age was obtained for each
country. According to the BVS, the prevalence of
venous disease in the population was 20%; there-
fore, the number of patients with potentially treata-
ble venous disease between these age ranges was
calculated. Subsequently, using data from the BVS
regarding the percentage distribution of patients
for each stage of clinical severity by CEAP classifi-
cation, the estimated number of population with
C0, C1, C2, C3, C4, C5 and C6 diseases were calcu-
lated. This is shown in Table 2.
A comparison of the calculated and actual
number of varicose vein procedures performed
In order to calculate the estimated number of
varicose vein procedures per year that would be
required to treat all patients at each stage of clinical
severity, the absolute numbers (Table 1), were
divided by 64 (the number of years in the age
range 15–79 years). The estimated number of treat-
ments that would be performed per year in
each European country if all patients with C2–C6,
C3–C6 and C4–C6 diseases were treated was cal-
culated. These are shown in Table 3.
Patients with C2 and more severe venous disease
are likely to be the population who would seek
treatment as visible varicosities and other symp-
toms may have an impact on their quality of life.
Patients with C1 disease generally do not require
treatment, apart from cosmesis. Therefore, a treat-
ment threshold of C2 disease and above was
assumed. The actual number of treatments carried
out in each country was compared with the
Table 1 The prevalence and distribution of varicose veins from epidemiological studies
Study Country Number of
patients
Prevalence of
venous disease (%)
Clinical disease class severity distribution (%)
Rabe et al. (2003)14 Germany 90.4 9.6 59 14.3 13.5 2.9 0.6 0.1
Chiesa et al. (2005)19 Italy 5187 62.9 22.7 64.8 29.4 13.6 13.6 3.4 8.6
Bihari et al. (2011)17 Hungary 566 57.1 42.0 31.1 10.1 7.1 6.9 1.8 1.0
Rabe et al. (2012)18 Worldwide 77,716 83.6 36.1 21.7 17.9 14.7 7.5 1.4 0.7
Table 2 The calculated number population in each European country with each stage of severity of venous disease
Number of population!1000
C0 930 83 1279 708 947 929 81 140 250 129
C1 5713 508 7859 4352 5819 5709 497 861 1536 794
C2 1385 123 1905 1055 1410 1384 121 209 372 192
C3 1307 116 1798 996 1332 1306 114 197 351 182
C4 281 25 386 214 286 281 24 42 75 39
C5–C6 68 6 93 52 69 67 6 10 18 9
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calculated figure of all patients with C2–C6 disease
were offered treatment. This is represented graphi-
cally in Figure 1. The line running through ‘0’ rep-
resents the level at which the calculated number
of required treatments is equal to the actual num-
ber of procedures carried out, that is if all patients
with C2–C6 disease were treated. Above the line
is additional actual number of procedures per-
formed, and below the line is the shortfall,
representing the predicted number of patients
with C2 disease and above who are not receiving
treatment. This is represented as a percentage rela-
tive to the predicted number of patients with C2
disease.
As shown on the graph, the UK, Finland and
Sweden, according to the calculated values are not
treating all patients predicted to have C2–C6
disease. In contrast to this, all other European
countries represented are treating more patients,
suggesting that they may be treating additional
patients, which may represent the treatment of
recurrent disease, multiple procedures on individ-
ual patients or that the calculated predicated
numbers of patients with C2–6 disease were
under-estimated.
The cost of performing varicose vein procedures
The number of additional procedures or the number
of patients with C2 disease not treated was com-
pared with the actual number of procedures
carried out in each country. The costs of performing
varicose vein procedures in each of the European
countries were obtained from recent health–
economic analyses, insurance reimbursement costs
and from European venous experts. The potential
additional costs for the countries performing
more varicose vein procedures than patients with
C2–C6 disease were calculated and are shown in
Table 4. The potential cost-savings by the countries
not treating all patients with C2–C6 disease are
shown in Table 5.
The term ‘potential’ is emphasized as these
calculations are based on the predicted numbers
of patients with C2–C6 disease and they do not
take into account the long-term costs of disease
Figure 1 A comparison of the actual number of procedures performed with the calculated number that
should be carried out if all patients with C2–C6 disease were treated
Table 3 Estimated annual number of procedures required to treat different CEAP ranges
CEAP range UK Denmark Germany Spain France Italy Finland Sweden Netherlands Austria
C2–C6 47,509 4225 65,350 36,188 48,393 47,477 4137 7160 12,770 6604
C3–C6 25,873 2301 35,589 19,708 26,354 25,856 2253 3899 6954 3597
C4–C6 5447 484 7492 4149 5548 5443 474 821 1464 757
CEAP, clinical, aetiological, anatomical and pathological elements
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progression, compression hosiery and societal costs
of not treating this group of patients.
Comparison of the actual number of varicose
vein procedures performed in different European
countries
The number of varicose vein procedures carried
out in each country in 2010 was compared with
the number of population, and the number of
procedures per million population was calculated
to see if there was a disparity across Europe. The
numbers of procedures per million ranged from
a low of 685 in the UK to a high of 2853 in
Germany. The values for each of the other European
countries is shown in Figure 2.
Discussion
From this study, there is currently a marked dis-
parity in the way in which varicose veins are
treated throughout Europe. This is shown by both
the wide variation in the numbers of procedures
per million persons as well as the calculated
values of the different numbers of patients with
different disease severity being treated. The UK is
performing the lowest number of varicose vein pro-
cedures per million persons and from the calculated
data if it is assumed that all patients with higher
disease class severities are being treated, the
majority of patients with uncomplicated varicose
veins are not undergoing intervention. Current
trends indicate that the number of varicose vein
procedures performed each year in the UK is
decreasing (Figure 3). This may increase costs
overall, and leave patients with worsening but
potentially treatable venous disease.
In the UK, patients with C2 disease, are often not
offered treatment on the NHS. Conversely, in other
European countries, notably Germany, the Nether-
lands and Austria, many more procedures are
being carried out per million population, up to
Figure 2 The number of varicose vein procedures carried out per million population in each European
country
Table 5 Potential cost-saving of not treating all patients with
C2–C6 disease
Country Cost of all
C2–C6
(millions)
Potential patients
with C2 not
treated
Potential
costs saving
(Emillions)
UK 67 14,327 23
Finland 6 1152 2
Sweden 10 697 1
Table 4 Potential additional costs of treating more patients than
those with C2–C6 disease
Country Cost of all C2–C6
(Emillions)
Additional
procedures
carried out
Potential costs
(Emillions)
Denmark 8 1775 4
Germany 105 124,650 199
Spain 58 30,812 49
France 77 31,607 50
Italy 76 22,523 36
The Netherlands 20 22,230 36
Austria 11 11,187 18
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four times more than that in the UK, and from the
calculated data, patients with disease class severity
of less than C2 disease are even being treated. The
differences between countries may occur for many
reasons, including primary health-care service
availability, patient and physician perceptions of
the importance of venous disease and the demand
for cosmetic treatment. Different procedures for
reimbursement may contribute, as in some coun-
tries procedures are carried out in stages as each
modality of treatment is separately reimbursed.
There is currently a paucity of accurate longi-
tudinal evidence to support this supposition, as
there are currently no studies that exist assessing
whether endovenous or open varicose vein pro-
cedures performed early in clinical disease have
an impact on progression. However, there is evi-
dence to suggest that the number of patients with
venous ulcers can be reduced by half if patients
with mild-to-moderate venous disease are offered
surgery.20 In the long-term, this may prove to be
more cost-effective, although larger studies are
needed. The calculated potential additional shown
in Tables 3 and 4 are only for the treatment of one
leg and not for recurrent varicose veins, so these
may be underestimated. In the UK, the procedures
performed in private practice are not included in
these calculations. However, estimates from
independent private health-care providers in the
UK suggest that these figures are not increasing as
the number of procedures performed within the
NHS are decreasing.
This study has limitations. The data from the
BVS on the distribution of clinical venous disease
severity by CEAP classification was applied to the
20% of patients with reflux in at least one superficial
vein, which represents those that would be suitable
for treatment, rather than the whole population.
This is likely to have resulted in an underestimation
of the number of patients that may be eligible for
treatment, as patients with radiological reflux are
probablymore likely to have signs of venous disease
than a selection of the population as a whole. The
costs of ongoing treatments including compression
stockings, treating higher classes of disease severity
and recurrence were not included. It was assumed
that each treatment was carried out on one limb of
one patient and costs of treating recurrence were
not included. This resulted in an underestimation
of the cost of treating venous disease. The costs
used were taken as either the reimbursement
tariffs for a procedure or the average costs of the
different procedures from the literature, but as
some procedures, for example sclerotherapy, are
less expensive than open surgery, this will alter
the results. Data regarding whether the procedures
were carried out under local or general anaesthetic
were not available and so could not be taken into
consideration.
In the current time of economic austerity, where
public spending is under considerable inspection,
treatment provision is an area of growing interest.
Across Europe, there is a wide disparity in the
number of procedures for varicose veins between
countries. Different clinical stages of disease are
being treated and there is little consistency. Impor-
tantly, the potential treatment costs of performing
these procedures need to be considered and the
Figure 3 The number of varicose vein procedures performed in the UK
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question asked: can they be justified? If the costs of
treating higher classes of disease severity and the
impact on patients’ quality of life are taken into con-
sideration, it may be that treating more patients
with varicose veins is more cost-effective in the
long term.
Conclusions
There is a marked disparity across Europe between
the predicted number of patients with varicose
veins requiring treatment and the actual care
given, with the UK, Finland and Sweden possibly
under-treating varicose veins. However, it may
prove more cost-effective in the long term to treat
all patients with varicose veins to prevent disease
progression which may prove more expensive to
treat. The factors influencing this need more
detailed investigation.
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Patterns of short saphenous vein incompetence
M I Qureshi, T R A Lane, H M Moore, I J Franklin and A H Davies
Academic Section of Vascular Surgery, Imperial College London, London, UK
Abstract
The significance of short saphenous vein (SSV) reflux is an under-explored territory in
chronic venous disease (CVD). We have examined the origin and significance of SSV reflux
in primary and secondary CVD. While the natural history of SSV incompetence remains
uncertain, its prevalence has been shown to approximate 3.5%, rising with progressing
clinical venous insufficiency, and bears an association with lateral malleolar venous
ulceration. The most common pattern of reflux extends throughout the SSV. Patterns of
incompetence in recurrent disease are highly variable, but SSV reflux may itself pose a risk
for recurrence, in part due to the complex anatomy of the saphenopopliteal system.
Further studies are required to delineate the impact of SSV reflux in secondary venous
disease and deep venous incompetence.
Keywords: anatomy; venous; pattern; varicose vein
Introduction
Chronic venous disease (CVD) is the most prevalent
vascular disorder, and can result in a spectrum of
disorders ranging from mild pain and oedema
through to frank ulceration.1 The advent of duplex
ultrasonography has permitted direct and accurate
visualization of incompetent venous segments
relating to reported symptomatology and clinical
findings. The most commonly documented site
of reflux is the great saphenous vein (GSV).2
While the association between small saphenous
vein (SSV) incompetence and venous disease was
established as early as 1959,3 the significance of
SSV reflux is an under-explored territory in CVD.4
Tributaries from the dorsal aspect of the foot
combine with those from the dorsal venous arch
to form the SSV, which drains the heel and subcu-
taneous tissues of the posterior aspect of the leg.5
Also termed the lesser or short saphenous vein,
the SSV runs posterior to the lateral malleolus,
within the saphenous fascia, and ascends to drain
into the popliteal vein via the saphenopopliteal
junction (SPJ). The latter is an entity of varying ana-
tomical position, with both ultrasound and cada-
veric studies showing little predictability in its
localization.6,7 This anatomical variation, together
with the proximity of the SPJ to important neuro-
vascular structures such as the common peroneal
nerve, may complicate the invasive management
of SSV disease.
Origin of SSV reflux
There remains no clear consensus on how super-
ficial primary CVD commences and progresses,
thus its natural history remains uncertain.8,9
Traditionally, superficial venous incompetence
was attributed to a primary valvular insufficiency
that commenced at the saphenous junction and
progressed distally10 – the ‘descending theory’.
This posed a significant problem for SSV reflux,
as without deep venous incompetence or an incom-
petent Giacomini vein, there could not be a continu-
ous blood column.
More recently, the advent of duplex ultrasono-
graphy has rendered support to an alternative
‘ascending theory’, that hypothesizes the proximal
progression of distal venous incompetence.2,11–14
This is supported by the observation that
superficial venous incompetence often occurs with
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a competent saphenous junction.15 Moreover, vari-
cose veins can occur with no evidence of truncal
incompetence (particularly in young patients),
suggesting that varicose disease can extend in an
antegrade manner, from saphenous tributaries to
saphenous veins.11
Duplex imaging has also shown vein dilation
occurring distal to an incompetent valve, as
opposed to proximal dilation that would be
expected as a consequence of descending incompe-
tence. Studies have demonstrated that tributary
incompetence predominates in younger patients
suggesting that saphenous trunk or junction reflux
may be a secondary occurrence.11
In fact, primary venous reflux can occur in any
superficial or deep vein of the lower limb. The
below-knee veins may well be affected in asympto-
matic individuals and in those who have prominent
or varicose veins. These data suggest that reflux
appears to be a local or multifocal process in
addition to or separate from a retrograde process.12
Prevalence of SSV incompetence
The Edinburgh Vein Study assessed subjects with
both clinical and duplex ultrasonographic examin-
ation, leading to a true estimate of the prevalence
of CVD among the population. Of the 1092 subjects
with complete scans, 43 had duplex evidence of SSV
incompetence (3.9%). The prevalence of SSV reflux
increased with progression of chronic venous insuf-
ficiency (P, 0.001).16 The Bonn Vein Study echoed
these findings with a prevalence of 3.5% and fur-
thermore showed that SSV reflux (as well as GSV
and deep venous incompetence) increased with
age, obesity and CEAP (clinical, aetiological, ana-
tomical and pathological elements) classification
of disease.17
SSV incompetence in primary CVD
Duplex ultrasonography studies have shown
marked variation in the prevalence of SSV reflux
in patients with symptoms and/or signs of
primary CVD.4,7,18–21
In a small study of 32 patients with symptomatic
venous disease, only 2% of limbs were shown to
have SSV incompetence.18 Kurt et al.4 found that
5.8% limbs from 178 patients with symptoms/
signs of primary CVD had evidence of isolated
SSV reflux; of note, there was no significant differ-
ence between the age, BMI, and gender of those
with and without SSV disease. Labropoulos et al.5
found a similar prevalence of isolated SSV incompe-
tence at 6.6% in their large duplex ultrasonographic
study of 2254 limbs. The most common pattern of
reflux in the short saphenous system extended
throughout the length of SSV (57%) without in-
volvement of Giacomini or gastrocnemial veins.
These patients were most likely to present at stage
C2–C4. Nuehardt et al.22 found a SSV reflux
prevalence of 13% in a study of 410 symptomatic
legs.
When considering patients with primary super-
ficial incompetence only (and competent deep and
perforating veins), the presence of isolated SSV
reflux rose to 33%, with 19% of limbs showing evi-
dence of both GSV and SSV incompetence.7 While
the presence of ache or pain was not related to the
extent of reflux, the presence of extensive reflux in
both GSV and SSV was associated with a higher
incidence of ulceration. This association is not clear-
cut, as early duplex ultrasonography studies related
ulceration to SPJ incompetence, as opposed to
reflux of the SSV.23
The influence of SPJ reflux on lateral leg ulcera-
tion was emphasized in a study of 20 legs with iso-
lated lateral malleolar ulceration. Ligation and
division of the refluxing SPJ in association with con-
servative management resulted in all ulcers healing
within 12 weeks.24 However, 15 of these limbs had
been previously treated as a non-venous aetiology,
and there was no control group. A larger study
compared patterns of venous incompetence in 776
limbs with primary uncomplicated varicose veins
with those in 166 limbs with the complications
of lipodermatosclerosis or past venous ulceration
(C4–C5). Limbs with complications more fre-
quently showed SSV reflux (P, 0.05).25
Despite the suggested association between SSV
incompetence and high CEAP classifications of
disease,21,24,25 short saphenous reflux has also
been demonstrated in patients with primary vari-
cose veins but no clinical suspicion of SSV incompe-
tence. Jutley et al.26 reported 42 of 223 scanned
limbs (19%) to demonstrate SSV reflux, of which
67% had not been clinically suspected. This
highlights the importance of preoperative duplex
assessment.
SSV incompetence in recurrent
venous disease
The recurrence of venous reflux following treatment
is highly variable and, like primary venous disease,
often multifocal.27
Studies have highlighted the increased likeli-
hood of recurrence in the presence of SSV reflux,
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following surgical treatment.28,29 This may be due
to anatomical variation in the position of the SPJ.30
Labropoulos et al. studied patterns of recurrent
venous incompetence following surgical interven-
tion in patients with CVD. One hundred and thirty-
four limbs from 123 patients with recurrent varicose
veins underwent duplex ultrasonography assess-
ment of GSV and SSV systems to determine extent
of reflux. Following SPJ ligation, the more
common pattern of incompetence observed was
SSV reflux (75%), whereas after SSV stripping was
performed, SSV tributary reflux predominated
(64%).31
Treatment of SSV incompetence
The pattern of venous reflux is often unpredictable,
and with specific regard to the short saphenous
system, the position of the SPJ is inconsistent. Inva-
sive management may be further complicated by
the proximity of the SPJ with important neuro-
vascular structures, such as the common peroneal
nerve, and the added anaesthetic risk of interven-
tion with the patient placed in the prone position.
Traditional open surgery – ligation of the PSJ with
or without vein stripping is effective, but has a
high recurrence rate, likely due to anatomical com-
plexity.32
However, with the advent of endovenous tech-
niques using ultrasound guidance, standardized
treatment of the SPJ and SSV is now far easier to
replicate with few side-effects.33
The degree of heterogeneity of patterns of SSV
incompetence and their clinical sequelae imply
that individualized treatment is necessary to
achieve the optimum outcome.18,19 Few studies
have investigated the effect of SSV treatment in
the context of deep venous incompetence, though
previous work has shown improvement in haemo-
dynamics with superficial vein ablation.34
Conclusion
SSV incompetence is a significant contributor to the
global burden of CVD but due to anatomical varia-
bility it remains a complex variable. Endovenous
treatments offer a reproducible answer to this
variability. Further work is needed to delineate
the impact of SSV disease in secondary venous
disease and in deep venous incompetence.
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a b s t r a c t
Venous disorder is common in the general population. Uncomplicated varicose veins represent
a signiﬁcant proportion of the disease burden, and can impact considerably on quality of life, producing
a wide spectrum of symptoms. Little is known about the natural course of the disease at this stage and
the treatment strategy employed is often not based on robust scientiﬁc evidence.
The aim of this article is to elucidate the options to manage uncomplicated varicose veins. There are
likely to be signiﬁcant geographic differences in the treatment strategy employed, and it is hoped that we
will arouse discussion among physicians regarding the management of this very common medical
condition. The reader will be asked for their preferred treatment choice for a given clinical case vignette.
! 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Background
Venous disorders affect a large proportion of the adult pop-
ulation, and are both commonly encountered in primary care and
frequently referred to hospital services.1 It encompasses a spectrum
of diseases, and there are a number of treatment options available,
which are likely to be variably practised. The aim of this article is to
evaluate current strategies in the management of uncomplicated
varicose veins, which represents a signiﬁcant portion of this
condition, in the context of the available evidence.
Recommendations for the treatment of patients with varicose
veins should be based on an understanding of the natural history of
the condition at this stage, taking into account the likely conse-
quences of leaving the disease untreated and the beneﬁts and risks
of any treatments. Conservative and invasive treatment options are
available and should be applied taking into account the impact of
disease progression, quality of life and health-care resources. In the
early disease stages Clear scientiﬁc evidence is lacking for one or
another management option. Therefore, differences in disease
awareness and treatment approaches are subject to an animated
discussion amongst specialists.
Following reading the clinical vignette, you will be asked to
select your preferred management option from a list of three
choices.
Case Vignette
A 48-year-old woman was seen by her general practitioner
(primary care physician) for a routine examination. He refers the
patient to you for your specialist opinion on ‘some varicosity’ on the
left leg. The patient has a past medical history of hypothyroidism
for which she takes thyroxin 50 mcg daily. She drinks alcohol rarely
and does not smoke.
She is overweight, with a body mass index of 28. Her blood
pressure is 130/85 mmHg, and heart rate is 84 beats per minute.
Cardiovascular examination is normal. Examination of the legs
demonstrates left leg varicosities along the distribution of the great
saphenous vein. There are no associated skin changes and no
oedema can be detected at this time of the day (10 am).
On questioning, the patient does not report any history of leg
trauma, deep vein thrombosis or superﬁcial thrombophlebitis. Her
mother suffered from varicose veins without progression to severe
skin changes or venous ulceration. She ﬁrst noticed her left leg
varicose veins after her ﬁrst pregnancy. They increased in promi-
nence during her second pregnancy at the age of 39, but subse-
quently have remained unchanged. When asked speciﬁcally, she
conﬁrms that she experiences symptoms of heaviness in the left leg,
which is worse in the evening and during hot summer days. She also
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reports mild swelling of the left calf and ankle. She has not been
previously investigated or received treatment for her varicose veins.
The patient following referral to you undergoes a duplex scan,
which reveals primary varicose veins with incompetence of the left
saphenoefemoral junction and long saphenous vein down to the
proximal calf region and two tributaries. The deep venous system is
normal and competent.
Which one of the following management strategies, any of
which would be considered correct, would you employ for this
patient? Please base your choice on your routine clinical practice.
a) No further diagnostic work-up or treatment. Follow-up at
routine visits with the GP once a year. No special treatment
recommendations.
b) Recommend the use of compression stockings (e.g.,
20e30mmHg) during work and periods of prolonged standing.
c) Ask the patient for her preferences, explain the evidence for the
natural course of the disease and for the various treatment
options and decide according to patient’s preference.
d) Consider ablative treatment for varicose veins, only if there is
secured funding.
e) Clear statement for varicose vein ablation. Treatment is indi-
cated to prevent further evolution of venous disorder in this
relatively young and otherwise healthy subject.
Comment on Case Vignette
In the case presented, the patient has clinical stage C2 according
to the clinical classiﬁcation of the Clinical Etiology Anatomical
Pathological (CEAP) system.2 Duplex scan reveals a primary vari-
cosity with complete incompetence of the long saphenous vein
down to the proximal calf level giving rise to two tributaries. The
deep venous system is normal and competent.
This is a commonly encountered situation and any interven-
tional treatment, given the above, might be considered to be fairly
controversial in this patient, as there are no signiﬁcant skin changes
and apparently no substantial reduction of quality of life. Conser-
vative and invasive treatment options will be brieﬂy presented
below. However, according to the latest recommendation of the
Venous Forum of the Royal Society of Medicine, ablative treatment
at this stage of disease should be considered, but is not compul-
sory.3 A slightly more aggressive stance is advocated in the recent
Clinical Practice Guidelines of the Society for Vascular Surgery and
the American Venous Forum. Based on grade 1B evidence (best
estimates of the critical beneﬁts and risks outcome from rando-
mised, controlled trials with important limitations), they advise
against compression therapy as a ﬁrst line approach, and recom-
mend endothermal saphenous vein ablation as the primary treat-
ment of symptomatic varicose veins in those patients who are
suitable for therapy.4
Treatment Options for Varicose Veins
Conservative treatment
Compression therapy forms the cornerstone of conservative
treatment for venous disorders independent of the underlying
cause.5 If no invasive or ablative treatment is being contemplated, it
can be suggested even without diagnostic work-up, in the absence
of signiﬁcant peripheral vascular disease. A calf-long medical
compression stockingwith adeﬁnedankle pressureof 20e30mmHg,
that is, class II compression hosiery is usually adequate. However, the
data available suggest that compliance to compression therapy is
generally poor.6 Moreover, given the relatively young age of the
patient, who is also likely to be in good health, lifelong medical
compression therapy is unlikely to be considered to be an accept-
able option by the patient and indeed is unlikely to be cost effective.
Anti-oedema drugs, for example, horse-chestnut-seed extracts,
hydroxyethylrutosides, (Daﬂon!) and red-vine-leaf extract AS195
(Antistax!), have been shown to be efﬁcacious in the treatment of
venous symptoms in previous trials and should be considered.7e10
However, their long-term impact on disease progression and skin
changes is unknown. Other conservativemeasures, such as lifestyle
changes, have not been shown to offer any long-term preventative
or beneﬁcial effect in the presented case vignette.
Invasive treatment
Nowadays, there are a number of treatment options available for
ablation of varicose veins.11e14 Surgery was previously considered
to be the gold standard, but is now sidelined by less invasive
techniques, such as, endothermal procedures, for example, laser or
radiofrequency ablation and ultrasound guided foam scle-
rotherapy.11e14 These treatment modalities can be performed in an
outpatient setting under local anaesthesia, and their use is guided
and dependent on the anatomic/physiological ﬁndings on duplex.
Patient co-morbidities, skill of the treating specialist, local
health-care system proprieties and patient preference are all
factors that will inﬂuence the therapeutic modality applied. Short-
and mid-term results for endothermal ablation are promising and
have led to their routine use in many centres. Severe adverse events
appear to be very rare with both endothermal ablation and foam
sclerotherapy.11e14
Conclusion
This case vignette presents a commonly encountered situation
for the venous specialist. Different treatment options, any of each to
be considered correct, can be applied. More long-term data of
randomised controlled trials are needed to tailor the management
of uncomplicated varicose veins.
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WHAT THIS PAPER ADDS
! This article highlights the need to regard venous disease as a chronic illness, and evaluates its impact on quality of life and
importantly on depression an area which has not been tackled previously. The article emphasises the need for vascular surgeons to
look beyond the disease process and take a more holistic approach to patient care.
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a b s t r a c t
Objective: To evaluate the burden and impact of depression in patients with symptomatic varicose veins.
Methods: Patients with varicose veins referred to the vascular surgeons for further management, were
invited to complete a validated questionnaire relating to quality of life, using the Aberdeen Varicose
Veins Questionnaire (AVVQ), EuroQol-5D questionnaire (EQ-5D) and the EuroQol-Visual Analogue Score
(EQ-VAS); and depressive symptoms, using the Centre of Epidemiological Studies Depression Scale
(CES-D). Social, demographic, clinical (CEAP classiﬁcation, venous clinical severity score (VCSS)) and
venous disability score (VDS) data was also collected.
Results: One hundred patients, mean age 52.7 years (63 females; 37 males) were recruited. Twenty-nine
per cent of patients with varicose veins had depression scores suggestive of depression; no patient had
previously been diagnosed or was on treatment. Depression scores were not inﬂuenced by age (p ¼ 0.30)
or gender (p ¼ 0.60); and there was no correlation between depression scores and VCSS (p ¼ 0.07,
r2 ¼ 0.034), or between VDS groups 1, 2 or 3 (p ¼ 0.75). There was a weak correlation between depression
scores and AVVQ (p ¼ 0.0009, r2 ¼ 0.12) and depression scores and EQ-5D (p < 0.0001, r2 ¼ 0.32) and
EQ-VAS (p < 0.0001, r2 ¼ 0.25).
Conclusion: Depression is prevalent in patients with symptomatic varicose veins, where it is commonly
undiagnosed and untreated. A more holistic approach to patients with venous disease is therefore
advocated.
! 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Introduction
Depression is a common mental health disorder, and affects
more than 120 million people worldwide.1 It is characterised by
symptoms of sadness, loss of interest or pleasure, feelings of guilt or
low self-worth, disturbed sleep or appetite, low energy and poor
concentration (WHO). These symptoms can become chronic or
recurrent impairing an individual’s ability to cope with daily life.
Depression costs the UK economy over £9 billion in lost working
days, and although it can be both reliably diagnosed and treated in
a primary care setting only a quarter of patients with depression
seek medical advice or are receiving treatment.2
Overall, 1 in 10 adults in Britain suffer from depression at any
one time and depression is approximately 2e3 times more
common in patients with chronic physical health problems,
compared to those who have good physical health.3 This observa-
tion led to the development in 2009 of NICE guidelines in the UK,3
recommending that all adults, aged 18 years and older, with chronic
physical illness be screened for depression.
Varicose veins have been shown to impact on quality of life
(QoL),4 with increasing severity of disease having a proportionately
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greater impact.5 Depression has also been shown to adversely affect
QoL.6 The effect of symptomatic varicose veins on mental health
outcomes and on depression speciﬁcally is less well deﬁned. The
aim of this study was to evaluate the burden of depression in
patients with symptomatic uncomplicated and complicated (asso-
ciated with skin changes which include eczema, lip-
odermatosclerosis and ulcers) varicose veins presenting to tertiary
care for treatment.7
Methods
Patient selection
All patients referred by their General Practitioner (GP) to the
vascular surgery outpatients clinic at Charing Cross Hospital, Lon-
don, for management of their varicose veins, over a 6 month period
from January to June 2011, were invited to complete a validated
questionnaire relating to disease-speciﬁc quality of life, using the
Aberdeen Varicose Veins Questionnaire (AVVQ)8 and health-related
QoL, using the EuroQol-5D questionnaire (EQ-5D, EuroQol Group,
Rotterdam, The Netherlands) and EuroQol-Visual Analogue Score
(EQ-VAS).9 The presence of depressive symptoms was determined
using the Centre for Epidemiological Studies Depression Scale (CES-
D Scale)10 (see Table 1). A 20 item self-reporting scale which has
been shown to be both a sensitive and valid screening tool for
detecting depressive symptoms10 across different populations.11
No patients were excluded from the study. Ethics approval was
obtained from the Local Research Ethics Committee (LREC). Ques-
tionnaires were administered in a clinic setting following the
consultation and prior to any intervention. Questionnaires typically
took 30 min to complete. Patients did not receive any direction
regarding how they should be ﬁlled, but were provided stand-
ardised guidance notes and given the opportunity to ask questions.
Generic QoL measurement tools, such as the EuroQol (EQ-5D),
are divided into domains of interest. They thereby allow mental,
physical and social aspects of QoL to be evaluated independently.
Disease-speciﬁc QoL measurement tools, such as the AVVQ,8
attempt to quantify the change in QoL due to an individual
disease state. In combination, these two types of tool provide
a powerful and robust method for assessing both the baseline QoL
and disease-speciﬁc QoL and were therefore both utilised in this
study.
Patient age, occupation, gender, medical co-morbidity and
history of previous intervention for varicose veins were also
determined. The clinical severity of venous disease was established
by the treating physician using the Clinical Etiologic Anatomic
Pathophysiologic (CEAP) classiﬁcation, Venous Clinical Severity
Score (VCSS) and Venous Disability Score (VDS).12
Once completed, all questionnaires were collated and analysed.
The number of eligible patients who did not complete the ques-
tionnaire was also recorded. Patients with CES-D scores of >16
were referred to their GP for further management.
Statistical analysis
Univariate linear correlation analysis was used to assess the
relationship between two independent variables. Mann-Whitney-
U test was used to assess the difference between two indepen-
dent groups. Statistical signiﬁcance was expressed as both p values
and 95% conﬁdence intervals. A p value <0.05 was considered
statistically signiﬁcant.
Results
Demographic data
A hundred patients were recruited from a total of 125 eligible
patients (80% uptake) over the 6 months study period. There were
37 men (37%) and 63 women (63%). All questionnaires were fully
completed and included in the analysis. The mean age of patients
was 52.7 years (range, 24e91 years), 72% of patients were under the
age of 65 and 28% were aged 65 years or more. There was no
signiﬁcant correlation between CES-D score and patient age
(p ¼ 0.30, r2 ¼ 0.011). There was no difference in depression scores
Table 1
An overview of the questionnaires used in this study.
Questionnaire Number
of items
Parameters evaluated Score
Aberdeen Varicose Vein
Questionnaire (AVVQ)
13 - Physical symptoms
- Compression therapy use
- Limitations of disease on daily and social activities
0 (no effect) to 100 (severe effect)
EuroQoL-5D (EQ-5D) 5 - Mobility
- Self-care
- Pain/Discomfort
- Anxiety/Depression
n/a
EuroQoL-Visual Analogue
Score (EQ-VAS)
n/a This is a 20 cm subjective visual analogue scale relating
to health-related quality of life
100-0
Centre of Epidemiological
Studies Depression Score (CES-D)
20 This is a sensitive and validated self-reporting
depression-symptom scale
0e60
>16 suggests depression
>26 suggests severe depression
Clinical Stage of the Clinical Etiologic
Anatomic Pathophysiologic
(CEAP) Classiﬁcation
6 C0 e no visible varicose veins
C1 e spider or reticular veins
2 e Varicose veins
3 e Oedema
4 e Skin changes
5 e Healed ulcer
6 e Active ulcer
0e6
Venous Clinical Severity Score (VCSS) 9 Evaluates for presence of skin changes and pigmentation,
inﬂammation and induration, presence of ulcers and use
of compression hosiery
Maximum score of 27
Venous Disability Score (VDS) 1 Based on the ability to work an 8-h day with or without
the requirement for external compression hosiery support
0e3
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between those patients aged over 65 years and those aged less than
65 years old (p ¼ 0.60).
Twenty-nine per cent of all patients had CES-D scores greater
than 16 and 5% of patients had CES-D scores greater than 26. No
patient had previously been diagnosed or treated, or were on
current treatment for depression.
In terms of past medical history, no patient had co-existing
peripheral vascular disease. Thirty-three patients (33%) had previ-
ously undergone intervention for their varicose veins. There was no
signiﬁcant difference in CES-D scores in patients who had previ-
ously undergone treatment for their varicose veins, compared to
those who had not (p ¼ 0.94).
Depression and quality of life
A weak positive correlation was seen between CES-D score and
disease-speciﬁc QoL as evaluated using the AVVQ (p ¼ 0.0009,
r2 ¼ 0.11) (see Fig. 1). A signiﬁcant negative correlation was seen
between CES-D score and health-related QoL as indicated by EQ-5D
(p < 0.0009, r2 ¼ 0.32) and EQ-VAS scores (p < 0.0009, r2 ¼ 0.25)
(see Figs. 2 and 3). Higher EQ-5D and EQ-VAS, unlike the AVVQ
score, indicate better QoL and lower EQ-5D and EQ-VAS scores
worse QoL.
Depression and clinical severity of venous disease
Patients with severe depression (n ¼ 5) were observed to have
venous disease of clinical stage 4e6, as deﬁned by the CEAP classi-
ﬁcation. However, overall there was no difference in CES-D scores
with varying clinical stage (p ¼ 0.30). CES-D score did not correlate
with theVCSS (p¼0.07, r2¼0.03)orVDS (p¼0.75) (see Figs. 4 and5).
Discussion
The presence of depression in patients with varicose veins has
undergone only limited investigation previously. In contrast, QoL
status in patients with varicose veins has been extensively inves-
tigated,8,13e15 and is an accepted outcome measure used both in
clinical practice and in clinical trials investigating varicose vein
treatment.5,16,17 QoL measures are also shown to be better corre-
lated with symptomatology and patient satisfaction than anatom-
ical or technical measures.18
Varicose veins are common with a reported incidence of
20e25% in women, and 10e15% in men.19,20 A number of studies
have shown an increased incidence of depression and anxiety in
patients with venous ulcers, with reported incidences ranging from
40 to 60%.21e23 Our study reports an incidence of depression in
patients with symptomatic varicose veins of 29% and this falls to
26% when patients with healed or active venous ulcers are
excluded. This is twice the reported prevalence of depression
within the general population,24 but is similar to that reported in
patients with chronic physical health problems.
Esteban et al, in a Spanish study of 7341 subjects aged>15 years
with a variety of chronic medical diseases, found that depression
had a signiﬁcant impact on health-related QoL.25 When looking
speciﬁcally at the impact of venous disease onmental health, Smith
et al in their study found no signiﬁcant difference in the mental
health domain of the SF-36 in patients with varicose veins
compared to those without,4 but following treatment with open
surgery there was a signiﬁcant improvement in the mental health
domain. In our study, depressive symptoms correlated with
disease-speciﬁc and health-related QoL outcomes, however, we
failed to demonstrate any correlation with clinical disease severity.
A possible explanation is that depression may alter a patient’s
perception of the severity of venous disease. Chronic physical
health problems are also seen to precipitate and exacerbate
depression and this may be true for varicose veins.26
In our study similar depression scores were reported amongst
men and women. This is in contrast to the incidence within the
general population, where women are twice as likely to suffer from
depression compared to men.27 The reasons for this are unclear. In
addition, there was no correlation with depression and age as
documented in other studies of depression in the general pop-
ulation. However, there were few patients in our study over the age
of 65 years (27%).
Both depression and varicose veins are treatable once diag-
nosed. Work by Chassany et al28 showed that general practitioners
Figure 1. Graph demonstrating a positive correlation between CES-D and disease
speciﬁc quality of life as indicated by the AVVQ score (p ¼ 0.0009, r2 ¼ 0.11).
Figure 2. Graph demonstrating a correlation between CES-D and health-related
quality of life as indicated by the EQ-5D (p < 0001, r2 ¼ 0.32) and EQ-VAS scores
(p ¼ 0.0009, r2 ¼ 0.25).
Figure 3. Graph demonstrating a correlation between CES-D and health-related
quality of life as indicated by the EQ-5D (p < 0001, r2 ¼ 0.32) and EQ-VAS scores
(p ¼ 0.0009, r2 ¼ 0.25).
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routinely under-estimate the quality of life impairment due to
venous disease whilst over-estimating that from peripheral arterial
occlusive disease. Notably, no patients in our study had previously
been diagnosed or were on treatment for their depression.
The aim of this study was to assess the burden of disease in
ambulatory patients with symptomatic varicose veins, who have
presented to their GP and subsequently to a vascular surgeon for
treatment. However, this group of patients may not reﬂect the
burden of depression in varicose veins patients within the general
population. Moreover, the inﬂuence of socioeconomic factors and
ethnicity on depression scores was not ascertained in this study.
Further information regarding depression scores following venous
intervention will be useful in establishing whether the symptoms
of depression are reversible following intervention and hence
would enhance our understanding of the problems these patients
face. This is part of on-going work by our group.
Conclusion
Patients with symptomatic varicose veins are at increased risk of
depression compared to the general population. This study reports
a high incidence of previously unreported and undiagnosed
depression in this group of patients. Further investigation of
a patient’s wellbeing and a more holistic approach in the
management of patients with venous disease is therefore
recommended.
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Editorial
Phlebectomies: to delay or not to delay?
Varicose veins are a common disease, with a
reported prevalence of 20–40%.1–3 Their treatment
represents one of the most common elective surgi-
cal procedures in vascular surgery. Numerous
advances have been made in this field, moving
away from surgical ligation of the saphenofemoral
junction and stripping, towards less invasive
options, including ultrasound-guided foam scler-
otherapy, radiofrequency ablation (RFA) and endo-
venous laser ablation (EVLA).
Although these methods all address the truncal
incompetence with similar technical success rates,4
residual superficial varicosities may remain post-
operatively and their treatment is still a matter of
debate.
There are two schools of thought with regard to
treating varicosities in those patients undergoing
truncal vein ablation. The first suggests simul-
taneous truncal treatment and phlebectomy as a
single procedure.5 The second advises delayed phle-
bectomy after monitoring for varicosity regression.
If still present, these can be addressed with ambulat-
ory phlebectomies or foam sclerotherapy.6
Advocates of the first option suggest that
immediate treatment of surface varicosities is
advantageous in that it ensures patients are
treated in a single session and reduces the varicosity
reservoir. However, this may increase operative
time,7 and could be over-treating patients whose
varicosities may regress.
Those in favour of delayed phlebectomies claim
that this treatment is shorter, saving operative
time. However, a variable number of patients do
come back with troublesome residual varicosities,
which require secondary procedures.
The evidence of the timing for phlebectomy is at
best confusing. Carradice et al.7’s 2009 study
showed that while there was no sustained differ-
ence in quality-of-life measures between delayed
and simultaneous phlebectomy in the context of
EVLA treatment, 66% of patients in the truncal abla-
tion only group required secondary interventions.
Monahan et al.6 suggested that after RFA, 13% of
patients had spontaneous varicosity regression
and 41% of patients did not require further treat-
ment, suggesting that monitoring for regression is
the best option.
This appears confusing and contradictory, but
both EVLA and RFA truncal ablation have been
shown to save 30–40% of patients from having
needless phlebectomies. However, Doganci et al.’s8
comparison of laser wavelengths utilized a
delayed approach but 100% of subjects required
further intervention.
Part of the issue is that the literature is very het-
erogeneous, making comparisons between studies
challenging.9 Variations exist in the reporting stan-
dards for surgical vs. EVLA/RFA or foam scler-
otherapy both in terms of vein classification, as
well as length to follow-up, objective assessments
and questionnaires. Studies looking at specifically
immediate vs. delayed phlebectomies are few in
number.5,10,11 Most randomized studies into cath-
eter type or modality to date have used standar-
dized delayed or simultaneous phlebectomies
across their study groups, with no clear definition
of the trigger to varicosity treatment. This makes
comparison difficult.
Furthermore, there are a number variables that
confound the picture. Patient factors such as age,
body habits and mobility will influence the result
of any intervention on the venous system. Patient
preference and expectations, as well as operator
experience, may have an effect on patient and oper-
ator satisfaction. Pain levels experienced have been
assessed in only one study, which showed no stat-
istical difference in pain or return to normal activi-
ties.7 Finally the anatomy of the venous system and
its preoperative haemodynamic state12,13 will also
influence the outcome of any intervention, as will
the condition of the patient and the venous calf
pump. These factors need to be considered when
considering treatment options, with the appreci-
ation that any alteration in the venous tree will
lead to haemodynamic changes.14
Ultimately, the aim of procedures for residual
venous disease are to provide the maximum symp-
tomatic relief for as long as possible. An ideal treat-
ment would be minimally invasive, safe, effective
from a functional and cosmetic point of view,
have low recurrence rates and be cost-effective.
However, the goal of ambulatory minimally inva-
sive treatment should not preclude the full manage-
ment of the disease.
Venous disease affects a large proportion of our
population. Despite advances in the field, the evi-
dence behind treatment is still unclear; this is par-
ticularly true of tributary vein treatment at the
Phlebology 2012;27:103–104
time of truncal ablation. Further studies, in terms of
randomized controlled trials targeting the questions
above, are required to provide evidence to best lead
our practice.
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Review article
Treatment options, clinical outcome (quality of life)
and cost benefit (quality-adjusted life year)
in varicose vein treatment
D Kelleher, T R A Lane, I J Franklin and A H Davies
Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, Charing Cross
Hospital, London, UK
Abstract
Varicose veins are an extremely common condition causing morbidity; however, with current
financial pressures, treatment of such benign diseases is controversial. Many procedures
allow the treatment of varicose veins with minimal cost and extensive literature
supporting differing approaches. Here we explore the underlying evidence base for
treatment options, the effect on clinical outcome and the cost-benefit economics associated
with varicose vein treatment. The method of defining clinical outcome with quality-of-life
assessment tools is also investigated to explain concepts of treatment success beyond
abolition of reflux.
Keywords: QALY; varicose veins; cost-effectiveness
Background
With the onset of the global economic crisis and the
threat of world recession, health economics has
become increasingly important in health-care
decision-making. Discussions on the health econ-
omic benefits or burdens of new endovascular tech-
niques are common.
Health-care costs are spiralling; in the UK they
have doubled over the last decade to £126 billion
annually,1 and a similar picture is seen in the USA
with spending now at $1.2 trillion/year,2 equivalent
to over 8% GDP, a value seen throughout Europe as
well.3 In the National Health Service (NHS), auster-
ity measures require a saving of £20 billion on this
budget of £126 billion (16%), whilst caring for an
ever more elderly and frail population.4
Although costs and value for money have always
had a role in the decision-making processes, these
increasing financial pressures at the hospital,
regional and national level have caused hospital
managers to look at ways to cut costs at all levels.
Varicose veins have been labelled as a ‘Procedure
of Low Clinical Value’ due to the low mortality
rates associated with this benign disease, leading
to a reduced rate of referral for treatment.5,6
With the majority of patients with varicose veins
being young and otherwise systemically well and
with varicose veins rarely having a significant
effect on mortality, they are afforded low priority.
Therefore, by reporting crude outcomes through
serious morbidity (or complications) and mortality,
the object of treatment is missed and it allows ques-
tions to be raised over the necessity for intervention.
In benign diseases quality-of-life (QOL) assess-
ments are invaluable in revealing the true clinical
benefit of intervention.7,8
Varicose veins are extremely common (approx.
25% of the population),9 and so even moderate
improvements in patient outcome generate large
overall population improvements.10
QOL assessment
QOL instruments include both generic and disease-
specific surveys. Generic surveys assess global
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states of wellbeing and provide a subjective
measure of treatment efficacy, while disease-specific
surveys focus on elements associated with particu-
lar disease processes and treatment effects.11–14
In the UK, the National Institute for Health and
Clinical Excellence (NICE) was founded in 1999.
NICE is an independent government-funded
organization that advises the National Health
Service and has become a role model for the devel-
opment of clinical guidelines and attempts to evalu-
ate the cost and cost-effectiveness of potential new
treatments and technologies within the NHS. It
has set a cost-effectiveness threshold of £20–
£30,000 per QALY (quality-adjusted life year) gain
for appraisal of surgical procedures.
Vascular surgery is a specialty where there has
been an ever-expanding introduction of new and
often expensive technologies, some of which have
not been fully evaluated.
Varicose veins
Varicose veins affect approximately 25–50% of the
adult population,15 and complications arising
from them are a significant cause of patient morbid-
ity and health service expense.16
Symptoms are often vague and non-specific but
include aching, discomfort, pruritus and muscle
cramps; however, there are more obvious and objec-
tive symptoms which include varicose eczema, pig-
mentation, bleeding and ulceration.17 Extensive
previous work has shown that venous disease sig-
nificantly impairs QOL.18–20
There are widespread misconceptions held by
both the general public and primary care physicians
with regard to varicose veins. The public fear that
there is an increased likelihood of deep vein throm-
bosis (DVT) and that chronic venous changes are a
common cause of limb amputation. However,
primary care physicians are often mistaken in
believing varicose veins are merely a cosmetic
concern and even the skin changes of chronic
venous insufficiency (a precursor to ulceration) are
inconsequential. Extensive evidence exists to show
the outcome of treatment of venous disease, but
this requires the use of QOL measures. All forms
of venous treatment have been shown to improve
QOL.10,21–26
Varicose vein assessment
CEAP classi¢cation
Varicose veins have often been inadequately
defined and have variously been described as
being visible subcutaneous veins, to dilated
palpable subcutaneous veins generally larger than
3 mm in the upright position. Due to this lack of
consensus in the reporting and classification in the
published literature, the CEAP (Clinical severity,
AEtiology, Anatomy, Pathophysiology) classifi-
cation for chronic venous disorders was developed
in 1994 by an international ad hoc committee of the
American Venous Forum, endorsed by the Society
for Vascular Surgery, and this classification
became incorporated into ‘Reporting Standards in
Venous Disease’ in 1995, with further refinements
made to it in 2004.27 This classification has been ubi-
quitously adopted and so allows more a direct com-
parison between studied modalities.
This is a clinician-implemented categorization
tool. The clinical component indicates disease
severity, ranging from zero points, for completely
asymptomatic patients, up to six points for active
ulcers. The aetiological component denotes the
venous disease as congenital, primary or secondary
in nature. The anatomic classification pinpoints the
veins involved as superficial, deep or perforating.
The pathophysiological classification identifies the
presence of reflux in the superficial, communicat-
ing, or deep systems, as well as the existence of
outflow obstruction. The CEAP classification is
doctor driven, and highlights the cause of the
underlying venous abnormality; however, it is not
sensitive enough to track progressive changes.
Venous clinical severity score
The venous clinical severity score (VCSS) is a
clinician-completed tool, which includes nine hall-
marks of venous disease, each scored on a severity
scale from 0 to 3. In order to generate a dynamic
score, VCSS categories are scored individually.
These include skin changes and pigmentation,
inflammation and induration, and ulcers (including
number, size and duration). In 2007, an inter-
national ad hoc working group was created to
revise the VCSS to update the terminology, simplify
the application and clarify ambiguities, which was
completed in 2010.28
The value of the VCSS is its ease of use along with
an emphasis on the most severe manifestations of
venous disease which are likely to show the greatest
response to therapy allowing tracking and quantifi-
cation of improvement (or deterioration).
Aberdeen varicose vein questionnaire
The Aberdeen varicose vein questionnaire is a
13-question patient-completed survey addressing
multiple elements of varicose vein disease, first
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developed in 1993.29 It has subsequently been trans-
lated into many languages.
Physical symptoms along with social issues,
including pain, ankle oedema, ulcers, compression
therapy use and limitations on daily activities are
examined, as well as the cosmetic effect of varicose
veins. The questionnaire is scored from 0 (no effect)
to 100 (severe effect).
Short form health survey (SF-36, SF-12, SF-8)
A widely used and well-validated generic health
QOL assessment tool is the short form health
survey (QualityMetric, Lincoln, RI, USA), devel-
oped over time with questions in physical and
mental health. These two categories have been
broken down into eight domains that include phys-
ical and social functioning, role limitations due to
physical or emotional problems, mental health,
pain, vitality and health perception. The survey
generates a score ranging from 0 to 100, with
higher scores indicating better general health
perception.
EuroQOL 5 domain
The EuroQOL 5 domain survey (Euroqol, Rotterdam,
The Netherlands) is an alternative validated patient
completed generic health QOL questionnaire that
measures mobility, self-care, usual activities, pain
and anxiety domains. The domains generate a
unique QOL outcome between 20.594 and 1 with
1 being perfect health.
It also provides a separate visual analogue scale
rendering of global health status, from 0 to 100,
with higher scores indicating better health.
Treatment of varicose veins
The treatment of patients with superficial venous
reflux has changed in recent years following the
widespread acceptance of minimally invasive,
endovenous modalities including ultrasound-
guided foam sclerotherapy (UGFS), radiofrequency
ablation (RFA) and endovenous laser ablation
(EVLA).30,31 All interventions are aimed at princi-
pally abolishing truncal reflux and then removing
or occluding any incompetent varicosities.
Postal surveys carried out in 2008 and 2009
revealed that most surgeons who performed
varicose vein surgery still regularly performed
traditional open surgery, but over one-third also
offered minimal access techniques either instead
of open surgery, or as an adjunct procedure.32,33 In
the UK, an average of 40,000 NHS-funded interven-
tional procedures are completed each year.34
Compression
Compression stockings may be employed as a
primary treatment for patients with symptomatic
varicose veins. They act by providing graduated
radial pressure between ankle and knee/thigh,
and this along with the calf muscle pump returns
venous blood cranially. Stockings are extremely
attractive for the cost-conscious initially; however,
the need for replacements (4 times per year) and
poor compliance greatly reduce their effective-
ness.35 Additionally some patients (37%) still com-
plain of persistent venous symptoms despite
stockings.36
Conventional surgery
Standard surgery for varicose veins was first
described over 100 years ago, and is still considered
the gold standard against which other treatment
modalities are tested. The results of surgery are
good and patients are generally satisfied. Surgery
is associated with an improvement in QOL in
most patients. However, there is a significant rate
of minor complications.37 Rates of morbidity vary
from series to series.21,22,38
New techniques that have arisen interrupt the
reflux haemodynamics while preserving the long
saphenous vein and include the ASVAL and
CHIVA techniques.39,40 These provide minimally
invasive treatments performed under tumescent
local anaesthesia, and have produced good results.
One single-centre series has shown that while
CHIVA offers improved recurrence rates compared
with open stripping in experienced hands, it has
a steep learning curve and can lead to worse
outcomes.41
Endovenous ablation
In the last decade the introduction of minimally
invasive endovenous ablation therapy has revolu-
tionized the treatment of varicose veins.30
Three endovenous modalities offer thermal abla-
tion – RFA, EVLA and steam (SVS). RFA and EVLA
have 10 years of evidential data, though with rapid
advances in technology many series have now been
superseded.
Current RFA technology includes the VNUS Clo-
sureFAST catheter and the Olympus CELON RFITT
catheter. These offer effective reproducible treat-
ments under local anaesthetic in the outpatient
setting.30,42 Direct comparisons with laser ablation
have shown an equivalent efficacy with a reduced
side-effect profile.22,24,43
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Laser treatment has expanded from the original
810 nm wavelength laser to a wealth of different
wavelengths, with different treatment profiles.30,31
These different wavelengths offer a flexibility
of treatment not found in other endovenous
modalities.44,45
Steam is a new technology of thermal ablation,
with only limited evidence of proof of concept at
present.46 Puffs of steam provide the energy for
thermal denaturing of the long saphenous vein.
New developments include Clarivein mechano-
chemical ablation and Sapheon cyanoacrylate glue
closure. Clarivein has shown encouraging early
results of 96.7% closure at six months.47 This tech-
nique of mechanical scarifying of the vein and
instillation of liquid sclerotherapy needs no tumes-
cent and so offers a less invasive alternative to
thermal ablation. A further option is the Sapheon
Venaseal Closure System, which utilizes proprietary
glue to seal the vein; however, this has only been
described at conference presentations so far.
Ultrasound-guided foam sclerotherapy
UGFS is an effective and cheap method of chemi-
cally ablating incompetent varicosities. It is truly
minimally invasive, requiring only a single needle
puncture and no catheterization48 and has been
shown to be more effective than conservative
therapy with compression.49 The literature on
foam sclerotherapy is extensive and it can provide
similar closure rates and significant improvements
in QOL outcomes at one year.22,50 It appears to be
more user-dependent than other modalities,
though in experienced hands can provide excellent
treatment at an unbeatable price.51 Recurrence,
however, can be a problem in some series.52
Cost-effectiveness
Despite being one of the most commonly performed
surgical procedures, very few cost-effectiveness
evaluations have been calculated. Ratcliffe et al.53
conducted a randomized trial comparing open
surgery with conservative management.
The surgical group was a heterogeneous collec-
tion of unilateral and bilateral procedures per-
formed under general anaesthesia as a day case,
and the conservative group was treated with com-
pression hosiery or bandaging. Not only did they
demonstrate that open surgery was cost-effective
using £20,000 QALY level, but a third of patients
allocated to the conservative group dropped out
to undergo surgery before the trial had finished.
The main aim of the REACTIV (Randomized and
Economic Assessment of Conservative and Thera-
peutic Interventions for Varicose Veins) study was
to investigate the clinical and cost-effectiveness of
varicose vein treatments.54 Patients were split into
three groups:
Group 1 – minor below knee varicose veins without
truncal reflux, randomized to conservative or
sclerotherapy treatment, n ¼ 34;
Group 2 – moderate below knee varicose veins with
truncal reflux, randomized to standard surgery or
sclerotherapy treatment, n ¼ 77;
Group 3 – significant varicose veins above and
below the knee with truncal reflux, randomized
to conservative treatment or standard surgery,
n ¼ 246.
Once again, a significant number of patients allo-
cated to a conservative management path became
dissatisfied and dropped out of the study so that
they could undergo surgery. Although numbers
were small in some groups, this study demon-
strated the economic value in treating patients
with symptomatic varicose veins.
Subramonia and Lees performed a study compar-
ing surgery and RFA55 which incorporated cost
analysis into the design.56 This study randomized
88 patients into RFA (VNUS ClosurePlusTM) and
conventional surgery (RFA 47, surgery 41) under
general anaesthetic. RFA was found to be signifi-
cantly more expensive (£1276 versus £559);
however, the RFA group returned to work an
average of one week earlier (10 days versus 18.5
days), at a cost of £6.14 per additional working
hour gained. However, this study utilized the
VNUS ClosurePlusTM catheter, which is six times
slower than the current VNUS ClosureFASTTM cath-
eter (0.05 cm/second versus 0.33 cm/second). The
cost difference was due to increased theatre time
(83.6 minutes versus 55.7 minutes, additional cost
£171.01) and catheter cost (£550).
Gohel et al.57 produced a Markov model to evalu-
ate the cost-effectiveness of traditional and endove-
nous treatments for patients with primary great
saphenous varicose veins. Day-case surgery or
endovenous ablation using EVLA or RFA per-
formed as an outpatient were shown to be the
most likely cost-effective treatment strategies for
patients with primary unilateral great saphenous
vein reflux requiring treatment. However day-case
traditional surgery was also shown to be below
the conventional threshold of the cost-per-QALY
in the UK and therefore cost-effective.
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Recent work by Rasmussen et al.22 showed equiv-
alence between all available modalities, in a direct
comparison trial of 580 legs. All procedures were
under local anaesthetic and treatment time was
19–32 minutes. RFA was shown to be associated
with less postoperative pain leading to a faster
return to work and therefore a better cost-
effectiveness analysis compared with open
surgery or laser ablation. Catheter costs were
EVLA £307 and RFA £371. Foam sclerotherapy
remained the cheapest option, but was associated
with a significantly higher recurrence rate at one
year (16% versus 5–6%).22
With a wide range of available treatments and
few comparative studies, treatment choices are cur-
rently made on the basis of local availability and
clinician preference, rather than clinical evidence.
All procedures have been shown to be effective
at both abolishing reflux and improving
QOL.22,24,52,55,58,59 Additionally, day-case surgery,
RFA, EVLA and UGFS have been demonstrated
to be cost-effective at the limit of £20,000 per
QALY.57
Patient preference
With the evolution of a patient-centred model of
health care, the preferences of the patient must be
one of the major contributors to the treatment
plan. Varicose veins have many options and these
should all be offered to patients with appropriate
guidance before a definitive plan is agreed. Recent
studies show that while patients felt unable to
access modalities formally, they had significant pre-
ferences for local anaesthetic and one sitting treat-
ment,60 though expectations need to managed
prospectively to avoid patient disappointment.61
Conclusion
Varicose veins have a multitude of treatment
options, all of which provide excellent improve-
ments in QOL at a cost-effective level. Overall
costs have fallen dramatically despite material
requirements, and no patient should be without a
treatment option. The treatment of varicose veins
is one of the few treatments that offer lowmorbidity
for large improvements in QOL. Importantly,
despite the higher incidence of varicose veins in
older patients, a high percentage of patients are of
working age when health improvements are most
cost-effective.
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ABSTRACT
Pharmacomechanical thrombolysis is being used increasingly for the treatment of deep vein thrombosis (DVT) and aims to re-
duce the severity of post-thrombotic syndrome. We report the case of a 60-year-old woman with extensive lower limb DVT that 
was treated using pharmacomechanical thrombolysis leading to complete recovery of her deep venous system. The prompt use 
of pharmacomechanical thrombolysis for the acute management of extensive DVT should be considered when treating patients 
with extensive DVT in order to facilitate return of normal function.
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Figure 3 Venography after Trellis®-8 and 16-hour 
thrombolysis showing thrombus resolution and patent common 
iliac vein stent
Figure 1 Computed tomography venography curved coronal 
reformat image showing left iliac system deep vein thrombosis 
(arrow)
Figure 2 Trellis®-8 device in situ from left common iliac vein 
to popliteal vein
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Conclusions
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Review article
Complications of radiofrequency ablation
of varicose veins
M A Anwar, T R A Lane, A H Davies and I J Franklin
Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, 4 North,
Charing Cross Hospital, London, UK
Abstract
Radiofrequency ablation (RFA) has become a valued weapon in the phlebologist’s armoury.
It offers ease of use and reproducibility with good outcomes. However, as with all
interventions, complications arise. In this review we examine the complications inherent
with RFA and their relative risk, with their avoidance measures if available. Overall, we
find that RFA offers a very safe procedure with rare severe complications.
Keywords: complications; endovenous; ablation; radiofrequency
Introduction
Varicose vein treatment is one of the most common
vascular operations performed in the National
Health Service1 with the aim of reducing symptoms
and the burden of skin ulceration.2 The manage-
ment of varicose veins has changed rapidly in
recent years. Saphenofemoral ligation and stripping
of the great saphenous vein (GSV) once used to be
the standard treatment for GSV reflux but has
been challenged and in some areas replaced by
endovenous therapies.3,4 Evidence has favoured
endovenous modalities in terms of reduced post-
operative hospital stay, early return to work and
low complication rates.3,5–7
The following endovenous therapies have
emerged in practice:
† Thermal ablation:
W Laser,
W Radiofrequency,
W Steam,
W Cryotherapy.
† Non-thermal ablation:
W Foam sclerotherapy,
W SapheonTM (glue),
W ClariveinTM (mechanical scarification and
liquid sclerosant).
The authors have reviewed the potential compli-
cations and possible risks associated with radiofre-
quency ablation (RFA) of varicose veins.
Radiofrequency ablation
RFA of varicose veins was first described by
Goldman in 20008 utilizing the VNUSClosurePlusTM
catheter (Covidien, Dublin, Ireland). Since then, two
further catheters have been introduced – VNUS
ClosureFastTM9 and Olympus Celon RFITTTM
(Olympus, Tetlow, Germany).10
Radiofrequency energy thermally denatures vein
wall collagen, leading first to vein wall inflam-
mation, then fibrosis and finally to occlusion. Sur-
rounding tissues are protected by tumescent local
anaesthesia, which acts as both a heat sink and as
anaesthetic.11 The vein lumen is compressed by
the tumescent solution around the tip of the cath-
eter, improving energy transfer and reducing
power requirements.
The original ClosurePlusTM catheter required a
constant pullback technique of 3 cm/minute
(0.05 cm/second), whereas the ClosureFASTTM cath-
eter treats a 7 cm segment of vein for 20 seconds
(0.33 cm/second). An electronic feedback mechanism
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with varying power maintains a constant catheter
temperature of 1208C in the ClosureFASTTM and
858C in the ClosurePlusTM system. The Olympus
Celon RFITTTM provides bipolar electrode treatment
and utilizes a pullback technique with an optimal
speed of 1–1.4 cm/second.12 ClosureFASTTM and
RFITTTM have similar treatment profiles versus
laser ablation but have not been directly compared.12
The ability of RFA to treat varicose veins under
local anaesthetic has aided the transformation
from inpatient operation to outpatient or office-
based procedure. The ease of use and high patient
satisfaction have led to a surge of interest.13,14
Complications with RFA
All treatments for venous disease involve the risk of
adverse events. It is important that the risk of a
treatment is small comparedwith the likely benefits.
Early complications
Closure success
Short-term technical success is defined as the suc-
cessful occlusion of the vein lumen. Immediate
failure of the technique should be identified at the
time of the procedure by the completion of a
duplex ultrasound scan. Immediate technical
success rates of more than 95% with RFA have
been reported.3,12,15 A multicentre trial using the
ClosureFASTTM catheter has achieved an occlusion
rate of 99.6% at six months.9
Pain
RFA has been found to be associated with less post-
operative pain, a lower requirement for analgesia
and a reduced impact on daily activities than other
treatment modalities.3,5 Rasmussen et al.3 reported
a mean pain score of 1.21/10 during the first 10
days and the time to return to normal activity was
only one day. In the VALVV randomized trial com-
paring RFA with laser ablation, RFA patients
reported a mean pain score of 2.2/10 and an analge-
sia requirement of 10.9 tablets over 10 postoperative
days. In all, 60% of patients returned to normal
activities within three days.5 The EVOLVeS study
compared RFA with surgery and found that RFA
patients returned to normal activities in 1.15 days
and had a persistently improved pain score (com-
pared with both baseline and surgery) throughout
two years of follow-up.15 Results from other
studies also suggest low pain and analgesic require-
ments following RFA treatment.16
Phlebitis
Thrombophlebitis is the presence of inflammation
at the site of the treated GSV associated with loca-
lized inflammatory changes such as hyperaemia,
oedema and tenderness. It can also occur in varicos-
ities and has an association with deep vein throm-
bosis (DVT).17 A recent meta-analysis reported an
early phlebitis rate of 8% with RFA (by combining
the results of three large trials).7 Recent studies
have reported rates of 7–9.6%.3,5 However,
Shepherd et al.5 also had one case of pulmonary
embolism following RFA but with no evidence of
deep vein thrombosis.
Endovenous heat-induced thrombosis
Thrombus can protrude into the common femoral
vein (CFV) as well, an entity called endovenous
heat-induced thrombosis (EHIT).18–20 For safety,
the manufacturers recommend the tip of the abla-
tion catheter should be at least 2 cm from the saphe-
nofemoral junction.
In EHIT, thrombus can be seen either:
(1) At the level of the deep vein without protrud-
ing into CFV;
(2) Projecting into the deep system with ,50%
luminal occlusion of CFV;
(3) Protruding into the deep system with more
than 50% luminal occlusion;
(4) Causing complete occlusion of the deep
system – in other words, a full DVT.
A recent small-scale study into GSV patency and
EHIT after RFA showed a 2.7% (2/73) rate of class
II EHIT with no DVT,20 which corresponds to
earlier work by Mozes et al.19 of 2.1% and Lawrence
et al.;21 however, Proebstle et al.9 found a rate of 0%
from 252 patients with ClosureFAST and Marsh
et al.22 found a rate of 0.4% from 2470 limbs.
Cases of EHIT class II have been successfully
treated with two weeks of low-molecular-weight
heparin (LMWH) with complete resolution in all
cases.20 For classes III–IV full DVT treatment is
recommended.18
Deep vein thrombosis
DVT can develop in the calf deep veins or a throm-
bus can circulate from the treated superficial veins
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(as described above) following RFA. DVTafter endo-
venous ablation is extremely rare and indeed most
case series and trials show no evidence of DVT at
all.3,7,23,24 This makes quoting advice and risks diffi-
cult – the 2011 Venous Forum meeting at the Royal
Society of Medicine had a dedicated session for
debate on this issue, due to limited evidence.
Most clinics quote risks of approximately 1:1000
and provide perioperative prophylaxis.22 Concomi-
tant small saphenous vein surgery or transluminal
occlusion of perforator with RFA have been con-
sidered risk factors for high calf DVT.22
Risks are reduced by the postprocedural use of
compression stockings, the use of local anaesthetic
and patients walking in and out. However, once
again there are no detailed data for guidance.
Pharmacological prophylaxis may be used for all
patients undergoing treatment or only in selected
cases. Universal coverage prevents missed cases
but is probably unnecessary in many patients.
Selective treatment provided on the basis of risk
assessment will miss some cases in need of prophy-
laxis and increase clinical load.
Patients at high risk of DVT (active malignancy,
age over 60, known coagulation disorders, one or
more significant medical co-morbidities, use of
oestrogen-containing oral contraceptive pills or hor-
monal replacement therapy, and previous history of
phlebitis or DVT) should have an injection of
LMWH before the endovenous treatment. There is
no evidence for prolonged anticoagulation as a pro-
phylatic measure (beyond the day of treatment),
but in the high-risk group, self-administration of
LMWH can be suggested until the patient is fully
mobile. Some surgeons request that female patients
stop oestrogen-containing oral contraceptive pills or
hormone replacement therapy a month before treat-
ment. There is no evidence in support of this prac-
tice, and there is a risk of unwanted pregnancy.
During ultrasound-guided endovenous therapy,
the presence of any thrombus in deep veins is
easy to recognize and should be treated with appro-
priate anticoagulation. For total deep vein occlu-
sion, full DVT treatment should be instigated
while for partial occlusion of a deep vein, a short
course of it may be sufficient.
Air travel of more than four hours duration
(especially in high-risk group patients) is generally
discouraged for two weeks following RFA treat-
ment, but again evidence is lacking due to the
rarity of DVT after ablation. Some surgeons extend
this delay to 4–6 weeks. Patients should be
advised to reduce their risk by keeping well-
hydrated, wearing compression stockings and exer-
cising their calf muscles.
Wound problems and skin burns
Other early complications including wound pro-
blems (6–8%) and skin burns (8%) have been
reported following RFA.5,7 The incidence of skin
burns has reduced since the advent of tumescent
anaesthesia from 1.8% to 0.5%.25 The treated vein
may be palpable as a cord; however, this rarely
causes significant discomfort, and is poorly
reported in studies.
Lignocaine toxicity
The routine use of tumescent anaesthesia in a clinic
room setting has now become an established way to
treat varicose veins. Tumescent anaesthesia consists
of lactated Ringer’s or normal saline fluid combined
with lidocaine, epinephrine and optionally bicar-
bonate to form a 0.1% anaesthetic solution (or
1 mg per mL).11 Tumescent anaesthesia has been
found to be very safe in large series,26 and previous
work on tumescent local anaesthetic has shown that
used subcutaneously a dose of 35 mg/kg is safe and
extremely effective in vein surgery.
In an average 70 kgman this equates to 2450 mL –
a substantial safety margin for most endothermal
procedures (35mg/kg for 70 kg person ¼
2450 mg ¼ 2450 mL of 0.1% solution). Despite this,
surgeons and phlebologists should be aware of the
potential for adverse events due to lidocaine injec-
tion. Complications of early or mild toxicity of lido-
caine may cause light-headedness, dizziness,
tinnitus, confusion and drowsiness. It is important
to talk to the patient throughout the procedure
and to discontinue injection if suspicious of any of
these symptoms arising. Tonic–clonic convulsions
leading to progressive loss of consciousness, coma,
respiratory depression and arrest are the signs of
serious toxicity.
Management of lidocaine toxicity involves stan-
dard resuscitation techniques, however patients
may require extended resuscitation.27 Hypoxia
needs to be prevented and hypotension and
arrhythmias treated. Grand mal convulsions may
require treatment with intravenous diazepam.
Lipid emulsion therapy has recently emerged as a
significant aid in managing toxicity.
Late complications
Skin pigmentation
Skin discolouration or hyperpigmentation may
occur following endovenous treatment due to the
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residual blood trapped within the veins. This nor-
mally resolves over a few months. The pooled rate
of bruising and skin pigmentation of 19% following
RFA has been reported in a meta-analysis.7 Other
studies have reported lower rates of skin staining,
between 6% and 9%.3,5 RFA (both VNUS and
RFiTT) has been shown to cause less pain and
ecchymosis than laser ablation.12,28 The risk of this
complication can be lessened by careful application
of tumescence and avoiding treating very super-
ficial veins with RFA.
Nerve damage (paraesthesia)
Nerve damage is one of the most common causes of
litigation after varicose veins surgery.29 Paraesthe-
sia or numbness may arise following RFA but in
most cases improves over the course of a fewweeks.
In a review of case series of patients who under-
went RFA, the median rate of paraesthesia has been
reported as high as 13%,30 with other studies report-
ing it as 4.8–12%.3,5 In the meta-analysis reported
by Nesbitt et al.,7 the pooled rate of paraesthesia
from three large studies was 20% at three months.
Significant reduction in the incidence of paraesthe-
sia has been shown after the introduction of tumes-
cent local anaesthesia to the RFA procedure – from
14.5% to 9.1%.25 For treatment of the short saphe-
nous vein, a study of laser ablation has shown
that mid-calf cannulation may avoid thermal
damage to the sural nerve (3% versus 20%, P,
0.05).31
Recurrence
Patients with late failure of RFA may remain
asymptomatic or present with recurrent varicose
veins (REVAS).32 REVAS is a clinical definition
that represents true recurrences in addition to
residual varicosities and the progression of venous
disease. Therefore, the presence or absence of
REVAS is dependent not only on efficacy of the
treatment to the saphenous trunk but also the man-
agement plan for the varicosities.33 It certainly has
an influence on patients34,35 and therefore the
concept of REVAS and asymptomatic recurrence
should be carefully explained. The management of
patient expectations plays a large role in treatment
satisfaction.36
The long-term outcome for RFA has also been
assessed in a number of studies. In a meta-analysis,
van den Bos et al.24 have looked into 64 eligible
studies comparing laser, RFA, surgery and foam
sclerotherapy. They identified that estimated
pooled success rates at three years for RFA was
84%. Recent separate one- and three-year follow-up
data have shown an absence of reflux in 95.2% at 12
months3 and 92.6% at 36 months postprocedure.23
Recanalization of a vein could be due to either
reflux from a tributary or an incompetent perfora-
tor. Similarly, if the main lumen is patent reflux
from the groin due to an accessory vein can also
lead to failure and recurrence.37 Technical problems
such as difficult access, problems in advancing the
catheter or a tortuous GSV can all play a role in
failure of the procedure or incomplete occlusion of
the vein ultimately causing recurrence.37 Neovascu-
larization, though less frequent with RFA than
surgery,7 is also considered a cause for REVAS and
has been seen in 2.8–7% of cases.15,38 Insufficient
energy delivery and too-rapid pullback have been
adjudged causes for incomplete obliteration of the
vein lumen.9,23 RFA for recurrence has been
shown to cause less pain and bruising than
surgery as well as taking less time.39
Discussion
In summary, RFA is associated with up to a 92%
occlusion rate at three years. The common risks
are of paraesthesia (4–20%), phlebitis (7–9%) and
bruising or skin pigmentation (6–19%). The risk of
DVT is low (,0.1%) but its consequences ensure
that it is a major risk that must be mentioned (see
Table 1). Technical failure and recurrence rates are
equivalent to the gold standard of open surgery
while neovascularization is significantly less fre-
quent after RFA.
The routine use of tumescent anaesthesia in a
clinic room setting has now become an established
and viable way to treat varicose veins.
There are certain points, which need to be care-
fully addressed during the RFA technique to
avoid complications:37
† Adequate vein emptying by leg elevation;
Table 1 Complication rates associated with radiofrequency abla-
tion of varicose veins
Complications Incidence (%)
Phlebitis 7–9
EHIT–DVT ,0.01
Skin burns 0.5
Skin pigmentations 6–19
Wounds problems 6–8
Nerve injury/paraesthesia 4–20
EHIT, endovenous heat-induced thrombosis; DVT, deep vein
thrombosis
M A Anwar et al. Complications of RFA 2012 Review article
Phlebology 2012;27 Suppl 1:34–39 37
† Tumescent anaesthesia should be instilled
below the saphenous fascia and above the
deep muscular fascia surrounding the vein
using ultrasound guidance;
† The GSV should be compressed to separate it
from the inflow tributaries;
† Appropriate use of tumescent anaesthesia and
maintenance of an adequate probe temperature
are vital to the RFA technique.
The advantages of RFA are far greater than its
associated risks. A full explanation of the procedure
along with its relevant risks is important in mana-
ging patient expectations. With the increased use
of endovenous therapy it is likely that the incidence
of varicose vein litigation will decrease in step.
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ABSTRACT
Chronic venous disorders remain a common problem worldwide; however,
despite increasing research into novel endovenous therapies for the
treatment of superficial venous disease, the natural history of primary venous
disorders remains poorly understood. The following article provides a review
of the longitudinal studies evaluating the progression of chronic venous
disorders in the published literature. This includes a summary of the rate of
development of venous disease in asymptomatic limbs and the rate of
progression of venous disease in terms of hemodynamic, anatomical, and
clinical progression including the development of skin changes and venous
ulceration.
Venous disorders, including varicose veins and superficial venous
insufficiency, are a common pathology, thought to affect between 15% and
40% of the adult population.1-2 They have plagued mankind for thousands
of years and there is documentation of their existence from as early as 3500
BC.3 In the last decade, the development of endovenous techniques has led
to a rapid increase in the popularity of many novel therapies including
thermal and chemical ablation techniques.4-7 Yet, despite the large number
of research studies supporting the use of new devices, the etiology and
natural history of the progression of venous disease remains poorly
understood. Evidence from clinical ultrasonographic and histological studies
supports a multicentric theory for the development of venous disorders due
to abnormalities in the composition of the vein wall leading to functional
changes.8-9 However, the investigation of the progression of venous disease
is complex and can be measured in a number of different ways. In recent
years, there has been a move away from the use of surrogate end points to
grade disease severity, such as the presence or absence of reflux, or the use
of hemodynamic parameters such as venous refill times. A greater emphasis
is now placed on the clinical assessment of disease severity and its functional
impact on the individual patient. The association between the presence of
superficial reflux and venous hemodynamic measurements with clinical and
functional outcomes has been shown to be weak,2,10,11 and the relationship
between these parameters remains poorly understood. 
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To date, there have been few studies that have
investigated the natural history of the progression of
primary venous disease. Much of the current
information is based on patients self-reporting their
symptoms, many of whom subsequently undergo
treatment, and the natural history of the condition is
infrequently documented. In the current financial
climate, the natural history of patients presenting with
mild or moderate venous disease becomes increasingly
important in order to justify the allocation of scarce
resources. The overall societal burden of venous disease
is unknown; however, chronic venous ulceration is
debilitating for patients and costly for society and
therefore preventative treatments are likely to be cost
effective.12,13 This article includes a review of the
available information from longitudinal studies to date.
LONGITUDINAL STUDIES EVALUATING
CLINICAL DISEASE PROGRESSION
The Framingham study (1988)14
One of the earliest longitudinal epidemiological studies
of varicose veins was the Framingham study, which
followed 5209 male and female subjects for 16 years at
2-yearly intervals starting in 1966. Subjects were
examined for the presence of varicose veins—defined as
dilated tortuous veins on the lower limbs—and potential
risk factors were recorded. At the beginning of the study,
1720 men and 2102 women had no clinical evidence of
varicose veins. Over the 16-year period, 396 men and
639 women developed varicose veins. The development
of varicose veins was significantly greater in obese
women. Significant differences were also noted in those
with a higher systolic blood pressure, and those who
were less physically active. The data suggested an
incidence of varicose veins of 39.4 per 1000 men and
51.9 per 1000 women with no significant increase with
age; however, there was an increase in prevalence with
age due to accumulation. The study provided useful
information regarding the incidence and potential risk
factors associated with the development of varicose
veins; however, it did not provide details of the
progression of venous disease. 
Brewster et al (1991)15
Brewster et al published one of the earliest longitudinal
studies documenting the details of venous disease
progression in 304 patients on an NHS waiting list for
superficial venous surgery. The median waiting time for
patients on the waiting list was 4 years (range, 6 months
to 13 years) and the median reported length of symptom
duration was 28 years (range, 2-47 years). Primary
varicose veins were observed in 85.5% of patients while
64% of patients reported that they felt that their venous
disease had progressed since their initial presentation,
and 5.2% suffered an episode of thrombophlebitis. In
the time since their initial presentation, 68 patients
(22%) had developed skin changes and 12 patients
(3.9%) had developed venous ulceration, although the
degree of clinical severity at baseline in those who
developed ulceration was not reported.15 As with
previous published studies, the development of further
varicosities did not necessarily correlate with worsening
of symptoms.
Sarin et al (1993)16
In a small study of 56 limbs in 36 patients on an NHS
waiting list for treatment of uncomplicated varicose
veins (43 primary and 13 recurrent), patients underwent
noninvasive imaging and clinical examination at initial
presentation and again prior to surgery. Superficial
venous surgery was delayed by a median of 20 months
(range, 15-27 months). An additional 3 patients had
developed varicosities along the distribution of the great
saphenous vein (GSV), and 11 had developed new
varicosities in the small saphenous vein (SSV)
distribution prior to treatment. There were no new cases
of venous ulceration; however, 1 patient developed
lipodermatosclerosis.16 Of the 16 previously clinically
normal contralateral limbs, 5 (31%) developed
varicosities. Duplex ultrasonography demonstrated that
an additional 14 patients developed superficial reflux at
new sites (27%) and 18% were shown to have
progressive reflux compared to initial duplex scans. New
reflux developed in 25% of normal contralateral limbs.
No significant deterioration in venous refill times was
observed. 
Labropoulos et al (2005)17
Labropoulos et al carried out a longitudinal study
comprising 116 limbs from 90 patients presenting with
symptomatic chronic venous disease, who—for various
reasons—did not undergo immediate treatment for their
venous disorder and underwent treatment at a later
date.17 All patients underwent two duplex ultrasound
scans prior to intervention and reflux was classified as
retrograde flow >0.5 s in truncal veins and >350 ms for
perforator veins. All changes were documented and the
time in between scans was specified. At the time of the
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initial duplex scan, 3.4% of patient had C1 disease,
43.8% had C2 disease, 23.3% had C3 disease, 13.8%
had C4 disease, and 6.9% and 4.3% had C5 and C6
disease, respectively.17 Over a total of 43 months, 27 of
116 limbs (23.3%) had changes on duplex
ultrasonography and patients reported worsening
symptoms at some point in 13 of 116 limbs (14.4%),
although patients underwent scans at different time
intervals. In patients who underwent a second duplex
between 1 and 3 months, 1 of 15 limbs exhibited
noticeable changes on duplex ultrasonography and 5 of
28 limbs showed duplex changes when scanned after 4-
6 months, although none of these patients had
worsening clinical symptoms. In the patients who
underwent their second scan at 7-9 months, 6 of 18
limbs showed duplex changes and worsening symptoms
were reported in 1 of 18 limbs. In the patients scanned
after 10-12 months, 3 of 15 limbs exhibited duplex
changes, and worsening symptoms were reported for 1
of 15 limbs. When scanned after 13-18 months, 3 of 12
limbs showed duplex changes and worsening symptoms
were reported for 3 of 12 limbs. At 19-24 months and
25-30 months, scans showed duplex changes in 3 of 10
limbs and 2 of 8 limbs, respectively, while worsening
symptoms were reported in 3 of 10 limbs and 2 of 8
limbs, respectively. Between 31 and 36 months, 3 of 7
limbs exhibited duplex changes and worsening
symptoms were reported in 2 of 7 limbs, while between
37 and 43 months, 1 of 3 limbs had duplex changes and
worsening symptoms were reported in 1 of 3 limbs. New
reflux was documented at 14 new sites including the
GSV (n=2), SSV (n=1), tributaries (n=4), nonsaphenous
vein (n=1), perforator veins (n=4), and deep veins (n=2).
Extension of reflux in existing refluxing veins was
documented in 17 limbs including at the saphenofemoral
junction (SFJ) (n=1), GSV (n=7), SSV (n=4), tributaries
(n=7), nonsaphenous veins (n=3), perforator veins
(n=6), and deep veins (n=3). Overall when compared
separately with other veins, saphenous veins and their
tributaries were significantly more likely to have
undergone change (P<0.01, Fisher exact test). Extension
was antegrade in 7 limbs, retrograde in 7 limbs, and in
both directions in 3 limbs. Worsening swelling (C2 to C3
change) was reported in 7 cases, worsening skin changes
(C3 to C4) in 4 cases, and there were 2 cases of venous
ulceration (C4 to C6). Overall 73% of limbs did not
undergo any change; in those that did, this was usually
after 6 months from the original scan. Approximately
half of the patients who had significant changes on
duplex ultrasonography reported a change in symptoms
that occurred after 1 year. In addition, a number of
patients who did not have noticeable changes on duplex
ultrasonography were observed to have progressive
clinical disease. 
The Bonn Vein Study – Rabe et al18; Pannier et al19
The aim of the Bonn Vein study was to investigate the
prevalence of deep and superficial reflux in the general
population.20 The most recent evidence from the Bonn
Vein Study—which surveyed over 1978 patients in
Germany—showed that over 6.6 years, progression of
C2 disease to higher C classes was 31.8% in patients with
saphenous reflux and 19.8% in patients with
nonsaphenous reflux.18 The prevalence of varicose veins
rose from 22.7% to 25.1%, and the prevalence of CVI
increased from 14.6% to 16%. Risk factors for disease
progression were identified using a multivariate analysis
and included increasing age, obesity, and arterial
hypertension.19
Kostas et al (2010)21
73 patients with primary superficial venous disease who
underwent unilateral varicose vein surgery were
followed up after 5 years with regard to the contralateral
limb, which was either asymptomatic or minimally
symptomatic at the time of initial treatment.21 Patients
underwent clinical examination and were graded
according to the Clinical-Etiological-Anatomical-
Pathophysiological (CEAP) classification. Duplex
ultrasonography was performed to establish the presence
of retrograde flow >0.5 s in either deep or superficial
veins. At initial recruitment, 5 of 73 patients had mild
symptoms in the contralateral limb and 56 patients
(77%) had no evidence of venous disease, 21% of
patients were graded as C1, and 4 patients (5%) were
graded as C2. A total of 12 limbs had isolated superficial
reflux, and 6 limbs had deep reflux on duplex
ultrasonography. At 5 years, 48 new sites of reflux were
found in 38 limbs, most frequently in the superficial
veins; however, 6 limbs developed deep venous reflux.
In the limbs where reflux had propagated, this was
antegrade in 10 limbs and retrograde in 8. In the
majority of patients, changes in detectable reflux were
associated with clinical changes, with 5 limbs progressing
from C0 to C1, 5 from C0 to C2, 2 from C0 to C3, and 5
from C0 to C2/3. Progression from C1 to C2 was
observed in 6 limbs, while 3 limbs progressed from C1 to
C3, and 2 from C2 to C3. There were 2 patients who
were initially classified as C2 who developed C4 skin
changes. The study found that the progression of CVD
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was significantly affected by orthostatism and obesity,
and that progression was reduced to some extent with
the use of elastic compression stockings. Conversely,
parity and estrogen treatments were not associated with
progression of CVD. Overall, approximately a third of
limbs with mild or asymptomatic reflux developed
clinical signs over 5 years. This is similar to the 27%
reported by Labropoulos.17
Labropoulos et al (2009)22
The progressions of primary and secondary venous
disorders are noticeably different. A prospective
comparison of the rate of progression of primary and
secondary venous disease was performed over a 5 year
period in 41 patients with a proximal DVT (group A),
compared with a cohort of 41 patients with primary
venous disease (group B) and followed up at 5 years with
duplex ultrasonography. These were also compared with
15 control cases with no evidence of venous disease
(group C). At 5 years, CEAP scores for the 3 groups were
as follows: group A, C0 n=6, C1 n=0, C2 n=0, C3 n=29,
C4 n=8 C5 n=1, C6 n=2; group B, C0/C1 n=0, C2 n=29,
C3 n=18, C4 n=3, C5/C6 n=0; group C, C0 n=25, C1
n=3, C2 n=2 C3/C4/C5/C6 n=0. All patients were
encouraged to wear compression stockings with 30 to
40mm Hg of graduated compression. Results confirmed
that patients with a previous history of DVT developed
significantly more skin changes compared with those
with primary venous disease (P=0.019), and those with
no venous disease (P<0.01) and that the progression was
more rapid in patients with a previous history of DVT.
Skin changes also occurred significantly more frequently
in patients with combined reflux and venous obstruction
(P=0.12).22
The Edinburgh Vein Study – Robertson et al (2011)23
Data from this cohort study included 1566 randomly
selected adults between 18 and 64 years of age who were
examined at baseline and then at 13 years as part of the
Edinburgh Vein Study. Recorded measurements included
a questionnaire of lifestyle factors, CEAP grade, and
duplex ultrasonography. Of the 1566 patients, 880 were
followed up at 13 years. A total of 325 patients had
truncal varicosities at baseline, and at 13 years, 154
patients had deterioration in their varicosities (47.4%)
while 62 had stayed the same (19.1%). Of the 555
patients with no truncal varices at baseline, 101
developed C2 varices during the 13-year follow-up. The
annual incidence of developing trunk varices was
1.35%, the rate of disease progression was 3.54% per
annum, and the number of patients with unilateral
disease who developed bilateral disease was 25.3%. A
total of 109 patients showed improvement (33.5%), of
which 16.6% had undergone surgery or sclerotherapy.
Patients who had not undergone treatment were all
reported to have mild disease and differences in grade
may be attributable to interobserver variability. 
LONGITUDINAL STUDIES EVALUATING VENOUS
HEMODYNAMICS 
The Bochum study – Stucker et al (2005)24
The Bochum study surveyed 73 pupils over a period of
9 years at the beginning, middle, and end of their
schooling. A fourth survey was also performed at 11
years. Pupils underwent clinical examination, duplex
ultrasonography, and digital PPG and were classified
according to the CEAP classification. Overall venous refill
times appeared to lengthen from childhood to
adulthood; this was thought to be due to maturation of
the venous calf pump during adolescence. Interestingly,
no clinical deterioration was observed in this cohort.24
LONGITUDINAL STUDIES EVALUATING THE
EFFECTS OF INTERVENTION ON DISEASE
PROGRESSION
Lurie et al (1998)25
This study evaluated 195 limbs in 183 patients with
primary chronic venous insufficiency and reflux affecting
the femoral vein, the SFJ, and the GSV.25 Venous
ulceration lasting for more than 6 months but less than 3
years was reported in 99 limbs. Patients underwent
ascending and descending venograms and duplex
scanning, and were randomized to receive one of three
treatment options including elastic compression hosiery
(n=68), surgical treatment of venous insufficiency/
saphenectomy (n=75), or deep vein reconstruction/
valvuloplasty with saphenectomy (n=52). Clinical results
were recorded based on the clinical severity scoring
system recommended by the subcommittee on the
reporting standards for venous disease.26 Over a mean
follow-up period of 6.2 years, no significant difference
was observed between the results of the three
interventions in patients who had a disease duration of
less than 5 years. However, in patients with a disease
history of greater than 5 years, the results of valvuloplasty
were significantly better, and the incidence of recurrent
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varicosities was significantly lower after valvuloplasty in
comparison with superficial vein repair alone. Recurrent
varicosities were observed in 18 patients (14.2%). The
authors concluded that valvuloplasty significantly
improved the results of superficial venous surgery and
that successful treatment was associated with an
improvement in valvular function.25
LONGITUDINAL STUDIES EVALUATING RISK
FACTORS AND THE DEVELOPMENT OF VENOUS
ULCERATION
It is known that disease progression is related to the
severity of venous reflux and duration of disease.27 The
sensation of leg swelling in otherwise mild disease was
found to be an indicator of likely disease progression and
poorer prognosis.28 The number of patients with
superficial reflux who are likely to progress to edema,
skin changes, lipodermatosclerosis, and venous
ulceration is unknown; however, the overall incidence of
edema and skin changes in the general UK population is
thought to be approximately 1% per year.27 The
incidence of venous ulceration is 1% in the UK and the
majority of those presenting with venous ulceration
have had venous disease for more than 20 years.15 29
Heit et al (2001)30
A retrospective population cohort study was conducted
in 1131 patients, including 263 patients who had venous
ulceration over a 25-year period, to evaluate the
incidence of venous stasis syndrome and venous
ulceration. The incidence of venous stasis was 76.1 per
100 000 person-years and the incidence of venous
ulceration was 18 per 100 000 person-years. Of the 945
patients who had venous reflux alone and no previous
history of ulceration, 60 (6.3%) developed venous
ulceration and the mean (±SD) time from the diagnosis
of venous stasis to the development of a venous ulcer
was 5 (±5) years with a range of 14 days to 24 years.30
Venous ulceration increased with age in linear fashion
and was higher in women than men.
A SUMMARY OF THE CLINICAL EVIDENCE ON
THE DEVELOPMENT AND PROGRESSION OF
VENOUS DISEASE 
A number of longitudinal studies have reported the
clinical development and progression of venous disease.
Regarding the development of venous disease in
asymptomatic patients (ie, patients not experiencing any
symptomatic discomfort), Kostas et al reported results
over a 5-year period where 22% of patients developed
new C1 disease, 31% developed new C2 disease, and
27% developed new C3 disease, while Sarin et al
reported that 25% of patients on a waiting list developed
new varicosities over a median of 20 months and 1
patient (3%) developed lipodermatosclerosis. Regarding
the progression of venous disease in patients with early
clinical stages, Kostas et al reported that 3% of patients
progressed from C2 to C4 disease.21 In the Bonn Vein
Study II, the rate of clinical progression from C2 to
higher C stages was 31.8% in patients with saphenous
reflux and 19.8% in those with nonsaphenous reflux
over an average of 6.6 years.18 Data from the Edinburgh
Vein study suggested that 47.4% of patients with truncal
varicosities showed clinical deterioration over a 13-year
period and the rate of disease progression was 3.54% per
annum.23 Brewster et al noted that 22% of patients
reported skin changes while waiting an average of 4
years for treatment of superficial venous disease.
Labropoulos et al reported 7 cases of progression from
C2 to C3, 4 cases of progression from C3 to C4, and 2
cases of venous ulceration (C4 to C6) over a period of
43 months. 
A SUMMARY OF THE ANATOMICAL AND
HEMODYNAMIC EVIDENCE FOR THE
PROGRESSION OF VENOUS DISEASE
Although the presence of superficial venous reflux and
abnormal venous hemodynamics are associated with
symptoms, the degree of symptoms reported and the
severity of venous disease frequently correlate poorly
with quantitative anatomical or hemodynamic findings.
Therefore, it is difficult to interpret the relevance of the
observed anatomical progression of venous reflux
demonstrated on duplex ultrasonography or the
deterioration in hemodynamic function. Nevertheless,
the evidence is summarized below. 
Sarin et al reported that 27% of patients developed sites
of new reflux in limbs where venous reflux previously
existed and 25% of normal contralateral limbs had
developed new reflux over this time, although no
significant deterioration in venous refill times were
observed. Labropoulos et al observed that over a total of
43 months, 23.3% of limbs had changes on duplex
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patient is a candidate for saphenous vein ablation.
Compression treatment is recommended for patients
with primary venous ulceration, with ablation of
superficial reflux to reduce the risk of ulcer recurrence.
Thermal ablation (radiofrequency or laser) is
recommended for the treatment of great saphenous vein
reflux in preference to high ligation and stripping,
although foam sclerotherapy is also suggested as a
treatment option. The treatment of tributaries with
phlebectomy or foam sclerotherapy is also
recommended. The routine treatment of perforating
veins in C2 patients is not supported, although the
selective treatment of perforators in patients with
ulceration is suggested.
CONCLUSION
Chronic venous insufficiency is a complex disorder with
an incompletely understood multifactorial etiology. The
majority of patients presenting with venous disorders
request treatment, so the natural history of the disorder
is difficult to evaluate. At present there is a lack of
published evidence from longitudinal studies that have
evaluated the natural history of disease progression.
Combining data from different studies is difficult due to
the heterogeneity of the outcome measures reported in
different studies and a lack of understanding of the
relationship between them. However, there is promising
data from large long-term studies, including the Bonn
Vein and Edinburgh Vein studies, which are likely to
allow a better understanding of disease progression in
the future. Nevertheless, based on the data currently
available in the published literature, it could be suggested
that in patients with uncomplicated varicose veins,
disease progression to higher C stages is likely to be
somewhere between 3.5% and 7% per annum15-17,21,28,35
and is subject to a number of patient and environmental
factors. The development of venous ulceration usually
occurs in patients who have had venous disease for over
20 years, and skin changes and deep venous
incompetence are associated with a significantly higher
risk of venous ulceration. The rate of progression from
C4 disease in patients with skin changes to venous
ulceration is unknown, but based on the available
evidence, it is estimated to be in the in the region of 1%
to 2% per annum.15,17,18,25 These figures become highly
important when considering the prevalence of venous
disease. A recent study evaluating the societal cost of C4-
C6 disease in European countries and the USA confirms
ultrasonography and an extension of existing reflux was
documented in 14.7% of limbs. Kostas et al reported 48
new sites of reflux in 38 limbs at 5 years (52%) and 6
limbs developed deep venous reflux compared with
baseline. 
A SUMMARY OF THE FACTORS AFFECTING THE
PROGRESSION OF VENOUS DISEASE
Although the etiology of venous disease is incompletely
understood, a number of factors appear to be related to
the progression of venous disease. There is good
evidence that obesity and arterial hypertension28
significantly affect disease progression. In addition, there
is evidence that prolonged standing increases the rate of
disease progression, and that the use of elastic
compression hosiery may reduce disease progression.21
The presence of deep venous reflux, a past history of
venous thromboembolism, and the presence of
lipodermatosclerosis, corona phlebectatica, or varicose
eczema are associated with an increased risk of
developing venous ulceration.31 In patients with
secondary venous disease following acute deep venous
thrombosis, the natural history of the disease is better
understood. Studies suggest that approximately 30% of
patients will go on to develop postthrombotic syndrome,
with 3% to 6% developing venous ulceration,32 and that
disease progression occurs more rapidly than in those
with primary venous disorders.22
Improving the diagnosis and treatment of patients with
venous ulceration has been shown to significantly
improve patient outcomes. Evidence from a Swedish
study confirmed that through education and a
coordinated multidisciplinary approach—including early
diagnosis, thorough investigation, and early use of
superficial venous surgery—venous ulceration was
reduced by 46% between 2002 and 2005.33
PRACTICAL GUIDANCE 
Based on the available evidence, the Society of Vascular
Surgery and the American Venous Forum have
produced practical guidance regarding the management
of primary venous disorders.34 According to this
guidance, there is weak evidence for compression
hosiery for patients with symptomatic varicose veins and
it is not recommended as the primary treatment if a
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First Author Year ofpublication
No. of study
participants
No. of
limbs Brief study description Duration of study
Brand14
(Framingham study) 1988 5209 -
Epidemiological study of the incidence prevalence and
risk factors for the development of varicose veins
16 years, patients reviewed at 2-
yearly intervals
Brewster15 1991 304 - Patients on an NHS waiting list for varicose vein surgery Median (range) waiting time ofpatients was 4 (6-13) years. 
Sarin16 1993 36 56 Patients on an NHS waiting list for varicose vein surgery Median (range) waiting time 20(15-27) months
Labropoulos17 2005 90 116 Longitudinal study of patients presenting with venousdisease who did not undergo immediate treatment 43 months
Rabe 20,19
(Bonn Vein Study II) 2008-ongoing 1978 -
Longitudinal study of the development and progression of
venous disease in the general population 6.6 years
Kostas21 2010 73 73
Patients undergoing superficial venous surgery for 5 years
were followed with regard to the contralateral limb,
which was asymptomatic or minimally symptomatic at
the time of surgery
5 years
Labropoulos22 2009
97
Group A: Proximal DVT
n=41, Group B: primary
venous disease n=41,
Group C: control group
n=15
126 Longitudinal study comparing the progression of primaryand secondary venous disease 5 years
Robertson23
(Edinburgh Vein Study) 2011 880
Longitudinal study of the prevalence of venous disease in
the general population 13 years
Stucker24 (Bochum
study) 2005 73
Study of venous refill times and duplex findings in school
pupils 9 years
Lurie25 1998 183 195
Randomized clinical trial comparing results following
treatment with compression hosiery (n=68), valvuloplasty
plus saphenectomy (n=52) or saphenectomy (n=75) in
patients with reflux of the SFV and superficial reflux.
Mean duration of follow-up 6.2
years
Heit30 2001 1131
A retrospective cohort study of patients to estimate the
incidence of venous stasis syndrome and venous
ulceration.
25 years
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Incidence/ Rate of development of venous
disease according to CEAP
Rate of progression of C2 disease
to higher disease stages
Rate of development
of venous ulceration Duplex findings Additional outcomes
Incidence of the development of varicose veins-
CEAP unspecified 39.4/1000 in males, 51.9/1000
in females
Not specified Not specified Not specified
Not specified 22% developed skin changes/C4disease from initial presentation 
3.9% developed venous
ulceration, baseline CEAP
unspecified.
Not specified
25% of contralateral limbs had developed new
reflux and 31% developed new varicosities in the
contralateral limb
1 patient (2.7%) developed
lipodermatosclerosis
No cases of venous
ulceration
27% had developed reflux
at new sites and 18% of
patients had progressive
reflux compared to baseline
studies
3 patients developed additional
varices of the GSV, 11 patients
developed new varices of the SSV
A change in either duplex findings or symptoms
occurred in 38 limbs at 6 months or later
11.6% progressed from C2 to C3
and 14.8% from C3 to C4
2 patients with C4
disease developed
ulceration (12.5%)
31 limbs (26.7) of limbs had
progression on venous
duplex, of these 29 were
symptomatic. 
14.4% of patients reported
worsening of symptoms
Prevalence of VVS rose from 22.7% to 25.1% over
the study duration 
31.8% of patients with saphenous
reflux and 19.8% of patients with
nonsaphenous reflux progressed
from C2 disease to higher C stages.
Not specified Details unpublished
16 (23.1%) of patients with C0 or C1 disease at
baseline developed C2 disease by 5 years. 
2 patients with C2 disease
developed C3 disease and 2
developed C4 disease
No patients developed
C5/C6 disease
48 new sites of reflux were
found in 38 limbs, including
6 limbs that showed
development of deep reflux.
13 patients with C0 disease at
baseline progressed to C3 disease
at 5 years.
2 patients in group C developed varicose veins at
5 years (13%)
In group A, the incidence of skin
changes at 1 year was 4% (2/46
limbs) and at 5 years was
24%(11/46) 
In group B, skin changes occurred in
3 patients (6%)
In group A, 9 limbs
progressed from C3 to C4
and C6 and 2 limbs from
C4 to C5 and C6.
47.4% had deterioration in their
varicosities.
A change in CEAP clinical class
occurred in 14 limbs in group A
(30%), of these 11 limbs had
progression of reflux or recurrence
of DVT.
101/ 555participants with no varices at baseline
developed C2 disease. The annual incidence of
developing trunk varices was 1.31%
The rate of disease progression was
3.54% per annum Not specified
25% of those with unilateral
disease developed bilateral
disease
Not specified No clinical deterioration wasobserved. Not specified -
Venous refill times lengthened
from childhood to adulthood,
thought to be due to the
maturation of the venous calf
pump.
Not specified Not specified Not specified
73% of patients had
decreased leakage of the
femoral vein after
valvuloplasty. This did not
occur in the saphenectomy
or compression hosiery
groups.
No significant difference in
outcomes was observed between
treatment groups in patients with
disease duration of greater than 5
years. Results after valvuloplasty
were significantly better than
saphenectomy or compression.
Recurrent varicosis occurred in
7.7% of cases following
valvuloplasty compared to 17.3%
following saphenectomy alone
(P<0.01).
Not specified Not specified
60/945 (6.3%) of
subjects with no previous
history of ulceration
developed venous
ulceration over 25 years.
The mean (sd) time for
the development of
ulceration was 5(5) years.
Not specified
The incidence of venous ulceration
was 18.0/ 100 000 persons per
year. The incidence of venous
stasis was 76.1/ 100 000 person-
years.
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that the costs run to hundreds of millions of euros each
year for the treatment of superficial reflux, the treatment
of venous ulcers, and the cost of days lost from work due
to venous disorders.36 A better understanding of the rate
of progression of venous disease, and the ability to
identify patients at risk of venous ulceration will help
with the allocation of healthcare resources and ensure
the appropriate management of patients with moderate
venous disorders, and, therefore, further data from
ongoing longitudinal studies is awaited
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Introduction
Superficial venous disease affects up to 1 in 4 of the UK
population (1) an d has been estimated to cost € 600-
900 million per year in Western European countries (2),
with over 37, 000 varicose vein procedures performed
each year in the UK, the majority of which as day
cases (3). The recent Bonn Vein Study found less than
10% of the Bonn general population had no evidence of
venous disease (CEAP class 0) (4). 
The treatment of superficial venous disease has been
standard for hundreds of years until the recent develop-
ment of sclerotherapy in the mid 20th century and then
ultrasound guided endovenous ablation. These recent
advances have greatly changed the patient experience,
the logistics of intervention and have provided the
 opportunity for ambulatory treatment. Treatment has
 previously been assessed by merely technical means –
occlusion and recurrence rates, however patient
 preference and quality of life assessments are also vital
components of treatment analysis. Quality of life
 assessment pre and post intervention allows a vital
 stratification of treatment methods.
Due to the lack of a perfect ‘one-size-fits-all’ solution
to superficial venous disease many treatments are avail-
able. This can make it extremely difficult for the clini-
cian to make a fully informed choice between modalities
let alone between equipment. With the huge patient pop-
ulation optimum treatment can lead to vast improve-
ments in both individual and population health and well-
being, in excess of that offered by optimal treatment of
arterial disease.
Compression Therapy
Compression therapy using either graduated elastic
hosiery or compressive bandaging has become the
 standard conservative treatment for patients with uncom-
plicated varicose vein disease. It has also become a
screening method for patients with aspecific symptoms,
with a trial of compression hosiery allowing symptom
improvement assessment and risk stratification for
 treatment. Such stratification is becoming especially
important in the current age of austerity. 
The evidence base for compressive hosiery is sparse,
and a recent systematic review (5) showed a sparse and
 heterogeneous evidence base, but stockings were shown
to improve symptoms, but not to effect progression or
recurrence of varicose veins.
Compressive hosiery is not without its own morbidi-
ty, leading to poor compliance. This led over half of
those patients randomised to conservative treatment in
the large REACTIV randomised controlled trial to chose
to withdraw and undergo surgery within 3 years (6).
Surgical intervention has been shown to provide
 significant quality of life improvement for minimal addi-
tional healthcare cost when compared to conservative
management (7).
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Superficial Venous Disease Treatment – Is There Still a Role for Open Surgery
in 2011 ?
T. R. A. Lane, V. A. Pandey, A. H. Davies
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Abstract. The treatment of superficial venous disease (commonly described as varicose veins by the general public) has
remained relatively constant over the past 100 years until the refinements of endovenous treatments such as sclero -
therapy and more recently, the development of endovenous ablation. This has radically changed the treatment profile of
this disease with treatments easily administered and well tolerated even in those patients who would not be considered
fit for open surgery previously. With the advent of day surgery and improved general and local anaesthetic techniques,
venous surgery has forged a path towards the end goal of outpatient treatment with no requirement for inpatient stay.
The end goal of all superficial venous surgery is an improvement in quality of life, and with such new treatments
 reducing the impact of the actual intervention, such gains are easier to make. 
This review assesses and presents the current literature describing superficial venous disease treatments covering all
treatment modalities.
With endovenous treatment, true ambulatory treatment is available, providing high quality treatment at speed and
 convenience for patients.
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In a recent cost effectiveness study, conservative man-
agement was considered to have a cost of zero for com-
parison with intervention (8). However this does not take
into account the significant expenditure in time and
materials associated with symptomatic venous disease
requiring compression hosiery or bandaging. Ulcer dis-
ease increases the cost of chronic venous insufficiency
enormously (2). The benefits of intervention to prevent
such complications are clear, with 2 million working
days lost to venous disease in 2002.
Sclerotherapy
The technique of liquid sclerotherapy with direct injec-
tion was described by Chassaignac in 1855 (9). This was
refined into foam sclerotherapy during the 20th century
with the Tessari method being most practiced (10) and
this has lead to improved occlusion and patient satisfac-
tion rates. Foam sclerotherapy is thought to improve
occlusion rates with smaller quantities of sclerosant by
displacing more blood and improving wall contact. It
allows the treatment of varicose veins in a true clinic
environment, with no assistance required once skilled at
the technique (11). Due to the simple cannulation nature
of the technique, minimal post-procedure morbidity is
encountered, leading to high patient acceptance.
The major failing of foam sclerotherapy has previous-
ly been occlusion and recurrence rates. However, with the
advent of foam, it has been shown that ultrasound guided
foam sclerotherapy (UFGS) has equivalent success and
recurrence rates to open surgery, as shown by a recent
meta-analysis (10), a recent systematic review (12) and a
recent Cochrane review (13). However, sclerotherapy
was found to be less effective than endovenous ablation,
although long-term data are lacking.
There is sparse evidence in the literature to guide the
actual application of sclerotherapy, with disparate scle-
rosant volumes, foaming techniques and concentrations
used, however Coleridge Smith has published recom-
mendations for clinic requirements and suggested
 technique (11).
Overall complications after sclerotherapy are rare,
however this much be weighed against the relatively
benign nature of varicose veins, and the availability of
effective conservative management. Major complica-
tions include deep vein thrombosis (DVT), pulmonary
embolism (PE), stroke and transient embolic events. The
event rate of these complications is very low, with an
event rate of 0.6% for DVT, 2.1% for cerebral events and
one previously reported PE (10). Air embolism is the
most feared complication, which can be fatal when
 associated with gas volumes of > 1 ml/kg injected into
the venous system, with 50 ml able to cause significant
complications. Most procedures utilise up to 10 ml of
foam, though some report use of up to 30 ml (14).
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One case report has been published of stroke follow-
ing UGFS (14). The risk of debilitating complications is
extremely rare. It further requires a patent foramen ovale.
Overall the risk profile of sclerotherapy is not signifi-
cantly altered in comparison to surgery and therefore is
gives a reasonable alternative for those patients for
whom surgery or endovenous ablation is deemed
 inappropriate or too strenuous.
Endovenous Ablation
The principles of endovenous ablation are the same –
minimally invasive destruction of the incompetent veins
using either thermal energy or sclerosant and mechanical
disruption. This leads to fibrosis of the vein wall and
ablation of vessel lumen, thus removing the incompetent
vein from the circulation. The advantages of endovenous
treatment are faster procedure times, reduced post-
 operative pain, optional general anaesthesia, patient pref-
erence and the possibility of truly ambulant treatment.
The various endovenous methods are detailed below.
The qualities of endovenous treatment have been
reviewed in depth with a meta-analysis of 64 studies,
covering over 12, 000 treated limbs, with a mean 2.5
year follow-up period (12). Whilst such analyses are hin-
dered by non-standardised reporting (15), it has pro-
duced significant positive data for endovenous treat-
ment. Endovenous  procedures have been shown to be at
least equivalent to open surgery for technical success.
Coupled with ease of use and patient acceptability, this
has led to a huge, increasing practice and success of the
procedure.
Endovenous Laser Ablation (EVLA)
The technique of endovenous laser ablation (EVLA) has
advanced greatly since its description in 2001 by
NAVARRO et al. (16). Following Food and Drug
Administration approval, the technique has grown enor-
mously. The major drawback of laser technology is the
requirement for a specially shielded, secure treatment
room and the requirement for laser goggles for all in that
room.
The advancement of technology has lead to a prolifer-
ation of different laser wavelengths, with the wave-
lengths offering different treatment profiles. The wave-
lengths used are based on the absorptive properties of
blood (17). The technical success rate is highly depend-
ent on energy delivered by unit length (J/cm) with the
target for occlusion being > 70 J/cm, but no ill effects of
increased energy delivery are seen until 160 J/cm (18,
19). A recent meta-analysis found that EVLA showed
significantly better technical success characteristics,
compared to open surgery, sclerotherapy and radiofre-
quency ablation (12). However the studies analysed did
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produce a surprising improvement in occlusion rates
over successive years despite no further intervention,
which is difficult to explain.
Differing wavelengths are available for use, with 810,
940, 980, 1064, 1320 and 1470 nm lasers available.
Shorter wavelength lasers were initially chosen due to
the correspondent absorption by deoxygenated haemo-
globin, however it has been found that longer wave-
length lasers produce less post-operative complications,
such as pain (20-22). This has lead to a proliferation of
longer wavelength lasers, focused on water absorption
wavelengths as opposed to haemoglobin absorption
wavelengths. This targets the vein wall, as opposed to the
blood in the vein, leading to reduced energy require-
ments for fibrosis (23).
Long-term outcomes are obviously lacking, due to the
young nature of the technique and the constantly chang-
ing laser wavelengths available. However, in series
reporting follow-up beyond one year, occlusion rates
remain high, ranging from 86% at 6.7 years in more than
2400 limbs (24) to 97.1% at 4 years in 511 limbs (25).
A recent study has showed that EVLA with concomi-
tant phlebectomies significantly improved quality of life
and reduced risk of delayed procedures. 66% of the
delayed phlebectomy group required secondary interven-
tion, compared with 4% (p = < 0.001) in the concomitant
group (26).
Overall EVLA offers a reliable, technically successful
technique for endovenous ablation, which can be done in
the day surgery or clinic setting. Current advances in
longer wavelength lasers are allowing stepwise progres-
sion to the ultimate aim of technical success without
post-operative complication.
Endovenous Radio-Frequency Ablation (RFA)
Endovenous Radiofrequency ablation (RFA) was first
described by GOLDMAN et al. in 2000 (27). A systematic
review in 2009 outlined the literature and status of the
two competing radiofrequency catheters currently
licensed for use in the UK and Europe – VNUS
ClosureFAST™ and Olympus Celon RFITT™ (28). In
the USA, only the VNUS™ brand is licensed for endove-
nous ablation.
The technique is the same as utilised for endovenous
laser ablation – ultrasound guided, under tumescent local
anaesthesia and Seldinger cannulation technique.
General anaesthesia is optional in most cases and the
procedures can be done in a clean clinic room environ-
ment. The VNUS™ system requires the use of tumescent
anaesthesia to ensure adequate pain relief and adequate
compression of the vein to allow secure ablation. The
RFITT™ system due to its induction heating technique
does not require tumescent anaesthesia, resulting in
fewer needle punctures for the anaesthetic.
The VNUS ClosureFAST™ system utilises a segmen-
tal treatment approach, ensuring that all sections of the
vein are treated equally. The RFITT™ system uses the
same continuous pullback mechanism as EVLA, which
can lead to areas of over and under treatment.
Several studies have been published showing signifi-
cantly improved quality of life scores and improved
venous clinical severity scores after RFA when com-
pared to laser (29) as well as reduced post-operative
pain (30-32). The recent meta-analysis of endovenous
treatment found that RFA offered at least equivalent
technical success as sclerotherapy and open surgery (12).
Overall RFA offers a safe, reliable, fast technique for
the treatment of varicose veins. With the recent launch of
the RFITT™ system, and its differing catheter profile
many more patients are now suitable for radiofrequency
ablation.
Conventional Surgery
Open surgery for varicose veins has been practiced in
varying forms since 500 BC (33) with saphenofemoral
junction ligation being the gold standard of care for vari-
cose veins since 1907 when the saphenofemoral junction
and ligation with vein stripping technique was first
described by BABCOCK (34). It has undergone refine-
ments since then, but the basic procedure has not altered.
Despite it’s venerable history it remains the gold stan-
dard against which all new methods must be judged, and
the most widely offered treatment (35).
Furthermore, it remains a cost-effective procedure
when performed as a day case (8), can be performed
under local anaesthesia (36) and achieves good improve-
ments in Quality of Life (QoL) scores such as the
Aberdeen Varicose Vein Questionanaire (AVVQ) and
clinical scores such as the Venous Clinical Severity
Score (VCSS). Ligation without stripping of the truncal
vein runs the significant risk of recurrence due to neo-
 vascularisation (6).
Recent studies with 2 year follow-up (37, 38) and a
meta-analysis (12) showed that open surgery is as
 effective as both RFA endovenous treatment and
 sclerotherapy. EVLA showed higher rates of technical
success, but no significant difference in clinical out-
comes.
Saphenofemoral junction ligation with stripping is
often, but not exclusively, paired with multiple phlebec-
tomies at the same sitting. There is evidence to show that
delayed procedures reduce the rate of eventual interven-
tion, with both phlebectomy first and ligation first pro-
viding complete relief in some patients (39). CARRADICE
et al. however showed a significant increase in AVVQ
scores at 6 weeks, with a significant drop in VCSS scores
when patients received multiple phlebectomies and
endovenous ablation in one sitting. Follow-up data at one
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year showed normalisation of both generic and disease
specific quality of life measures with no significant
 difference between delayed and concurrent multiple
phlebectomies (26).
Future Advances
The advent of steam producing devices as shown by the
recent pilot study (40) which suggests steam catheters
offer a further modality for endovenous treatment, based
on thermal ablation. The principle behind this technique
is to ‘cut out the middle man’ and use discrete bursts of
steam to transfer energy to the vein wall, as opposed to
utilising laser or radio-frequency energy to heat the
blood at the catheter tip to create steam. In the pilot study
of 20 limbs, an occlusion rate of 65% was obtained at
6 months, with significant improvements in disease
severity at 3 months. One major benefit of the steam
 system is a much finer and more flexible catheter than
comparable endovenous treatments. Large-scale efficacy
trials comparing energy modalities are required.
The Clarivein™ treatment is now also available,
offering endovenous ablation without thermal energy.
This alternative technology uses a battery-powered rotat-
ing catheter tip, which both macerates the vein and can
infuse sclerosant. No clinical trials have been published
in peer reviewed literature, however initial trial data
(2010) available from the company website claims a
97% truncal vein closure rate at six months, in the
 doctor’s office setting. The procedure utilises no
 tumescence and requires no generator for ablative
 energy. Long-term data is unavailable currently.
Cost Effectiveness
A cost analysis of chronic venous insufficiency was
 performed as part of the REACTIV trial (7), which
assessed conservative treatment, sclerotherapy and open
surgery (6). A further cost-effectiveness study also
included endovenous ablation techniques which were not
available for formal comparison in the first analysis (8).
Both studies have found that intervention is cost
 effective, when performed as a day case or in clinic.
Conclusion
The treatment of chronic venous disease has entered a
new and exciting era. With the multitude of options
available, very few patients should be left without a
treatment pathway that alleviates their symptoms and
ideally cures the source of those symptoms. Endovenous
treatments have allowed ambulatory and day case man-
agement of venous insufficiency reducing costs and
increasing acceptability. 
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In an era of austerity, the treatment of chronic venous
insufficiency at an early stage is of paramount impor-
tance to reduce the long-term healthcare burden. Despite
the initial high cost of endovenous ablation techniques,
this is more than offset by increased throughput.
Open ‘traditional’ surgery remains the gold standard
treatment with no studies yet showing significant superi-
ority for endovenous modalities.
Local anaesthetic treatment, whether open surgery or
endovenous ablation, is highly acceptable to patients and
provides an appropriate and cost-effective pathway for
most cases. The vast majority can now be treated with a
combination of endovenous ablation and foam scle-
rotherapy, with the associated reduced post-operative
morbidity. With rapid developments in laser technologies
and long-term data available for radiofrequency ablation,
a patient and physician choice can be made between
energy modalities. Radiofrequency ablation offers treat-
ment with a reduced burden of morbidity with slightly
reduced technical success rates, and can be performed
without additional safety requirements. Laser ablation
offers the best technical success rate but has worse post-
operative side effects and limited long-term data due to
the proliferation of new devices. Further long-term ran-
domised trials and data collection registries are both in
progress and are required to provide a definitive answer
for the appropriate energy source.
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